Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Saturday, 17. July 2021
SSC Session 08:00 - 10:00 R1 Factor VIII, Factor IX and Rare Coagulation Disorders Introduction 08:00 - 08:02 Speaker: Johnny Mahlangu, ZA
Non-Factor Replacement Therapies 08:02 - 08:02
Moderators: Johnny Mahlangu, South Africa, Tarek Owaidah, Saudi Arabia
In Patients on Non-Factor Therapies, Exposure to Clotting 08:02 - 08:14 Factor Replacement Should Be Early (Debate) Speaker: Manuel Carcao, CA
In Patients on Non-Factor Therapies, Exposure to Clotting 08:14 - 08:26 Factor Replacement Should Be Early (Debate) Speaker: Jayanthi Alamelu, GB
Non-Factor Replacement Therapy Versus Factor Replacement 08:26 - 08:38 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Bhavya Doshi, US
Non-Factor Replacement Therapy Versus Factor Replacement 08:38 - 08:50 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Gili Kenet, IL
Beyond Annualized Bleed Rates What Should Be the Alternative 08:50 - 09:02 Endpoints for Non-Replacement Therapies Speaker: Alok Srivastava, IN
Q&A Session 09:02 - 09:06
Gene Therapy 09:06 - 09:06
Moderators: Valder Arruda, United States, Savita Rangarajan, United Kingdom
Anti Adeno-Associated Virus Antibodies Antibodies: What Are 09:06 - 09:18 the Standardization Issues? Speaker: David Lillicrap, CA
Rationale for Adeno-associated Virus (AAV) Mediated Gene 09:24 - 09:30 Therapy in Patients With Anti Adeno-associated Virus Antibodies Speaker: David Cooper, NL
What Should We Be Following-up Post Gene Therapy? 09:30 - 09:42 Speaker: Barbara A. Konkle, US
Q&A Session 09:42 - 09:46
New SSC Projects
1 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
09:46 - 09:46 Moderators: Sabine Heine, Germany, John Pasi, United Kingdom
Proposal for New Nomenclature for Previously Untreated 09:46 - 09:50 Patients Speaker: Guy Young, US
Proposal for Value Assignment to the WHO 9th International 09:50 - 09:54 Standard for Factor VIII Concentrate Speaker: Sanj Raut, GB
Q&A Session / Conclusion 09:54 - 10:00
SSC Session 08:00 - 10:00 R2 Platelet Immunology Moderator: Tamam Bakchoul, Germany 08:00 - 08:00
Introduction 08:00 - 08:01 Speaker: Tamam Bakchoul, DE
Platelet Immunology and COVID-19 08:01 - 08:01
Antibody-Mediated Procoagulant Platelets in COVID-19 08:01 - 08:11 Speaker: Karina Althaus, DE
Platelet Activating Immune Complexes in COVID-19 08:11 - 08:21 Speaker: Stefan Jevtic, CA
Discussion I / Q&A Session I 08:21 - 08:31 Speaker: Steve McKenzie, US
Heparin Induced Thrombocytopenia 08:31 - 08:31
Standardization of Functional Heparin Induced 08:31 - 08:41 Thrombocytopenia Assays Speaker: Ishac Nazy, CA
5B9 mAB as Internal Control for Heparin Induced 08:41 - 08:51 Thrombocytopenia Testing Speaker: Claire Pouplard, FR
Discussion II / Q&A Session II 08:51 - 08:56 Speaker: Ruchika Sharma, US
Immune Thrombocytopenia 08:56 - 08:56
Standardization of Clinical Outcomes in Immune 08:56 - 09:06 Thrombocytopenia Speaker: Rachael Grace, US
Guideline for the Management of Critical ITP Bleeding 09:06 - 09:16 Speaker: Donald M. Arnold, CA
2 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Discussion III / Q&A Session III 09:16 - 09:21 Speaker: Philip Choi, AU
Fetal and Neonatal Alloimmune Thrombocytopenia 09:21 - 09:21
Recent Advances in the Antenatal Diagnosis of Fetal and 09:21 - 09:31 Neonatal Alloimmune Thrombocytopenia Speaker: Ruchika Sharma, US
Update on the SSC Survey On the Postnatal Fetal and Neonatal 09:31 - 09:36 Alloimmune Thrombocytopenia Speaker: Maria Therese Ahlen, NO
Discussion IV / Q&A Session IV 09:36 - 09:41 Speaker: Rachael Grace, US
Update On On-going and Proposed Projects 09:41 - 09:41
Platelet Autoantibody Detection in Immune Thrombocytopenia 09:41 - 09:46 Speaker: Maria Therese Ahlen, NO
Identification of Good Platelet Responders For Functional 09:46 - 09:51 Heparin Induced Thrombocytopenia Assays Speaker: Steve McKenzie, US
Summary and Roadmap 09:51 - 09:56 Speaker: Tamam Bakchoul, DE
Discussion V / Q&A Session V 09:56 - 10:00 Speaker: Tamam Bakchoul, DE
SSC Session 08:00 - 10:00 R3 Vascular Biology Introduction 08:00 - 08:01 Speaker: Johannes Thaler, AT
Moderators: Claudine Graf, Germany, Kimberly Martinod, 08:01 - 08:01 Belgium
An Update on the SSC Neutrophil Extracellular Trap (NETs) 08:01 - 08:13 Standardization Project Speaker: Kimberly Martinod, BE
Enzyme-Linked Immunoassay (ELISA) Detection of MPO-DNA 08:13 - 08:25 Complexes in Human Plasma Speaker: Christine Brostjan, AT
Establishment of a Flow Cytometric Panel for the 08:25 - 08:37 Characterization of Factor X Expressing Tumor Macrophages in Mice Speaker: Claudine Graf, DE
Q&A Session 08:37 - 08:42
3 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Moderators: Johannes Thaler, Austria, David Smadja, France, 08:42 - 08:42 Juan Melero-Martin, United States
Identification of Markers That Can Separate Procoagulant 08:42 - 08:54 Platelets From Apoptotic Platelets Speaker: Emma Josefsson, AU
Endothelial Cells and COVID-19: Marker or Active Partner 08:54 - 09:06 Speaker: David Smadja, FR
Endothelial Senescence in Chronic Lung Disease and Possible 09:06 - 09:18 Implications in Severe COVID-19: Studies on ECFC Speaker: Koralia Paschalaki, GB
Q&A Session 09:18 - 09:23
Moderator: Romaric Lacroix, France 09:23 - 09:23
ISEV-ISAC-ISTH EV Flow Cytometry Working Group Updates 09:23 - 09:33 Speaker: Joshua A. Welsh, US
Standardization of Extracellular Vesicle Concentration 09:33 - 09:43 Measurements - An Update on the METVES II Project Speaker: Britta A. Bettin, NL
Extracellular Vesicle-Tissue Factor Assays in COVID-19 Time 09:43 - 09:53 Speaker: Amandine Bonifay, FR
Q&A Session 09:53 - 10:00
SSC Session 08:00 - 10:00 R4 Lupus Anticoagulant/Antiphospholipid Antibodies Moderator: Katrien Devreese, Belgium, Hannah Cohen, United 08:00 - 08:00 Kingdom
Introduction 08:00 - 08:03 Speaker: Katrien Devreese, BE
Treatment of Antiphospholipid Antibody Syndrome 08:03 - 08:03
Registry on Augmented Antithrombotic Treatment Regimens for 08:03 - 08:13 Patients With Arterial Thrombotic Antiphospholipid Antibody Syndrome Speaker: Sam Schulman, CA
Current Treatments Practice in Women With Obstetric 08:13 - 08:18 Antiphospholipid Antibody Syndrome and Women With Obstetrical Morbidity and “Non-Criteria” Antiphospholipid Antibody Syndrome and Adverse Obstetrical Outcomes: Cora International Registry Speaker: Patricia Casais, AR
Current Treatments Practice in Women With Obstetric 08:18 - 08:23
4 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Antiphospholipid Antibody Syndrome and Women With Obstetrical Morbidity and “Non-Criteria” Antiphospholipid Antibody Syndrome and Adverse Obstetrical Outcomes: Cora International Registry Speaker: Cristina Belizna, FR
Survey on Diagnosis and Antithrombotic Treatment in 08:23 - 08:33 Antiphospholipid Antibody Syndrome Patients With Ischemic Stroke, Other Brain Ischemic Injury or Arterial Thromboembolism in Other Sites Speaker: Hannah Cohen, GB
Update on International Registry of Thrombotic 08:33 - 08:43 Antiphospholipid Antibody Syndrome Patients Treated With Direct Oral Anticoagulants Speaker: Stéphane Zuily, FR
Q&A Session on Registries On Treatment of Antiphospholipid 08:43 - 08:53 Antibody Syndrome
Laboratory Diagnosis of Antiphospholipid Antibody Syndrome 08:53 - 08:53
Why Antiphosphatidylserine/Prothrombin Antibodies and Other 08:53 - 09:05 Second Level Antiphospholipid Antibody Tests Should Be Added to Improve on the Definition of Antiphospholipid Antibody Syndrome Speaker: Vittorio Pengo, IT
An International, Multi-Centre Study to Validate the Taipan 09:05 - 09:17 Snake Venom Time as a Lupus Anticoagulant Screening Test With Ecarin Time as Confirmatory Test Speaker: Gary Moore, GB
Qualitative Classification of Anticardiolipin and Anti- 09:17 - 09:29 beta2glycoprotein I Antibodies Speaker: Katrien Devreese, BE
Q&A Session on Laboratory Diagnosis 09:29 - 09:37
Standardization of Thrombin Generation Assays 09:37 - 09:49 Speaker: Marisa Ninivaggi, NL
Update on the SKYLARK Project (Successive Follow up of 09:49 - 09:54 Antiphospholipid Antibodies Fluctuations in Patients With Clinical Sydney Criteria for Antiphospholipid Antibody Syndrome) and the Nymphea Project (Antiphospholipid Antibodies and Lymphoma) Speaker: Cristina Belizna, FR
Q&A Session and Closing Remarks 09:54 - 10:00
SSC Session 08:00 - 10:00 R5 Women’s Health in Thrombosis and Hemostasis
5 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Introduction/Outline of the Women’s SSC and Overview of 08:00 - 08:10 Activities Speaker: Maha Othman, CA
Update On On-going SSC Projects - Moderators: Ann Kinga Malinowski, Canada, Patricia Casais, Argentina
Physicians’ Knowledge and Practices of Management of 08:10 - 08:20 COVID-19 Coagulopathies in Pregnancy Speaker: Stefan D. Jevti, CA
Obstetrics and Gynecological Outcomes of Women with Platelet 08:20 - 08:30 Function Disorders Speaker: Deborah Obeng-Tuudah, GB
Women International TEAM (WiTEAM) Study on Placenta- 08:30 - 08:40 Mediated Pregnancy Complications and Thrombophilia Speaker: Mariola Ortin Marci, ES
COVID-19 and Pregnancy 08:40 - 08:50 Speaker: A. Kinga Malinowski, CA
COVID-19 Coagulopathies & Pregnancy - COV-PREG-COAG 08:50 - 09:00 Registry Speaker: Sajida Kazi, GB
Risks and Outcomes of Anticoagulation-Associated Abnormal 09:00 - 09:10 Menstrual Bleeding in Patients with Venous Thromboembolism (VTE) - The TEAM-VTE Study Speaker: Erik Klok, NL
Joint SSC Projects & New Guidance - Moderator: Elvira Grandone, Italy
ISTH Guidance on Diagnosis and Management of Severe 09:10 - 09:20 Congenital Protein C Deficiency - Joint SSCs Project Speaker: Adrian Minford, GB
Global Registry of Disseminated Intravascular Coagulation and 09:20 - 09:30 Pregnancy Speaker: Offer Erez, IL
New Initiatives/Topics For Discussion - Moderators: Maha Othman, Canada, Rezan Abdul-Kadir, United Kingdom
ISTH Common Data Elements in Postpartum Hemorrhage 09:30 - 09:50 Speaker: Maha Othman, CA
Women with Inherited Bleeding Disorders e-Learning 09:50 - 09:55 Programme Speaker: Rezan Abdul-Kadir, GB
Briefing and Announcements 09:55 - 10:00
6 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Maha Othman, CA
SSC Session 08:00 - 10:00 R6 Fibrinolysis Moderator: Paul Kim, Canada, Ze Zheng, United States -
Introduction 08:00 - 08:02 Speaker: Paul Y. Kim, CA
Tissue Plasminogen Activator for COVID-19 Acute Respiratory 08:02 - 08:12 Distress Syndrome Speaker: Ernest Moore, US
Update on SSC Project: The Assessment of Fibrinolytic 08:12 - 08:22 Resistance in Septic Patients Using the Rotem Velocity Curves of Clot Formation Speaker: Ecaterina Scarlatescu, RO
Q&A Session 08:22 - 08:32
The Basis and Application of Assays Measuring Fibrinolytic 08:32 - 08:42 Parameters Speaker: Ze Zheng, US
Application of Fibrinolytic Assays: Strengths and Limitations 08:42 - 08:52 Speaker: Tetsumei Urano, JP
Plasmin Generation Assays: Tailoring Experimental Design 08:52 - 09:02 Speaker: Alisa S. Wolberg, US
Q&A Session 09:02 - 09:17
Euglobulin Lysis Assay Standardization: Project Proposal 09:17 - 09:27 Speaker: Anton Ilich, US
Standardization of a Functional Soluble Thrombomodulin 09:27 - 09:37 Assay: Project Proposal Speaker: Michael Boffa, CA
NIBSC Standards Updates: D-dimer, PAI-1 and TAFI 09:37 - 09:47 Speaker: Colin Longstaff, GB
Q&A Session / Conclusion 09:47 - 10:00
SSC Session 08:00 - 10:00 R7 Predictive and Diagnostic Variables in Thrombotic Disease Moderator: John-Bjarne Hansen, Norway, Camila Masias, United - States
Welcome 08:00 - 08:05 Speaker: John-Bjarne Hansen, NO
7 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Diagnostic Standards for Pulmonary Embolism and Deep Vein 08:05 - 08:20 Thrombosis in Cancer Patients Speaker: Kerstin de Wit, CA
Venous Thromboembolism in Stroke – an Update on Risk 08:20 - 08:30 Factors and Future Steps Speaker: Vania Morelli, NO
Standardization of Assessment of Bleeding Risk During 08:30 - 08:45 Anticoagulant Treatment for Venous Thromboembolism Speaker: Erik Klok, NL
International Consortium for Health Outcomes Measurement in 08:45 - 08:55 VTE: ICHOM-VTE Speaker: Cindy de Jong, NL
Establishing an International Core Outcome Set for Clinical 08:55 - 09:05 Trials of Interventions for Venous Thromboembolism – The VTE- COS Project Speaker: Helia Robert-Ebadi, CH
Biomarkers Predicative of Venous Thromboembolism in 09:05 - 09:20 Patients With COVID-19 Speaker: Scott Woller, US
Q&A Session 09:20 - 09:30
Polls 09:30 - 09:55
Conclusion 09:55 - 10:00 Speaker: John-Bjarne Hansen, NO
Nurses Forum 08:00 - 10:00 R8 NUF 01 - Nurses Forum Moderator: James E. Munn, US Moderator: Sulochana Badagabettu, IN NUF 01.1 New Anticoagulant Starts: What Every Patient Needs to Know 08:00 - 08:30 Speaker: Daryl Pollock, NZ
NUF 01.2 The Challenge of Inherited Platelet Disorders 08:30 - 09:00 Speaker: Penny McCarthy, AU
NUF 01.3 Emerging Novel Therapies: The Ever Evolving Role of the 09:00 - 09:30 Hemophilia Nurse Speaker: Stephen John Matthews, AU
NUR 01.1 An Exploration of Venous Thromboembolism (VTE) Prophylaxis 09:30 - 09:45 Administration Practices across a Hospital Network Speaker: Julianne Chong, AU
NUR 01.2 COVID-19 and its Impact on the Pediatric Bleeding Disorders 09:45 - 10:00 Population: Soaring BMIs Speaker: Vanessa Bouskill, CA
8 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Coffee Break 10:00 - 10:30 R1 Coffee Break
SSC Session 10:30 - 12:30 R1 Von Willebrand Factor Moderator: Ross Baker, Australia 10:30 - 10:30
Welcome and Brief Introduction to Von Willebrand Factor SSC 10:30 - 10:32 2021 Speaker: Ross Baker, AU
Moderators: Peter Kouides, United States, Michelle Lavin, 10:32 - 10:32 Ireland
The Von Willebrand Disease 2021 Guidelines: Clarity and 10:32 - 10:47 Controversy Speaker: Michael Makris, GB
Beyond Von Willebrand Disease - Bleeding Disorder of 10:47 - 10:59 Unknown Cause Speaker: Will Thomas, GB
Pathogenesis of Microthrombi in SARS-CoV2 Infection: Role of 10:59 - 11:11 Von Willebrand Factor and ADAMTS-13 Speaker: Annabelle Dupont, FR
Collaborative Study of the WHO von Willebrand Factor 11:11 - 11:20 Concentrate Speaker: Craig Thelwell, GB
Q&A Session 11:20 - 11:30
Moderators: Renhao Li, United States, Ross Baker, Australia 11:30 - 11:30
Towards a Unifying Activation Mechanism of Von Willebrand 11:30 - 11:42 Factor Speaker: Renhao Li, US
ADAMTS13 Auto-Antibody Binding 11:42 - 11:54 Speaker: Karen Vanhoorelbeke, BE
New Treatment Options for VWD 11:54 - 12:06 Speaker: Caterina Casari, FR
Project Updates: Von Willebrand Factor Nomenclature 12:06 - 12:10 Speaker: Sandra Haberichter, US
Project Updates: Post Partum Hemorrhage 12:10 - 12:14 Speaker: Peter Kouides, US
Project Updates: IMATAS (International Microangiopathic 12:14 - 12:18 Thrombocytopenia ADAMTS13 Standardisation) Collaborative Study
9 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Ross Baker, AU
Q&A Session 12:18 - 12:28
Closing Remarks 12:28 - 12:30 Speaker: Ross Baker, AU
SSC Session 10:30 - 12:30 R2 Pediatric/Neonatal Thrombosis and Hemostasis Moderator: Neil Goldenberg, United States, Courtney - Thornburg, United States
Introduction / Pediatric SSC Overview 10:30 - 10:35 Speaker: Neil A. Goldenberg, US
Update From Antithrombotic Trials Task Force 10:35 - 10:45 Speaker: Christoph Male, AT
Update From Arterial Thromboembolism Working Group 10:45 - 11:00 Speaker: Mattia Rizzi, CH
Update From the Emerging Hemostasis Working Group 11:05 - 11:15 Speaker: Nongnuch Sirachainan, TH
Update From Medication Adherence Working Group 11:15 - 11:30 Speaker: Lori Luchtman-Jones, US
Update From Post-Thrombotic Sequelae Working Group 11:30 - 11:45 Speaker: Ayesha Zia, US
Update From Pulmonary Embolism Working Group 11:45 - 12:00 Speaker: Madhvi Rajupurkar, US
Update From Venous Thromboembolism Risk Factors and 12:00 - 12:15 Thromboprophylaxis Working Group Speaker: Leslie Raffini, US
Update From the Emerging Working Group on ExtraCorporeal 12:15 - 12:25 Life Support/Ventricular Assist Device Speaker: Meera Chitlur, US
Closing Remarks / Conclusion 12:25 - 12:30 Speaker: Neil A. Goldenberg, US
SSC Session 10:30 - 12:30 R3 Perioperative and Critical Care in Thrombosis and Hemostasis Coagulation and Anticoagulation in Critical Care and - Perioperative Settings: COVID-19 and Beyond Moderators: Jerrold Levy, United States, Jean Marie Connors, United States
10 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Introduction and Current Projects 10:30 - 10:40 Speaker: Jerrold Levy, US
New Insights for Venous Thromboembolism Prevention and 10:40 - 11:00 Treatment in COVID-19 Critically-Ill Speaker: Alex Spyropoulos, US
COVID-19 Coagulopathy in Critically-Ill Patients: Is There a Role 11:00 - 11:15 for Viscoelastic Testing, Endogenous Thrombin Generation, or Other Biomarkers? Speaker: Julie Helms, FR
Heparin Resistance: Definitions, Clinical Considerations, and 11:15 - 11:30 Alternative Strategies Speaker: Jerrold Levy, US
Perioperative DOAC Management in Elective and Urgent 11:30 - 11:50 Settings: How Will Recent and Emerging Studies Inform Best Practices and Guidelines? Speaker: James Douketis, CA
Perioperative Bleeding: Clinical Importance, and Are There 11:50 - 12:05 Standardized Definitions to Harmonize Future Research? Speaker: Marie Steiner, US
Perioperative Bleeding: Platelet Transfusions and Alternatives 12:05 - 12:20 Speaker: Thomas Thiele, DE
Q&A Session / Discussion 12:20 - 12:30
SSC Session 10:30 - 12:30 R4 Factor XIII and Fibrinogen Moderators: Sanj Raut, United Kingdom, Verena Schroeder, 10:30 - 10:30 Switzerland
Introduction 10:30 - 10:32 Speaker: Sanj Raut, GB
Standardization Topics 10:32 - 10:32
Establishment of the WHO 3rd International Standard for 10:32 - 10:36 Thrombin (19/188) Speaker: Sanj Raut, GB
Proposed WHO 2nd International Standard for Factor XIII, 10:36 - 10:44 Plasma (Replacement Standard) Speaker: Andrew Riches, GB
Standardisation of Scanning Electron Microscope Image 10:44 - 10:54 Analysis of Fibrin Clots - SSC Project Speaker: Marlien Pieters, ZA
Q&A Session 10:54 - 11:04
11 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Moderators: Sanj Raut, United Kingdom, Alessandro Casini, 11:04 - 11:04 Switzerland Scientific & Clinical Topics
Bleeding of Unknown Cause - Evidence for Impairment of the 11:04 - 11:14 Hemostatic Potential
Automated Measurement of Fibrin Fiber Diameters in Images 11:14 - 11:24 Obtained Using Fluorescence Microscopy Speaker: Judith de Vries, NL
Automated Fiber Diameter and Porosity Measurements of Fibrin 11:24 - 11:34 Clots in Scanning Electron Microscopy Images Speaker: Martin Guthold, US
M1 Protein From Group a Streptococcus Impacts Fibrin Clot 11:34 - 11:44 Formation, Structure and Fibrinolytic Potential Speaker: Sophie Cherrington, GB
Clinical Features in Afibrinogenemia: Insights From the 11:44 - 11:54 QualyAFIB Study Speaker: Alessandro Casini, CH
Comprehensive Evaluation of Coagulation and Fibrinolysis 11:54 - 11:59 Parameters in Patients With Congenital Factor XIII Deficiency in Pakistan - an Introduction and Outline of the SSC Project Speaker: Munira Borhany, PK
Q&A Session / Conclusion and Closing Remarks 11:59 - 12:25
SSC Session 10:30 - 12:30 R5 Hemostasis & Malignancy Moderators: Anna Falanga, Italy, Anthony Maraveyas, United - Kingdom Speaker: Anna Falanga, IT
Introduction 10:30 - 10:33 Speaker: Jeffrey Zwicker, US
Overview: The Unknowns of Direct Oral Anticoagulants in 10:33 - 10:41 Cancer Associated Thrombosis Speaker: Fionnuala Ni Ainle, IE
ISTH SSC Supported Project: Registry on Concurrent Direct 10:41 - 10:51 Oral Anticoagulants and Targeted Cancer Therapies Speaker: Tzu-Fei Wang, CA
Overview: Strengths and Limitations of Khorana Score 10:51 - 10:59 Speaker: Alok A. Khorana, US
ISTH SSC Communication: Developing and Validating Risk 10:59 - 11:09 Assessment Scores in Cancer Associated Thrombosis Speaker: Kristen M. Sanfilippo, US
12 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Overview: Anticoagulation in Brain Tumors 11:09 - 11:17 Speaker: Jeffrey Zwicker, US
ISTH Supported Project: Anticoagulation Brain Cancer (ABC) 11:17 - 11:22 Registry for Anticoagulation and Brain Tumors Speaker: Avi Leader, IL
ISTH Supported Project: Anticoagulation Brain Cancer (ABC) 11:22 - 11:27 Registry for Anticoagulation and Brain Tumors Speaker: Eva Hamulyak, NL
Overview: Managing Recurrent Venous Thromboembolism on 11:27 - 11:35 Anticoagulation Speaker: Agnes Y.Y. Lee, CA
ISTH Supported Project: Recurrent Venous Thromboembolism 11:35 - 11:45 During Anticoagulation Speaker: Floris Bosch, NL
How to Utilize ISTH Common Data Elements in Cancer 11:45 - 11:53 Associated Thrombosis Studies Speaker: Grégoire Le Gal, CA
Treatment of Chemotherapy-Induced Thrombocytopenia with 11:53 - 12:01 TPO Receptor Agonists Speaker: Gerald Soff, US
In Remembrance of Guy Meyer 12:01 - 12:07 Speaker: Isabelle Mahe, FR
Q&A Session / Conclusion 12:07 - 12:30
SSC Session 10:30 - 12:30 R6 Biorheology Introduction 10:30 - 10:33 Speaker: David Bark, US
Thrombus Formation on Artificial Surfaces 10:33 - 10:33 Moderator: David Bark, United States
Valve Thrombosis in Trans-Catheter Aortic Valves: Influence of 10:33 - 10:53 Patient Anatomy Speaker: Lakshmi Prasad Dasi, US
Thrombosis on Artificial Materials: Extracorporeal Circuits and 10:53 - 11:13 Beyond Speaker: Anna Waterhouse, AU
Thrombosis in Mechanical Circulatory Support 11:13 - 11:33 Speaker: Sophie Susen, FR
Minimizing Thrombus Formation in a Novel Polymeric TAVR 11:33 - 11:53 Valve and Modeling Thrombus Initiation Across the Scales
13 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Danny Bluestein, US
Thrombosis Related to Artificial Valves 11:53 - 12:13 Speaker: Cécile Oury, BE
Q&A Session / Conclusion 12:13 - 12:30
SSC Session 10:30 - 12:30 R7 Plasma Coagulation Inhibitors Moderator: Jun Teruya, United States 10:30 - 10:30
Welcome/Introduction 10:30 - 10:35 Speaker: Jun Teruya, US
In Memory of Professor Elizabeth Van Cott 10:35 - 10:45 Speaker: Jun Teruya, US
Antithrombin 10:45 - 10:45
Antithrombin Deficiency Registry, an Update 10:45 - 10:55 Speaker: Zsuzsanna Bereczky, HU
Beta Antithrombin – Measurement and Clinical Significance 10:55 - 11:08 Speaker: Javier Corral, ES
Tissue Factor Pathway Inhibitor 11:08 - 11:08
Tissue Factor Pathway Inhibitor in Bleeding Disorders 11:08 - 11:21 Speaker: Alan E. Mast, US
Protein C System 11:21 - 11:21
Developmental Changes in the Protein C Structure 11:21 - 11:34 Speaker: Vera Ignjatovic, AU
Non-Factor V Leiden Activated Protein C Resistance 11:34 - 11:47 Speaker: Gary Moore, GB
Which Test to Choose: Activated Protein C Resistance First or 11:47 - 11:55 Factor V Leiden Directly? Speaker: Jun Teruya, US
Updates on Using Recombinant Thrombomodulin for 11:55 - 12:08 Disseminated Intravascular Coagulation Speaker: Eriko Morihsita, JP
Q&A Session / Conclusion 12:08 - 12:30
Nurses Forum 10:30 - 12:30 R8 NUF 02 - Nurses Forum Moderator: José Miguel Rivera Caravaca, ES Moderator: Regina B. Butler, US
14 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
NUF 02.1 Prevention of Injuries Among Children With Hemophilia and 10:30 - 11:00 Other Bleeding Disorders Speaker: Francis Mkwenembera, MW
NUF 02.2 Cancer Associated Thrombosis 11:00 - 11:30 Speaker: Annie Young, GB
NUF 02.3 COVID-19 and Thrombosis 11:30 - 12:00 Speaker: José Miguel Rivera Caravaca, ES
NUF 02.4 Antithrombotic Therapy: A Focus on Psychosocial Impact 12:00 - 12:30 Speaker: Deirdre A. Lane, GB
SSC Session 10:30 - 11:30 R9 Platelet Immunology and VITT Introduction 10:30 - 10:31 Speaker: Tamam Bakchoul, DE
Report on First Description of VITT 10:31 - 10:36 Speaker: Maria Therese Ahlen, NO
The Performance of Immunoassays in VITT 10:36 - 10:41 Speaker: Ulrich J. Sachs, DE
Results of the First EQA 10:41 - 10:46 Speaker: Christopher Reilly-Sitt, GB
Discussion/Q&A 10:46 - 11:01
Functional Assays 11:01 - 11:06 Speaker: Karina Althaus, DE
Antibody Epitopes in Vaccine-Induced Immune Thrombotic 11:06 - 11:11 Thrombocytopenia Speaker: Ishac Nazy, CA
SSC VITT and VIITP Registry 11:11 - 11:16 Speaker: Philip Choi, AU
Discussion/Q&A 11:16 - 11:30
Lunch, Industry Exhibits and Poster Viewing 12:30 - 13:30 R1 Lunch
SSC Session 13:30 - 15:30 R1 Control of Anticoagulation Moderator: Adam Cuker, United States 13:30 - 13:30
Introduction 13:30 - 13:32
15 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Adam Cuker, US
Unusual Site Thrombosis 13:32 - 13:32
International Registry on the Diagnosis and Treatment of 13:32 - 13:42 Inferior Vena Cava Thrombosis Speaker: Omri Cohen, IT
International Registry on the Use of the Direct Oral 13:42 - 13:52 Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism Speaker: Nicoletta Riva, MT
Laboratory Measurement of Anticoagulants 13:52 - 13:52
Toward a Universal Anti-Xa Assay 13:52 - 14:02 Speaker: Ravi Sarode, US
First 5 Years of New Oral Anticoagulant Analyses at Karolinska 14:02 - 14:12 University Laboratory – a Study of Patients With High and Low Drug Concentrations at a Tertiary Care Center Speaker: Henrik von Horn, SE Speaker: Karolina Nowinski, SE
Antithrombotic Therapy-Associated Bleeding 14:12 - 14:12
Management of Antithrombotic Therapy After Gastrointestinal 14:12 - 14:22 Bleeding: A Mixed Methods Study of Healthcare Providers Speaker: Deborah Siegal, CA
Bleeding and Thrombotic Events After Resumption of Oral 14:22 - 14:32 Anticoagulants Following Gastrointestinal Bleeding Speaker: Marcello di Nisio, IT
SSC Communications and Guidance 14:32 - 14:32
Standardization of the Definition of Clinical Outcome for 14:32 - 14:42 Patients Treated for a Major Oral Anticoagulant Related Bleed Speaker: Nakisa Khorsand, NL
Use of Direct Oral Anticoagulants in Obese Patients With 14:42 - 14:52 Venous Thromboembolism Updated Guidance From the SSC on Control of Anticoagulation Speaker: Karlyn Martin, US
Q&A Session / Conclusion 14:52 - 15:30
SSC Session 13:30 - 15:30 R2 Platelet Physiology Moderators: Herve Falet, United States, Marie Lordkipanidzé, 13:30 - 13:30 Canada
Welcoming Remarks and Introduction 13:30 - 13:31
16 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Marie Lordkipanidzé, CA
Overview of Platelet Physiology SSC and Projects 13:31 - 13:40 Speaker: Marie Lordkipanidzé, CA
Evaluation of the Isth Bleeding Assessment Tool (BAT) for the 13:40 - 13:55 Assessment of Inherited Platelet Disorders: Individual-Level Meta-Analysis Speaker: Paolo Gresele, IT
Biomarkers of in Vivo Platelet Activation ? a Systematic Review 13:55 - 14:03 and Meta-Analysis Speaker: Marina Camera, IT
Biomarkers of in Vivo Platelet Activation ? a Systematic Review 14:03 - 14:10 and Meta-Analysis Speaker: Sofia Ramstrom, SE
A Multicentric Comparison of Platelet Aggregation Agonists 14:10 - 14:25 Against NIBSC Standards: An Update Speaker: Marie Christine Alessi, FR
Q&A Session 14:25 - 14:35
Standardizing Platelet Transcriptomics for Discovery, 14:35 - 14:50 Diagnostics, and Therapeutics in the Thrombosis and Hemostasis Community ? the STRIDE Study: An Update Speaker: Matthew Rondina, US
Platelet Function Testing in Patients with Low Platelet Counts 14:50 - 15:00 Speaker: Sofia Ramstrom, SE Speaker: Georges Jourdi, CA
New Project: Standardization of Nomenclature of Platelet Type- 15:05 - 15:15 Von Willebrand Disease Speaker: Maha Othman, CA Speaker: Paolo Gresele, IT
Q&A Session 15:15 - 15:25
Concluding Remarks 15:25 - 15:30 Speaker: Marie Lordkipanidzé, CA
SSC Session 13:30 - 15:30 R3 Factor XI and the Contact System Moderator: Coen Maas, the Netherlands 13:30 - 13:30
Introduction 13:30 - 13:32 Speaker: Coen Maas, NL
FXII Zymogen Contact Activation 13:32 - 13:42 Speaker: Marco Heestermans, DE
The Activated Partial Thromboplastin Time 2.0 13:42 - 13:52
17 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Thomas Renné, DE
Prevalence of Prekallikrein and High Molecular Weight 13:52 - 14:02 Kininogen Deficiency Speaker: Anke Adenauer, DE
Plasma Prekallikrein as Coagulation Factor 14:02 - 14:12 Speaker: Nigel Key, US
Plasma Prekallikrein as Coagulation Factor 14:12 - 14:22 Speaker: Helen Phillippou, GB
Assignment of FXII to SSC Lot #5 Plasma 14:22 - 14:32 Speaker: Helen Wilmot, GB
Therapeutic Contact System Inhibitors for Sepsis 14:32 - 14:42 Speaker: Florea Lupu, US
Cyclic Peptide FXII Inhibitor Provides Safe Anticoagulation in a 14:42 - 14:52 Thrombosis Model and in Artificial Lungs Speaker: Bjoern Burckhardt, DE
Q&A Session / Conclusion 15:12 - 15:40
SSC Session 13:30 - 15:30 R4 Genomics in Thrombosis and Hemostasis Moderator: Kathleen Freson, Belgium -
Introduction and Gene Curation Update 13:30 - 13:35 Speaker: Kathleen Freson, BE
GoldVariant Database 13:35 - 13:50 Speaker: Karyn Megy, GB
Variant Curation for Clinical Practice 13:50 - 14:00 Speaker: Shruthi Mohan, US
Variant Curation for Clinical Practice 14:00 - 14:10 Speaker: Justyne Ross, US
Diagnostic Strategy to Search for Rare Inherited Thrombophilia 14:10 - 14:20 in Clinical Setting Speaker: Bengt Zöller, SE
Human Mutational Constraint as a Tool to Understand Variants 14:20 - 14:30 in Platelet-Associated Genes Speaker: Joe (Joseph) Oved, US
VarioPath: Leveraging UK Biobank Data to Advance Variant 14:30 - 14:40 Pathogenicity Interpretation Speaker: Janine Collins, GB
Thrombosis Genetics at Scale: Lessons from Electronic Health 14:40 - 14:50 Record Biobanks
18 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Scott M. Damrauer, US
A Genome-Wide Association Study Meta-Analysis for Venous 14:50 - 15:00 Thromboembolism Speaker: Florian Thibord, US
Discussion / Conclusion 15:00 - 15:30
SSC Session 13:30 - 15:30 R5 SSC Working Group on Hemostatic Management of Patients with Liver Disease Moderator: Ton Lisman, the Netherlands -
Introduction/Goals of the Working Group 13:30 - 13:40 Speaker: Ton Lisman, NL
Rebalanced Hemostasis in Liver Disease 13:40 - 13:55 Speaker: Armando Tripodi, IT
What Is the Current State of Trial Evidence for Alternatives to 13:55 - 14:10 Plasma Speaker: Simon Stanworth, GB
Guidance on Prophylactic Prohemostatic Therapy in Patients 14:10 - 14:25 With Cirrhosis Speaker: Lara Roberts, GB
Risk Factors for Cirrhotic Portal Vein Thrombosis 14:25 - 14:40 Speaker: Virginia Hernandez-Gea, ES
Composition of the Portal Vein Thrombus 14:40 - 14:50 Speaker: Ton Lisman, NL
Animal Models of Hemostasis in Liver Disease - What Have We 14:50 - 15:05 Learned? Speaker: Jim Luyendyk, US
General Discussion 15:05 - 15:20
Discussion: Future Activities of the Working Group / 15:20 - 15:30 Conclusion
SSC Session 13:30 - 15:30 R6 Disseminated Intravascular Coagulation Moderator: Toshiaki Iba, Japan 13:30 - 13:30
Introduction 13:30 - 13:32 Speaker: Toshiaki Iba, JP
Sepsis 13:32 - 13:32
Inhibition of Contact Activation in a Baboon Model of Sepsis 13:32 - 13:44
19 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Disseminated Intravascular Coagulation Speaker: Florea Lupu, US
Novel Biomarkers of Sepsis and Disseminated Intravascular 13:44 - 14:01 Coagulation Speaker: Patricia Liaw, CA
The Management of Disseminated Intravascular Coagulation in 14:01 - 14:18 Japanese Sepsis Guidelines 2020 Speaker: Yutaka Umemura, JP
COVID-19 14:18 - 14:18
Fibrinolytic Therapy for COVID-19 14:18 - 14:35 Speaker: Hunter Moore, US
Disseminated Intravascular Coagulation 14:35 - 14:35
Disseminated Intravascular Coagulation in Patients With 14:35 - 14:52 Cirrhosis - Need for Better Diagnostic Tools Speaker: Ecaterina Scarlatescu, RO
Heparin Induced 14:52 - 14:52
Disseminated Intravascular Coagulation and NETosis in Heparin 14:52 - 15:09 Induced Thrombocytopenia Speaker: Beng H. Chong, AU
Disseminated Intravascular Coagulation 15:09 - 15:09
Disseminated Intravascular Coagulation of Vaccine-Induced 15:09 - 15:26 Thrombotic Thrombocytopenia Speaker: Theodore (Ted) E. Warkentin, CA
Q&A Session / Conclusion 15:26 - 15:30
SSC Session 13:30 - 15:30 R7 Models of Thrombosis and Hemostasis Introduction 13:30 - 13:32 Speaker: Laura Gutierrez,
Moderators: Laura Gutierrez, Spain, Peter Gross, Canada, 13:32 - 13:32 Beatrice Hechler, France
In Vivo Imaging of Venous Thrombus and Pulmonary Embolism 13:32 - 13:47 Using Novel Murine Venous Thromboembolism Model Speaker: Tetsuya Hara, JP
Preclinical Models of Transfusion-Related Acute Lung Injury 13:47 - 14:02 Speaker: Rick Kapur, NL
Preclinical Models of Platelet Allo-Immunization / Refractoriness 14:02 - 14:17 Speaker: Jacqueline Poston, US
20 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Bleeding in Hypermobile Ehlers?Danlos Syndrome: Demand for 14:17 - 14:32 Diagnostic and Prognostic Test Models for Bleeding Speaker: Rohith Jesudas, US
Q&A Session 14:32 - 14:40
Joint Session: Platelet Physiology and Diagnosis Markers SSCs 14:40 - 14:40 Moderators: Margarethe Geiger, Austria, John-Bjarne Hansen, Norway
State-of-the-Art Advances and Cautionary Insights in 14:40 - 15:00 Proteomics and Systems Biology Studies of Platelet Phenotype and Function Speaker: Joseph Aslan, US
Roundtable: Relevance of Platelet/Beyond Platelet Proteomics 15:00 - 15:20 and the Challenges Young Researchers Encounter, Patricia Maguire, Ángel García, Johan Heemskerk, Patricia Martínez- Botía
Q&A Session / Conclusion 15:20 - 15:30
Nurses Forum 13:30 - 15:30 R8 NUF 03 - Nurses Forum Moderator: Anne-Louise Cruickshank, ZA Moderator: Maura Malone, US NUF 03.1 Rare Bleeding Disorders: Discrepancies in Genotype Phenotype 13:30 - 14:00 Clinical Presentations Speaker: Chris Guelcher, US
NUR 01.3 Improving Post-Thrombotic Syndrome (PTS) Care in Children: A 14:00 - 14:15 Child’s Voice Speaker: Jennifer Vincelli, CA
NUR 01.4 The DATCH Project: Developmentally Appropriate Tools for C 14:15 - 14:30 hildren with Hemophilia to Help Them Better Understand Their Disease Speaker: Casey L Li, CA
NUR 01.5 Managing Outpatients on Vitamin K Antagonists (VKAs) during 14:30 - 14:45 the COVID-19 Pandemic in a Tertiary Referral Hospital Speaker: Catriona O'Leary, IE
NUR 01.6 Anticoagulation Stewardship - Time To Formalize the Role? 14:45 - 15:00 Speaker: Virginia Silvari, IE
NUR 01.7 Direct Oral Anticoagulants after Bariatric Surgery: A Quality 15:00 - 15:15 Improvement Project Speaker: Julia Bayadinova, CA
21 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Break 15:30 - 15:45 R1 Break
Plenary Session 15:45 - 16:45 R1 PL 01 - Opening Ceremony and Judith Graham Pool Memorial Plenary Lecture - Gene Therapy in Hemophilia: Will There be a New Era in Hemophilia Treatment? Moderator: Lindsey A. George, US PL 01.1 Gene Therapy in Hemophilia: Will There be a New Era in 15:45 - 16:15 Hemophilia Treatment? Speaker: Katherine A. High, US
Poster Networking Session 16:00 - 17:00 R3 ePosters LPB0001 Impact of Heparin Induced Thrombocytopenia on the Outcomes 16:00 - 16:00 of Hospitalizations for Acute Myocardial Infarction: Analysis of National Inpatient Sample Speaker: Muhammad Usman Almani, US
PB0001 High Concentration of Symmetric Dimethylarginine is 16:00 - 16:00 Associated with Low Platelet Reactivity and Increased Bleeding Risk in Patients with Acute Coronary Syndrome Speaker: Ceren Eyileten, PL
PB0002 A Machine-learning-Based Bio-psycho-Social Model for the 16:00 - 16:00 Prediction of Non-obstructive and Obstructive Coronary Artery Disease Speaker: Lucia Stefanini, IT
PB0003 A Coupled 1D-3D Hybrid Model for Patient-specific Coronary 16:00 - 16:00 Flow Simulations: Bridging the Gap between Macroscale Hemodynamics and Microscale Thrombosis Models Speaker: Noelia Grande Gutierrez, US
PB0004 Comparison of Platelet Function Tests during P2Y12 Inhibition 16:00 - 16:00 Speaker: Patricia Pia Wadowski, AT
PB0005 A Rare Presentation of ST-segment Elevation Myocardial 16:00 - 16:00 Infarction Associated with Ovarian Stimulation in the Absence of Ovarian Hyperstimulation Syndrome Speaker: Keun Young Kim, US
PB0006 Flowcytometric Assay of Platelet-derived Microparticles and the 16:00 - 16:00 Dual Anti-platelet Therapy in Egyptian Patients with Ischemic Heart Disease, a Promising Indicator Speaker: Nermeen Farouqe, EG
LPB0048 Association between Plaque Vulnerability and Neutrophil 16:00 - 16:00 Extracellular Traps (NETs) Levels: The Plaque at RISK Study Speaker: Judith de Vries, NL
22 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0096 Development of a 3D Tissue-engineered Neointimal Model as an 16:00 - 16:00 Alternative to Animal Models of Human Atherosclerosis Speaker: Jassim Echrish, GB
LPB0097 Role of Low-dose Aspirin on the Release of Circulating 16:00 - 16:00 Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes Speaker: Paola Simeone, IT
PB0007 The Role of TEC Family Kinases in oxLDL-mediated Platelet 16:00 - 16:00 Activity in vitro and Platelet and Endothelial Dysfunction in vivo Speaker: Tia Kohs, US
PB0008 Tissue Inhibitor of Metalloproteinases-1 (TIMP1) is Related to 16:00 - 16:00 Residual Thromboxane Dependent Platelet Activation in Patients with Type 2 Diabetes Mellitus Receiving Low Dose Aspirin Speaker: Paola Simeone, IT
PB0009 Combined Focused Ultrasound and Electrohydraulic Shock 16:00 - 16:00 Wave Thrombolytic Therapy Accompanied by Tissue Plasminogen Activator Administration Reduce Thrombus Content in the Arterial Atherothrombotic Stenosis Speaker: Hossein Mehrad, IR
PB0010 Investigation of Red Blood Cells Influence on Atherosclerotic 16:00 - 16:00 Plaque by Scanning Flow Cytometry Speaker: Ekaterina Yastrebova, RU
LPB0049 Cardiovascular Outcomes in Patients with Essential 16:00 - 16:00 Thrombocythemia: Analysis of the National Inpatient Sample (NIS) Speaker: Guillermo Tafur, US
LPB0050 History of Cancer is Associated with Increased Platelet Activity 16:00 - 16:00 and Atherothrombosis in Patients with Peripheral Artery Disease Speaker: Lucas Cofer, US
LPB0098 A Simple Score to Evaluate Bleeding Risk in Medical Patients 16:00 - 16:00 Taking Antiplatelets for Cardiovascular Prevention Speaker: Sofia Barbar, IT
PB0011 Platelet-derived Let-7e is an Independent Predictor of Long-term 16:00 - 16:00 All-cause Mortality in Patients with Type 2 Diabetes Mellitus Speaker: Ceren Eyileten, PL
PB0012 Prognostic Significance of von Willebrand Factor in Flow- 16:00 - 16:00 mediated Dilatation Test at Patients with Arterial Hypertension and Diabetes Type 2 Speaker: Eugene Shorikov, UA
PB0013 The Coagulation and Fibrinolisys Changes Undergoing the 16:00 - 16:00 Ramipril and Losartan Treatment of Concomitant Arterial Hypertension and Diabetes Mellitus Type 2
23 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Eugene Shorikov, UA
LPB0002 Safety and Pharmacokinetics of Direct Oral Anticoagulants after 16:00 - 16:00 Bariatric Surgery: A Systematic Review Speaker: Russell Leong, CA
LPB0003 Persistence Pattern to Oral Anticoagulants among Non-valvular 16:00 - 16:00 Atrial Fibrillation Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants: A Cohort Study Speaker: Myrthe M.A. Toorop, NL
LPB0004 Safety and Efficacy of Using Direct Oral Anticoagulants for 16:00 - 16:00 Stroke Prevention in Atrial Fibrillation Patients with Pre-obesity and Obesity Speaker: Qingui Chen, NL
LPB0051 ACTIMIS Trial: Safety Interim Analysis Data of Glenzocimab, a 16:00 - 16:00 Novel Antiplatelet Agent on Top of Acute Ischemic Stroke Standard of Care Speaker: Andrea Comenducci, FR
PB0014 Natural Changes in CHA2DS2-VASc Scores in Newly Diagnosed 16:00 - 16:00 Non-valvular Atrial Fibrillation Patients with Low Stroke Risk Speaker: Qingui Chen, NL
PB0015 Is Microvessel Perfusion Associated with Platelets in Acute 16:00 - 16:00 Cerebrovascular Disorders? Speaker: Patricia Pia Wadowski, AT
PB0016 “Red Cardiac versus White Atherosclerotic Thromboemboli in 16:00 - 16:00 Acute Ischemic Stroke”: Challenging the Concept via a Large- scale, Detailed Multi-parametric Histological Analysis Speaker: Senna Staessens, BE
PB0017 Soluble P-selectin is Associated with Increased Risk of 16:00 - 16:00 Ischemic Stroke in Patients with Atrial Fibrillation on Hemodialysis: Results from the VIVALDI Study Speaker: Oliver Koenigsbruegge, AT
PB0018 Evaluation of the Need for Cytoreduction and its Potential 16:00 - 16:00 Carcinogenicity in Children and Young Adults with Myeloproliferative Neoplasms Speaker: Hyoung Soo Choi, KR
PB0019 Long-term Outcome of Percutaneous or Surgical 16:00 - 16:00 revascularization with and without Prior Stroke in patients with Three-vessel Disease Speaker: Na Xu, CN
PB0020 Single Centre Retrospective Chart Review to Examine the 16:00 - 16:00 Management of Timing of Anticoagulation and Outcomes in Patients with Cerebral Venous Sinus Thrombosis Speaker: Gloria Mak, CA
PB0021 Platelet-derived microRNAs Are Increased after Transcatheter 16:00 - 16:00 Aortic Valve Implantation and May Predict Adverse Outcomes in
24 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Patients with Heart Failure Speaker: Ceren Eyileten, PL
PB0022 Role of the Interaction between Thrombophilia and Other Risk 16:00 - 16:00 Factors in the Occurring of Ischemic Stroke in Young Patients: Algerian Restrospective Study about 75 Cases Speaker: Mohamed EL HORRI, DZ
PB0023 Photodynamic Therapy with 5- Aminolevulinic Acid and B-mode 16:00 - 16:00 Ultrasound-guided Catheter-based Low-level Red Laser Results in Cerebrovascular Neointimal Hyperplasia Regression Speaker: Hossein Mehrad, IR
PB0024 miR-19a-3p Predicts Stroke Severity and miR-186-5p Might Be a 16:00 - 16:00 Diagnostic Biomarker in Ischemic Stroke Patients with Hyper Platelet Reactivity Speaker: Ceren Eyileten, PL
PB0025 Characterisation of Patients with Peripheral Artery Disease at 16:00 - 16:00 Increased Risk for Cardiovascular Events and Mortality Speaker: Bram Kremers, NL
PB0026 Leo Buerger's Disease: About 13 Cases 16:00 - 16:00 Speaker: Imen chabchoub, TN
PB0027 Changes in Vascular Physiology in Patients with End Stage 16:00 - 16:00 Renal Disease Compared to Patients with ESRD and Concomitant Cardiovascular Disease Speaker: Jake Goldstein, US
LPB0005 Tissue-engineered Human Arteries Replicate Primary and 16:00 - 16:00 Secondary Haemostatic Functions Seen in vivo: A Replacement for Mouse Arterial Thrombosis Models? Speaker: Jacob Ranjbar, GB
LPB0099 Absence of CCR5/CCL5 Axis Inhibits Thrombus Resolution 16:00 - 16:00 through Reduced uPA, tPA and VEGF Expressions in DVT Model Speaker: Mizuho Nosaka, JP
PB0029 A Novel Mouse Model for Cerebral Venous Thrombosis 16:00 - 16:00 Speaker: Marie-Charlotte Bourrienne, FR
PB0030 High Shear Conditions Takes Place at the Edge of the Wound 16:00 - 16:00 after Human and Mouse Vessel Injury Speaker: Alexandra Yakusheva, FR
PB0031 Mass Cytometry Analysis of Venous Thrombi Demonstrates Key 16:00 - 16:00 Roles for VWF Interactions in Inflammation-associated DVT Speaker: Seon Jae Choi, CA
PB0032 Absolute Measurement of Bovine and Porcine Heparin Red 16:00 - 16:00 Assay Utilizing the Heparin Red Assay. Applications in the Study of Pharmacokinetics and Pharmacodynamics Speaker: Walter Jeske, US
25 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0033 Short Peptides in the Regulation Blood Cells Aggregation in 16:00 - 16:00 Thrombogenesis Speaker: Maria Golubeva, RU
PB0034 USP Potency Adjusted Bovine Mucosal Heparins Are 16:00 - 16:00 Comparable to Porcine Mucosal Heparin and may be interchangeable for anticoagulation Speaker: Ahmed Kouta, US
PB0035 Coagulation Potential, Electrophysiological Characteristics and 16:00 - 16:00 Structural Remodeling due to Atrial Fibrillation in Young and Aged Goats Speaker: Elisa D'Alessandro, NL
PB0036 New Thromboplastin-based Modification of Thromboembolic 16:00 - 16:00 Ischemic Stroke Model in Rats Speaker: Sergei Kalabushev, RU
PB0037 Rat Model of Metabolic Disorders: Dynamics of Hemostasis and 16:00 - 16:00 Endothelial Function Changes Speaker: Tamara Obergan, RU
LPB0006 Recombinant Heparin: An Old Drug for the Modern World 16:00 - 16:00 Speaker: Bryan E. Thacker, US
LPB0100 Mapping Prothrombin Binding on Pseutarin C by Site-directed 16:00 - 16:00 PEGylation Speaker: Fatma Isik Ustok, GB
LPB0101 Nucleotides Inhibit Serine Proteases Involved in Blood Clotting 16:00 - 16:00 and Other Cellular Processes Speaker: Fabienne Birkle, US
PB0038 Generation of Anticoagulant RNA Aptamers Targeting Cofactors 16:00 - 16:00 that Inhibit Clotting in Normal and COVID-19 Patient Samples Speaker: Haixiang Yu, US
PB0039 The FV East Texas Variant Causes Bleeding in a Three 16:00 - 16:00 Generation Family from Indiana Speaker: Julie Peterson, US
PB0040 Reversal of Oral Anticoagulants: A Survey of Contemporary 16:00 - 16:00 Practice Trends (ReACT) Speaker: Huiwen Deng, US
PB0041 Reversal of Antithrombotic Effects of FXIa Inhibitor Milvexian 16:00 - 16:00 (BMS-986177/JNJ-70033093) by Non-specific Agents in a Rabbit AV-shunt Model of Thrombosis Speaker: Xinkang Wang, US
PB0042 Polycationic Molecules Towards the Inhibition of Procoagulant 16:00 - 16:00 and Antifibrinolytic Properties of Nucleic Acids Speaker: Sreeparna Vappala, CA
PB0043 Management of Intentional Low Molecular Weight Heparin 16:00 - 16:00 Overdose: The McMaster University Experience
26 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Clara Lu, CA
PB0044 Factor XIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) 16:00 - 16:00 Suppresses Plasma Clot Formation and Reduces Resistance to Fibrinolysis in vitro Speaker: Alisa S. Wolberg, US
PB0045 D-dimer and the Risk of Diabetes: The REasons for Geographic 16:00 - 16:00 and Racial Differences in Stroke (REGARDS) Speaker: Debora Kamin Mukaz, US
PB0046 Induced Forms of ?2-Macroglobulin Neutralize Heparin and 16:00 - 16:00 Direct Oral AntiCoagulant Effects Speaker: Georges Jourdi, CA
PB0047 Comparing the Real-world and Clinical Trial Bleeding Rates 16:00 - 16:00 Associated with Anticoagulation Treatment for Atrial Fibrillation Speaker: Aaron Galaznik, US
PB0048 Sensitivity Analysis of a Reduced Model of Thrombosis under 16:00 - 16:00 Flow: Roles of Factor IX, Factor XI, and ?’-Fibrin Speaker: Scott L. Diamond, US
PB0049 Rapid Detection of DOACs in DVT Patients Using a Single-use 16:00 - 16:00 Microfluidic Chip under Whole Blood Flow Speaker: Jason M. Rossi, US
PB0050 The Relationship of 4 Factor PCC or Plasma to INR and Factor 16:00 - 16:00 Levels: An Exploratory Analysis of 2 Clinical Trials Speaker: Ravi Sarode, US
PB0051 Combining Heparin with a FX/FXa Aptamer to Reduce Thrombin 16:00 - 16:00 Generation in Models of Cardiopulmonary Bypass and COVID-19 Associated Coagulopathy Speaker: Charlene V. Chabata, US
PB0052 Evaluation of a New Thromboplastin Reagent Containing 16:00 - 16:00 Human Recombinant Tissue Factor for the Determination of Prothrombin Time Reagent: the (h)PT-Phen™ LRT Speaker: Corinne Frere, FR
PB0053 The Effect of Lower-leg Trauma and Knee Arthroscopy on 16:00 - 16:00 Thrombin Generation Speaker: Carolina Eveline Touw, NL
PB0055 HemosIL Liquid Anti-Xa Apixaban Measurement in Patients with 16:00 - 16:00 High Risk of Major Bleeding Speaker: Judith Hammelburger, US
PB0056 The Impact of Lower-leg Injury and Knee Arthroscopy on 16:00 - 16:00 Procoagulant Factor Levels Speaker: Carolina Eveline Touw, NL
PB0057 Ex vivo Evaluation of the Effect of Plasma-derived Factor 16:00 - 16:00 VIII/von Willebrand Factor in Patients with Severe Hemophilia A on Prophylaxis with Emicizumab by ROTEM
27 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Elena Monzón Manzano, ES
PB0058 Are Direct Oral Anti-Xa Inhibitors Absorbed in Cancer Patients 16:00 - 16:00 after Gastrectomy? A Case Series Speaker: Hannah Christina Puhr, AT
PB0059 Synthesis and Binding Study of Two Small Heterocyclic 16:00 - 16:00 Compounds with factor Xa Inhibitory Activity Speaker: Tanusree Sengupta, IN
PB0060 The Effect of Dextran Sulfate in Heparin Monitoring Reagents 16:00 - 16:00 Speaker: Elysse Dean, AU
PB0061 Influence of Low-generation Polyamidoamine (PAMAM) 16:00 - 16:00 Dendrimers on Structure and Function of Fibrinogen, Generation, Amidolytic and Coagulating Activity of Thrombin in vitro Speaker: Liliya Mukhametova, RU
PB0062 Influence of Tissue-factor Pathway Inhibitor on Thrombin 16:00 - 16:00 Generation Assay Speaker: Marie Didembourg, BE
PB0063 Monitoring Heparin: Stability of Two Different Anti-Xa Assays in 16:00 - 16:00 Citrated vs CTAD Tubes Speaker: THOMAS SINEGRE, FR
PB0064 Performance Evaluation of the INNOVANCE Anti-Xa Assay for 16:00 - 16:00 the Quantitative Determination of Rivaroxaban Speaker: Dominik Pahren, DE
PB0065 The Coagulation Balance: Intracranial Hemorrhage in a Patient 16:00 - 16:00 with Antithrombin Deficiency. A Case Report Speaker: Inês Machado, PT
PB0066 Non-thrombogenic Effect Observed with Simulated 16:00 - 16:00 Concomitant Administration of Anti-hemophilic Factor, Emicizumab and rFVIIa on Thrombin Generation Speaker: Maria-Isabel Bravo, ES
PB0067 Evaluation and Performance Characteristics of the Automated 16:00 - 16:00 Sysmex CN-6000 Haemostasis Analyzer Speaker: Corinne Frere, FR
PB0068 Performance Evaluation of a New VWF:GPIbM VWF Activity 16:00 - 16:00 Assay in a Multicenter Study Speaker: Mareike Kahl, DE
PB0069 Influence of Para-sulfonato-calixarenes on Components of 16:00 - 16:00 Coagulation System Speaker: Elizaveta Ivanova, RU
PB0071 Performance Evaluation of the INNOVANCE Anti-Xa Assay for 16:00 - 16:00 the Quantitative Determination of Apixaban Speaker: Matthias Wilkens, DE
28 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0072 Analysis of Coagulation Factors in Fresh-frozen Plasma 16:00 - 16:00 Speaker: Marika Pikta, EE
PB0073 Selective Small Molecule Factor XIIa Inhibitor KV998083 16:00 - 16:00 Protects against FeCl3 Induced Arterial Thrombosis in Mice Speaker: Samantha Whitney, US
PB0074 Extra-terrestrial Soils Activate Coagulation Factor XII and 16:00 - 16:00 Manage Bleeding in a Porcine Model of Liver Laceration: Implications for Hemorrhage Control during Space Exploration Speaker: Nabil Ali-Mohamad, CA
PB0075 Titanium Compounds Bind and Activate Factor XII and 16:00 - 16:00 Prekallikrein Speaker: Maxim Litvak, US
PB0076 FXI-independent Pathways of Contact Activation: Analysis of 16:00 - 16:00 Activated Partial Thromboplastin Time (aPTT) Data Using Mathematical Modelling Speaker: Alireza Rezvani-Sharif, AU
PB0077 Pharmacokinetics and Pharmacodynamics of Abelacimab 16:00 - 16:00 (MAA868), a Novel Dual Inhibitor of Factor XI and Factor XIa Speaker: B. Alexander Yi, US
LPB0052 Characterization of Andexanet Alfa-associated Heparin 16:00 - 16:00 Resistance: Implications for Management Speaker: Nabil Thalji, US
PB0078 ?ig-data and Machine Learning Prediction of Early and Late 16:00 - 16:00 Mortality in ICU Patients with Venous Thromboembolism and Comparison with Classic Scoring Systems Speaker: Vasiliki Danilatou, CY
PB0079 Elucidating Thrombus Formation in ECMO Circuits: A Detailed 16:00 - 16:00 Histological Study Speaker: Senna Staessens, BE
PB0080 A Comparative Study of SEER Sonorheometry versus 16:00 - 16:00 Thromboelastography during Cardiac Surgery with Cardiopulmonary Bypass Speaker: Corinne Frere, FR
PB0081 Management of Bleeding and Urgent Invasive Procedures in 16:00 - 16:00 Patients Treated with Direct Oral Anticoagulants: An Observational Study over a Five-year Perio Speaker: Adeline Pontis, FR
PB0082 Altered Hemostasis and Complement in Pediatric Patients 16:00 - 16:00 Treated with Cardiopulmonary Bypass Speaker: Kevin Todd Jr., US
PB0083 Changes in the Global Hemostatic Profile after Subarachnoid 16:00 - 16:00 Aneurismatic Hemorrhage Speaker: Kapil Nanwani, ES
29 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0084 Coagulation Management Strategies in Cardiac Surgery: 16:00 - 16:00 Viscoelastic tests Speaker: Isabel Rodriguez Martin, ES
PB0085 Evolution of Thrombin Generation in Pediatric Liver 16:00 - 16:00 Transplantation Speaker: Katherine Regling, US
PB0086 Anticoagulation and Antiplatelet Management during the 16:00 - 16:00 Perioperative Period: A Daily Practice Cohort Prospective Study Speaker: Olivier DURANTEAU, FR
PB0087 Off-label Use of Prothrombin Complex Concentrate in the 16:00 - 16:00 Clinical Practice of a Portuguese Tertiary Hospital Speaker: Diana Cibele, PT
PB0088 Adaptation of fixed prothrombin complex concentrate dosing 16:00 - 16:00 for vitamin K antagonist-related bleeding in the Netherlands Speaker: Rahat Abdoellakhan, NL
PB0089 Persistently Low Levels of Antithrombin in Trauma Patients 16:00 - 16:00 Associated with Disseminated Intravascular Coagulation Speaker: Satoshi Gando, JP
PB0090 Global Coagulation Assay in a Patient Affected by AL 16:00 - 16:00 Amyloidosis Speaker: Sara Arcudi, IT
PB0091 Severe Coagulopathy Induced by Therapeutic Plasma Exchange 16:00 - 16:00 – A Case Report Speaker: Sara Lopes, PT
PB0092 Viscoelastic Haemostatic Assay Comparison for Perioperative 16:00 - 16:00 Coagulation Assessment Speaker: Jonathon Fanning, AU
PB0093 Surveillance of Anticoagulation in Patients with Extracorporal 16:00 - 16:00 Oxygenation Membrane (ECMO) Speaker: Luz Hermila Gonzalez-Figueroa, MX
PB0094 Control of Anti-coagulant Treatment in Patients with Acute 16:00 - 16:00 Stroke by the Results of the «Thrombodynamics» Test Speaker: Elena Klychnikova, RU
PB0095 Ability of Fibrin Monomers and Fibrinogen Levels to Predict In- 16:00 - 16:00 hospital Mortality in Patients with Severe Trauma Speaker: Tuan Nguyen, VN
PB0096 Preoperative Hemorrhagic Risk Assessment: Knowledge, 16:00 - 16:00 Attitude and Practice among Surgeons and Anesthesiologists Speaker: Emna Hammami, TN
PB0097 First Case of Wunderlich Syndrome under Apixaban – Case 16:00 - 16:00 Report Speaker: Tiago Quaresma, PT
30 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0053 Activated FVIII Inactivation Occurs Outside of the Intrinsic Xase 16:00 - 16:00 Complex Speaker: Amelia Wilhelm, US
PB0098 Development of a Cell-based Assay to Test Factor VIII 16:00 - 16:00 Internalization Mediated by the Low-density Lipoprotein Receptor (LDLR) and LDLR-related Protein 1 (LRP1) Speaker: Haarin Chun, US
PB0099 Real-world Effectiveness of BAY 94-9027 to Treat Hemophilia A 16:00 - 16:00 in the ATHNdataset Speaker: Thomas Moulton, US
PB0100 Validation of a New Kit for the Quantitative Determination of 16:00 - 16:00 Chromogenic Factor IX Activity Speaker: Tara Quinton, CA
PB0101 Comparison of a Chromogenic vs. APTT-based Factor VIII 16:00 - 16:00 Activity Assay in the Recovery of a Pegylated Factor VIII Replacement Therapy in Plasma Samples Speaker: Tara Quinton, CA
PB0102 Optimizing Variant Curation Guidelines to Improve Clinical 16:00 - 16:00 Genetic Testing for Hemophilia A and B Speaker: Kristy Lee, US
PB0103 Interaction of the Factor IXa with the Subpopulations of 16:00 - 16:00 Activated Platelets Speaker: Polina A. Soloveva, RU
LPB0054 Experimental Acetaminophen-induced Acute Liver Failure Is 16:00 - 16:00 Associated with a Profound Consumptive Coagulopathy Speaker: Dafna Jordana Groeneveld, US
PB0104 Risk Factors for Non-variceal Hemorrhage in Patients with 16:00 - 16:00 Chronic Liver Disease Speaker: Preethi Kesavan, US
PB0105 Thrombin Generation Assay in Crohn Disease 16:00 - 16:00 Speaker: hela ben youssef, TN
PB0106 Delivery of a Resuscitation Fluid Cocktail Containing Fibrinogen 16:00 - 16:00 and Vasopressin as an Infusion Rather than Boluses Improves Hemorrhage in Swine Polytrauma Model Speaker: Alexander St. John, US
PB0107 Atrial Flutter and Intracardiac Thrombus after Cardiac Surgery 16:00 - 16:00 Speaker: SERAP KARAMAN, TR
PB0108 Coagulation Abnormalities in Patients without Congenital 16:00 - 16:00 Bleeding Disorders: Analysis of Secondary Causes of Low Clotting Factors Levels Speaker: ALICIA LORENZO JAMBRINA, ES
PB0109 Peridontal Injury Prompts Remote Spleen Activation and the 16:00 - 16:00 Generation of Spleen Procoagulant Microvesicles in a
31 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Periodontitis Murine Model Speaker: Hanine EL Itawi, FR
PB0110 Coagulation Activity of Circulating Microparticles in Patients 16:00 - 16:00 with Cardiovascular Diseases Speaker: Alexey Mazurov, RU
PB0111 Extracellular Microparticles as Aortic Valves Calcification 16:00 - 16:00 Vectors, Proof of Concepts Speaker: Mirthala Flores Garcia, MX
LPB0007 Activated Protein C (APC) Resistance in FV-W1920R (FV-NARA) 16:00 - 16:00 Was Caused by the Defective Association between FV-W1920R and Protein S (PS) in the APC/PS/FVa Assembly Speaker: Naruto Shimonishi, JP
PB0112 Identification of a Novel PROC Mutation in a Newborn Causing 16:00 - 16:00 Severe Protein C Deficiency Successfully Treated with Liver Transplantation Speaker: Valérie PROULLE, FR
PB0113 HIV-1 and SARS-CoV-2 Both Cause Protein S, but through 16:00 - 16:00 Different Mechanisms Speaker: Martha M.S. Sim, US
PB0114 Various Receptors Are Related with the APC-induced 16:00 - 16:00 Suppression of Osteoclast Differentiation Speaker: Nobuyuki Akita, JP
LPB0055 Exploration of TFPI-mediated Inhibitory Mechanisms in 16:00 - 16:00 Coagulation Flow Model Speaker: Kenji Miyazawa, US
PB0115 Refining and Validating a Model of FXI Activation and Activity in 16:00 - 16:00 Thrombin Generation and Blood Coagulation Speaker: Hari Hara Sudhan Lakshmanan, US
PB0117 Differences in Thrombin and Plasmin Generation Potential 16:00 - 16:00 between East African and Western European Adults: The Role of Genetic and Non-genetic Factors Speaker: Godfrey S. Temba, NL
PB0118 Neutrophils Can Promote Clotting by Secreting Proteins that 16:00 - 16:00 Activate FXI while NETs Promote Clotting Independently of FXI in vitro Speaker: Yu Shi, GB
PB0119 Neutrophils Promote Tissue Factor-dependent Thrombin 16:00 - 16:00 Generation in the Absence of Platelets Speaker: Matthew Harper, GB
PB0120 Identifying Vulnerable Patients with Direct Oral Anticoagulant 16:00 - 16:00 (DOAC) Levels Outside the Expected Range Speaker: Dionne Braeken, NL
PB0121 Fixed-dose 1500-unit 4F-PCC for Factor Xa inhibitor Reversal in 16:00 - 16:00
32 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Spontaneous or Traumatic Intracranial Hemorrhage Speaker: Allison E. Burnett, US
PB0122 Interaction of Phenyramidol HCl and Warfarin: A Case Series 16:00 - 16:00 Report Speaker: Bektas murat, TR
PB0123 On the Diagnosis of Thrombinemia in the Arctic 16:00 - 16:00 Speaker: Nadezda Vorobyeva, RU
PB0124 Thrombin Generation is Affected by Freezing Independent of 16:00 - 16:00 Storage Temperature Speaker: Marisa Ninivaggi, NL
PB0126 Validation of the Bioequivalence of USP Potency Adjusted 16:00 - 16:00 Porcine, Ovine and Bovine Heparins Speaker: Nausheen Baig, US
PB0127 Heparin-binding Copolymer Completely Reverses the 16:00 - 16:00 Anticoagulant Effect of Subcutaneously Administered Enoxaparin in Mice Speaker: Justyna Swieton, PL
PB0128 The Thickness of Fibrin Fibers is Associated with High Fibrin 16:00 - 16:00 Clot Visco-elasticity in Carcinomatosis Patients Speaker: Massoud Mirshahi, FR
PB0129 Determination of DNA and Histone 3 Plasma Levels for 16:00 - 16:00 Evaluation of Leukocyte Activation in Plasma of Patients with Peritoneal Carcinomatosis Speaker: Shahsoltan Mirshahi, FR
PB0130 Impact of DNA on the Fibrin Clot Structure in Peritoneal 16:00 - 16:00 Carcinomatosis Patients Speaker: Shahsoltan Mirshahi, FR
PB0131 Management of a Non-vitamin K Antagonist Oral Anticoagulant 16:00 - 16:00 Associated Bleeding - A Case Report Speaker: Rita Pombal, PT
PB0132 Natural Anticoagulants from Peonies 16:00 - 16:00 Speaker: Margarita Lyapina, RU
LPB0008 ADP-induced Platelet-associated Tissue Factor Expression: 16:00 - 16:00 Unique Involvement of the P2Y12 Receptor and Modulation by Clopidogrel Treatment Speaker: Marta Brambilla, IT
PB0133 Mutagenesis Study Reveals Factor X Gla-domain Residues 16:00 - 16:00 Critical for Initiation of the Clotting Cascade Speaker: Divyani Paul, US
PB0134 Genome-wide Knockdown of Chromatin Binding and Regulatory 16:00 - 16:00 Protein Genes and Regulation of Zebrafish tfpia Gene Expression
33 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Ayah Al Qaryoute, US
PB0135 Anti TFPI for Hemostasis Induction in Patients with Rare 16:00 - 16:00 Bleeding Disorders, an ex vivo Thrombin Generation (TG) Guided Study Speaker: Tami Brutman-Barazani, IL
LPB0102 Blockade Of COVID-19 Antiphospholipid Antibody-Induced 16:00 - 16:00 Thrombosis by a Specific Inhibitor of the TF Initiation Complex Speaker: Denise Pedrosa, DE
LPB0103 Circulating Cellular Clusters Are Correlated with Thrombotic 16:00 - 16:00 Complications and Clinical Outcomes in COVID-19 Speaker: Ander Dorken Gallastegi, US
LPB0104 Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 16:00 - 16:00 Can Be Overcome by N-acetylcysteine in vitro Speaker: Dorothée Faille, FR
PB0136 SARS-CoV-2 Derived Peptides Potentiate Pro-inflammatory and 16:00 - 16:00 Pro-coagulant Responses to the TLR3 Ligand Poly(I:C) in Human Endothelial Cells and Mice Speaker: Vanthana Bharathi, US
PB0137 Impact of COVID-19 on Platelet Activity and the Platelet 16:00 - 16:00 Releasate Speaker: Shane Comer, IE
PB0138 Immunothrombosis Biomarkers for Distinguishing COVID-19 16:00 - 16:00 Patients from Non-COVID Septic Pneumonia Patients and for Predicting ICU Mortality Speaker: Erblin Cani, CA
PB0139 Fibrinogen Adsorption on Hemofilter Membranes Associates 16:00 - 16:00 with Severe COVID-19 and Renal Replacement Therapy Circuit Failure Speaker: Daniel Choi, US
PB0141 Contact System and Intrinsic Pathway Are Activated and 16:00 - 16:00 Associated with Clinical and Laboratory Outcomes in COVID-19 Patients Speaker: Michael W Henderson, US
PB0142 Time Course of the Development of Immunothrombosis during 16:00 - 16:00 COVID-19 Hospitalization Speaker: José Oliveira, BR
PB0143 Whole Blood Assays Demonstrate Reduced Platelet Function in 16:00 - 16:00 Early SARS-CoV-2 Infection Speaker: Krystin Krauel, DE
PB0144 Association of the Angiopoietin/Tie2 and VEGF-A Pathways 16:00 - 16:00 with clinical and Laboratory Markers of Disease Severity in COVID-19 Speaker: Carla Roberta Peachazepi Moraes, BR
34 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0145 Fibrin Clot Characteristics and Anticoagulant Response in a 16:00 - 16:00 SARS-CoV-2 Infected Endothelial Cell Model Speaker: Conor McCafferty, AU
PB0146 Increased Thrombin Generation in COVID-19 is Mediated by 16:00 - 16:00 Platelet-dependent and -Independent Mechanisms Speaker: Alicia S. Eustes, US
PB0147 Thrombotic Events in COVID-19 Are Associated with a Lower 16:00 - 16:00 Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity Speaker: Chantal Clark, NL
PB0148 Targeting Thymidine Phosphorylase May Be a Novel Therapy 16:00 - 16:00 for COVID-19 Speaker: Wei Li, US
PB0149 Distinctive Biomarker Features in the Endotheliopathy of 16:00 - 16:00 Covid-19 and Septic Syndromes Speaker: Ana Belen Moreno-Castaño, ES
PB0150 Multi-organ Vascular Defects and General Morphological 16:00 - 16:00 Changes in a Murine Model of SARS CoV-2 Infection Speaker: Michael Paidas, US
PB0152 Identifying Tools to Track Hypercoagulability in COVID-19 16:00 - 16:00 Patients. Exploring Global Haemostasis (ROTEM) and Neutrophil Extracellular Traps (NETs) Immunoassays Speaker: Sophia Stanford, GB
PB0153 Tissue Factor-stimulated Plasma Thrombin Generation Is 16:00 - 16:00 Enhanced in Hospitalised Patients with COVID-19 Despite Pharmacological Thromboprophylaxis Speaker: Sarah Kelliher, IE
PB0154 Haematological, Coagulation and Biochemical Abnormalities in 16:00 - 16:00 Covid-19 Patients in India: Do We Behave Differently? Speaker: Namrata Awasthi, IN
PB0155 Platelets of COVID-19 Patients Are Refractory due to Thrombin 16:00 - 16:00 Receptor Desensitizing in the Bloodstream Speaker: Alexey Martyanov, RU
PB0156 Thrombin Generation Kinetics, Neutrophil Extracellular Traps, 16:00 - 16:00 and von Willebrand Factor in COVID-19 Associated Coagulopathy: A Pilot Study Speaker: Taleen MacArthur, US
PB0157 SARS-CoV2 Spike Protein Can Activate Platelets through 16:00 - 16:00 Integrin Alpha IIb Beta 3 Speaker: Ingeborg Hers, GB
PB0159 Altered Protein S Activity Contributes Significantly to COVID-19 16:00 - 16:00 Pro-thrombotic State Speaker: Tina Nguyen, US
35 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0160 Lymphocyte-Platelet Adhesion and Lymphocyte-platelet 16:00 - 16:00 Clusters in Patients with Coronavirus Infection SARS-COV-2 (COVID-19) Speaker: Artur Emelyanov, RU
PB0161 Is Viscoelastometric Testing a Good Tool to Assess Hemostasis 16:00 - 16:00 of COVID-19 Patients? Speaker: Marion Bareille, BE
PB0162 Hemostasiological Blood Properties in Patients with COVID-19 16:00 - 16:00 Associated Viral Pneumonia Speaker: Marina Presnyakova, RU
PB0163 Thrombotic Microangiopathy in Two Patient with Covid 19 16:00 - 16:00 Disease Speaker: Pavla Bradacova, CZ
LPB0009 Systematic Screening for Pulmonary Embolism in Patients with 16:00 - 16:00 Suspected Covid-19 in the Emergency Department: A Prospective Cohort Study Speaker: Inge Luu, NL
LPB0010 Prevalence of Venous Thromboembolism and Pulmonary 16:00 - 16:00 Embolism among Patients Hospitalized with a COVID-19 Diagnosis in France Speaker: Amélie Gabet, FR
LPB0011 Immature Platelets as a Biomarker for Disease Severity and 16:00 - 16:00 Mortality in COVID-19 Patients Speaker: Daniel Welder, US
LPB0056 Pre-admission Anticoagulant Therapy and Mortality in 16:00 - 16:00 Hospitalized COVID-19 Patients: A Covid Predict Retrospective Cohort Study Speaker: Thijs F. van Haaps, NL
LPB0057 Diagnostic Management of Suspected Pulmonary Embolism in 16:00 - 16:00 Patients with COVID-19: A Prospective Cohort Study Speaker: Milou Anne Maria Stals, NL
LPB0058 D-dimer Elevation at Time of Admission Is Associated with 16:00 - 16:00 Need for Ventilator Support among Pediatric Patients with COVID-19 Infection Speaker: Nathan Wilken, US
LPB0059 Population Pharmacokinetics of Anti-Xa Levels in COVID-19 ICU 16:00 - 16:00 Patients Receiving Prophylaxis for Thrombo-embolic Events Using Nadroparin Speaker: Lorenzo Gaetano Renata Romano, NL
LPB0105 External Validation of IMPROVE-DD Risk Assessment Model for 16:00 - 16:00 Venous Thromboembolism among Inpatients with COVID-19 Speaker: Stephanie K. Lin, US
PB0164 Circulating Histones Are Associated with Disease Severity and 16:00 - 16:00
36 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Coagulopathy in COVID-19 Speaker: Rebecca J Shaw, GB
PB0165 COVID-19-Related Thrombosis in Japan: Results of a 16:00 - 16:00 Questionnaire-based Survey in 2020 Speaker: Hisanori Horiuchi, JP
PB0166 Von Willebrand Factor and ADAMTS13 Activity as Endothelial 16:00 - 16:00 Injury Markers and their Prognostic Value in COVID-19 Speaker: Ana Marco, ES
PB0167 The Kallikrein-kinin System in Bronchoalveolar Lavage Fluid 16:00 - 16:00 from Patients with COVID-19 Speaker: Caroline Paola Martens, BE
PB0168 Adjusting D-dimer to Lung Disease Extent to Exclude 16:00 - 16:00 Pulmonary Embolism in COVID-19 Patients (Co-LEAD) Speaker: Lina Khider, FR
PB0169 ITP Secondary to COVID-19: A Comprehensive Review of 16:00 - 16:00 Reported Cases Speaker: Ben Berger, US
PB0170 Extended Outpatient Thromboprophylaxis for Individuals with 16:00 - 16:00 COVID-19 Speaker: Amy Szuman, GB
PB0171 Venous Thromboembolism in Hospitalized Critical and Non- 16:00 - 16:00 critical COVID-19 Patients: A Systematic Review and Meta- analysis Speaker: Eman Mansory, CA
PB0172 Does Hydroxychloroquine Prevent Symptomatic Venous 16:00 - 16:00 Thromboembolism in Patients with Mild to Moderate COVID-19? Speaker: Pierre-Marie Roy, FR
PB0173 Are Mild or Moderate COVID-19 Patients at Higher Risk of VTE? 16:00 - 16:00 A Comparison of Two Prospective European Cohorts in Emergency Departments Speaker: Pierre-Marie Roy, FR
PB0174 High Incidence and Early Presence of arterial thrombotic events 16:00 - 16:00 in a COVID-19 hospitalized population: an overlooked problem? Speaker: Miguel de Oliveira, PT
PB0175 Prior Use of Therapeutic Anticoagulation Does Not Protect 16:00 - 16:00 against COVID-19 Related Clinical Outcomes in Hospitalized Patients: A Propensity Score-matched Cohort Study Speaker: Jenneke Leentjens, NL
PB0176 Pulmonary Thromboembolism (PTE) in Hospitalised Patients 16:00 - 16:00 with COVID-19: A National Study of Patients Managed in Critical Care and Ward Environments Speaker: Michael McGettrick, GB
PB0177 COVID-19 Vaccination and Anticoagulation: Potential Effects on 16:00 - 16:00
37 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Anticoagulation Control in Patients Using Vitamin K Antagonists Speaker: Chantal Visser, NL
PB0178 COVID-19 Diagnosis and its Impact on Thrombotic Risk in a 16:00 - 16:00 Cohort of Consecutive Patients Hospitalized due to Severe Acute Respiratory Syndrome Speaker: Andréa Coy Canguçu, BR
PB0179 COVID-19 Infection is Associated with Antibody-mediated 16:00 - 16:00 Procoagulant Platelets: Data from an Observational Study Speaker: Karina Althaus, DE
PB0180 Weight Adjusted Prophylactic to Intermediate Dosed 16:00 - 16:00 Thromboprophylaxis in COVID-19 Speaker: Matthias M Engelen, BE
PB0181 Hemostatic Disorders Are Associated with the Course and 16:00 - 16:00 Outcomes of COVID-19 Speaker: Rustem I. Litvinov, US
PB0183 COVID-19 Related Abnormalities in the Hematologic 16:00 - 16:00 Characteristics among Inpatient Children. Results of the PICNIC Registry Speaker: Sarah Tehseen, CA
PB0184 Anti-factor Xa Activity after Intermediate Dose Nadroparin for 16:00 - 16:00 Thrombosis Prophylaxis in Critically Ill COVID-19 Patients with and without Acute Kidney Injury Speaker: Ruben Eck, NL
PB0185 Post Hospital Discharge Thrombosis in Patients with COVID-19 16:00 - 16:00 Speaker: Pin Li, US
PB0186 A Weight-based Approach to Thromboprophylaxis Dosing for 16:00 - 16:00 Medical Inpatients with COVID-19 Speaker: Rebecca Price, GB
PB0187 Physicians’ Knowledge and Management Practices of 16:00 - 16:00 COVID-19 Coagulopathies in Pregnancy Speaker: Stefan Jevtic, CA
PB0188 COVID-19 Pneumonia Worse Prognosis Related to Lupus 16:00 - 16:00 Anticoagulant Transient Positive Test Speaker: Jose Manuel Ceresetto, AR
PB0189 Does Thromboelastography Predict Clinical Outcomes in 16:00 - 16:00 COVID-19? Speaker: Mamatha Gaddam, US
PB0190 ACE2, ACE and Thromboinflammation in COVID-19 16:00 - 16:00 Speaker: Annika Lundström, SE
PB0191 Differences of Venous Thromboembolism (VTE) Events in 16:00 - 16:00 COVID-19 and Non-COVID-19 Hospitalized Patients
38 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: MARIA CHIARA CHINDAMO, BR
PB0192 Lupus Anticoagulant Positivity is Not Associated with Venous 16:00 - 16:00 Thromboembolism or In-hospital Mortality In COVID-19 Speaker: Nicolas Gendron, FR
PB0193 Atherothrombotic Events in Hospitalized COVID-19 Patients Are 16:00 - 16:00 Associated with Diabetes mellitus Speaker: Daria Morozova, RU
PB0194 COVID-19 and Patients with Hemorrhagic Congenital Disease: 16:00 - 16:00 Experience from Regional Heamophilia Treatment Center of Strasbourg (France) Speaker: Dominique Desprez, FR
PB0195 Clinical Outcomes of Prophylactic vs. Therapeutic Doses of 16:00 - 16:00 Anticoagulation In COVID-19 Patients: A Systematic Review and Meta-analysis Speaker: Maha AT Elsebaie, US
PB0196 Bleeding in Critically Ill Patients with COVID-19 16:00 - 16:00 Speaker: Cherise Callahan, US
PB0197 Stability of Oral Anticoagulant Treatment with Vitamin K 16:00 - 16:00 Antagonists in COVID-19 Patients Speaker: Eleonora Camilleri, NL
PB0198 Increased von Willebrand Factor (VWF) and Factor VIII (FVIII) 16:00 - 16:00 Levels in Severe Acute Respiratory Syndrome Sars- Cov2-positive Pneumonia Compared with Severe Acute Respiratory Syndrome Sars-Cov2-negative: A Case-control Study Speaker: Monica Sacco, IT
PB0199 TEG/ROTEM: A Tool to Aid in the Diagnosis and Management of 16:00 - 16:00 COVID 19 Coagulopathies - A Systematic Review Speaker: Sajida Kazi, GB
PB0200 Does a National Lockdown Affect the Characterises of Deep 16:00 - 16:00 Vein Thromboses and Patients in the Community? Speaker: Abbas Shahid, GB
PB0201 Platelets from Donors of Convalescent Plasma after Mild 16:00 - 16:00 COVID-19 Do Not Express Procoagulant Phenotype Speaker: Günalp Uzun, DE
PB0202 Anticoagulation Strategies and Risk Of Bleeding Events in 16:00 - 16:00 Critically ill COVID-19 Patients Speaker: Cristina Gabara, ES
PB0203 Management of COVID-19 Related Venous Thromboembolism - 16:00 - 16:00 Data from Ljubljana Registry Speaker: Gregor Tratar, SI
PB0204 Anemia and Enhancement of Coagulation Are Associated 16:00 - 16:00 during Severe COVID-19 Infection
39 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Tuukka Helin, FI
PB0205 Impact of COVID-19 Pandemic on the Quality and Performance 16:00 - 16:00 of Haemostasis Laboratories Speaker: Ryanne Astrid Arisz, NL
PB0206 Hypercoagulability Detected by Seer Sonorheometry in 16:00 - 16:00 Covid-19 Patients at Hospital Admission Speaker: Francisco José López Jaime, ES
PB0207 Effects of Dalteparin on Anti-Xa Levels Cannot Be Predicted in 16:00 - 16:00 Critically Ill COVID-19 Patients Speaker: Charlotte van der Heijden, NL
PB0208 Platelet Dynamics in Hospitalized Patients with SARS CoV-2 16:00 - 16:00 Infection Speaker: Valeria Estefanía Delgado Pinos, ES
PB0209 Hemoreologic Disorders in COVID-19 Patients 16:00 - 16:00 Speaker: Olga Kostina, RU
PB0210 Do Thrombotic and Bleeding Phenotypes Differ in Patients with 16:00 - 16:00 Severe COVID-19 Compared to Other Viral Pneumonias in the Context of Extracorporeal Membrane Oxygenation? Speaker: Anna Weatherill, GB
PB0211 Serum ACE2 Activity for the Assessment of Disease Prognosis 16:00 - 16:00 in COVID-19 Speaker: Béla Nagy Jr., HU
PB0212 Thrombotic Risk of Hospitalized Patients with COVID-19 and a 16:00 - 16:00 Co-infection Speaker: Imo Akpan, US
PB0213 Excess Mortality in a Population of Vitamin K Antagonist Users 16:00 - 16:00 during the First Wave of the COVID-19 Pandemic in the Netherlands Compared with Excess Mortality in the General Dutch Population Speaker: Qingui Chen, NL
PB0215 Hypercoagulation by Rotational Thromboelastometry (ROTEM) 16:00 - 16:00 Predicts Mortality in COVID-19: A Prospective Observational Study Speaker: Lou Almskog, SE
PB0216 Extracorporeal Membrane Oxygenation Induces Early 16:00 - 16:00 Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome Speaker: Corinne Frere, FR
PB0217 Impact of the COVID-19 Pandemic and a National Lockdown on 16:00 - 16:00 Hospitalizations for Venous Thromboembolism and Pulmonary Embolism in France Speaker: Amélie Gabet, FR
PB0218 Systemic Platelet Exhaustion in Critically-ill Covid-19 Patients 16:00 - 16:00
40 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Harald Schulze, DE
PB0219 Role of Endothelium Activation Biomarkers in Prediction 16:00 - 16:00 COVID-19 Related Intra-hospital Mortality Speaker: Marina Marchetti, IT
PB0220 Extracellular Vesicles and Citrullinated Histone H3 in 16:00 - 16:00 Coronavirus Disease 2019 (COVID-19) Patients Speaker: Ludwig Traby, AT
PB0221 D-dimer as a Predictive Marker for Mortality in Hospitalized 16:00 - 16:00 COVID-19 Patients Speaker: Shermarke Hassan, IT
PB0222 Dynamic Monitoring of Hemostasis and Correction of Heparin 16:00 - 16:00 Therapy Can Halve the Number of Thrombotic Complications in Patients with Severe COVID-19 Speaker: Fazly Ataullakhanov, RU
PB0223 Use of D-Dimer as a Predictor of Venous Thromboembolism 16:00 - 16:00 Events (VTE) in Covid-19 Patients Speaker: MARIA CHIARA CHINDAMO, BR
PB0224 Significance of D-Dimers in Patients with COVID-19 Having 16:00 - 16:00 Venous Thromboembolism Speaker: Bushra Moiz, PK
PB0225 Venous Thromboembolism in Cancer Patients with SARS-CoV-2 16:00 - 16:00 Infection Speaker: Doaa Attia, US
PB0226 Hypercoagulable Rotational Thromboelastometry NaHEPTEM 16:00 - 16:00 Profile is Related to Mechanical Ventilation Requirement among Critically ill COVID-19 Patients Speaker: Marta Martinuzzo, AR
PB0228 Suspicion of Heparin-induced Thrombocytopenia in COVID-19: 16:00 - 16:00 Results from a Multi-centric Retrospective Study Speaker: Nicolas Gendron, FR
PB0229 The Characteristics and Outcomes of Critically Ill Patients with 16:00 - 16:00 COVID-19 who Received Systemic Thrombolysis for Presumed Pulmonary Embolism: An Observational Study Speaker: Matsuo So, US
PB0230 Anticoagulation with Tinzaparin in COVID-19 Patients in ICU: 16:00 - 16:00 Are Low Anti-Xa Levels Associated with the Development of Thrombo-embolic Events? Speaker: Ruth Van Lancker, BE
PB0231 Effect of Dexamethasone on Direct Oral Anticoagulant Plasma 16:00 - 16:00 Levels in Patients with COVID-19 Speaker: Floris Bosch, NL
PB0232 Coagulopathy in Patients with Severe COVID-19 16:00 - 16:00 Speaker: Rossella Cacciola, IT
41 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0233 Rotational Thromboelastometry (ROTEM) Profiling of COVID–19 16:00 - 16:00 Patients Speaker: Mirjana Mitrovic, RS
PB0234 Severe SARS-CoV-2 Infection is Associated with Impaired 16:00 - 16:00 Fibrinolysis: A Single Center Study of the Viscoelastic Properties of Blood Clot Speaker: Stefanie Hammer, DE
PB0235 Fibrinogen and D-dimer Are Significantly Associated with 16:00 - 16:00 Severity of COVID-19 Disease Speaker: Mohamed EL HORRI, DZ
PB0236 Prognostic Coagulation Parameters in COVID-19 Patients at the 16:00 - 16:00 ICU Speaker: Sjef van de Leur, NL
PB0237 Thrombosis and Bleeding in Critically Ill COVID-19 Patients at 16:00 - 16:00 Higher than Prophylactic Dose of Heparins Speaker: Alenka Mavri, SI
PB0239 Hemostastatic Alterations with Disease Severity in the Early 16:00 - 16:00 Symptomatic Phase of COVID-19 Speaker: Joyce Annichino-Bizzacchi, BR
PB0240 The Comparison of Different Coagulation Markers in 16:00 - 16:00 Thrombosis Prediction in COVID-19 Pneumonia Speaker: Mariia Krykhtina, UA
PB0241 Efficiency of Anticoagulant Protein C System in Patients with 16:00 - 16:00 Coronavirus Infection Caused by the SARS-CoV-2 Speaker: Natalya Korsakova, RU
PB0242 Indices of the Hemostasis System in Patients with COVID-19 16:00 - 16:00 Depending on the Outcome Speaker: Elena Klychnikova, RU
PB0243 Influence of C-reactive Protein on Thrombin Generation Assay 16:00 - 16:00 Speaker: Marie Didembourg, BE
PB0244 Global Haemostatic Tests Demonstrate the Absence of 16:00 - 16:00 Hypercoagulability in Non-supplemental Oxygen Dependent COVID-19 Patients Speaker: Bingwen Eugene Fan, SG
PB0245 Sex Differences in Thromboinflammatory Biomarkers in 16:00 - 16:00 Patients with COVID-19: Preliminary Findings from a Retrospective, Single Center Study Speaker: Lucia Stefanini, IT
PB0246 Enoxaparin in COVID-19 Moderate to Severe Hospitalized 16:00 - 16:00 Patients (INHIXACOV19) Speaker: Benilde Cosmi, IT
PB0247 Apparent Different of Lupus Anticoagulant Disappearance in 16:00 - 16:00 Novel Coronavirus 2019 Patients as a Distinct Clinical Feature
42 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Hyunji Kim, KR
PB0248 Low Incidence of Thrombotic Events in Patients with Covid19: A 16:00 - 16:00 Cohort Study Speaker: Augusto Ferraris, AR
PB0249 Artificial Neural Networks to Predict Covid-19 Progression of 16:00 - 16:00 Moderate Hospitalized Patients using Early Clinical Parameters and Blood Tests Speaker: Tiago D. Martins, BR
PB0250 The Role of Thromboelastography and Follow-up of Fibrinolysis 16:00 - 16:00 in Evaluating the Course of the Disease, Treatment Response, and Outcome of Pediatric Patients with COVID-19 Speaker: Hale Ören, TR
PB0251 Potential Markers to Predict Mortality in COVID-19 16:00 - 16:00 Speaker: Catherine Klapheke, US
PB0252 IMPACT of COVID-19 Associated Coagulopathy in Disease 16:00 - 16:00 Severity Speaker: Filipa Santos, PT
PB0253 Platelets and Neutrophil Extracellular Traps (NETs) in 16:00 - 16:00 Immunothrombosis Progression at COVID-19 Speaker: Irina Vasilenko, RU
PB0254 Oral Anticoagulation with Rivaroxaban as Thromboprophylaxis 16:00 - 16:00 in Patients Recovered from COVID-19 Pneumonia in Veracruz, Mexico Speaker: Luis Del Carpio-Orantes, MX
PB0255 Cross-talk between the Inflammatory Response and 16:00 - 16:00 Coagulopathy: Single-center Report Speaker: Sevgi Kalayoglu Besisik, TR
PB0256 Association of Elevated D-dimers with Severity and Outcome of 16:00 - 16:00 Covid-19 Infection in Children Speaker: Nazish Saqlain, PK
PB0257 Value of Laboratory Parameters in the Clinical Monitoring of 16:00 - 16:00 Patients with SARS-COV-2 Infection (COVID-19) Speaker: Nuria Fernández Mosteirin, ES
PB0258 D-dimer Increase during Hospitalization is Associated with 16:00 - 16:00 Negative Outcomes in Patients with COVID-19 Infection Speaker: Ekaterina Kropacheva, RU
PB0259 Heparin-induced Thrombocytopenia (HIT) during Extracorporeal 16:00 - 16:00 Membrane Oxygenation (ECMO) in COVID-19: A Case Report Speaker: Gyna Alejandra Altamirano-Solorzano, MX
PB0260 Clinical Course of COVID-19 in Patients with Inherited Bleeding 16:00 - 16:00 Disorders: An Interim Analysis of 28 Cases Speaker: Jerzy Windyga, PL
43 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0261 Venous Thromboembolic Disease in Patients Wwith SARS-CoV2 16:00 - 16:00 Infection: In Search of a Predictive Biomarker Speaker: Pablo Silva de Tena, ES
PB0262 Anticoagulant Response to Tailored Low Molecular Weight 16:00 - 16:00 Heparin Regimens in Patients with COVID-19 Infection Speaker: Andrea Artoni, IT
PB0263 Longitudinal Measurement of Whole Blood Viscoelastic 16:00 - 16:00 Properties throughout the Course of Extracorporeal Membrane Oxygenation in COVID-19 Patients with Severe Acute Respiratory Distress Syndrome Speaker: Corinne Frere, FR
PB0264 Correlation of Coagulation Parameters with Prognosis of 16:00 - 16:00 COVID-19 Speaker: Natalya Korsakova, RU
PB0265 Pulmonary Embolism in COVID-19-Patients: Diagnostic 16:00 - 16:00 Accuracy of D-dimer Speaker: Falmata Laouan Brem, MA
PB0266 Hemostasis Disorder in COVID-19 Patients: Disseminated 16:00 - 16:00 Intravascular Clotting (DIC)? Speaker: Elena Klychnikova, RU
PB0267 Incidence of Disseminated Intravascular Coagulation (DIC) in 16:00 - 16:00 Critical Patients with Covid-19 Speaker: CARLOS FRANCISCO HERNANDEZ MATA, ES
PB0268 Circulating Nucleosome Immunoassay: Evaluating a Clinically- 16:00 - 16:00 applicable Test to Risk Stratify COVID-19 and Target Anticoagulation Speaker: Catherine Rea, GB
PB0269 Immune Thrombocytopenia during Covid-19 Pandemic: An 16:00 - 16:00 Italian Monocentric Experience Speaker: Gianfranco Lapietra, IT
PB0270 After the Storm; 6-month Follow up Outcomes and Management 16:00 - 16:00 of COVID-19 Related Venous Thromboembolism Speaker: Charalampos Kartsios, GB
PB0271 Association between Race and the Incidence of Thrombosis in 16:00 - 16:00 Hospitalized COVID-19 Patients Across a New York City Hospital System Speaker: Poy P. Theprungsirikul, US
PB0272 Hemostasis Abnormalities in Post-COVID-19 Syndrome 16:00 - 16:00 Speaker: Marina Noniashvili, GE
PB0273 Is Procalcitonin Involved on the Severity of COVID-19? 16:00 - 16:00 Speaker: Elnaz Rezaei Ghalechi, US
PB0274 National Survey about Management of Venous 16:00 - 16:00 Thromboembolism (VTE) Prevention in COVID-19 Patients in
44 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Uruguay Speaker: Ana Pizzarossa, UY
PB0275 The Role of D-dimer in Prognosis of Patients with Pulmonary 16:00 - 16:00 Thrombembolism: Some Aspects for COVID-19 Speaker: Marijan Bosevski, MK
PB0276 Optimization of Operational Flow of D-dimer Test in a Core 16:00 - 16:00 Laboratory in a Brazilian Tertiary Hospital to Ensure Operational Efficiency during the COVID-19 Pandemic Speaker: João Guerra, BR
PB0277 The Effect of Covid-19 Lockdown on Patients Taking Warfarin 16:00 - 16:00 Speaker: Matthew Roberts, GB
PB0278 Glenzocimab, a Novel Antiplatelet Therapy in COVID-19 Related 16:00 - 16:00 Acute Respiratory Distress Syndrome (ARDS): The GARDEN Study, a Phase 2 Clinical Trial Speaker: Andrea Comenducci, FR
PB0279 Change in Platelet Indices in Patients with Coronavirus 16:00 - 16:00 Infection Disease (COVID-19): A Reflection of Platelet Activation and Contribution to Immunothrombosis? Speaker: Susan Louw, ZA
PB0280 Anti-coagulant Drugs among Moderate, Severe and Critically Ill 16:00 - 16:00 COVID 19 Patients in the Second Referral Hospital in Surabaya Speaker: Pradana Zaky Romadhon, ID
PB0281 Prevalence, Clinical Profile and Bleeding Risk of Hospitalized 16:00 - 16:00 COVID-19 Patients Receiving Anticoagulation: A Retrospective Cross-sectional Study Speaker: Clarisse Imperial, PH
PB0282 Hematologic Parameters of Ghanaian COVID-19 Patients at 16:00 - 16:00 Diagnosis Speaker: Dela FIAWOO, GH
PB0283 Hematologic Abnormalities in Moderate Forms of Covid-19 16:00 - 16:00 Speaker: Mayssa Ben Ayed, TN
PB0284 Lupus Anticoagulant and Outcome of COVID-19 Patients 16:00 - 16:00 Speaker: Oluwayomi Oyedeji, US
PB0285 The Comparison of ISTH Criteria for Disseminated Intravascular 16:00 - 16:00 Coagulation (DIC) Scale, Padua Scale, D-dimer and Fibrinogen Like the Best Predictor of Thrombosis in COVID-19 Pneumonia Speaker: Mariia Krykhtina, UA
PB0286 Head-to-Head Comparison of Cytokines Storm-induced 16:00 - 16:00 Coagulopathy in Septic Shock and Covid-19 Speaker: Julien De Poortere, BE
PB0287 Clinical Impact of Immune Thrombocytopenic Purpura in the 16:00 - 16:00 Context of SARS-CoV-2 Infection
45 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Cristina Tarniceriu, RO
PB0288 Prophylactic Anticoagulation in Hospitalized Patients with 16:00 - 16:00 COVID-19: A Survey of Practices in Latin America Speaker: Fernanda de Andrade Orsi, BR
PB0289 Haemostatic Dysfunctions in COVID-19 Infection: A Systematic 16:00 - 16:00 Review Speaker: Samuel Abegunde, CA
PB0290 Native Rotational Thromboelastometry Observations in 16:00 - 16:00 Critically Ill COVID-19 Patients Speaker: Anne-Marije Hulshof, NL
PB0291 CATS-MICA Score in Predicting Venous Thromboembolism in 16:00 - 16:00 SARS-CoV-2-infected Cancer Patients Speaker: David Salomon Juliao Caamaño, ES
PB0292 Thromboembolism and Coagulopathy in COVID-19: A Review of 16:00 - 16:00 Quality Indicators at Sunnybrook Health Sciences Centre Speaker: Adam Suleman, CA
PB0293 The Assessment of Thrombotic Complication in Patients with 16:00 - 16:00 COVID-19 Speaker: Viola Maria Popov, RO
PB0294 Circulating Biologic Markers of Endothelial Dysfunction in 16:00 - 16:00 COVID-19 Patients Speaker: Natalya Korsakova, RU
PB0295 The Effects of COVID-19 Pandemic on Children with 16:00 - 16:00 Haemophilia Speaker: Fatma Burçin Kurtipek, TR
PB0296 Management of Clot in Transit in a Postpartum COVID-19 16:00 - 16:00 Patient Speaker: Adithya Peruri, US
PB0297 The Effect of Chronic Anticoagulation and Antiplatelets on 16:00 - 16:00 COVID-19 Infection Speaker: Jasmeet Kaur, US
PB0298 Relationship between von Willebrand Factor and Clinical 16:00 - 16:00 Outcome in Patients with Severe COVID-19 Speaker: Frida Rivera-Buendia, MX
PB0299 Acute Liver Necrosis in a Sars-Cov-2 Positive Patient with Triple 16:00 - 16:00 Positive Antiphospholipid Syndrome Speaker: Vincenzo La Mura, IT
PB0300 Analysing Risk Factors for Thrombosis in Covid-19 and Cancer 16:00 - 16:00 Patients Speaker: Berta Obispo Portero, ES
PB0301 Combining Artificial Neural Networks and Blood Tests to 16:00 - 16:00 Diagnose Covid-19 Infection
46 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Tiago D. Martins, BR
PB0302 Incidence of Spontaneous Iliopsoas Hematoma in COVID-19 16:00 - 16:00 Patients Speaker: Gianluca Sottilotta, IT
PB0303 Immune Thrombocytopenia Purpura Associated with Novel 16:00 - 16:00 Coronavirus Infection Speaker: Ricardo Camelo, BR
PB0304 Transient Lupus Anticoagulant Presence in COVID-19 16:00 - 16:00 Pneumonia, a Probably Epiphenomenon Speaker: Marta Martinuzzo, AR
PB0305 Role of Hematological Parameters in Stratification of Covid-19 16:00 - 16:00 Disease Severity Speaker: Sadia Taj, PK
PB0306 Ddimer and the Correlation with the Mortality Rate in Covid 16:00 - 16:00 Patients: A Single Centre Report in Medan Indonesia Speaker: Sry Suryani widjaja, ID
PB0307 Thrombin Generation (TG) Reveals Underlying Hypercoagulable 16:00 - 16:00 Process in COVID-19 Patients Despite Low Molecular Weight Heparin (LMWH) Therapy Speaker: Alejandra Scazziota, AR
LPB0012 Effects of Liraglutide vs. Lifestyle Changes on sST2 and 16:00 - 16:00 Galectin-3 in Obese Subjects with Prediabetes or Type 2 Diabetes after Comparable Weight Loss Speaker: Romina Tripaldi, IT
PB0308 Overall Haemostatic Potential Assay Can Detect 16:00 - 16:00 Hypercoagulability and Hypofibrinolysis in Anticoagulated Patients Following Venous Thromboembolism Speaker: Julie Wang, AU
PB0310 Use of MRX PT DOAC in a Routine Laboratory Setting for 16:00 - 16:00 Detection of Interfering DOACs in Thrombophilia Investigation Speaker: Tomas Lindahl, SE
PB0311 Circulating Biologic Markers of Endothelial Dysfunction in 16:00 - 16:00 Chronic Myeloproliferative Neoplasms Speaker: Natalya Korsakova, RU
PB0313 Profiling of Inflammatory Biomarkers and Coagulation Factors 16:00 - 16:00 in End-stage Renal Disease Speaker: Emily Bontekoe, US
PB0314 Clinical Relevance of JAK2V617F on Patients with Philadelphia- 16:00 - 16:00 negative Myeloproliferative Neoplasms Speaker: Rim Frikha, TN
PB0315 Proteome Analysis of Extracellular Vesicles from Patients with 16:00 - 16:00 Myocardial Infarction and Relation to Heart Function: An Observational Study
47 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Avinash Khandagale, SE
PB0316 Anti-annexinv Serum Levels and Haematological Indices in 16:00 - 16:00 Sickle Cell Anaemia Patients in Vasooclusive Crisis and Steady States Seen at Lagos University Teaching Hospital Lagos Nigeria Speaker: Deborah Edewor-Okiyo, NG
PB0317 Evaluation of Oxidative Stress, Thrombosis, and Inflammation 16:00 - 16:00 in Patients with End-stage Osteoarthritis Speaker: Vikrum Jain, US
PB0318 Features of the Coagulation Potential of Blood in Patients with 16:00 - 16:00 Endometriosis Speaker: Irina Vasilenko, RU
LPB0060 The Incidence of Severe Infusion Reactions Associated with 16:00 - 16:00 Common Iron Repletion Strategies Speaker: Asad Arastu, US
PB0319 Platelets Collected from Blood Diversion Pouches Are an 16:00 - 16:00 Appropriate Alternative for Functional and Bioenergetic Analyses Speaker: Orlando Esparza, US
PB0320 Calculation of Fresh Frozen Plasma Amount to Correct 16:00 - 16:00 Prolonged International Normalized Ratio Speaker: Lalarwan Pinitsubsin, TH
PB0321 A Service Evaluation of Prothrombin Complex Concentrate Use 16:00 - 16:00 and Safe Administration Procedures in a Tertiary Hospital and Trauma Centre Speaker: Charlotte Hickman, GB
PB0322 Use of Blood Products and Hemostatic Agents during Massive 16:00 - 16:00 Transfusions: Review of our Practice Speaker: Gabriela Simona Ene, ES
LPB0106 Enhancing Transfusable Platelets Using mRNA Therapy to 16:00 - 16:00 Produce Exogenous Proteins Speaker: Jerry Leung, CA
PB0325 Hemostatic and Thrombogenic Properties of Lyophilized Human 16:00 - 16:00 Platelets Speaker: Thomas Diacovo, US
PB0326 In silico Methods of Structural Biology for Studying (Not Only) 16:00 - 16:00 Coagulation Proteins Speaker: Zofie Sovova, CZ
PB0327 The Prevalence of Gene Polymorphism of the Cytochrome 16:00 - 16:00 P-450 and VKORC1 System among the Indigenous Population of the Arctic Speaker: Nadezda Vorobyeva, RU
LPB0013 Evaluation of Heparin-induced Thrombocytopenia Before and 16:00 - 16:00
48 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
during the COVID-19 Pandemic at a US National Reference Laboratory Speaker: Edward Wong, US
LPB0014 Global Thrombosis Test: Occlusion by Coagulation or SIPA? 16:00 - 16:00 Speaker: Viviana Clavería, US
LPB0015 Comparison of D-dimer values at peak and trough 16:00 - 16:00 concentrations of direct oral anticoagulants: result of D-dimer testing is not affected by plasma drug concentration Speaker: Sandra Margeti?, HR
LPB0061 Impact of Characteristic Inhibition Kinetics of Different FVIII 16:00 - 16:00 Inhibitors on the Inhibitor Titer Quantification in the Modified Nijmegen-Bethesda Assay Speaker: Carolin Ketteler, DE
LPB0062 Smartphone-based Detection of Platelet Activation in 16:00 - 16:00 Microfluidic Strips Speaker: Daniel Hodge, GB
LPB0107 Preoperative Measurement of Platelet Contribution to Clot 16:00 - 16:00 Stiffness (PCS) with the Quantra® QPlus® System and Bleeding after Cardiac Surgery Speaker: Wim Houdijk, US
LPB0108 Usefulness of an Academic High-throughput Sequencing Panel 16:00 - 16:00 to Detect Copy Number Variations in Patients with Syndromic Thrombocytopenia Speaker: Sandra Santos-Mínguez, ES
LPB0109 Full Automation of the Bethesda Assay 16:00 - 16:00 Speaker: Thomas Siegemund, DE
PB0329 Newly Developed Dilute Russell’s Viper Venom Reagents for 16:00 - 16:00 Lupus Anticoagulant Detection Speaker: Laurie Talon, FR
PB0330 Risk of Misdiagnosis for Patients Presenting the Closed 16:00 - 16:00 Variants E1359K or V1360A in Exon 28 of VWF due to a Major Discordance on VWF Activity Results between the VWF:GpIbM and VWF:GpIbR Assays Speaker: Fanny Lassalle, FR
PB0331 Evaluation of Activated Clotting Time (ACT) Results on a New 16:00 - 16:00 POC Coagulation Analyzer Speaker: Anna Leung, US
PB0332 Endothelial Dysfunction in Patients with Ph-negative 16:00 - 16:00 Myeloproliferative Neoplasms Speaker: Natalya Korsakova, RU
PB0333 The Effect of DOAC StopTM on Measuring Antithrombin Activity 16:00 - 16:00 Speaker: Katarzyna Mayger, GB
PB0334 Use of Rotational Thromboelastometry (ROTEM) to Monitor 16:00 - 16:00
49 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Patients with Severe Haemophilia A on Emicizumab Speaker: Anne Riddell, GB
PB0335 Ring Trial for Quality Assurance of the Manual Tilt Tube 16:00 - 16:00 Technique for Prothrombin Time and INR Determinations in WHO Calibration Laboratories Speaker: Antonius van den Besselaar, NL
PB0336 Laboratory Assessment of DOAC Assays for FXa Inhibitors in 16:00 - 16:00 the Presence of Reversal Agent Andexanet Alfa on the ACL TOP/TOP 50 Coagulation Analyzers Speaker: Anuja Khan, US
PB0337 Diagnosis of Disseminated Intravascular Coagulation in the 16:00 - 16:00 Context of Human Immunodeficiency Viral (HIV) Infections in a South African Tertiary Care Setting Speaker: Elizabeth Mayne, ZA
PB0338 The Red Blood Cell Paradox in Viscoelastic Coagulation Tests – 16:00 - 16:00 Hemoglobin Concentration as a Confounder for Test Reliability? Speaker: Isabell Pekrul, DE
PB0339 Quantra: The Influence of Hematocrit, Platelet Count, Ringer 16:00 - 16:00 Lactate, and Acetylsalicylic Acid on Viscoelastic Properties of Clot Formation Speaker: Anne-Marije Hulshof, NL
PB0340 The Impact of Inactive FVIII Antigen in Factor VIII Deficient 16:00 - 16:00 Plasma on the Measurement of FVIII Inhibitors Speaker: Amanda Wood, CA
PB0341 Cost-effectiveness of a Stepwise versus an All-in-One Approach 16:00 - 16:00 to Diagnose Mild Bleeding Disorders Speaker: Floor Heubel-Moenen, NL
PB0342 A Novel Paper-based Test for Diagnostic of Fibrinogen Levels 16:00 - 16:00 on Whole Blood Speaker: Ana T. A. Sachetto, BR
PB0343 Heparin Interference of the Thrombin Generation Assay Can Be 16:00 - 16:00 Eliminated by Heparinase Treatment Speaker: Alfred Weber, AT
PB0344 Comparison of Peak Plasma Concentrations of Apixaban in 16:00 - 16:00 Adolescent and Adult Patients Speaker: Ivana Celap, HR
PB0345 Development of a New ELISA Method for Anti-FVIIa Antibody 16:00 - 16:00 Measurement Speaker: Carla Valsecchi, IT
PB0346 Frequency and Clinical Significance of Different Types of 16:00 - 16:00 Calreticulin (CALR) Mutations in Myeloproliferative Neoplasms (MPNs): A Cohort of Patients from Pakistan Speaker: Rifat Ahmed, PK
50 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0347 Plasmatic Rivaroxaban Concentration Estimation through the 16:00 - 16:00 Measurement of Anti Xa Activity Calibrated with Heparin Calibrators Using 3 Reactive/Instrument Systems: Multicenter Study Speaker: Marta Martinuzzo, AR
PB0348 Comparison of Platelet Counts Using Impedance, Optical and 16:00 - 16:00 CD61-immunoplatelet Methods in Thrombocytopenic Patients Speaker: Tuan Nguyen, VN
PB0349 Assessment of Sample Stability after Freezing on ST Genesia 16:00 - 16:00 System Using the STG-BleedScreen Application Speaker: Audrey Carlo, FR
PB0350 Hemolysis Interference in the Anti-Xa Heparin Activity Assay 16:00 - 16:00 Speaker: Kristen Ruby, US
PB0351 Measurement of Factor VIII in the Presence of Emicizumab Is 16:00 - 16:00 dependent on the chromogenic assay selected for use Speaker: Mary Byrne, IE
PB0352 Normal Values in Thrombin Generation Parameters in 16:00 - 16:00 Hemorraghic Diseases Speaker: Isabel Tirado, ES
PB0353 Evaluation of a New Fully Automated ADAMTS13 Activity Assay 16:00 - 16:00 Speaker: Lieselotte Wagner, AT
PB0354 Correlation between the Rosner Index with the Etiological 16:00 - 16:00 Diagnosis of the Prolongation of the Activated Partial Thromboplastin Time (aPTT) in Asymptomatic Presurgical Patients Speaker: Bolivar Luis Diaz Jordan, ES
PB0355 Utility of the STG-Bleedscreen Assay in Clinical Routine 16:00 - 16:00 Speaker: Thomas Siegemund, DE
PB0356 Activated charcoal can be used as an effective in vitro removal 16:00 - 16:00 agent of direct oral anticoagulants dabigatran, rivaroxaban and apixaban in plasma of patients with protein S activity testing Speaker: Sandra Margeti?, HR
PB0357 Evaluation of Intra-site and Inter-site Precision of PT 16:00 - 16:00 Determination with STA-NeoPTimal on Start Max Semi- automated Instrument Speaker: Gaëlle Le Goff, FR
PB0358 Analytical Performances of a New Immunoturbidimetric D-Dimer 16:00 - 16:00 Assay Speaker: Laurie Talon, FR
PB0359 Next Generation Sequencing in Patients with Bleeding, 16:00 - 16:00 Thrombotic and Platelet Disorders: A Single Centre Experience Speaker: Noèlia Vilalta, ES
PB0360 The Effect of Trough Dabigatran Plasma Concentration on 16:00 - 16:00
51 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Rotational Thromboelastometry Parameters Speaker: Marija Mili?, HR
PB0361 Effect and Stability of Dabigatran on Thrombin Generation over 16:00 - 16:00 a Year in Elderly Patients with Atrial Fibrillation Speaker: Daniela Calderaro, BR
PB0362 In vitro Neutralization of Unfractionated Heparin for the 16:00 - 16:00 Measurement of Thrombin Generation with the STG-drugScreen Reagent on ST Genesia Speaker: Sylviane Fontaine, FR
PB0363 Evaluation of Effect of Extracorporeal Near-infrared Laser- 16:00 - 16:00 mediated Photobiomodulation Therapy on Endothelial Dysfunction Improvement Using a New B-mode Ultrasound Image Processing Software-based Automatic Method Speaker: Hossein Mehrad, IR
PB0364 A Comparison of Functional Methods with Absolute 16:00 - 16:00 Quantification of Heparin Levels in Clinical Samples by Heparin Red Assay Speaker: Emily Bontekoe, US
PB0365 Presentation of the Patient with Low Peak Dabigatran Levels in 16:00 - 16:00 Plasma Suggests the Importance of Quantitative Measurement of DOAC Drugs in Clinical Decision Making and Treatment Speaker: Sandra Margeti?, HR
PB0366 Multicenter Performance Evaluation and Reference Ranges for 16:00 - 16:00 the Quantitative Determination of Factor XII Activity by One- stage Factor Assay on the Cobas t 711 Analyzer Speaker: Martin Büchsel, DE
PB0367 A Systematic Review and Meta-analysis of Performances of 16:00 - 16:00 Prototype and Commercial DOAC Dipstick Tests for Detecting Direct Oral Anticoagulants in Patient Urine Samples – Increasing Confidence for Testing in Emergency Care Speaker: Job Harenberg, DE
PB0368 Comparison of PT/INR Assessment with STA-NeoPTimal on an 16:00 - 16:00 Automated and Semi-automated Test Platform Speaker: François Depasse, FR
PB0369 Effect of NETS from Different Models on Fibrin Polymerization 16:00 - 16:00 Profile and Coagulation-fibrinolysis Balance Speaker: Nakougou Mo?-bohm BIATOUGOU, FR
PB0370 Anticoagulated Patients Exhibit Intact Endogenous Thrombin 16:00 - 16:00 Potential Using ST Genesia Unlike the Calibrated Automated Thrombogram Speaker: Tuukka Helin, FI
PB0371 Standardization and Automation of Lupus Anticoagulant 16:00 - 16:00 Diagnosis Using a Complex Automated Algorithm Speaker: María Alejandra Chang Azancot, ES
52 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0372 Evaluation of Silica Clotting Time and Hexagonal (II) Phase 16:00 - 16:00 Phospholipid Neutralization for Lupus Anticoagulant Detection Speaker: Paul Lindholm, US
PB0375 In vitro Neutralization of Low Molecular Weight Heparins for the 16:00 - 16:00 Measurement of Fibrin Polymerization Profile and Coagulation- fibrinolysis Balance Speaker: Marc-Antoine Bildan, FR
PB0376 Correlation between Plasma Levels, Anti-FXa Activity and 16:00 - 16:00 Coagulation Parameters in Real-world Patients on Treatment with Edoxaban Speaker: Mariana Corrochano, ES
PB0377 Immune Mediators in Pediatric Patients with Chronic Kidney 16:00 - 16:00 Disease Speaker: Aislander Silva, BR
PB0379 Comparability of PT Determination with STA-NeoPTimal on 16:00 - 16:00 STart and STart Max Semi-automated Instruments Speaker: Gaëlle Le Goff, FR
PB0380 FVIII Stability, the Limiting Factor in Chromogenic Fix Kits? 16:00 - 16:00 Speaker: Anton Evenepoel, BE
PB0381 Newly Developed Ellagic Acid Based APTT Reagent Showed 16:00 - 16:00 High Lupus Anticoagulant Sensitivity Speaker: Osamu Kumano, JP
PB0382 Validation of Mixing Test Formula for the Discrimination 16:00 - 16:00 between Lupus Anticoagulant and Acquired Hemophilia A in New APTT Reagent Speaker: Osamu Kumano, JP
PB0383 Comparison of Visual Interpretation of the DOAC Dipstick Test 16:00 - 16:00 with a Reader System for Rapid and Accurate Detection of Direct Oral Anticoagulants in Neurology and Cardiology – Interim Data from a Prospective Consecutive Comparative Study Speaker: Job Harenberg, DE
PB0384 Assessment of Low Response Rates to P2Y12 Inhibition in 16:00 - 16:00 Cardiology Patients: Comparison of the VerifyNow P2Y12 and Anysis-P2Y12 Assay Speaker: Sehyun Shin, KR
PB0385 Analytical Performance of the Novel Haema T4 16:00 - 16:00 Thromboelastograph Speaker: Marianne Schoorl, NL
PB0386 Effect of Warfarin on Thrombin Generation Parameters in 16:00 - 16:00 Elderly Patients with Atrial Fibrillation Speaker: Daniela Calderaro, BR
PB0387 Prevalence of Hemolysis, Icterus and Lipemia in the 16:00 - 16:00
53 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Coagulation Laboratory: Database Analyses Speaker: Audrey Carlo, FR
PB0388 Main Blood Serum Metabolites Responsible for the 16:00 - 16:00 Discrimination of Hospitalized Patients with Moderate Symptoms with or without COVID-19 Speaker: Joyce Annichino-Bizzacchi, BR
PB0389 Utility of Platelet Parameters in Pediatric Outpatient Setting: 16:00 - 16:00 Experience from a Single Institution Speaker: Rungrote Natesirinilkul, TH
PB0390 Comparison between Coagulation Factor Deficiencies versus 16:00 - 16:00 Pharmacological Inhibition of Activated Coagulation Factors Using Clot Waveform Analysis Speaker: Yuta Fujimori, JP
PB0391 Natural Fluorescence of Thrombin Substrate Z-Gly-Gly-Arg 16:00 - 16:00 7-amino-4-methylcoumarin: Considerations for Wavelength Choice Speaker: Joseph Jackson, US
PB0392 Effect of Edoxaban on Laboratory Methods 16:00 - 16:00 Speaker: Henrik von Horn, SE
PB0393 Establishing Reference Values in Burkina Faso: A Study of 16:00 - 16:00 Haemostasis Global Assays and Coagulation Factors Eight and Nine, Based on Blood Donors Speaker: Koumpingnin NEBIE, BF
PB0394 Laboratory Testing in Patients Treated with Direct Oral 16:00 - 16:00 Anticoagulants: Our Experience Speaker: Gloria Garcia-Donas, ES
PB0395 Protein S Gla Domain as Theranostic for Early Vascular 16:00 - 16:00 Calcification Speaker: Anouk Gentier, NL
PB0396 Single-cell Level Quantification of Surface Proteins in Platelets 16:00 - 16:00 and Platelet-derived EVs Using SC-ICP-MS Speaker: Eunjin Choi, KR
PB0397 Development of an Anti-thrombotic and Anti-inflammatory 16:00 - 16:00 Coating for Medical Devices Speaker: Kevin Gonzalez, CA
LPB0016 The Fibrin(ogen) ?-chain Integrin ?IIb?3 Binding Motif is 16:00 - 16:00 Dispensable for Platelet Accumulation but Modifies Cross- linking in the Injured Liver Speaker: Lauren G. Poole, US
LPB0017 Activation Mechanism Dependent Surface Exposure of Cellular 16:00 - 16:00 FXIII on Platelets and Platelet Microparticles: Immunofluorescence and Immune Electron Microscopic Study Speaker: László Muszbek, HU
54 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0063 Epigenome-wide Association Study of DNA Methylation in 16:00 - 16:00 Blood and Circulating Fibrinogen Levels Speaker: Julie Hahn, US
LPB0110 FXIIIa-mediated Fibrin ?-chain Crosslinks Are Critical for Fibrin 16:00 - 16:00 Fiber Stiffness and Resistance to Rupture Speaker: Tímea Feller, GB
LPB0111 Molecular Interactions of Coagulation Factor XIII B Subunit 16:00 - 16:00 Speaker: Krisztina Pénzes, HU
LPB0112 Monocytes Expose Factor XIII-A and Stabilize Thrombi against 16:00 - 16:00 Fibrinolytic Degradation Speaker: Fahad Alshehri, GB
PB0399 Biomechanics, Thermodynamics and Mechanisms of Rupture of 16:00 - 16:00 Fibrin Clots Speaker: Farkhad Maksudov, US
PB0400 Fibrinogen B Arg448Lys and Factor XIII Val34Leu 16:00 - 16:00 Polymorphisms Are Associated with Prothrombotic Fibrin Clot Properties in Patients with Acute Pulmonary Embolism Speaker: Adrianna Klajmon, PL
PB0401 Decreased Hepatic Fibrin(ogen) Deposition in a Mouse Model of 16:00 - 16:00 Failed Liver Regeneration Is Not Associated with Systemic Coagulation Changes Speaker: Dafna Jordana Groeneveld, US
PB0402 A Patient with Congenital Hypofibrinogenemia who Showed 16:00 - 16:00 Embryo Implantation, Continuation of Pregnancy, and Delivery Following Continuous Transfusion of Dry Human Fibrinogen Preparations Speaker: Yoshinobu Seki, JP
PB0403 Thermal Shift Assay to Probe Melting of Thrombin, Fibrinogen, 16:00 - 16:00 Fibrin Monomer and Fibrin: Gly-Pro-Arg-Pro Induces a Fibrin Monomer-like State in Fibrinogen Speaker: Jennifer Crossen, US
PB0404 Strength and Deformability of Fibrin Clots: Biomechanics, 16:00 - 16:00 Thermodynamics, and Mechanisms of Rupture Speaker: Valerie Tutwiler, US
PB0406 Application of the ISTH-BAT In Congenital Fibrinogen Disorders 16:00 - 16:00 Speaker: Samin Mohsenian, IR
PB0407 Effect of Flow and Shear Rate on Structural Properties and 16:00 - 16:00 Fibrinolysis of the Fibrin Network Speaker: Judith de Vries, NL
PB0408 A Case of Congenital Afibrinogenemia with Two Successful 16:00 - 16:00 Spontaneous Delivery after Recurrent Pregnancy Losses Speaker: Metban Mastanzade, TR
PB0409 Clinical and Molecular Characterization of Iranian Patients with 16:00 - 16:00
55 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Congenital Qualitative Fibrinogen Disorders Speaker: Samin Mohsenian, IR
LPB0018 Role of the "Mobile Loop" (Residues 142-150) in the Intrinsic 16:00 - 16:00 Instability of TAFIa Speaker: Haley Marier, CA
LPB0064 The Role of Activated Thrombin Activatable Fibrinolysis 16:00 - 16:00 Inhibitor on Thrombus Stability in Venous Thromboembolism Speaker: James Chessum, CA
PB0410 Tranexamic acid for Hyperacute Primary Intracerebral 16:00 - 16:00 Haemorrhage (TICH-3): Protocol for a Multinational Phase 3 Placebo-controlled Randomised Trial Speaker: Michael Desborough, GB
PB0411 Utility of Lysis Time (Global Fibrinolytic Capacity) Assay for 16:00 - 16:00 Detection of Hyperfibrinolysis in Trauma Speaker: Andrea Rossetto, GB
PB0412 Tranexamic Acid to Reduce Bleeding in Patients Treated with 16:00 - 16:00 Non-Vitamin K Oral Anticoagulants Undergoing Dental Extraction: The EXTRACT-NOAC Randomized Clinical Trial Speaker: Anna Ockerman, BE
PB0413 The Effect of Lower-leg Trauma and Knee Arthroscopy on the 16:00 - 16:00 Natural Anticoagulant and Fibrinolytic Systems Speaker: Carolina Eveline Touw, NL
PB0414 EACA Loaded Platelets Sustain Clots More Efficiently then Free 16:00 - 16:00 EACA Speaker: Shan Xu, US
PB0416 Fibrinolytic Disorders as Cause of Bleeding in Patients with an 16:00 - 16:00 Increased Bleeding Tendency Speaker: Lars Valke, NL
PB0417 Assessment of ?ardiometabolic Biomarkers in Young Adults 16:00 - 16:00 with Normal Body Weight and Obesity Speaker: Vasilii Chulkov, RU
PB0418 Prolonged Tourniquet Application in the Hind Limb of Rats Is 16:00 - 16:00 Associated with Fibrinolysis Speaker: Jason Chung, CA
PB0419 Thromboelastography for the Evaluation and Management of 16:00 - 16:00 Patients with Traumatic Brain Injury Speaker: Joao Dias, US
PB0420 Effect of Alpha2-plasmin Inhibitor C-terminal Forms on in vitro 16:00 - 16:00 Clot Lysis Speaker: Barbara Baráth, HU
PB0421 Assessment of DOACs Effect on Clot Formation and 16:00 - 16:00 Fibrinolysis Using the FibWave
56 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Jonathan Evrard, BE
PB0422 Thrombolysis and Anti-cancer Activity of Koji-Natto (Kojikinase) 16:00 - 16:00 Speaker: Hiroyuki Sumi, JP
PB0423 Evaluation of the Lysis Timer to Investigate ‘Global Fibrinolysis 16:00 - 16:00 Capacity’ in Plasma Speaker: Marion Bareille, BE
PB0424 Thrombolytic Activity of Pearl-like Tempeh 16:00 - 16:00 Speaker: Hiroyuki Sumi, JP
LPB0065 Mutation of Sortase A Cleavage Site and Potential Impact on 16:00 - 16:00 Human Plasminogen Binding by PAM Speaker: Bradley Readnour, US
LPB0113 Streptococcal Surface Enolase (SEN) Is Overshadowed by P 16:00 - 16:00 lasminogen-binding Group A Streptococcal M-protein (PAM) for Human Plasminogen Acquisition and Activation Speaker: Sheiny Tjia-Fleck, US
PB0425 Changes in Plasminogen Binding and Cell Surface Properties in 16:00 - 16:00 Streptococcus pyogenes in the Absence of Sortase A Are Due to Disruptions in Localization of M-protein Speaker: Brady Russo, US
LPB0066 Decreased Clot Burden is Associated with Factor XIII Val34Leu 16:00 - 16:00 Polymorphism and Better Functional Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis Speaker: Zsuzsa Bagoly, HU
PB0426 Co-delivery of Tissue Plasminogen Activator and Plasminogen 16:00 - 16:00 Using Magnetically Powered Microwheels Speaker: Dante Disharoon, US
PB0427 P2Y12 Inhibitors Administration in Intracranial Stent Procedure, 16:00 - 16:00 the Usefulness of Monitoring Speaker: Olivier DURANTEAU, FR
PB0428 Producing if Tenecteplase with High Activity 16:00 - 16:00 Speaker: Daria Chashchinova, RU
PB0429 Cangrelor Long Term Prescription, Several Scenarios: A Case 16:00 - 16:00 Report Series Speaker: Olivier DURANTEAU, FR
PB0430 Subcasular Hepatic Hematoma as Thrombolysis Complication. 16:00 - 16:00 Case Report Speaker: David Alberto Madrigal-Campos, MX
PB0431 The Use of Emicizumab for Acquired Hemophilia A at US 16:00 - 16:00 Hemophilia Treatment Centers Speaker: Jacqueline Poston, US
PB0432 Development of a Computable Phenotype for Hospital- 16:00 - 16:00
57 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
associated Bleeding: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study Speaker: Mansour Gergi, US
PB0433 Clinical Characteristics of Acquired Haemophilia A Patients in 5 16:00 - 16:00 European Countries Speaker: Isabel Palau, GB
PB0434 Efficacy of Rituximab for the Treatment of Acquired Hemophilia 16:00 - 16:00 A: A Systematic Review Speaker: Surasit Moonla, TH
PB0435 Hemostatic Evaluation by Global Coagulation Assays in 16:00 - 16:00 Patients with Acquired Hemophilia A: Analysis of Multi Centers in Japan Speaker: Masahiro Takeyama, JP
PB0436 NSAIDs prescription use and subsequent risk of upper 16:00 - 16:00 gastrointestinal bleeding: a time-trend analysis Speaker: Ajda Bedene, NL
PB0437 Why Measure von Willebrand Factor Levels for Biological 16:00 - 16:00 Follow-up of Acquired Haemophilia A Patients? Speaker: Claire Pouplard, FR
PB0438 Incidence Comparison and The Antiplatelet Effect on Bleeding 16:00 - 16:00 Risk Between Chronic Kidney Disease Undergoing Haemodialysis and Peritoneal Dialysis: A Meta-analysis of Cohort Studies Speaker: Boby Pratama Putra, ID
PB0439 Rutin Succinate Acts as an Anticoagulant and Inhibits Snake 16:00 - 16:00 Venom Metalloproteinases in an Acute Thrombo-hemorrhagic Disorder Model Speaker: Ana T. A. Sachetto, BR
PB0440 Life-threatening Bleeding in Acquired Factor V Inhibitor Can Be 16:00 - 16:00 Controlled Combining Platelet Transfusion and Recombinant Activated Factor VII Administration Speaker: Verónica Robles, ES
PB0441 To Treat or Not? Remission Induction of Acquired von 16:00 - 16:00 Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report Speaker: Roy Khalife, CA
PB0442 Acquired Haemophilia A - Data from a Regional Blood Center in 16:00 - 16:00 Rio de Janeiro, Brazil Speaker: Pedro Henrique Jardim Santos, BR
PB0443 Acquired Hemophilia A Presenting as Spontaneous 16:00 - 16:00 Intramuscular Hematomas Speaker: Sabaa Ahmed, US
PB0444 Refractory Acquired Hemophilia A (Even More) Complicated 16:00 - 16:00
58 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
with SARS-CoV-2 Infection Speaker: Alejandro Hevilla Carmona, ES
PB0445 The Experience of Oran University Hospital in Algeria in the 16:00 - 16:00 Management of Acquired Hemophilia Speaker: Reda MESSAOUDI, DZ
PB0446 Acquired Hemophilia after Chemotherapy: Oxaliplatin and 16:00 - 16:00 Capecitabine, a Case Report Speaker: Mercedes Mijares, CL
PB0447 Acquired Hemophilia A - Misdiagnosis and Possible Hazards: A 16:00 - 16:00 Case Report Speaker: Diana Carneiro-Leão, PT
PB0448 Acquired Hemophilia A: Pediatric Case Report 16:00 - 16:00 Speaker: Lizette Velazquez Marmolejo, MX
PB0449 Acquired Hemophilia A as a Complication of Multiple Myeloma 16:00 - 16:00 Speaker: Anna Hoppe, PL
PB0450 A Prospective Comparison Study of the Diagnosis of 16:00 - 16:00 Disseminated Intravascular Coagulation (DIC) Comparing Between ISTH DIC Scoring system and General Practice in Prediction of 28-day Mortality Speaker: Tanapun Thamgrang, TH
PB0451 Hemostatic Effect of Tranexamic Acid Combined with 16:00 - 16:00 Emicizumab in Prophylactic Setting in Severe Hemophilia A: A Preclinical Study Speaker: Yesim Dargaud, FR
PB0452 Real-world Clinical and Patient-centric Outcomes in People with 16:00 - 16:00 Haemophilia A in France: Findings from the CHESS II Study Speaker: Charlotte Camp, GB
PB0453 Mitigation of Injection Site Reactions after Subcutaneous 16:00 - 16:00 Administration of Dalcinonacog Alfa (DalcA) in Hemophilia B Using Preclinical Models Speaker: Natacha Le Moan, US
PB0454 Impact of Adherence to Prophylactic Treatment on Real-world 16:00 - 16:00 Outcomes in Adults with Severe Haemophilia: A CHESS II Analysis in Europe Speaker: Sharmila Kar, GB
PB0455 Immune Complex Formation of Factor VIII (FVIII) with Inhibitors 16:00 - 16:00 is Modulated by von Willebrand Factor (vWF) Speaker: Olga Oleshko, DE
PB0456 Real-world Clinical and Patient-centric Outcomes in People with 16:00 - 16:00 Haemophilia A in Spain: Findings from the CHESS II Study Speaker: Anum Shaikh, GB
PB0457 Frequency of Dosing and Presence of Endogenous VWF 16:00 - 16:00 Influences FVIII Inhibitor Development
59 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Matthew Cormier, CA
PB0458 Dose Selection of Marzeptacog Alfa (Activated) in Children with 16:00 - 16:00 Hemophilia: A Population Pharmacokinetic Exposure Matching Strategy Speaker: Tom Knudsen, US
PB0459 Optimization of Thrombin Generation for Hemophilia A 16:00 - 16:00 Speaker: Tom van de Berg, NL
PB0460 Influence of Activated Factor XI on Simultaneous Thrombin 16:00 - 16:00 Generation and Fibrin Clot Lysis in Factor Deficiencies Speaker: Ivan Tarandovskiy, US
PB0461 Monocytes Express Different Cytokines upon Stimulations with 16:00 - 16:00 a Variety of FVIII but Not FIX Concentrates Speaker: Sarah Scatigna, DE
PB0462 Monocytes Show Differences in Cytokine Expression after 16:00 - 16:00 Stimulation with FVIII Concentrates Compared to FIX or MOG Speaker: Anja Schmidt, DE
PB0463 Real-world Outcomes in People with Severe Hemophilia B 16:00 - 16:00 Receiving FIX Prophylaxis across Europe: A CHESS II Analysis Speaker: Tom Burke, GB
PB0464 Real-world Clinical and Patient-centric Outcomes in People with 16:00 - 16:00 Haemophilia A in Italy: Findings from the CHESS II Study Speaker: Anum Shaikh, GB
PB0465 Thrombin Generation by Genesia in Patients with Haemophilia 16:00 - 16:00 A and Inhibitors during Immune Tolerance Induction Speaker: Timea Szanto, FI
PB0466 GEPHARD – The PUP Cohort of the `Standing Commission 16:00 - 16:00 Paediatrics of the Society for Thrombosis and Haemostasis Research´ - A Progress Report Speaker: Mira Türknetz, DE
PB0467 Effects of von Willebrand Factor on Plasma Haemostasis 16:00 - 16:00 Speaker: Cornelis Kluft, NL
PB0468 Examination and Validation of a Patient-centric Joint Metric: 16:00 - 16:00 “PROBLEM JOINT”; Empirical Evidence from the CHESS Paediatrics Dataset Speaker: Idaira Rodriguez Santana, GB
PB0469 Dose Selection for Subcutaneous Marzeptacog Alfa (Activated) 16:00 - 16:00 in Subjects with Factor Vll Deficiency Using Population Pharmacometric Clinical Trial Simulations Speaker: Tom Knudsen, US
PB0470 Predicting the Duration of Recombinant Factor VIIa Effect on 16:00 - 16:00 Tail Bleeding by the Thrombin Generation Assay in Hemophilia A Mice Speaker: Stepan Surov, US
60 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0471 Comparative Recovery of FVIII Antigen with Various FVIII 16:00 - 16:00 Therapeutic Concentrates Using an Improved 2nd Generation ELISA Kit Speaker: Ran Ni, CA
PB0472 Results of Thrombin Generation Assay in Patients Treated with 16:00 - 16:00 Emicizumab Speaker: Beata Baran, PL
PB0473 Clinical Characteristics and Incidence of Inhibitors in Previously 16:00 - 16:00 Untreated Children with Haemophilia: An Update of the Hemfil Cohort Study Speaker: Leticia Lemos Jardim, BR
PB0474 Is Standardisation the Key? FVIII Inhibitor Results: A UK 16:00 - 16:00 National External Quality Assessment Scheme for Blood Coagulation (UK NEQAS BC) Exercise Speaker: Anna Lowe, GB
PB0475 Spectrum of F8/F9 Gene Mutations in the PedNet Cohort 16:00 - 16:00 Speaker: Veerle Labarque, BE
PB0476 Association between Factor VIII Deficiency and Low Bone 16:00 - 16:00 Mineral Density in Children with Hemophilia Speaker: Laura Villarreal Martínez, MX
PB0477 Differences in Thrombin Generating Capacity in Severe 16:00 - 16:00 Haemophilia A Speaker: Colleen Hamid, GB
PB0478 Laboratory Verification of a Chromogenic Factor IX Assay Kit 16:00 - 16:00 Speaker: Julie Tange, US
PB0479 Real-world Clinical and Patient-centric Outcomes in People with 16:00 - 16:00 Haemophilia A in the United Kingdom: Findings from the CHESS II Study Speaker: Charlotte Camp, GB
PB0480 Usefulness of Global Coagulation Assays to Monitor 16:00 - 16:00 Emicizumab Therapy Speaker: Debora Bertaggia Calderara, CH
PB0481 Analysis of the Percentage of Persons with Severe Hemophilia 16:00 - 16:00 A as an Indicator of Care Speaker: Ellia Tootoonchian, CA
PB0482 Evaluation of Primary Haemostasis in Children and Young 16:00 - 16:00 Adults with Haemophilia Speaker: Maria Kürschner, DE
PB0483 New Likely Pathogenic Variants in Three Spanish Patients with 16:00 - 16:00 Mild Hemophilia A and B: Importance of Genetic Counseling Speaker: Maria Civeira, ES
PB0484 Is Zero Bleeds a Realistic Goal for Hemophilia Patients in the 16:00 - 16:00 Real World Setting?
61 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Alkistis Adramerina, GR
PB0485 Laboratory Monitoring of Emicizumab in Treated Patients - How 16:00 - 16:00 Does APTT Compare? Speaker: Aine McCormick, GB
PB0486 Characteristics of Anti-drug Antibody against Emicizumab 16:00 - 16:00 Analyzed Using Hemophilia A Patient-derived Plasma Samples Speaker: Ryohei Kawasaki, JP
PB0487 Real-world Clinical and Patient-centric Outcomes in People with 16:00 - 16:00 Haemophilia A in Germany: Findings from the CHESS II Study Speaker: Anum Shaikh, GB
PB0488 Exploring the Level of Congruence between Patient- and 16:00 - 16:00 Haematologist-reporting of Anxiety and Depression in People with Haemophilia A Speaker: Charles Hawes, GB
PB0490 Properties of FVIII Concentrate Were Obtained by the Method of 16:00 - 16:00 Dye-ligand Affinity Chromatography Speaker: Nataliya Shurko, UA
PB0491 A Review Following Implemented Training for Health Care 16:00 - 16:00 Practitioners in Primary Care Settings of Immunisation Practice in Children with Bleeding Disorders Speaker: Marie Eales, GB
PB0492 Clinical Profile and Bleeding Outcome of Pediatric Hemophilia 16:00 - 16:00 A: The Royal Hospital’s Experience, Oman Speaker: Anood Al Rawahi, OM
PB0493 Acute Myelogenous Leukemia in a Patient with Mild 16:00 - 16:00 Haemophilia A. A Case Report at Hospital Infantil de México Federico Gómez Speaker: Lucía Mariana Muñoz Juárez Díaz, MX
LPB0067 Drastic Decrease in FVIII Response after Repeated Daily 16:00 - 16:00 Desmopressin Administrations in Peri-operative Non-severe Hemophilia A Patients: Final Results of Tachyphylaxis in the DAVID and Little DAVID Study Speaker: Lorenzo Gaetano Renata Romano, NL
LPB0114 Safety of FEIBA and Emicizumab (SAFE): Dose Escalation 16:00 - 16:00 Study Evaluating the Safety of in vivo Administration of Activated Prothrombin Complex Concentrate in Hemophilia A Patients with Inhibitors on Emicizumab Speaker: Hande Kizilocak, US
LPB0115 High Impact and Severe Outcomes of Intracranial Hemorrhage 16:00 - 16:00 (ICH) in an Italian Population of Adult Mild Hemophiliac Patients: Data from the EMO.REC Registry Speaker: Ezio Zanon, IT
PB0494 Evolution of Emicizumab Plasma Concentrations and aPTT 16:00 - 16:00 rratio in 183 Treated Patients with Severe Haemophilia A. A Real
62 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Life and Multi-centre Analysis Speaker: Claire Pouplard, FR
PB0495 Emicizumab in Obese Adults with Hemophilia A – Pooled Data 16:00 - 16:00 from Three Phase III Studies (HAVEN 1, 3 and 4) Speaker: Michael Recht, US
PB0496 Increased Prevalence of Age-related Comorbidities and Health 16:00 - 16:00 Service Utilization among Adult Men with Hemophilia in Alberta, Canada Speaker: Arafat Ul Alam, CA
PB0498 Prevalence of Hypertension in Hemophilia Patients: A 16:00 - 16:00 Systematic Review Speaker: Anna Ter-Zakarian, US
PB0499 Understanding the burden of Care for Haemophilia in the UK: 16:00 - 16:00 Direct Medical Costs and Associated Predictors from the CHESS I and II Studies Speaker: Amit Chhabra, GB
PB0500 Inhibitor Development upon Switch from Plasma-derived to 16:00 - 16:00 Recombinant FVIII in PUPs with Severe Haemophilia A: Preliminary Analysis from the PUP-SWITCH Study Speaker: Syna Miri, IT
PB0501 Real-world Use of FVIII in People with Severe Hemophilia A 16:00 - 16:00 without Inhibitor on Prophylaxis, Comparing Switched to rFVIII- Fc versus Non-switched Patients: A Multicentre, Retrospective, Non Interventional, before-after Study with the French Nationwide Claims Database (MOTHIF-II) Speaker: Valerie HORVAIS, FR
PB0502 Prospective, Open-label, Multicentre Phase II Study (PeKaFIX) 16:00 - 16:00 to Evaluate the Pharmacokinetic Parameters of a Plasma Derived Factor IX Concentrate and Build a Pharmacokinetic Bayesian Model Speaker: Claude Negrier, FR
PB0503 Safety and Efficacy of Concizumab Prophylaxis Following a 16:00 - 16:00 Switch from rFVIIa on-demand Treatment: Sub-analysis Results from the Phase 2 Explorer4 Trial in Patients with Hemophilia A or B with Inhibitors Speaker: Guy Young, US
PB0504 Emicizumab Treatment in Pediatric Haemophilia A Patients: >1 16:00 - 16:00 Year Safety Based on Real-world Data from the PedNet Cohorts Speaker: Gili Kenet, IL
PB0505 Incorporating Patient Reported Outcomes into Clinical Practice: 16:00 - 16:00 A 360-degree Clinical Evaluation for Better Care and Treatment of People with Hemophilia through myWBDR and myPROBE Speaker: Toong Youttananukorn, CA
PB0506 Interim Analysis of the PREVENT Study: Real World Prospective 16:00 - 16:00
63 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Data from Children and Adolescents with Haemophilia A or B Treated with Recombinant Factor VIII Fc (rFVIIIFc) or Recombinant Factor IX Fc (rFIXFc) Speaker: Christine Heller, DE
PB0507 Hemophilia A Patients with Factor ? Inhibitor Feature Reduced 16:00 - 16:00 Levels of CD4+CD25+CD127- Treg Cells and Plasma IL-35 Speaker: ZHEN YU YAN, CN
PB0508 Clinical Outcomes after Joint Surgery in Patients on Turoctocog 16:00 - 16:00 Alfa Pegol Prophylaxis Speaker: Andreas Tiede, DE
PB0509 Does Pharmacokinetic-guided Prophylaxis with Antihemophilic 16:00 - 16:00 Factor (Recombinant) Improve Bleeding Rates over Standard Prophylaxis? Real-world Data from the AHEAD German Study Speaker: Johannes Oldenburg, DE
PB0510 Updates on the Atlanta Protocol Cohort: Two-year Institutional 16:00 - 16:00 Outcomes on Immune Tolerance Induction in Children with Hemophilia A and Inhibitors on Emicizumab Speaker: Glaivy Batsuli, US
PB0511 Efficacy and Safety of Emicizumab Prophylaxis in Severe 16:00 - 16:00 Haemophilia A without Inhibitors: A Report from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) Speaker: Caroline Wall, GB
PB0512 Association of Physical Activity with Bleeding Frequency in 16:00 - 16:00 Children with Hemophilia A: A CHESS PAEDs Study Analysis Speaker: Richard Ofori-Asenso, GB
PB0513 Developing Predictive Models of rFVIII-Fc Half Life for 16:00 - 16:00 Personalized Prophylaxis in Patients with Hemophilia A Speaker: Chia-Yau Chang, TW
PB0514 Longer-term Efficacy and Safety of Concizumab Prophylaxis in 16:00 - 16:00 Hemophilia A and Hemophilia A/B with Inhibitors: Results from the Main and Extension Parts of Concizumab Phase 2 Trials Speaker: Jan Astermark, SE
PB0515 Reviewing HJHS as a Tool to Assess Outcome Measures in 16:00 - 16:00 Patients with Haemophilia A in Australia Speaker: Sumit PARIKH, AU
PB0516 Sports Injuries in Dutch People with Hemophilia: Results of a 12 16:00 - 16:00 Months’ Prospective Study Speaker: Olav Versloot, NL
PB0517 Soccer Is Popular and Relatively Safe for Children and Young 16:00 - 16:00 Adults with Hemophilia: Experiences from the Netherlands Speaker: Olav Versloot, NL
PB0518 Treatment Patterns and Clinical Outcomes among Patients with 16:00 - 16:00 Hemophilia A Treated with Factor VIII Replacement Therapies
64 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
and Nonfactor Therapy: An Assessment of US Real-world Data Speaker: Ayoade Adeyemi, US
PB0520 The Efficacy and Prognosticator for Inhibitor Eradication in 16:00 - 16:00 Hemophilia A Boys with High-titer Inhibitors Using a Low-dose Immune Tolerance Induction Strategy (with or without Immunosuppressants): Data from the National Center for Children’s Health of China Speaker: Zekun Li, CN
PB0521 Final Analysis of the STASEY Trial: A Single-arm, Multicenter, 16:00 - 16:00 Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors Speaker: Victor Jiménez-Yuste, ES
PB0522 Final Results of ReITIrate - A Prospective Study of Rescue 16:00 - 16:00 Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc (rFVIIIFc) in Patients who Have Failed Previous ITI Attempts Speaker: Christoph Königs, DE
PB0523 Hemophilia Treatment in 2021: Choosing the ‘Optimal’ 16:00 - 16:00 Treatment Using an Integrative, Patient-orientated Approach to Shared Decision-making between Patients and Clinicians Speaker: Cedric Hermans, BE
PB0524 Efficacy and Safety of rIX-FP: A Longitudinal Analysis of 16:00 - 16:00 Patients Treated across the PROLONG-9FP Clinical Trials Program Speaker: Ingrid Pabinger, AT
PB0525 Emicizumab Dosing in Children and Adults with Hemophilia A: 16:00 - 16:00 Simulating a User-friendly and Cost-efficient Regimen Speaker: Laura H. Bukkems, NL
PB0526 Fitusiran Population Pharmacokinetic and Pharmacodynamic 16:00 - 16:00 (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme Speaker: Pratik Bhagunde, US
PB0527 Postoperative Bleeding Complications in Patients with 16:00 - 16:00 Hemophilia Undergoing Major Orthopedic Surgery: A Prospective, Multicenter Observational Study Speaker: Tyler W. Buckner, US
PB0528 Assessment of the Bleeding Phenotype in Patients with Non- 16:00 - 16:00 severe Hemophilia According to the ISTH Bleeding Assessment Tool (BAT) Speaker: Fabienne Kloosterman, NL
PB0529 Changes in Treatment Patterns in Patients with Severe 16:00 - 16:00 Haemophilia - a Longitudinal Analysis of the Austrian Haemophilia Registry Speaker: Daniel Kraemmer, AT
65 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0530 Adoption of Emicizumab for Hemophilia A in Europe: Data from 16:00 - 16:00 the 2020 European Association for Haemophilia and Allied Disorders Survey Speaker: Evelien Krumb, BE
PB0531 Use of Desmopressin in the Treatment of Bleeding in Non- 16:00 - 16:00 severe Hemophilia A Speaker: Annefleur Zwagemaker, NL
PB0532 Evaluation of Liver Health after Fidanacogene Elaparvovec 16:00 - 16:00 Gene Therapy: Data from Study Participants with up to 5 Years of Follow-up Speaker: Lindsey A. George, US
PB0533 A single center study of bone mineral density in adult patients 16:00 - 16:00 with severe Haemophilia A and correlation with markers of bone metabolism Speaker: Hristina Ivanova, BG
PB0534 Dutch Overweight People with Hemophilia Report More 16:00 - 16:00 Limitations in Activities, but No Association with Sports Speaker: Olav Versloot, NL
PB0535 Long-term Prophylaxis with Simoctocog Alfa in Children 16:00 - 16:00 Speaker: Anna Klukowska, PL
PB0536 Results from the Eptacog Beta in the Treatment of Bleeding 16:00 - 16:00 Episodes of all Severities in Pediatric Hemophilia A or B Patients with Inhibitors Speaker: Giancarlo Castaman, IT
PB0537 Real-world Experience in Introducing Emicizumab Prophylaxis 16:00 - 16:00 for Adults with Haemophilia A without Inhibitors Speaker: Niamh Larkin, IE
PB0538 Efficacy and Safety Analysis of the Use of rIX-FP in Patients 16:00 - 16:00 with Hemophilia B: A Prospective, Non-interventional, Surveillance Study from Germany Speaker: Johannes Oldenburg, DE
PB0539 Is Zero Bleeds in PWH an Achievable Goal? 3 Years of 16:00 - 16:00 Emicizumab in Persons with Hemophilia A and Inhibitors in a Portuguese Hemophilia Treatment Centers Speaker: Soraia Campaniço, PT
PB0540 Feasibility of Measuring through PROMIS Computer Adaptive 16:00 - 16:00 Tests (CATs) and Short Forms (SFs) in Haemophilia – Preliminary Data Speaker: Isolde A.R. Kuijlaars, NL
PB0541 Warfarin Resistance Is Rare but Has Heterogeneous Origin in an 16:00 - 16:00 Anticoagulation Clinic Population Speaker: Rachel Peck, GB
PB0542 Looking Beyond Fixed-Dose Rurioctocog Alfa Pegol 16:00 - 16:00
66 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Prophylaxis: Post Hoc Analysis of PK-guided Regimens from the PROPEL Phase 3 Study Speaker: Carmen Escuriola-Ettingshausen, DE
PB0543 Thrombin Generation Capacity of Patients with Severe 16:00 - 16:00 Haemophilia Receiving Prophylaxis (HOPE Study) Speaker: Yesim Dargaud, FR
PB0544 Eptacog Beta (Factor VIIa, Recombinant) Provides Rapid Bleed 16:00 - 16:00 Resolution and Pain Relief in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors Speaker: Wolfgang Miesbach, DE
PB0546 Ultrasound Assessment of the Joint Status in Hemophilia 16:00 - 16:00 Patients under Prophylaxis Using the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Score Speaker: Irene Ricca, IT
PB0547 The Safety of Eptacog Beta in Hemophilia Patients with 16:00 - 16:00 Inhibitors in Adult, Pediatric, and Perisurgical Settings Speaker: Johnny Mahlangu, ZA
PB0548 The Clinical Bleeding Phenotype of Patients with Non-severe 16:00 - 16:00 Hemophilia A and B Speaker: Annefleur Zwagemaker, NL
PB0549 Immunogenicity and Safety of Simoctocog Alfa in Previously 16:00 - 16:00 Treated Patients Switching to Simoctocog Alfa in the GENA Clinical Trial Programme Speaker: Andreas Tiede, DE
PB0550 Real-world Joint Bleeding Rates in Patients with Congenital 16:00 - 16:00 Hemophilia and Inhibitors: Final Data from the FEIBA Global Outcome (FEIBA GO) Study Speaker: Jerzy Windyga, PL
PB0551 Real-world Usage of rFIXFc in Sweden: A Report from the 16:00 - 16:00 Swedish National Registry for Bleedings Disorders Speaker: Margareta Holmström, SE
PB0552 B-MORE, Baseline Analysis from a 24-month Prospective, Non- 16:00 - 16:00 interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B Speaker: Giancarlo Castaman, IT
PB0553 Tissue Factor Pathway Inhibitor (TFPI) Levels and Bleeding Risk 16:00 - 16:00 in Patients with Severe Hemophilia A or B Speaker: Brigitte Tardy-Poncet, FR
PB0554 The Impact of PK-guided Prophylaxis on Clinical Outcomes and 16:00 - 16:00 Resource Utilization in Hemophilia A Patients: Real-world Evidence From the CHESS II Study Speaker: Shawn X Sun, US
67 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0555 Identify Clinical and Laboratory Phenotypes of People with 16:00 - 16:00 Hemophilia in Southwest Nigeria Speaker: Titilope Adeyemo, NG
PB0556 Randomized Clinical Trial of PK-guided Treatment of 16:00 - 16:00 Desmopressin Combined with FVIII Concentrate versus Only FVIII Concentrate in Peri-operative Hemophilia A Patients: Final Results of the Little DAVID Study Speaker: Lorenzo Gaetano Renata Romano, NL
PB0558 The Devil is in the Detail: An Irish Approach to Switching to 16:00 - 16:00 Emicizumab Prophylaxis in an Adult Comprehensive Care Centre (CCC) Speaker: Evelyn Singleton, IE
PB0559 Predicted FVIII Consumption of BAY 94-9027 Compared with 16:00 - 16:00 Standard- and Extended-half-Life FVIII Products in Patients with Severe Hemophilia A Speaker: Alfonso Iorio, CA
PB0560 Time from the Inhibitor Detection to the Start of Immune 16:00 - 16:00 Tolerance Induction and the Outcome of Immune Tolerance Induction: Results from the Brazilian Immune Tolerance (BrazIT) Study Speaker: Ricardo Camelo, BR
PB0561 Impact of Prophylactic Treatment on Employment and Disability 16:00 - 16:00 in Persons with Hemophilia Speaker: Pal Andre Holme, NO
PB0562 User Evaluation of a Home-treatment Recording Smartphone 16:00 - 16:00 App Speaker: Mairead O'Donovan, IE
PB0563 Genetic and Clinical Determinants for the Outcome of Immune 16:00 - 16:00 Tolerance Induction in Severe Hemophilia A – Preliminary Results Speaker: Ilja Oomen, NL
PB0564 Real World Data on Haemophilia A Patients Switching to 16:00 - 16:00 rFVIIIFc Treatment in Greece. Interim Results from the Multicenter Observational Study TOOL Speaker: Olga Katsarou, GR
PB0565 Emicizumab in Pediatric Hemophilia: A Single-center 16:00 - 16:00 Retrospective Study Speaker: Clay Cohen, US
PB0566 In vitro Analysis of Coagulation Function in Emicizumab-treated 16:00 - 16:00 Hemophilia A Patients with Inhibitors under Immune Tolerance Induction Treatment Speaker: Yuto Nakajima, JP
PB0567 Efficacy of Reduced-dose Emicizumab in Haemophilia A with 16:00 - 16:00 Inhibitors: Real World Experience in East Malaysia
68 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Lee Ping Chew, MY
PB0568 Pharmacokinetic-guided Prophylaxis Improved Clinical 16:00 - 16:00 Outcomes in 46 Pediatric Patients with Severe Hemophilia A Speaker: Huang Kun, CN
PB0569 The Role of Familial Mediterranean Fever in Hemophilia: Should 16:00 - 16:00 We Tested? Speaker: ZÜHRE KAYA, TR
PB0570 First Interim Analysis from the Observational HEM-POWR Study 16:00 - 16:00 Evaluating Effectiveness and Safety of Real-world Treatment with Damoctocog Alfa Pegol in Previously Treated Patients with Hemophilia A Speaker: Mark Reding, US
PB0571 Health Care Resource Use (HRU) among Adult Persons with 16:00 - 16:00 Hemophilia B (PwHB) and Concurrent Joint Disease (JD) in the United States Speaker: Patrick F. Fogarty, US
PB0572 Health Care Resource Use (HRU) among Adult Persons with 16:00 - 16:00 Hemophilia A (PwHA) and Concurrent Joint Disease (JD) in the United States Speaker: Leona E. Markson, US
PB0573 Patients with Severe Hemophilia A under Middle-dosed 16:00 - 16:00 Prophylaxis Benefit from Multi-disciplinary Team Management, an Experience Speaker: Zhou Shiqiu, CN
PB0574 Adherence to Prophylaxis and Recording of Home-treatment 16:00 - 16:00 Following a Switch to Extended Half-life Clotting Factor Concentrate Speaker: Mairead O'Donovan, IE
PB0575 The Potential Benefits of Physical Exercises for Reducing Pain 16:00 - 16:00 in Adult Haemophilic Arthropathy Patients: A Meta-analysis of Randomized Controlled Trials Speaker: Boby Pratama Putra, ID
PB0576 Impact of COVID-19 Pandemic on the Joint Bleeding Pattern and 16:00 - 16:00 Prophylactic Management of Hemophilia Patients: A Single Centre Study in a Tertiary Care Centre of Eastern India Speaker: Abhilash Chatterjee, IN
PB0577 Real-world Annual Bleeding Rate in People with Severe 16:00 - 16:00 Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non interventional, before-after Study with the French BERHLINGO Database (MOTHIF-II) Speaker: Valerie HORVAIS, FR
PB0578 Evaluating the Effectiveness of Recombinant Factor VIII Fc 16:00 - 16:00 Fusion Protein (rFVIIIFc) in Adolescents and Children with Hemophilia A in the Real World in Japan: Interim Analysis of the
69 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Multicenter, Observational Fc Adolescent and Children Treatment Study (FACTs) Speaker: Mutsumi Shiraishi, JP
PB0579 Evaluation of Real-world Effectiveness of BAY 81-8973 to Treat 16:00 - 16:00 Hemophilia A: An Analysis within the ATHNdataset Speaker: Thomas Moulton, US
PB0580 Population Pharmacokinetic Modeling of Factor Concentrates in 16:00 - 16:00 Hemophilia: A Detailed, Clinical Overview and Evaluation of Best Practice Speaker: MarieChristine H.J. Goedhart, NL
PB0581 Intracranial Haemorrhage (ICH) in Egyptian Children with 16:00 - 16:00 Haemophilia A and B: A 15 Year Retrospective Single Center Study Speaker: Magy Abdelwahab, EG
PB0582 Reducing the Time of HAL and pedHAL Assessment 16:00 - 16:00 Speaker: Isolde A.R. Kuijlaars, NL
PB0583 Left Atrial Appendage Occlusion for the Management of Atrial 16:00 - 16:00 Fibrillation in Persons with Hemophilia: A Case Report and Systematic Review of the Literature Speaker: Ming Yeong Lim, US
PB0584 Patients with Hemophilia B with Inhibitors in China 16:00 - 16:00 Speaker: Xueqing Dou, CN
PB0585 Mental Health Status of Hemophilia Carriers in China 16:00 - 16:00 Speaker: Dongyan Cui, CN
PB0586 A Qualitative Study on the Experiences of Hemophilia Carriers 16:00 - 16:00 before, during and after Pregnancy Speaker: Marieke C. Punt, NL
PB0587 Posttraumatic Stress Disorder and Posttraumatic Stress 16:00 - 16:00 Symptoms Among Adults with Hemophilia A and B Speaker: Amanda Stahl, US
PB0588 The F? Gene Mutation Analysis of Hemophilia B in China 16:00 - 16:00 Central and Western Regions Speaker: Wen Wang, CN
PB0589 Impact of Switching to Recombinant Factor IX Fc Fusion Protein 16:00 - 16:00 Prophylaxis: A Qualitative Study Speaker: Mairead O'Donovan, IE
PB0590 Efficacy of Simoctocog Alfa in Previously Untreated Patients 16:00 - 16:00 with Severe Haemophilia A: Final Results from the NuProtect Study Speaker: Ellis J. Neufeld, US
PB0591 Development of a Scale in the Diagnosis and Monitoring of 16:00 - 16:00 Arthropathy in Patients with Hemophilia Using Ultrasound (US) and MRI: Initial Report
70 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Pawel Laguna, PL
PB0592 Assessment of Thrombin Generation on Severe Haemophilia A 16:00 - 16:00 Patients in the Clinical Laboratory Speaker: Stephen Mac Donald, GB
PB0593 Promising Prospective Data on the Effect of Ankle Joint 16:00 - 16:00 Distraction in Hemophilic Arthropathy: Three Year Follow-up Speaker: E.D.P. van Bergen, NL
PB0594 2 Years ofPprophylaxis with rFVIII-Fc in Haemophilia in a 16:00 - 16:00 Portuguese Haemophilia Center: Did Doctors and Patients See a Change? Speaker: Soraia Campaniço, PT
PB0595 Emicizumab in Acquired Hemophilia A: A Scoping Review 16:00 - 16:00 Speaker: William Shi, CA
PB0596 Usefulness of Clot Waveform Analysis as a Perioperative 16:00 - 16:00 Monitoring in Arthroscopic Synovectomy to a Pediatric Patient with Hemophilia A and Inhibitor Receiving Emicizumab Speaker: Kuniyoshi Mizumachi, JP
PB0597 Telemedicine in Hemophilia: A Comprehensive Review 16:00 - 16:00 Speaker: Casey L Li, CA
PB0598 Demographic and Clinical Characteristics of Patients with 16:00 - 16:00 Hemophilia A in Brazil: Real-world Data from the 6th Interim Analysis of the AHEAD International Study Speaker: Margareth C. Ozelo, BR
PB0599 Prospective, Non-interventional Study with a Cohort to Assess 16:00 - 16:00 Real-world Effectiveness (RWE) and Safety of Emicizumab in Persons with Hemophilia A (PwHA) without Inhibitors in Spain, Hemolution Cohort Speaker: María Teresa Álvarez Román, ES
PB0600 Cost-effectiveness of rFVIII Single-chain in an Italian Population 16:00 - 16:00 of Hemophilia A Patients: The Veneto Experience Speaker: Ezio Zanon, IT
PB0601 Estimation of Secondary Prophylaxis Effectiveness in Patients 16:00 - 16:00 with Severe Form of Hemophilia A Speaker: Tatsiana Talako, BY
PB0602 Emicizumab: What Can Patients Expect Regarding Hemostasis, 16:00 - 16:00 Bleeding and Sports Capacity? Speaker: Beth Boulden Warren, US
PB0603 Update on Real Life Use of Emicizumsb in Pediatric Patients 16:00 - 16:00 without Inhibitors Speaker: Sabine Heine, DE
PB0604 Can Plasminogen Activator Inhibitor 1 and Thrombin Activitable 16:00 - 16:00 Fibrinolysis Inhibitor Explain Bleeding Phenotype in Hemophilia A?
71 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Somaya Elhefnawy, EG
PB0605 Recommendations for Intramuscular COVID-19 Vaccination in 16:00 - 16:00 Patients with Hemophilia Speaker: Christian Pfrepper, DE
PB0606 Emicizumab in the Treatment of Adult Haemophilia Patients 16:00 - 16:00 Real-world Data Speaker: Jerzy Windyga, PL
PB0607 Chinese Real-world Experience of Product Switching in Severe 16:00 - 16:00 Hemophilia Patients: from rFVIII-FS(Kogenate®) to BAY 81-8973 (Kovaltry®) Speaker: Chen Rong, CN
PB0608 MOdern Treatment of Inhibitor-PositiVe PATiEnts with 16:00 - 16:00 Haemophilia A – MOTIVATE (www.motivate-study.com) Speaker: Carmen Escuriola Ettingshausen, DE
PB0609 Rationale and Design of the “International Registry on the 16:00 - 16:00 Symptomatic Hemophilia A/B Carriers” Speaker: Samantha Pasca, IT
PB0610 Intracranial Hemorrhage in Hemophiliac Patients at Chiang Mai 16:00 - 16:00 University Hospital: A 10-year Retrospective Study Speaker: Jetniphat Khamyuang, TH
PB0611 Clinicopathological Parameters and Influence of Blood Group 16:00 - 16:00 and von Willebrand Factor (vWF) Levels on Residual Factor VIII (FVIII) Levels in Haemophilia A Patients Speaker: Debadrita Ray, IN
PB0612 Prevalence of Hematuria in Patients with Hemophilia A and B 16:00 - 16:00 and its Association with Comorbidities: Experience from a Brazilian Center Speaker: Paula Villaca, BR
PB0613 Thrombin Generation in Hemophilia A Patients after Infusion of 16:00 - 16:00 Recombinant and PlasmadDerived Factor VIII Concentrates Speaker: Olga Smirnova, RU
PB0614 Pharmacokinetics-adjusted Dosing of Rurioctocog Alfa Pegol 16:00 - 16:00 (Adynovi) in Adult Patients with Haemophilia A Speaker: Jacek Treli?ski, PL
PB0615 Prostate Surgery in Patients with Hemophilia: A Monocentric 16:00 - 16:00 Real-life Experience Speaker: Nicolas Drillaud, FR
PB0616 Association of Individual Pharmacokinetics-guided Regimen in 16:00 - 16:00 Hemophilia A Patients and FVIII Consumption: A Single-center Study Speaker: qu hong, CN
PB0617 Comprehensive Genotype Characterization in Non-severe 16:00 - 16:00 Hemophilia A. Mutational Profile and Assessment of the
72 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Bleeding Phenotype in Argentine Patients Speaker: Liliana Rossetti, AR
PB0618 Genetic and Non-genetic Determinants for the Outcome of 16:00 - 16:00 Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors – A Systematic Review Speaker: Ilja Oomen, NL
PB0619 Patient and Healthcare Professional Perspectives on the Use of 16:00 - 16:00 a Personal Health Record in Hemophilia Care: A Qualitative Study Speaker: Martijn R Brands, NL
PB0620 Haemophilia A Genotyping in Patients with Discrepancy in FVIII 16:00 - 16:00 Activity Levels Measured with One-stage and Chromogenic Assays Speaker: Liliana Rossetti, AR
PB0621 Influence of Pregnancy on the Pharmacokinetic Profile of a 16:00 - 16:00 Severe Hemophilia A Female Speaker: Lidia Costa, PT
PB0622 AOZORA Study: Long-Term Safety and Joint Health in Pediatric 16:00 - 16:00 Patients with Hemophilia A without FVIII Inhibitors Receiving Emicizumab – Protocol for a Multicenter, Open-label, Phase IV Clinical Study Speaker: Midori Shima, JP
PB0623 AKATSUKI Study: A Prospective, Multicenter, Phase IV Study to 16:00 - 16:00 Evaluate the Safety of Emicizumab Under and Immediately after Immune Tolerance Induction (ITI) Therapy in Persons with Congenital Hemophilia A (PwHA) with Factor (F) VIII Inhibitors Speaker: Tadashi Matsushita, JP
PB0624 A Bleed Suppression Efficacy of Emicizumab in Patients with 16:00 - 16:00 Hemophilia A whose Therapies Switched from Conventional Prophylaxis Speaker: Teruhisa Fujii, JP
PB0625 Primary Prophiliaxis was Associated with a Lower Risk of Joint 16:00 - 16:00 Damage in Colombian Men Patients with Hemophilia A Speaker: Gina Alejandra Diaz Mosquera, CO
PB0626 Feasibility of Integrating PROBE (Patient Reported Outcomes, 16:00 - 16:00 Burdens and Experiences) into a Clinical Care Pathway to Facilitate Transformation to a Value-based Health Care Model in Hemophilia Speaker: Shannon C. Jackson, CA
PB0627 PRactical Utilisation of Octapharma FVIII Concentrates in 16:00 - 16:00 Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq®, o ctanate® or wilate® – The Protect-NOW Study Speaker: Susan Halimeh, DE
73 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0628 A Study of Psychosocial Issues for Mothers of Children with 16:00 - 16:00 Hemophilia Speaker: Aya Nakao, JP
PB0629 Clinical Assessment with the Evaluation of Joint Disease and 16:00 - 16:00 Haemostatic Treatment in Patients with Severe Haemophilia B Speaker: Anna Buczma, PL
PB0630 Benefits of Prophylactic Emicizumab in Enhancing Immune 16:00 - 16:00 Tolerance Induction in a Hemophiliac Boy with Very High Inhibitor Titer Speaker: Nongnuch Sirachainan, TH
PB0631 Standard Prophylactic Regimen Is Three Times and Twice a 16:00 - 16:00 Week in Hemophilia A and B, Respectively. The Low Dose Tailoring Method of Prophylaxis Has Been Introduced for Patients with Hemophilia Speaker: Mehran Karimi, IR
PB0632 Emicizumab Therapy for Neonatal Intracranial Hemorrhage 16:00 - 16:00 Speaker: Amy Dunn, US
PB0633 Compare the Efficacy and Safety of Low-dose and Intermediate- 16:00 - 16:00 dose Prophylactic Therapy in Adult Patients with Severe Hemophilia A, a Self-control Study Speaker: hua ??, CN
PB0634 Effectiveness, Safety and Cost Assessment of Emicizumab in 16:00 - 16:00 Clinical Practice Speaker: Adrià Riera, ES
PB0635 Hemophilia and Concussion Outcome Study (HeCos): 16:00 - 16:00 Neurological Status of Children with Hemophilia – Prevalence and Relevance of Mild Traumatic Brain Injury Speaker: Agnes Berghuber, DE
PB0636 Discrepancies in Non-severe Hemophilia A. Experience in a 16:00 - 16:00 Hemophilia Center in Argentina Speaker: Emanuel Sueldo, AR
PB0637 Real World Experience with Emicizumab with Hemophilia A 16:00 - 16:00 Treated in Private Practice in Mexico Speaker: Maria Teresa Pompa Garza, MX
PB0638 Low-dose Prophylaxis in Severe Hemophilia A: A Single-center 16:00 - 16:00 Study Speaker: Munira Borhany, PK
PB0639 Off-pump Coronary Artery Bypass Graft Management in a 16:00 - 16:00 Severe Hemophilia B Patient Speaker: Giovanni Barillari, IT
PB0640 A Prospective Cohort Study on Disabilities in Patients with 16:00 - 16:00 Haemophilia Using Orthopaedic Scores Speaker: Malika Bajracharya, NP
74 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0641 Patient-centered Digital Health Interventions and their Effects 16:00 - 16:00 on Health Outcomes: A Systematic Review Speaker: Martijn R Brands, NL
PB0642 Joint Health Improvement Following a Switch to Prophylaxis 16:00 - 16:00 with rVIII-SingleChain: A Patient Case Speaker: Olga Benítez Hidalgo, ES
PB0643 Urosurgical Management in Mild Hemophilia with Inhibitor: A 16:00 - 16:00 Case Report Speaker: Lia Phillips, US
PB0644 Consistency Analysis and Data Validation Regarding 16:00 - 16:00 Hospitalization among Hemophilic Patients from the Hemophilia Center of the Hematology Service of HC FMUSP – (2008-2018) Speaker: Ana Claudia Guersoni, BR
PB0645 Real-world Experience of rIX-FP Prophylaxis at Dosing Intervals 16:00 - 16:00 of up to 14 Days in a Pediatric Patient with Hemophilia B during the COVID-19 Pandemic Speaker: Bolivar Luis Díaz Jordan, ES
PB0646 Clinical and Pharmacokinetic Assessment after Switching to an 16:00 - 16:00 Extended Half-life Product for Prophylaxis in Haemophilia B Speaker: Karen Ilenia Álvarez Tosco, ES
PB0647 Inhibitors in Non Severe Haemophilia A (NS-HA): A Case Report 16:00 - 16:00 Speaker: MANUEL R. LOPEZ, ES
PB0648 Infectious Complications in Hemophilia Patients 16:00 - 16:00 Speaker: Heghine Khachatryan, AM
PB0649 From Stroke Treatment, through a Tongue Bite, until Intensive 16:00 - 16:00 Care Unit: The Challenge of Antithrombotic Treatment in People with Haemophilia. A Case Report Speaker: Inês Machado, PT
LPB0019 Expression of Adenovirus-mediated Human Coagulation Factor 16:00 - 16:00 IX Gene in SD Rat Adipose Mesenchymal Stem cells Speaker: ZHEN YU YAN, CN
LPB0020 Etranacogene Dezaparvovec (AAV5-Padua hFIX Variant, 16:00 - 16:00 AMT-061), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-severe Hemophilia B: 2.5 Year Data from a Phase 2b Trial Speaker: Annette von Drygalski, US
LPB0021 Practical Application of FIX-Padua Field Study Results Enables 16:00 - 16:00 a Comparison of FIX:C Results Across AAV Gene Therapy Trials Independent of FIX:C Assay Reported Speaker: Erald Shehu, GB
LPB0022 Global Seroprevalence of Pre-existing Immunity against AAV 16:00 - 16:00 Serotypes in People with Hemophilia A Speaker: Robert Klamroth, DE
75 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0650 A Novel Strategy for Platelet-specific Gene Therapy for the 16:00 - 16:00 Treatment of Hemophilia A via Intranasal Delivery Lentiviral Vectors Containing Factor VIII Speaker: Cameron W. Rementer, US
PB0651 The Impact of Platelet ?IIb?3 on the Hemostatic Efficacy of 16:00 - 16:00 Platelet-derived FVIII Gene Therapy Speaker: Hongyin Yu, US
PB0652 Evolution of AAV Vector Gene Therapy is Ongoing In 16:00 - 16:00 Hemophilia. Will the Unique Features of BAY 2599023 Address the Outstanding Needs? Speaker: Steven W. Pipe, US
PB0653 52 Week Efficacy and Safety of Etranacogene Dezaparvovec in 16:00 - 16:00 Adults with Severe or Moderate-severe Hemophilia B: Data from the Phase 3 HOPE-B Gene Therapy Trial Speaker: Steven W. Pipe, US
PB0654 Clinical Translatable Preconditioning for Platelet Gene Therapy 16:00 - 16:00 in Murine Hemophilia A with Inhibitors Speaker: Qizhen Shi, US
PB0655 Development of Ordinary Differential Equation-based aPTT and 16:00 - 16:00 Thrombin Generation Models for Characterizing FIX-Padua Gain of Function Speaker: Thomas Orfeo, US
PB0656 Targeted CRISPR/Cas9-mediated Gene Addition to a Safe 16:00 - 16:00 Harbor in Placental Cells for the Treatment of Hemophilia A Speaker: Ritu M. Ramamurthy, US
PB0657 Novel Hyperactive FIX Variants and their Potential for 16:00 - 16:00 Hemophilia B Therapy Speaker: Ann-Kathrin Urbanowitz, DE
PB0658 Preferences of People with Hemophilia A and B for Treatments 16:00 - 16:00 Including Gene Therapies in the US: A Discrete Choice Experiment Speaker: George Morgan, GB
PB0659 Management of Infusion Reactions: Lessons from the Phase 3 16:00 - 16:00 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B Speaker: Michael Recht, US
PB0660 Exigency: The Real-world Impact of Gene Therapy on the Lives 16:00 - 16:00 of People with Haemophilia and their Families. An Interim Report Speaker: Simon Fletcher, GB
PB0661 The World Federation of Hemophilia Gene Therapy Registry 16:00 - 16:00 Speaker: Donna Coffin, CA
PB0662 Responses to Anxiety and Depression Items in People with 16:00 - 16:00
76 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Hemophilia who Tested a Patient Reported Outcome Measure: The coreHEM MH Study Speaker: Elizabeth Clearfield, US
PB0663 A Savvy Approach to Clinical Trial Recruitment for the SAAVY 16:00 - 16:00 (Seroprevalence of AAV AntibodY) Study in the Era of COVID-19: Designing for a Prospective, Observational Study in the United States during a Global Pandemic Speaker: Manil Vaghela, US
PB0664 The Importance of Patient Preferences and Other Patient- 16:00 - 16:00 Centric Metrics in Developing and Evaluating New Haemophilia Treatments Speaker: Sharmila Kar, GB
LPB0068 Efficacy of Parenteral Formulations of Desmopressin in the 16:00 - 16:00 Treatment of Bleeding Disorders: A Systematic Review Speaker: Stuart McKinlay, CA
LPB0069 Self-Propelled Hemostatic Powder Safely Achieves and 16:00 - 16:00 Maintains Hemostasis in a Live Porcine Model of Upper Gastrointestinal Bleeding Speaker: Nabil Ali-Mohamad, CA
PB0665 Off-label Use of Emicizumab in Persons with Acquired 16:00 - 16:00 Hemophilia A and von Willebrand Disease: A Scoping Review of the Literature Speaker: Vinay Mathew Thomas, US
PB0666 Functional Transitory Anti-emicizumab Antibody Creating 16:00 - 16:00 Bleeding Episodes Speaker: Flora Peyvandi, IT
PB0667 Differential Neutralization of Apixaban, Betrixaban, Edoxaban, 16:00 - 16:00 and Rivaroxaban by Andexanet Alfa as measured by Whole Blood Thromboelastographic Analysis Speaker: Siddharth Mehrotra, US
PB0668 Global Octim® Shortage: Experience in Strasbourg 16:00 - 16:00 Speaker: Dominique Desprez, FR
PB0669 Thromboelastography to Monitor Periprocedural Hemostasis in 16:00 - 16:00 Advanced Liver Disease: A Systematic Review and Meta- analysis Speaker: Jan Hartmann, US
PB0670 Success of Online CME at Improving Knowledge, Competence, 16:00 - 16:00 and Confidence around Guideline-directed Management of Oral Anticoagulant-related Urgent Bleeding Speaker: Margaret Harris, US
PB0671 Extended Half-life Products for Perioperative Hemostasis in 16:00 - 16:00 Major Orthopedic Surgery: Real-world Data from the LASH Study Speaker: Luigi Piero Solimeno, IT
77 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0672 Late Prophylaxis in Severe Hemophilia A: Effect on Functional 16:00 - 16:00 Abilities Speaker: Mário Sousa-Pimenta, PT
PB0673 Decreased Annual Bleeding Rate in Paediatric Patients with 16:00 - 16:00 Hemophilia a and Inhibitors Treated with Emicizumab vs Bypassing Agents Experience at the National Institute of Pediatrics, Mexico City, Mexico Speaker: MARA NUNEZ TOSCANO, MX
LPB0116 An Accurate and Simple Liquid Chromatography Tandem Mass- 16:00 - 16:00 spectrometric Method for the Quantification of Emicizumab in People with Hemophilia A Speaker: Anouk Donners, NL
PB0674 The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like 16:00 - 16:00 Blood Speaker: Mirella Ezban, DK
PB0675 Administration of fVIII Protein through Human Placental Cells 16:00 - 16:00 Reduces the Risk of an Antibody Response in Juvenile Sheep Speaker: Brady Trevisan, US
PB0676 Tailoring the Effect of Antithrombin-targeting Therapy in 16:00 - 16:00 Hemophilia A Using in Silico Thrombin Generation Speaker: Romy de Laat-Kremers, NL
PB0677 Real-world Experience of Emicizumab Treatment Using Entire 16:00 - 16:00 Vials Only Speaker: Kathelijn Fischer, NL
PB0678 Cost-effectiveness Analysis of the Brazilian Immune Tolerance 16:00 - 16:00 Induction Protocol with Recombinant Factor VIII and Prophylaxis with Bypassing Agents or Emicizumab Speaker: Ricardo Camelo, BR
PB0679 Measuring the Chromogenic FVIII Mimetic Activity of the New 16:00 - 16:00 Bispecific Antibody, Mim8, in Artificially Spiked Severe Haemophilia A Plasma Speaker: Annette Bowyer, GB
PB0680 Measuring the FVIII Mimetic Activity of the New Bispecific 16:00 - 16:00 Antibody, Mim8, in Severe Haemophilia A Plasma Using APTT and One-stage FVIII Assays Speaker: Annette Bowyer, GB
PB0681 Emicizumab Assays: One Stage vs. Chromogenic Stage Assay 16:00 - 16:00 Speaker: Melissa Stuart, US
PB0682 A Systematic Review on the Pharmacokinetics and Associated 16:00 - 16:00 Pharmacodynamics of Emicizumab in Humans Speaker: Anouk Donners, NL
PB0683 Twelve Months of Emicizumab Prophylaxis in a Woman with 16:00 - 16:00 Mild Hemophilia A and Inhibitor: Effectiveness, Safety and
78 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Economic Outcome Speaker: Ricardo Camelo, BR
PB0684 Emi and Me: The Real-world Impact of Emicizumab on the Lives 16:00 - 16:00 of People with Haemophilia A with Inhibitors and their Families Speaker: Simon Fletcher, GB
PB0685 Twelve Months of Emicizumab Prophylaxis in a Severe 16:00 - 16:00 Hemophilia A Man with Inhibitor who Failed Immune Tolerance Induction: Effectiveness, Economic, and Safety Outcomes Speaker: Ricardo Camelo, BR
PB0686 Do New Therapies alter the Treatment of Hemophilia Patients? 16:00 - 16:00 Speaker: Christine Keipert, DE
PB0687 Successful Experience of Emicizumab Prophylaxis in a Child 16:00 - 16:00 with Severe Hemophilia A and Inhibitor without Previous Immune Tolerance Induction Speaker: Ricardo Camelo, BR
LPB0070 Efficacy and Safety of Human Fibrinogen Concentrate for 16:00 - 16:00 Treatment of on-demand Bleeding in Adolescent and Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-02 and FORMA-04 Clinical Trials Speaker: Claudia Djambas-Khayat, LB
PB0688 High-throughput Screening for Pharmacological Enhancers of 16:00 - 16:00 Mutated Factor VII Activity Speaker: Maria Eugenia Chollet, NO
PB0689 GGCX Mutations Lead to Different ?-carboxylation Status of 16:00 - 16:00 Vitamin K Dependent Coagulation Proteins Speaker: Suvoshree Ghosh, DE
PB0690 Concurrent Use of Tranexamic Acid and Hormonal Therapy: 16:00 - 16:00 Management of Heavy Menstrual Bleeding in Women with Inherited Bleeding Disorders Speaker: Audrey Epstein, GB
PB0691 Unclassified Bleeding Disorders and Inherited Platelet Function 16:00 - 16:00 Disorders: Response to Desmopressin Challenge Speaker: Michael Desborough, GB
PB0692 Population Parmacokinetics of rFXIII (Catridecacog) and Clinical 16:00 - 16:00 Outcomes of Prophylaxis in an Italian Population of Patients with Factor XIII Deficiency Speaker: Ezio Zanon, IT
PB0693 Clinical and Genetic Analysis of Nine Cases of Hereditary 16:00 - 16:00 Factor V Deficiency Speaker: Donglei Zhang, CN
PB0694 Monitoring Rare Bleeding Disorders and their Response to 16:00 - 16:00 Therapeutic Treatments with a Microchip Flow-chamber Assay Speaker: Paula Acuña, ES
79 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0695 Outcomes of a Bleeding Disorders Diagnostic Multi-disciplinary 16:00 - 16:00 Team Meeting for Diagnosing Unclassified Bleeding Disorder / Bleeding of Unknown Cause Speaker: Will Thomas, GB
PB0696 Implementation of a National Reference Service for Activity 16:00 - 16:00 Testing, Typing, and Genotyping of Hereditary Factor XIII Deficiency (Project BR-13) Speaker: Ricardo Camelo, BR
PB0697 Factor XI Deficiency in Pregnant Women: A Genotype to 16:00 - 16:00 Phenotype Correlation and Analysis Speaker: Guilherme Sacchi de Camargo Correia, US
PB0698 Human Fibrinogen Concentrate for Bleeding Prophylaxis During 16:00 - 16:00 Surgery in Adult, Adolescent and Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-02 and FORMA-04 Clinical Trials Speaker: Claudia Djambas-Khayat, LB
PB0699 Subcutaneous Marzeptacog Alfa (Activated) is Effective 16:00 - 16:00 Treatment of Bleeding in FVII Deficient Rats Speaker: Tom Knudsen, US
PB0700 Phenotype-Genotype Relationship in Patients with Hereditary 16:00 - 16:00 FXI Deficiency Speaker: Canan Albayrak, TR
PB0701 Evaluation of Coagulation Profile in FVII Deficiency with 16:00 - 16:00 Inhibitor Using Global Coagulation Tests: A Case Report Speaker: MARIA ISABEL RIVAS POLLMAR, ES
PB0702 Hereditary Haemorrhagic Telangiectasia (HHT) or Rendu-Osler 16:00 - 16:00 Weber Disease as an Important Rare Haemorrhagic Disorder in Costa Rica: A Report of Costa Rica Speaker: Lizbeth Salazar-Sanchez, CR
PB0703 A Review of Beighton Scores Recorded for All Patients with a 16:00 - 16:00 Bleeding Tendency Registered at One Haemophilia Centre without Another Formal Bleeding Disorder Diagnosis Speaker: James Clark, GB
PB0704 Congenital Factor XI Deficiency: A Single-center Retrospective 16:00 - 16:00 Analysis of 80 Cases Speaker: Xiyan Wang, CN
PB0705 Increased Risk for Re-bleeding after Hemostatic Challenges in 16:00 - 16:00 Patients with a Mild to Moderate Bleeding Tendency Speaker: Dino Mehic, AT
PB0706 ROTEM in Combination with Bleeding History - Can it Serve as a 16:00 - 16:00 Screening Test for Factor XIII Deficiency in Patients with Suspected Bleeding Disorder? Speaker: Tulasi Geevar, IN
80 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0707 Fibrinogen Austin (A?17Gly?Cys and A?381Ser?Phe); 16:00 - 16:00 Identification of a Novel Fibrinogen Mutation Causing Dysfibrinogenaemia Speaker: Joseph Rigano, AU
PB0708 Rare Bleeding Disorders in Children. Towards Establishing a 16:00 - 16:00 Local Registry Speaker: Dmitry Florinskiy, RU
PB0710 Hemorrhagic Adventitious Bursitis of the Foot in a Patient with 16:00 - 16:00 Congenital Type 3 von Willebrand Disease Speaker: Roberta Gualtierotti, IT
PB0711 Registry of Patients with Congenital Bleeding Disorders from a 16:00 - 16:00 Single Centre: Clinical and Analytical Characteristics Speaker: ALICIA LORENZO JAMBRINA, ES
PB0712 Quality of Life of People with Hereditary Factor XIII Deficiency 16:00 - 16:00 Treated at a Reference Centre Speaker: Ricardo Camelo, BR
PB0713 Impact of Inherited Bleeding Disorders on Pregnancy and 16:00 - 16:00 Postpartum Hemorrhage Speaker: Nuria Fernández Mosteirín, ES
PB0714 Successful Prophylactic Use of Coagulation Factor X in an 16:00 - 16:00 Infant Patient in the Home Environment Speaker: Yvonne Lantz, US
PB0715 Safe and Effective Prophylaxis with Plasma-derived Factor X 16:00 - 16:00 Concentrate in an Elderly Patient with Hereditary Factor X Deficiency Speaker: Mark Reding, US
PB0716 Congenital Factor Vii Deficiency and Vacterl Association: An 16:00 - 16:00 Unusual Combination Speaker: Ayelet Ramirez, CO
PB0717 Clinical Profile and Bleeding Outcome of Pediatric Rare 16:00 - 16:00 Bleeding Disorders: The Royal Hospital’s Experience, Oman Speaker: Mazoon AL Saadi, OM
PB0718 Familial Multiple Coagulation Factor Deficiencies (FMCFDs); A 16:00 - 16:00 Rare Case of Combined Deficiency of Factor V and Factor VIII (F5F8D) Speaker: Joseph Rigano, AU
PB0719 Inherited Factor XIII Deficiency: A Mild and a Severe Case 16:00 - 16:00 Reports Speaker: Daniela Oliveira Werneck Rodrigues, BR
PB0720 Epidemiology of Severe Rare Congenital Bleeding Disorders at 16:00 - 16:00 a Bleeding Disorders Reference Center in Spain Speaker: Maria Fernanda Martinez Garcia, ES
PB0721 Thromboembolic Disease in Severe Factor V (FV) Deficiency: A 16:00 - 16:00
81 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Case Report: “Anticoagulating the Anticoagulable” Speaker: MANUEL R. LOPEZ, ES
PB0722 Safety and Efficacy of Fibrinogen Concentrate in Congenital 16:00 - 16:00 Fibrinogen Deficiency: A Post-marketing Observational Study Speaker: Bruce Schwartz, US
PB0723 Evaluation of FXI-deficiency Treatment in Pediatric Patients: A 16:00 - 16:00 Case-series Speaker: Dhulfiha Muzafar Gani, BH
PB0724 Severe Congenital Factor XIII-A Deficiency: A Clinical Case 16:00 - 16:00 Speaker: Izarbe Delgado, ES
PB0725 Successful Pregnancy in a Patient with Factor XIII Deficiency 16:00 - 16:00 and Recurrent Miscarriages Speaker: Tarakeswari Surapaneni, IN
PB0726 Bleeding and Thrombosis in One Patient - Management of 16:00 - 16:00 Challenging Disorders of Hemostasis Speaker: Lucia Stanciakova, SK
PB0727 The Paradoxal Association beetween Congenital FVII Deficiency 16:00 - 16:00 and Thromboembolism Speaker: Imen krichen, TN
LPB0023 Role of Tissue Factor in Delayed Bone Repair Induced by 16:00 - 16:00 Diabetic State in Mice Speaker: Kohei Tatsumi, JP
LPB0024 Coagulation-cancer Crosstalk; Von Willebrand Factor 16:00 - 16:00 Contributes to Pro-invasive and Pro-angiogenic Properties in Breast Cancer Cells Speaker: Sean Patmore, IE
LPB0071 Coagulation Factor 5 (F5) Is an Estrogen-responsive Gene in 16:00 - 16:00 Breast Cancer Cells Speaker: Benedicte Stavik, NO
PB0728 Antigenic Levels of von Willebrand Factor Predict 16:00 - 16:00 Complications and Mortality in Patients with Liver Cirrhosis Speaker: Mohamed EL HORRI, DZ
PB0729 Dual Effect of Hepsin Expression on Tumor Phenotype and 16:00 - 16:00 Prothrombotic Potential of Colorectal Cancer Cells and Inhibition by Venetoclax Speaker: David Zaragoza-Huesca, ES
PB0730 Comparison of the Relative PAR1, PAR2 and PAR3 Cleavage 16:00 - 16:00 Profiles by Thrombin, APC, Factor Xa and Factor VIIa Speaker: Atsuki Yamashita, US
PB0731 Activated Protein C Impacts Survival and Activity of Mast Cells 16:00 - 16:00 and Neurons via the Modulation of Nuclear Factor-?B Activation Speaker: Liubov Gorbacheva, RU
82 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0732 Acute Promyelocytic Leukaemia with Anti Phospholipid 16:00 - 16:00 Antibody Syndrome – Double Trouble Speaker: Sindhura Lakshmi Koulmane Laxminarayana, IN
PB0733 Plasma D-dimer and Fibrinogen Levels Correlates with Tumour 16:00 - 16:00 Size and Disease Progression in Nigerian Breast Cancer Patients Speaker: Ogochukwu Izuegbuna, NG
PB0734 Malignant Clonal Cell Proliferation in Multiple Myeloma and the 16:00 - 16:00 Hypercoagulable State Speaker: Tishya Indran, AU
PB0735 Fibrinogen Binding to Macrophages Attenuates Antiviral 16:00 - 16:00 Responses to dsRNA Speaker: David Martinez, US
PB0737 An Assessment of Some Inflammatory and Haemostatic 16:00 - 16:00 Proteins as Biomarkers for Vaso-occlusive Crises in Sickle Cell Anaemia Patients Speaker: Ogochukwu Izuegbuna, NG
PB0738 Biomarkers of Inflammation and Thrombosis in Hepatocellular 16:00 - 16:00 Carcinoma Speaker: Ambar Farooqui, US
LPB0118 Clinically Meaningful and Long-term Improvements in Fatigue 16:00 - 16:00 with the C3 Inhibitor Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria: Post-hoc Analyses from the PEGASUS Study Week 48 Speaker: David Cella, US
PB0739 Acquired Isolated FVII Deficiency in Oncological Patients 16:00 - 16:00 Speaker: NATALIA GARCÍA-LEÓN, ES
PB0740 Coagulopathy in Multiple Myeloma 16:00 - 16:00 Speaker: Katerina Chasakova, CZ
PB0741 Elucidating the Relationship between Thrombo-inflammatory 16:00 - 16:00 Biomarkers and Blood Cellular Indices in Lymphoma Patients Speaker: Mark Jaradeh, US
LPB0119 Impact of Vancomycin-induced Shift of the Gut Microbiome in 16:00 - 16:00 Gram Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized, Controlled Trial Speaker: Soerajja Bhoelan, NO
PB0743 Von Willebrand Factor Propeptide to Antigen Ratio: Evidence of 16:00 - 16:00 Endothelial Activation in HIV Infected Pregnancy Speaker: Elise Schapkaitz, ZA
PB0744 Long Term Trends of Coagulation Parameters in People Living 16:00 - 16:00 with HIV-1 Treated with Combined Antiretroviral Therapy Speaker: Soerajja Bhoelan, NO
PB0745 Endothelial Protein C Receptor (EPCR)-dependent 16:00 - 16:00
83 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Sequestration of P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1)-derived Fluorescent Microspheres in the Brain Vasculature of a Humanized Mouse Speaker: Roberto Aiolfi, US
LPB0072 Aspirin vs P2RY12-Inhibitors to Reduce Cancer Associated 16:00 - 16:00 Thrombosis and Tumor Growth in Digestive Cancers Speaker: Ana Luisa Palacios Acedo, FR
LPB0120 Correlation between Procoagulant Platelets and 16:00 - 16:00 Hypercoagulability in Lung Cancer Patients Speaker: Mark Schreuder, AU
LPB0121 Quantitative and Qualitative Changes in Platelet Traits of 16:00 - 16:00 Sunitinib-treated Patients with Renal Cell Carcinoma in Relation to Circulating Sunitinib Levels: A Proof-of-Concept Study Speaker: Marijke J.E. Kuijpers, NL
PB0746 Tumor Cell-induced Platelet Aggregation is Sustained by 16:00 - 16:00 Platelet Entrapment into the Fibrin Network Formed by Thrombin Speaker: Ivan Tesakov, RU
PB0747 Platelets Promoted Malignancy Involving Exosomal HMGB1 16:00 - 16:00 Speaker: Jiaan-Der Wang, TW
PB0748 Anti-platelet Drugs and Risk of Intracranial Hemorrhage in 16:00 - 16:00 Patients with Metastatic Brain Tumors Speaker: Eric Miller, US
PB0749 Native Rotational Thromboelastometry in Chemotherapy 16:00 - 16:00 Induced Thrombocytopenia Speaker: Anne-Marije Hulshof, NL
PB0750 Correlation between Serum PDGF-CC Levels with Clinical Stage 16:00 - 16:00 of Colorectal Cancer Speaker: Erty Sundarita, ID
PB0751 A Role of Possible Synergistic Effect of P Selectin Glycoprotein 16:00 - 16:00 Ligand 1 Polymorphism and Antiphosholipid Antibodies on Thrombosis in Myeloproliferative Neoplasia Patients Speaker: Rolandas Gerbutavi?ius, LT
PB0752 Chemotherapy Induced Thrombocytopenia: Is it Inducing 16:00 - 16:00 Additional Social, Economic and Clinical Burden? Speaker: Nida Anwar, PK
PB0753 Association of Platelet Count and Coagulopathy before, during 16:00 - 16:00 and Post Chemotherapy: Is it Worth Doing? Speaker: Nida Anwar, PK
PB0754 Antiplatelet and Cytostatic Properties of Nilotinib Synthetic 16:00 - 16:00 Analogues Speaker: Louisa M. Pechlivani, GR
PB0755 Characteristics and Management of a Series of TAFRO 16:00 - 16:00
84 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Syndrome Speaker: Xu Ye, CN
PB0756 Chronic Myeloid Leukemia with Extreme Thrombocytosis as 16:00 - 16:00 Unusual Initial Presentation Speaker: Nina Petkova, BG
PB0757 Chemotherapy-induced Thrombocytopenia and Platelet 16:00 - 16:00 Transfusions in Hematology/Oncology Practice Speaker: Liana Hambardzumyan, AM
PB0758 Hemostatic Evaluation by Thromboelastography in Patients 16:00 - 16:00 from a Peruvian Oncologic Center Speaker: Liberdi Froydi Motta Rosada, PE
LPB0073 Platelet Function Is Inhibited by Dengue Virus 16:00 - 16:00 Speaker: M Alejandro Mosso-Pani, US
LPB0074 Platelet Transfusion Does Not Prevent Experimental 16:00 - 16:00 Polymicrobial-induced Septic Shock in Mice Speaker: Yannick RABOUEL, FR
PB0759 Platelets Show a Distinct Response in a Controlled Human 16:00 - 16:00 Malaria Infection (CHMI) Model Speaker: Anurag Singh, DE
PB0760 PSGL-1 is Important for Platelet-monocyte Aggregate Formation 16:00 - 16:00 and Monocyte Maturation in Lentiviral Infection Speaker: Claire Lyons, US
PB0761 Phenotypic Changes in Platelets during Measles Virus Infection 16:00 - 16:00 of Rhesus Macaques (Macaca Mulatta) Speaker: Selena Guerrero-Martin, US
PB0762 Effect of Social Stress on Innate Immune Activation in an SIV- 16:00 - 16:00 infected Pigtail Macaque (Macaca nemestrina) Model of Acute HIV Infection Speaker: Natalie Castell, US
PB0763 Incidence and Correlation of Thrombocytopenia to Blood 16:00 - 16:00 Stream Infections; Does this Correlation Really Matter? Speaker: Nida Anwar, PK
PB0764 Platelet Involvement and its Association with Mortality in 16:00 - 16:00 COVID-19 Patients at a Safety-net Hospital Speaker: Luis Fernando Gonzalez Mosquera, US
PB0765 Human Myeloperoxidase Enhances Thrombin Induced 16:00 - 16:00 Phosphatidylserine Exposure in Human Platelets through Tyrosine Kinase/Calcium/Potassium Channels-mediated Pathway Speaker: E Shamova, BY
PB0767 Selected Platelet Parameters in Patients with Rheumatoid 16:00 - 16:00 Arthritis at Total Hip Arthroplasty
85 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Irina P. Antropova, RU
PB0768 The Intact Heavy Chain of Plasminogen Supresses 16:00 - 16:00 Angiogenesis More Strongly than the Known Angiostatin Speaker: Karina Gershkovich, RU
PB0769 Anti-cancer Activity of Tempeh - Spermine Can Induce the 16:00 - 16:00 Necrosis of HeLa Cells Speaker: Hiroyuki Sumi, JP
PB0770 Effect of Aroma Hand Massage on the Plasma Concentration of 16:00 - 16:00 Plasminogen Activator Inhibitor-1 Produced by Endothelial Cells in Healthy Subjects Speaker: Tatsuya Hayashi, JP
PB0772 The Importance of Follow up Post PE 16:00 - 16:00 Speaker: Matthew Roberts, GB
PB0773 Depression and Anxiety Screening in a Pediatric Coagulation 16:00 - 16:00 Disorder Program: A Brief Description of a 7-week Pilot Speaker: Chi Braunreiter, US
PB0774 Development of Decision-making Process to Support Equitable 16:00 - 16:00 Participant Selection in Pediatric Hemophilia Trials Speaker: Korinne Hamilton, CA
PB0775 Clinical Factors Predicting Decrease in Hemoglobin Levels 16:00 - 16:00 during Preoperative Autologous Blood Donation by Patients Undergoing Major Orthopedic Surgery Speaker: Satoshi Fujii, JP
LPB0122 Severe FXI Deficiency a Pediatric Cohort 16:00 - 16:00 Speaker: Assaf Arie Barg, IL
PB0776 A Retrospective Review of Diagnosis and Management of Heavy 16:00 - 16:00 Menstrual Bleeding and Co-morbidities in Patients Seen in Young Women’s Blood Clinic Speaker: Mahima Joshi, CA
PB0777 Blood Transfusion is Associated with Mortality among 16:00 - 16:00 Neonates with Congenital Diaphragmatic Hernia on ECMO Support Speaker: Yu Yang, US
PB0778 Emergency Department Care in Pediatric and Adolescent 16:00 - 16:00 Patients Presenting with Abnormal Uterine Bleeding Speaker: Nicole Kendel, US
PB0779 Specificity and Sensitivity of Pediatric Bleeding Questionnaire 16:00 - 16:00 (PBQ) in Identifying Patients Requiring further Laboratory Evaluation Speaker: Tatyana Yafoshkina, RU
PB0780 The Distribution of Anti-platelet Membrane Glycoprotein 16:00 - 16:00 Antibodies Subtypes in Children with Primary Immune Thrombocytopenia and its Relationship with Therapeutic Effect
86 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Rongwei Li, CN
PB0781 A Conservative Therapy Spontaneous Intracranial Hemorrhage 16:00 - 16:00 in a Pediatric Patient with Severe Acquired Aplastic Anemia Speaker: Maria-Manuel Deveza, PT
PB0782 Children with Bleeding and Clotting Disorders: Reviewing 16:00 - 16:00 Quality of Life Tools Speaker: Sophie Jones, AU
PB0783 Use of Single Photon Emission Computed Tomography and 16:00 - 16:00 Arthrocentesis in the Management of Hip Hemarthrosis in Hemophilia A Speaker: Jennifer Mooney, CA
LPB0026 How to Use Thrombolytic Agents in the Treatment of Neonatal 16:00 - 16:00 Thrombosis: A Systematic Review Speaker: Jay Patel, CA
LPB0027 Systematic Review on Neonatal Portal Vein Thrombosis 16:00 - 16:00 Speaker: Muneera Alhaddad, CA
LPB0028 Difference is Risk Factors and Clinical Outcomes in Pediatric 16:00 - 16:00 Patients with Deep Venous Thrombosis as Compared to Pulmonary Embolism Speaker: Shruthi Suryaprakash, US
LPB0075 Treatment of Catheter-related Arterial Thrombosis in Children: 16:00 - 16:00 A 15-year Single Center Experience Speaker: Manuela Albisetti, CH
LPB0076 Cerebral Sinovenous Thrombosis and Asparaginase Re- 16:00 - 16:00 exposure in Patients Aged 1 to 45 Years with Acute Lymphoblastic Leukemia: A NOPHO ALL2008 Study Speaker: Mette Tiedemann Skipper, DK
LPB0077 Management of Localized Intravascular Coagulopathy with 16:00 - 16:00 Rivaroxaban in Children with Venous Malformations: Report of 6 Cases Speaker: Fatma Burcu Belen Apak, TR
LPB0078 Intracranial Involvement and Neurologic Manifestations in 16:00 - 16:00 Lemierre Syndrome: Analysis of 712 Patients Speaker: Luca Valerio, DE
LPB0123 Thrombotic Complications in a Cohort of Children with 16:00 - 16:00 Myeloproliferative Neoplasms Speaker: Nicole Kucine, US
LPB0124 Low Hemoglobin as a Biomarker for Paediatric Sinus 16:00 - 16:00 Thrombosis Speaker: Bushra Moiz, PK
LPB0125 Characteristics of Pediatric Oncology Patients with Tumour 16:00 - 16:00 Thrombus Speaker: Nasrin Samji, CA
87 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0784 A 5-Year Study of Arterial and Venous Thromboses in Greek 16:00 - 16:00 Infants, Children and Adolescents. Comparison of Data Before and during the Pandemic Period Speaker: Loukia Ioannidou, GR
PB0785 Utility of Antithrombotic Therapy in Pediatric Portal Vein 16:00 - 16:00 Thrombosis after Endovascular Procedure Speaker: Katie Na, AE
PB0786 Analysis of Novel Risk Factors for Arterial or Venous 16:00 - 16:00 Thrombosis in Neonates Speaker: Kulsajan Bhatia, US
PB0787 Efficacy and Safety of Dabigatran in the Treatment and 16:00 - 16:00 Secondary Prevention of Venous Thromboembolism in Children with Cerebral Venous and Sinus Thrombosis Speaker: Leonardo Brandão, CA
PB0788 Outcomes of Prophylactic Enoxaparin against Venous 16:00 - 16:00 Thromboembolism in Hospitalized Children Speaker: Erin Bennett, US
PB0789 Management of Iliofemoral Deep Vein Thrombosis (DVT) in 16:00 - 16:00 Pediatric Patients in the Context of May-Thurner Syndrome (MTS) Speaker: Vivek Patel, CA
PB0790 Management of Antithrombotic Treatment and 16:00 - 16:00 Thrombohaemorragic Events in Children under Berlin Heart Excor Devices Speaker: Cristina Pascual Izquierdo, ES
PB0791 Essential Thrombocythemia in Children: A Retrospective, Real- 16:00 - 16:00 world Study Conducted in China Speaker: Rongfeng Fu, CN
PB0792 VTE Incidence in Children with Different Blood Disorders: Data 16:00 - 16:00 from a Large Monocenter Retrospective Cohort Study Speaker: Pavel A Zharkov, RU
PB0793 In Children Receiving Long-term Anticoagulation Decreased 16:00 - 16:00 Bone Mineral Density is Associated with Pubertal Development Speaker: Katharina Thom, AT
PB0794 The Bacteria-associated Thrombosis, Thrombophlebitis and 16:00 - 16:00 LEmierre Syndrome (BATTLE) Registry: Background and Rationale Speaker: Luca Valerio, DE
PB0796 Results of a Multinational Survey of Diagnosis, Practices and 16:00 - 16:00 Expertise in the Management of Venous Thromboembolism (VTE) in Pediatric Patients with Sickle Cell Disease (SCD) Speaker: Marisol Betensky, US
PB0797 Once a Day Compared to Twice a Day Enoxaparin in Children 16:00 - 16:00
88 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
with Venous Thromboembolism: A Single Center Experience Speaker: Amber Gibson, US
PB0798 Validation of a de novo Paediatric Warfarin Nomogram 16:00 - 16:00 Speaker: Sophie Jones, AU
PB0799 Pediatric Thromboembolism in Chiang Mai University Hospital: 16:00 - 16:00 A 10-year Review Speaker: Kanita Mankan, TH
PB0800 Factors, Determining Thrombus Recanalization in Children with 16:00 - 16:00 Different Blood Disorders Speaker: Pavel A Zharkov, RU
PB0801 A Rare Case of Thrombotic Storm in Henoch-Schonlein Purpura 16:00 - 16:00 Speaker: Angelica Kristine Baylon, PH
PB0802 Inherited Antithrombin Deficiency in Childhood: A Multicenter 16:00 - 16:00 National Study Speaker: Aysegul Unuvar, TR
PB0803 Resolution Rates of Provoked Deep Vein Thrombosis and 16:00 - 16:00 Pulmonary Embolism in Pediatric Patients Managed at a Tertiary Care Center Speaker: Manmeet Dhaliwal, CA
PB0804 Acquired von Willebrand Disease in a Child as Leading 16:00 - 16:00 Symptom of Systemic Lupus Erythematosus Speaker: Federica Achini-Gutzwiller, CH
PB0805 Preliminary Results of the Adventh-pediatric Registry in a 16:00 - 16:00 Southeastern Brazilian City Speaker: Joyce Annichino-Bizzacchi, BR
PB0806 A Prospective Data Collection Utilizing the International 16:00 - 16:00 Pediatric Thrombosis Network (IPTN) to Understand the Epidemiology for the Development of Neonatal Renal Vein Thrombosis Speaker: Gary Woods, US
PB0807 A Case of a Pediatric Patient with Protein S Heerlen 16:00 - 16:00 Polymorphism and Deep Venous Thrombosis Speaker: Marija Kacar, CA
PB0808 Catastrophic Thrombotic Syndrome in 8 Year Old Boy: Clinical 16:00 - 16:00 Case Report Speaker: Yuliia Kashpurenko, UA
PB0809 Severe Thrombosis Progression Despite Anticoagulation – Case 16:00 - 16:00 Report of Antithrombin Deficiency Speaker: Tiago Quaresma, PT
PB0810 A Comprehensive Review of Tumour Thrombus in Pediatric 16:00 - 16:00 Wilms Tumour Patients Speaker: Kaitlyn Kwok, CA
89 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0811 Prevalence of Venous Thrombembolic Events in the Czech 16:00 - 16:00 Pediatric Population - Epidemiological Study Speaker: Tomas Kuhn, CZ
PB0812 A Case Report and Comprehensive Review of Acquired Purpura 16:00 - 16:00 Fulminans in Children Speaker: Sophie Zarb, CA
PB0813 Identification of a Common PROC Gene Mutation in Children 16:00 - 16:00 with Moyamoya Disease Using Whole Exome Sequencing Speaker: Nongnuch Sirachainan, TH
PB0814 The Correlation of Vascular Platelet Hemostasis Disorders and 16:00 - 16:00 Typical Autoantibodies in Hepatic Cirrhosis at the Outcome of Autoimmune Hepatitis in Children Speaker: Ekaterina Konovalova, RU
PB0815 Time Course of Response to Fostamatinib, an Oral Spleen 16:00 - 16:00 Tyrosine Kinase (SYK) Inhibitor for the Treatment of Immune Thrombocytopenia (ITP) Speaker: Michelle Sholzberg, CA
PB0816 Exploring the Immune-related Biomarkers for Predicting the 16:00 - 16:00 Efficacy of Rituximab Treatment in Patients with Chronic Immune Thrombocytopenia Speaker: Xiyan Wang, CN
PB0817 Platelet Apoptosis and Autophagy in Pediatric Immune 16:00 - 16:00 Thrombocytopenia: New Mechanistic Insights Speaker: Francesca Daniela Franzoso, CH
PB0818 Therapeutic Landscape in Primary Immune Thrombocytopenia 16:00 - 16:00 (ITP) over the Last Three Decades in the United Kingdom (UK Adult Primary ITP Registry Project) Speaker: Priyanka Raheja, GB
PB0819 Length of Thrombopoietin Receptor Agonist (TPO-RA) 16:00 - 16:00 Treatment and Persistence in Immune Thrombocytopenia (ITP): Real World United States Claims Analyses Speaker: Scott Kolodny, US
PB0820 Altered Hemostatic Potential in Adults with Primary ITP 16:00 - 16:00 Speaker: Theresa Schramm, AT
PB0821 A Multicenter Double-blind, Double-dummy, Randomized Study 16:00 - 16:00 of rhTPO vs Eltrombopag in the Treatment of Chinese Immune Thrombocytopenia Speaker: Min Xu, CN
PB0822 Platelet Activation and Function in Adult Patients with Primary 16:00 - 16:00 Immune Thrombocytopenia Speaker: Dino Mehic, AT
PB0823 Switching from Eltrombopag or Romiplostim to Avatrombopag 16:00 - 16:00 in Immune Thrombocytopenia: A Multicenter Study of U.S. ITP
90 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Referral Centers Speaker: Hanny Al-Samkari, US
PB0824 Refractory Immune Thrombocytopenia (ITP): The Combination 16:00 - 16:00 of Thrombopoietin Analogs and Immunosuppressants, Experience in a Single Spanish Center Speaker: Irene Sánchez Bazán, ES
PB0825 Immature Platelet Fraction in Systemic Lupus Erythematosus- 16:00 - 16:00 Related Thrombocytopenia: Potential Predictor of Platelet Response to Treatment? Speaker: Tuan Nguyen, VN
PB0826 Off-label Use of Thrombopoietin Receptor Agonists: Case 16:00 - 16:00 Series and Review of the Literature Speaker: Marco Capecchi, IT
PB0827 Fatigue in Chronic Immune Thrombocytopenia Patients: 16:00 - 16:00 Validation of the Checklist Individual Strength and Comparison to Other Chronically Ill Populations Speaker: Wobke E. M. van Dijk, NL
PB0828 Autoimmune Platelet Function Disorders: Systematic Review of 16:00 - 16:00 Acquired Glanzmann Thrombasthenia and Acquired Delta Storage Pool Disease Cases Speaker: Antonietta Ferretti, IT
PB0829 The Spectrum of Immune Thrombocytopenia with COVID-19 16:00 - 16:00 Infection Speaker: Ibrahim Muhsen, US
PB0830 Efficacy and Safety of Efgartigimod PH20 Subcutaneous in 16:00 - 16:00 Adult Patients with Primary Immune Thrombocytopenia: ADVANCE SC, a Global Phase 3 Clinical Trial in Progress Speaker: Catherine Broome, US
PB0831 Prevalence of Thrombotic Events and Risk Factors in Patients 16:00 - 16:00 with Primary Immune Thrombocytopenia Speaker: Alberto Doblas-Marquez, ES
PB0832 Drug Induced Purpura in Autologous Hematopoietic Stem Cell 16:00 - 16:00 Transplantation – A Case Report Speaker: Tiago Quaresma, PT
PB0833 Treatment of Immune Thrombocytopenia (ITP) in the COVID-19 16:00 - 16:00 Era: Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor Speaker: Christine Ademokun, GB
PB0834 Idiopathic Thrombocytopenic Purpura: Conventional 16:00 - 16:00 Prednisolone vs High-dose Dexamethasone Speaker: Cameron Lewis, AU
PB0835 Serum Complement Levels in Immune Thrombocytopenia: 16:00 - 16:00 Relation with Clinical Presentation and Treatment Response
91 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Sandra Pérez -León, ES
LPB0079 Evaluation of the Different Platelet-dependent von Willebrand 16:00 - 16:00 Factor Activity Assays Capacity to Assess the in vivo Inhibitory Effect of Caplacizumab on the VWF-platelet Interaction Speaker: Paola Colpani, IT
PB0836 Melanoma Triggers Severe Thrombotic Thrombocytopenic 16:00 - 16:00 Purpura and Results in a High Mortality Rate in adamt13-/- Zebrafish Speaker: Liang Zheng, US
PB0837 Design of a Phase 3, Randomized, Controlled Study of 16:00 - 16:00 Prophylactic and On-demand Treatment with Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura Speaker: Cecilia Marquez, US
PB0838 Caplacizumab Rapidly Inhibits VWF-platelet Interaction: 16:00 - 16:00 Pharmacodynamic Data from Healthy Volunteers and Patients with aTTP Speaker: Filip Callewaert, BE
PB0839 Low Plasma ADAMTS13 Activity Contributes to Increased 16:00 - 16:00 Mortality Rate in Hospitalized Patients with Suspected Heparin- induced Thrombocytopenia Speaker: Meng Chan, US
PB0840 Plasma BioID of ADAMTS13 16:00 - 16:00 Speaker: Hasam Madarati, CA
PB0841 The Value of a Rapid, On-demand ADAMTS13 Activity Assay for 16:00 - 16:00 the Diagnosis of Thrombotic Thrombocytopenic Purpura Speaker: Alicia White, GB
PB0842 HIV is Not the Trigger for HIV-associated TTP 16:00 - 16:00 Speaker: Muriel Meiring, ZA
PB0843 The Clinical Burden of Congenital and Immune-mediated 16:00 - 16:00 Thrombotic Thrombocytopenic Purpura: A Retrospective Cohort Analysis Speaker: Spiros Tzivelekis, US
PB0844 Loss of Diagnostic Utility of D-dimers in Secondary Thrombotic 16:00 - 16:00 Thrombocytopenic Purpura (TTP) in Patients with Human Immunodeficiency Virus (HIV) Infection Speaker: Susan Louw, ZA
PB0845 Evaluation of the Local Tolerability of Recombinant ADAMTS13 16:00 - 16:00 Following Subcutaneous Injection in Rabbits Speaker: Jim Blank, US
PB0846 Thirty-five Years of Follow up of a Patient with Congenital 16:00 - 16:00 Thrombotic Thrombocytopenic Purpura Speaker: Miguel de Oliveira, PT
92 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0848 Validating Lactate Dehydrogenase (LDH) as a Component of the 16:00 - 16:00 PLASMIC Predictive Tool (PLASMIC-LDH) Speaker: Christopher Chin Keong Liam, AU
PB0849 TTP during Pregnancy: Acquired or Late-Onset Congenital? A 16:00 - 16:00 Diagnostic Challenge Speaker: Simke Demeester, BE
PB0850 Delayed Diagnosis of Congenital Thrombotic 16:00 - 16:00 Thrombocytopenic Purpura Presenting as Recurrent Cryptogenic Strokes Speaker: Marina Beltrami Moreira, US
PB0851 PK/PD Modeling and Simulations Highlight the Importance of 16:00 - 16:00 the Intravenous Loading Dose and Daily Dosing Regimen with Caplacizumab for Patients with aTTP Speaker: Tomás Sou, BE
PB0852 Desmopressin for Reversal of Antiplatelet Drugs in Stroke due 16:00 - 16:00 to Haemorrhage (DASH): Second Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial Speaker: Michael Desborough, GB
PB0853 Arginine-containing Peptides and Acetylsalicylic Acid: 16:00 - 16:00 Evaluation of Antiplatelet Effects Speaker: Marina Grigorjeva, RU
PB0854 Variable Serotonin Release Assay Pattern and Characteristics 16:00 - 16:00 of PF4-specific Antibodies in Heparin-Induced Thrombocytopenia, and Clinical Impact Speaker: Caroline Vayne, FR
PB0855 Diagnosing Heparin-induced Thrombocytopenia Using Machine 16:00 - 16:00 Learning Algorithms: First Data of the TORADI-HIT Study Speaker: Henning Nilius, CH
PB0856 Minimal Role of the Alternative Pathway in Complement 16:00 - 16:00 Aactivation by HIT Immune Complexes Speaker: Ayiesha Barnes, US
PB0857 A Multicenter Retrospective Evaluation of Direct Oral 16:00 - 16:00 Anticoagulants for the Treatment of Heparin Induced Thrombocytopenia Speaker: Sarah Nisly, US
PB0859 PF4/Polyanion ELISA-negative Antibodies to PF4 and Non-PF4 16:00 - 16:00 Targets Can Mediate Platelet Activation and Cause Heparin- induced Thrombocytopenia (HIT) Speaker: Bandana Singh, US
PB0860 Incidence of Heparin Induced Thrombocytopenia 2009-2017: 16:00 - 16:00 Analysis of the National Inpatient Sample Database Speaker: Yacki Hayashi-Tanner, US
PB0861 Incidence of Heparin-induced Thrombocytopenia in Patients 16:00 - 16:00
93 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Treated with Mechanical Circulatory Support: Results from a Prospective Study Speaker: Alisha Gaupp, DE
PB0862 Urgent Cardiac Surgery in a Patient with Heparin Induced 16:00 - 16:00 Thrombocytopenia Speaker: Marcela Romi?, HR
PB0863 A Puzzling HIT History: HIT Associated with Fondaparinux or 16:00 - 16:00 True Autoimmune HIT? Speaker: Nicolas Sillamy, FR
PB0864 Successful Treatment with Edoxaban in Heparin-induced 16:00 - 16:00 Thrombocytopenia with Thrombosis: A Case Report Speaker: Mateo Porres-Aguilar, US
PB0865 Role of Soluble C5b-9 (sC5b-9) in Dosing Adjustments of Anti- 16:00 - 16:00 complement Therapy during Pregnancy in a Patient with History of Atypical Hemolytic Uremic Syndrome (aHUS) Speaker: Célia Dos Santos, AR
LPB0080 Clinical and Biological Assessment of the Second Pedigree 16:00 - 16:00 Affected with X-linked GATA-1 Related Thrombocytopenia and Blood Group Lutheran Null Speaker: Verónica Palma-Barqueros, ES
PB0866 The Copenhagen Founder Variant GP1BA c.58T>G is Causal of 16:00 - 16:00 Monoallelic Bernard-Soulier Syndrome Speaker: Eva Leinøe, DK
PB0867 Investigations of the Impact of Sialidase-mediated Changes on 16:00 - 16:00 Bleeding Using a Humanized in vivo Mouse Model Speaker: Lisann Pelzl, DE
PB0868 Assigning Pathogenicity to a Novel de Novo ACTN1 Variant in a 16:00 - 16:00 Child with Macrothrombocytopenia: A Case Description And Review of Previously Identified Variants Speaker: Lucy FitzGibbon, GB
PB0869 Targeted Next Generation Sequencing for the Diagnosis of 16:00 - 16:00 Patients with Inherited Thrombocytopenias Speaker: Oded Gilad, IL
PB0870 Disturbed Platelet Activation in Children with 16:00 - 16:00 ANKRD26-associated Thrombocytopenia Speaker: Dmitrii Polokhov, RU
PB0871 Evaluation of the Sialidase Inhibitor Oseltamivir in GNE 16:00 - 16:00 -associated Thrombocytopenia Speaker: Marcus Fager Ferrari, SE
PB0872 Immunofluorescence Staining of Blood Smears for the 16:00 - 16:00 Diagnostics of Platelet Disorders: A Single-center Experience in a Pediatric Hospital Speaker: Nadezhda Podoplelova, RU
94 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0873 Clinical Application of Genetic Testing in Patients with Not 16:00 - 16:00 Acquired Thrombocytopenia: One Center Experience Speaker: Pablo Silva de Tena, ES
PB0874 Evolution over 50 Years of a Patient with Undiagnosed Gray 16:00 - 16:00 Platelet Syndrome Speaker: Andrés Peleteiro Raíndo, ES
PB0875 The Analysis of Platelet Functional Activity in Patients with 16:00 - 16:00 Thrombocytopenia Speaker: Marina Reshetova, RU
PB0876 P2Y12 Receptor Antagonists and Drug-induced Thrombotic 16:00 - 16:00 Microangiopathies: A Systematic Review of the Primary Evidence Speaker: Jasper C Ho, CA
PB0877 Vitamin B-12 Deficiency and Pseudo Thrombotic 16:00 - 16:00 Microangiopathy: A Case Series Speaker: Claire Jones, US
PB0878 Development of a Novel “Arterial Thrombosis-on-a-chip” 16:00 - 16:00 Microfluidic Device Speaker: Jess Berry, GB
PB0879 Structure-based Design of Cyclic Glycoprotein Ib?-derived 16:00 - 16:00 Peptides Affecting Platelet Interaction with von Willebrand Factor under Shear Conditions Speaker: Delia I. Fernández, NL
PB0880 A Novel Dual AntiPlatelet and AntiCoagulant APAC: Interaction 16:00 - 16:00 Between Platelet Factor 4 (PF4) and APAC Decreases Functional Activity Speaker: Ilja Nevzorov, FI
PB0881 Thrombotic Microangiopathies (TMA): In vivo Evidence for 16:00 - 16:00 Platelet Activation and Endothelial Cell Injury, and Potential for Therapeutic Intervention with Defibrotide Speaker: Jeffrey Laurence, US
PB0882 Lyophilized Human Platelets Support Thrombosis Unlike 16:00 - 16:00 Normal Platelets in the Presence of GPIIb/IIIa Antagonists Speaker: Matthew Dickerson, US
LPB0029 Distinct Clonal Mutation Patterns between JAK2 V617F Positive 16:00 - 16:00 and CALR-mutated Essential Thrombocythemia Speaker: Rongfeng Fu, CN
PB0883 Importance of Platelet’s Sialic Acid Residues on Haemostasis 16:00 - 16:00 and Immune System of Patients with Immune Thrombocytopenia Speaker: Nora Viviana Butta Coll, ES
PB0884 Evaluation of an Automated Platelet Aggregation Method for the 16:00 - 16:00 Detection of Patients with Congenital or Acquired Platelet
95 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Function Defects Speaker: Marco Capecchi, IT
PB0885 Frequent Platelet Dysfunction and Fibrinolysis in Patients with 16:00 - 16:00 Intracerebral Hemorrhage Speaker: Paul Lindholm, US
PB0888 Acquired ?-Storage Pool Disorder Co-existing with Acquired 16:00 - 16:00 Factor V Deficiency in Myelodysplastic Syndrome / Myeloproliferative Neoplasm Speaker: Rutvi Dave, IN
PB0889 Emergency Splenectomy for Immune Thrombocytopenia (ITP) 16:00 - 16:00 Patients with Life-threatening Bleeding: A Report of Three Cases and Review of the Literature Speaker: Muran Yang, CN
PB0890 Aspirin Resistance after Total Hip or Knee Arthroplasties 16:00 - 16:00 Speaker: Nameer van Oosterom, AU
LPB0081 Low Adhesion and Interaction Forces of Myh9 Mutant Platelets 16:00 - 16:00 Lead to Impaired Clot Retraction and Unstable Thrombus Formation Speaker: Juliane Baumann, DE
LPB0082 Enrichment of Variants in Platelet Genes in Patients with 16:00 - 16:00 Bleeding of Unknown Cause Speaker: Mackenzie Bowman, CA
LPB0126 Whole Blood Impedance Aggregometry: A Usefool Tool but Still 16:00 - 16:00 Not the Gold Standard Speaker: Syrine Ellouze, FR
LPB0127 Defective Platelet Endocytosis of Albumin in RUNX1 16:00 - 16:00 Haplodeficiency Associated with Altered Caveolin-dependent Albumin Trafficking in Megakaryocytic Cells Speaker: Fabiola Del Carpio-Cano, US
PB0891 Noonan Syndrome Bleeding Diathesis: Coagulation Factor 16:00 - 16:00 Deficiencies and/or Platelet Function Disorders? Speaker: Sandra Le Quellec, FR
PB0892 Platelet Dysfunction in Noonan Syndrome 16:00 - 16:00 Speaker: Silvia Sorrentino, IT
PB0893 The Glanzmann’s Thrombasthenia Registry (GTR): Safety of 16:00 - 16:00 Platelet Therapy in Patients with Glanzmann’s Thrombasthenia, with a Focus on Changes in alloimmunization Status Speaker: Man-Chiu Poon, CA
PB0894 Modelling Studies to Characterize a Novel Disease-causing 16:00 - 16:00 Variant in the GP1BA Gene Related to Bernard Soulier Syndrome Speaker: Adriana Inés Woods, AR
PB0895 Light Transmission Aggregometry (LTA) on TA-8V (Stago®): 16:00 - 16:00
96 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
What about Normal Values? Speaker: Sandra Le Quellec, FR
PB0896 A Novel Hemizygous Variant in GATA1 Associated with 16:00 - 16:00 Bleeding Diathesis and Platelet Dysfunction in Two Unrelated Patients Speaker: Jose Maria Bastida, ES
PB0897 Utility of Modified Ivy’s Bleeding Time and Closure Time on 16:00 - 16:00 Platelet Function Analyzer-200 as a Screening Tool to Identify Platelet Function Disorders Speaker: Rutvi Dave, IN
PB0899 Investigation of the Epidemiology of Inherited Platelet Disorders 16:00 - 16:00 in Patients Attending the Royal Hospital, Muscat, Oman Speaker: Rashid Al Ghaithi, OM
PB0900 Hemorrhagic Phenotype in Pediatric Patients with Glanzmann 16:00 - 16:00 Thrombasthenia (GT) Speaker: Daria Fedorova, RU
PB0901 Impact of Iron Deficiency Anemia on Bleeding Management in 16:00 - 16:00 Pediatric Patients with Bernard-Soulier Syndrome and Glanzmann Thrombasthenia: A Single-institution Analysis Speaker: Annika Lee, US
PB0903 Identification of ADP P2y12 Receptor Defect by Functional 16:00 - 16:00 Assays Using Algorithmic Approach – A Case Series Speaker: Rutvi Dave, IN
PB0904 A Novel Disease-causing Variant in the GP1BA Gene Related to 16:00 - 16:00 Bernard Soulier Syndrome Speaker: Adriana Inés Woods, AR
LPB0030 Investigating Impact of von Willebrand Factor Deficiencies on 16:00 - 16:00 the Biogenesis of Weibel-Palade Bodies and Endothelial Cells Signaling Pathways Speaker: Hamideh Yadegari, DE
PB0905 Mutations at p.C1190 in VWF D3 Retain VWF in the ER in VWD 16:00 - 16:00 2A Patient-derived ECFCs Speaker: Iris Van Moort, NL
PB0906 Evaluation of von Willebrand Factor (VWF) Replacement on in 16:00 - 16:00 vivo Angiogenesis in VWF?deficient Mice Speaker: Edwin Ocran, CA
PB0907 Agglomeration and then Capture within 10 ms Creates Shear- 16:00 - 16:00 induced Platelet Aggregation Controlled by von Willebrand Factor Concentration Speaker: Zixiang Liu, US
PB0908 Developing a Model for Studying von Willebrand Disease with 16:00 - 16:00 hiPSC-derived Endothelial Cells Speaker: Suzan de Boer, NL
97 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0909 Age-specific Changes in von Willebrand Factor Multimers in 16:00 - 16:00 Healthy Children and Adults Speaker: Natasha Letunica, AU
PB0910 Differential Release of VWF and VWF-propeptide from Platelet 16:00 - 16:00 Alpha-granules Speaker: Maurice Swinkels, NL
PB0911 Low Temperature Induces von-Willebrand Factor Expression via 16:00 - 16:00 Increased Early Growth Response 1 Transcriptional Activity in Splenic Sinusoidal Endothelial Cells Speaker: Kie Horioka, JP
PB0912 Palmitate Increases Gene Expression and Stimulated Secretion 16:00 - 16:00 of von Willebrand Factor in Human Umbilical Vein Endothelial Cells Speaker: Agnieszka Kinga Seliga, PL
PB0913 Prevailing c.2435delC and Other VWF Gene Defects in Russian 16:00 - 16:00 Patients with von Willebrand Disease Type 3. Four New Pathogenic Variants Found Speaker: Daria Chernetskaya, RU
LPB0031 Activity and Cleavage of von Willebrand Disease Type 2B 16:00 - 16:00 Variants Speaker: Maria Brehm, DE
LPB0032 Genetic Characterization of von Willebrand Disease Type 2 in 16:00 - 16:00 Milan Cohort Patients Speaker: Omid Seidizadeh, IT
LPB0128 Phase 3 Trial Results: Prophylaxis with Recombinant von 16:00 - 16:00 Willebrand Factor in Patients with Severe von Willebrand Disease Speaker: Flora Peyvandi, IT
PB0915 von Willebrand Factor (VWF) Multiplex Activity Assay 16:00 - 16:00 Differentiation of Low VWF/Type 1 von Willebrand Disease (VWD) and Variant VWD: Analysis from the Comparative Effectiveness in the Diagnosis of VWD Speaker: Jonathan C. Roberts, US
PB0916 Increased Cleavage of VWF by ADAMTS13 Might Reduce High- 16:00 - 16:00 molecular-weight VWF Multimers, Leading to Acquired von Willebrand Syndrome in Patients with Essential Thrombocythemia Speaker: Masayuki Kubo, JP
PB0917 Pharmacokinetics/Pharmacodynamics (PK/PD) of Recombinant 16:00 - 16:00 von Willebrand Factor (Vonicog Alfa) in Adult Patients with von Willebrand Disease (VWD) during Prophylactic Treatment Speaker: Alfonso Iorio, CA
PB0918 Low VWF Level due to Heterozygous p.P1127S Mutation of 16:00 - 16:00 VWF: Clinical Phenotype and Biochemical Effects
98 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Maira Tardugno, IT
PB0919 Prophylactic Subcutaneous Emicizumab-kxwh in Adults and 16:00 - 16:00 Children with Symptomatic Type 3 von Willebrand Disease Speaker: Kenny Vo, US
PB0920 Investigating Pathomolecular Mechanisms von Willebrand 16:00 - 16:00 Disease Variants Located in a Domains of the von Willebrand Factor Speaker: Hamideh Yadegari, DE
PB0921 Sensitivity of ISTH Bleeding Assessment Tool, Bleeding Time 16:00 - 16:00 and PFA-200 in the Diagnosis of von Willebrand Disease Speaker: Tulasi Geevar, IN
PB0922 Utility of a New, Rapid Automated von Willebrand Factor (VWF) 16:00 - 16:00 Multimer Assay for the Diagnosis of von Willebrand Disease Speaker: Justine Brodard, CH
PB0923 Clinical, Economic, and Quality of Life Burden Associated with 16:00 - 16:00 von Willebrand Disease (VWD) in Adults and Children: Systematic and Targeted Literature Reviews Speaker: Giancarlo Castaman, IT
PB0924 Burden of Illness in Patients with von Willebrand Disease: A 16:00 - 16:00 Systematic Review Speaker: Ping Du, US
PB0925 p.G2752S Severely Affects Dimerization of von Willebrand 16:00 - 16:00 Factor: An Analysis of Type 3 von Willebrand Disease Speaker: Shuichi Okamoto, JP
PB0926 Don’t Let Bleeding Go Unnoticed – A Global Initiative to 16:00 - 16:00 Increase Awareness of von Willebrand Disease Speaker: Fernando F. Corrales-Medina, US
PB0927 Characteristics and Treatment of Patients with von Willebrand 16:00 - 16:00 Disease (VWD) in General Practice Settings in the United Kingdom Speaker: Ping Du, US
PB0928 Results of a Survey Regarding the Diagnosis, Investigation and 16:00 - 16:00 Management of Unclassified Bleeding Disorders amongst United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Members Speaker: Will Thomas, GB
PB0929 Prevalence and Predictors of Iron Deficiency Anemia in Women 16:00 - 16:00 with von Willebrand Disease: An NIS Study Speaker: Afsaneh Amouzegar, US
PB0930 Von Willebrand Factor (VWF) Collagen IV Binding Defect – A 16:00 - 16:00 Potentially Overlooked Cause for Excessive Bleeding Phenotype Speaker: Miguel Escobar, US
99 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB0931 Vascular Abnormalities in Patients with Von Willebrand 16:00 - 16:00 Disease: A Scoping Review Speaker: Nicholas Chornenki, CA
PB0932 Patient-reported Outcomes in Autosomal Inherited Bleeding 16:00 - 16:00 Disorders: A Systematic Literature Review Speaker: Wala Al Arashi, NL
PB0933 A Quantitative Evaluation of vWF Multimeric Structure in 16:00 - 16:00 Patients with Different Types of vWD and aVWS Speaker: Alexander Poletaev, RU
PB0934 Efficacy of hFVIII/VWF Concentrate in Pediatric Patients with 16:00 - 16:00 von Willebrand Disease (VWD): The French Experience Speaker: Annie Harroche, FR
PB0935 Congenital Bleeding Disorders in Adolescent Females 16:00 - 16:00 Evaluated for Menorrhagia and Iron Deficiency Anemia Speaker: Alyson Trillo, US
PB0936 High Plasma von Willebrand Factor Level is Associated with 16:00 - 16:00 Increased Risk of upper Gastrointestinal Bleeding in Patients with Chronic Coronary Syndromes Receiving Long-term Antiplatelet Therapy Speaker: Valeriia Korobkova, RU
PB0937 Diagnosis of von Willebrand Disease-intricacies and 16:00 - 16:00 Challenges: An Experience from a Tertiary Care Centre in Southern India Speaker: Rakhee Kar, IN
PB0938 Acquired von Willebrand Disease: The Diagnosis and 16:00 - 16:00 Management of an Underdiagnosed Coagulopathy Speaker: Antonietta Ferretti, IT
PB0939 Plasma-derived VWF/FVIII Concentrate (wilate®) for 16:00 - 16:00 Haemostasis in Women with VWD during Childbirth Speaker: Alfonso Iorio, CA
PB0941 Perioperative Management of Patients with von Willebrand 16:00 - 16:00 Disease Undergoing Surgical Interventions Speaker: Beate Krammer-Steiner, DE
PB0942 Molecular Heterogeneity in von Willebrand Disease in North 16:00 - 16:00 Indian Patients Speaker: Ritika Sharma, IN
PB0943 Atypical Presentation of VWD Leading to Discovery of Novel 16:00 - 16:00 VWF Mutation Speaker: Tom van de Berg, NL
PB0944 The von Willebrand Disease-Woman (VWD-Woman) Trial: A 16:00 - 16:00 Pilot Study Comparing Recombinant von Willebrand Factor (rVWF) plus Tranexamic Acid (TA) vs. rVWF Alone in the Prevention of Postpartum Hemorrhage in Women with von
100 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Willebrand Disease Speaker: Nicoletta Machin, US
PB0945 Finding the Balance between Bleeding Risk and 16:00 - 16:00 Thromboembolic Risk: A Case Report Speaker: Beatriz Merchan Muñoz, ES
PB0946 Reclassification of von Willebrand Disease Classification and 16:00 - 16:00 Effects of Vascular Dysfunction on von Willebrand Factor Speaker: Henry Watson, GB
PB0947 Correlation of VWF:Ab to VWF:Ag Ratio and Abnormal VWF 16:00 - 16:00 Multimer Pattern Speaker: Melissa Stuart, US
PB0948 Intermittent Prophylaxis for Heavy Menstrual Bleeding in Von 16:00 - 16:00 Willebrand Disease Speaker: Pawel Laguna, PL
PB0949 Modern Diagnosis of von Willebrand Disease in Children in 16:00 - 16:00 Russia: Experience in Centralized Diagnostics Speaker: Alexander Poletaev, RU
PB0950 Nationwide Screening Programme for Bleeding Disorders 16:00 - 16:00 Among Adolescent Girls Speaker: Mariken Ross, EE
PB0951 Neurosurgery in a Patient with von Willebrand Disease: A Case- 16:00 - 16:00 report Speaker: Joana Cabral, PT
PB0952 Acquired von Willebrand Disease 16:00 - 16:00 Speaker: Miguel Escobar, US
PB0953 Bifunctional Effect of Inflammatory Cytokine TNF? on Human 16:00 - 16:00 Megakaryopoiesis and Platelet Production Speaker: Tiantian Chu, CN
PB0954 Aberrant Expression of Lnc-MEG3 and Lnc-NOTCH1 Predicts 16:00 - 16:00 Refractory Phenotype in Chronic Idiopathic Thrombocytopenic Purpura Speaker: Nashwa El-Khazragy, EG
PB0955 Single-cell RNA Sequencing Reveals Features of Hematopoietic 16:00 - 16:00 Stem and Progenitor Cells in Immune Thrombocytopenia Speaker: Yan Liu, CN
PB0956 The Role of Matrix-metalloproteinase 9 in Bone Marrow 16:00 - 16:00 Remodeling after Total Body Irradiation and Hematopoietic Stem Cell Transplantation Speaker: Kristina Mott, DE
PB0958 Pharmacological Characterization of eNOS-based 16:00 - 16:00 Megakaryocyte Subpopulations and its Implications for their Platelet Progeny
101 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Amir Asgari, CA
PB0959 Medium Plate Volume as a Predictor of Plate Engraftment Time 16:00 - 16:00 in Patients with Bone Marrow Transplant Speaker: Jose Manuel Ceresetto, AR
LPB0033 The Role of RAP1 Signaling in Platelet-coagulation Interplay 16:00 - 16:00 Speaker: Abigail Ballard, US
LPB0034 Effects of Depression and Antidepressant Use on Platelet 16:00 - 16:00 Reactivity Traits Speaker: Joseph Grech, US
LPB0035 Desialylation Primes Platelets for Apoptosis: A New Role for ß1 16:00 - 16:00 Integrin Speaker: Renata Grozovsky, US
LPB0036 Elevated Platelet-derived sGPVI Is a Biomarker of Venous In- 16:00 - 16:00 stent Stenosis in Patients with Post-thrombotic Syndrome Speaker: Adam Michael Gwozdz, GB
LPB0129 Platelet-specific Deletion of Acetyl-CoA Carboxylase 1 16:00 - 16:00 Decreases Phospholipid Content and Impairs Platelet Functions Speaker: Marie Octave, BE
LPB0130 A Multiscale Framework for Patient-specific Predictions of 16:00 - 16:00 Thrombus Growth Speaker: Kaushik Shankar, US
LPB0131 Inhibition of Surface-induced Platelet Activation on Hydrogel 16:00 - 16:00 Films Speaker: Gurunath Apte, DE
PB0960 Identification of Marginal Zone B Cells as Key Players in a 16:00 - 16:00 Mouse Model of Platelet Alloimmunization Speaker: Adèle COUVIDOU, FR
PB0961 ?-Synuclein: A VAMP Chaperone in the Platelet Release 16:00 - 16:00 Reaction Speaker: Alexis Smith, US
PB0963 Stimulation of Calpain Activity, Facilitation of Talin Degradation 16:00 - 16:00 and Shedding of PMPs Exist as the Modalities of Prion- mediated Pathological Effects in Human Platelets Speaker: Chandra Prakash Gaire, NP
PB0964 Genetic and Non-genetic Regulators of Platelet Function in 16:00 - 16:00 Healthy Tanzanian Individuals Speaker: Vesla Kullaya, TZ
PB0965 Expression and Localization of Rab GTPase Proteins in 16:00 - 16:00 Platelets Speaker: Nhu Nguyen, US
PB0966 MAS9 – A Novel Small Molecule Inhibitor of the 16:00 - 16:00 CLEC-2-Podoplanin Interaction
102 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Marcin A. Sowa, GB
PB0967 Machine Learning-guided Analysis of Adult and Cord Platelet 16:00 - 16:00 Adhesion Dynamics Speaker: Jawaad Sheriff, US
PB0968 The Role of Septins in Platelet Structure and Function 16:00 - 16:00 Speaker: Oleg V. Kim, US
PB0969 Rapid and Complete Clearance of HPA-1a Mismatched Platelets 16:00 - 16:00 in a Human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a Hyperimmune Plasma Derived Polyclonal Anti HPA-1a Antibody Speaker: Christof Geisen, DE
PB0970 Highly Reactive Juvenile Platelets Express Higher Levels of 16:00 - 16:00 GPVI in a Size-related Manner Speaker: Alicia Veninga, NL
PB0971 A Novel Therapeutic Strategy for Hepatocellular Carcinoma 16:00 - 16:00 Based on the Tumor-platelet Interaction Speaker: Hiroki Tanaka, JP
PB0972 Serglycin, an Intragranular Proteoglycan with Many Effects on 16:00 - 16:00 Platelet Function Speaker: Harry Chanzu, US
PB0973 Utilizing CRISPR-CAS9 Gene Editing Technology in Human 16:00 - 16:00 Pluripotent Stem Cells to Study Platelet Integrin ?IIb?3 Function Speaker: Karen Pei Yi Fong, US
PB0974 Modification of Platelet Characteristics and Hemostasis in 16:00 - 16:00 Children with Inflammatory Bowel Diseases under Hyperbaric Oxygenation Speaker: alexandra popovicheva, RU
PB0975 Effects of Different Concentrations of Apixaban Combined with 16:00 - 16:00 Antiplatelet Therapies on Platelet Hemostatic and Thrombogenic Functions. Ex-vivo Exploratory Study in Patients under Various Antiplatelet Regimens Speaker: Julia Martinez-Sanchez, ES
PB0976 Ponatinib Inhibits Collagen Induced Platelet Aggregation and 16:00 - 16:00 Coated-platelet Formation in Human Platelets Speaker: Ildikó Beke Debreceni, HU
PB0977 Coagulation and Anticoagulation Factors Affecting Platelet 16:00 - 16:00 Responses Independently of Thrombin and Fibrin Speaker: Ilaria De Simone, NL
PB0978 Platelet Activity and Platelet-induced Endothelial Inflammatory 16:00 - 16:00 Pathways in Treated HIV Is Lowered by Clopidogrel: A Randomized Control Trial Speaker: Tamar Schwartz, US
PB0979 Sex Differences in Thrombosis through Platelet Nitric Oxide 16:00 - 16:00
103 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Production Speaker: Matthew Godwin, US
PB0981 Role of Platelet’s Heme Oxygenase-1 in Obese Patients with 16:00 - 16:00 and without Type 2 Diabetes Mellitus Speaker: Rossella Liani, IT
PB0982 Role of Platelet HIF-2 Alpha to Indorse Thrombogenicity 16:00 - 16:00 through Synthesis of PAI-1 during Hypoxia Speaker: Ram Lala Mallick, NP
PB0984 A comparison of Five Platelet Reactivity Tests in Over 3,000 16:00 - 16:00 Participants of the Framingham Heart Study Speaker: Melissa V. Chan, US
PB0985 New Strategies for Minimization of Surface-induced Platelet 16:00 - 16:00 Activation Speaker: Thi Huong Nguyen, DE
PB0986 Role of Platelet GARP in TGF? Activation 16:00 - 16:00 Speaker: Julie Bodart, BE
PB0987 PI4P and PI(4,5)P2 Immunofluorescence Staining Optimization 16:00 - 16:00 in Human Platelets Speaker: Ana Bura, HR
PB0988 Prototyping of Physiological Stenosis with 2-photon 16:00 - 16:00 Lithography for Thrombosis Studies Speaker: Yean Jin Lim, AU
PB0989 Assessment of the Effects of Syk and BTK Inhibitors on GPVI- 16:00 - 16:00 mediated Platelet Signaling and Function Speaker: Tony Zheng, US
PB0990 Lyophilized Human Platelets Interact with Fresh Platelets to 16:00 - 16:00 Promote Hemostasis Under Shear in vitro Speaker: Braden Ishler, US
PB0991 Iron Repletion Decreases Platelet Count in Iron Deficient 16:00 - 16:00 Premenopausal Women Speaker: Benjamin Elstrott, US
PB0992 Desipramine Reduces the Exposure of Phosphatidylserine on 16:00 - 16:00 the Surface of Human Platelets, but Does Not Inhibit Platelet TF- induced Procoagulant Activity Speaker: Olga Panes, CL
PB0993 Effect of Antiplatelet Therapy on Monocyte-Platelet Aggregates 16:00 - 16:00 Speaker: Christina C. Rolling, US
PB0994 Stripping a Platelet “Sugar Coat” by Shear: Shear-mediated 16:00 - 16:00 Platelet Desialylation Promotes Reduction in Platelet Count and Increased Microvesiculation Speaker: Yana Roka-Moiia, US
PB0995 Inhibition of ADP and Thromboxane A2 Production Results in 16:00 - 16:00
104 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Decreased Global Platelet Contraction, but Thromboxane A2 Inhibition Plays a Greater Role in Limiting Local Platelet Contraction Speaker: Kevin Trigani, US
PB0996 The Proteasome Inhibitor, Bortezomib Induces Apoptosis and 16:00 - 16:00 Activation in Gel Filtered Human Platelets Speaker: Harriet Ghansah, HU
PB0998 Antiplatelet Activity Produced by Chloroacilhidroquinones via 16:00 - 16:00 Inhibition of the Mitochondrial Bioenergy Speaker: Eduardo Fuentes, CL
PB0999 An Oxidative Stress-induced Platelet-associated Tissue Factor 16:00 - 16:00 Expression Characterizes Patients with Migraine and Patent Foramen Ovale Speaker: Paola Canzano, IT
PB1000 Reticulated Platelets in Healthy Volunteers. Relationships with 16:00 - 16:00 Platelet Size Indexes and Platelet Activity Speaker: Alexey Mazurov, RU
PB1001 Standardization of Platelet-rich Plasma Preparation with 16:00 - 16:00 Optimal Platelet Function for the Use in Veterinary Regenerative Medicine Speaker: Sanggu Kim, KR
PB1002 Pandrial Platelet Reactivity in Aspirin-treated Individuals: A 16:00 - 16:00 Comparison between Fasting and Non Fasting On-treatment Platelet Responses Speaker: Bongani Nkambule, US
PB1003 Evaluation of Platelet Dense Granules by Transmission Electron 16:00 - 16:00 Microscopy (PTEM) in Pediatric Patients and Healthy Pediatric Donors Speaker: Jacob Greenmyer, US
PB1004 The Effects of Iron Deficiency on Platelet Function, Indices, and 16:00 - 16:00 Clinically Reported Hemostasis: A Prospective Clinical Study of Iron Deficient Women Receiving IV Iron Speaker: Benjamin Elstrott, US
PB1005 Case Report: Skin Necrosis in setting of Heparin and Warfarin 16:00 - 16:00 Exposure Speaker: Donna Zhe Sian Eng, AU
PB1006 Interaction of Blood Platelets with Engineered Fibrinogen 16:00 - 16:00 Scaffolds of Different Topographies Speaker: Martin Kenny, IE
PB1007 Thrombogenic Potential in Patients Undergoing Hemodialysis 16:00 - 16:00 Using Central Venous Catheter and Arteriovenous Fistula Speaker: Thabata Coaglio Lucas, BR
PB1009 Importance of Consideration to Differetial Diagnosis of ITP 16:00 - 16:00
105 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Nargesbeigom Mirbehbahani, IR
PB1010 Pathogen-reduced Platelet Concentrates: Novel Concepts to 16:00 - 16:00 Elucidate the Impact of Different Technologies on Platelet Function Speaker: Mayken Visser, DE
PB1011 Immune Thrombocytopenic Purpura: A Case Report 16:00 - 16:00 Speaker: Adriatik Berisha, AL
LPB0083 Temporal Assessment of Platelet Proteome and fFnction during 16:00 - 16:00 ex vivo Anticoagulation Speaker: Samuel Tassi Yunga, US
PB1012 Single-cell Transcriptomics of Young and Mature Thrombocytes 16:00 - 16:00 in Zebrafish Speaker: Weam Fallatah, US
PB1013 Common Cardiovascular Disease Polygenic Risk Scores for 16:00 - 16:00 Arterial and Venous Disease Influence Different Platelet Reactivity Tests Speaker: Joseph Grech, US
PB1014 Long-term Severe Platelet Dysfunction as a Form of 16:00 - 16:00 Presentation of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML), due to a RUNX1 Variant Speaker: Mário Sousa-Pimenta, PT
LPB0084 GPVI, a New Binding Partner for pro-coagulant Factor VIII on 16:00 - 16:00 Platelets Speaker: Rohini Sekar, FR
PB1015 Salt Bridge Formation Between A1 Domain of von Willebrand 16:00 - 16:00 Factor and Platelet Glycoprotein (GP) Ib? by Molecular Dynamics Simulations Speaker: Masamitsu Nakayama, JP
PB1016 Defining the Molecular Features of Inverse Agonism: Insights 16:00 - 16:00 from the P2Y12 Receptor and the Antiplatelet Drug Ticagrelor Speaker: Sukhvinder Bancroft, GB
PB1017 Study of the Affinity of Thrombin towards its Receptors on 16:00 - 16:00 Platelets Speaker: Ankit Macwan, SE
PB1018 Structural Characterisation of GPVI in Complex with Nanobody 16:00 - 16:00 2 Generates a Domain-swapped GPVI Dimer: Could this Represent a Biologically Active Conformation? Speaker: Alexandre Slater, GB
PB1019 Charactering the Role of TLT-1 in Inflammatory Pathogenesis of 16:00 - 16:00 Obesity and Nonalcoholic Fatty Liver Disease (NAFLD) Speaker: Siobhan Branfield, US
PB1020 The Role of Platelet CLEC-2 and GPVI in Rhabdomyolysis- 16:00 - 16:00 induced Acute Kidney Injury
106 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Saori Oishi, JP
PB1021 Impact of the Common GPVI Polymorphism Is Limited to 16:00 - 16:00 Intracellular Calcium Response upon Activation Speaker: Maria Stepanyan, RU
PB1022 Soluble Triggering Receptor Expressed on Myeloid Cells Like 16:00 - 16:00 Transcript-1 (sTLT-1) as a Biomarker for Stable Cardiovascular Diseases Speaker: Zaida Bayron, PR
LPB0085 The Predominant Role of Arrestin3 in General GPCR 16:00 - 16:00 Desensitization in Platelets Speaker: PREETI KUMARI CHAUDHARY, KR
LPB0132 Chronic Edible Dosing of ?9-tetrahydrocannabinol (THC) in Non- 16:00 - 16:00 human Primates Reduces Systemic Platelet Activity and Function Speaker: Stephanie E. Reitsma, US
PB1023 Discovery of WNT/Planar Cell Polarity Membrane Receptors in 16:00 - 16:00 Platelets Speaker: Shane Comer, IE
PB1024 Integrin ?IIb?3 Regulates Platelet Procoagulant Activity in the 16:00 - 16:00 Lung Speaker: Tomasz Brzoska, US
PB1025 A rRle for the JAK/STAT5 Axis in GPVI-mediated Platelet 16:00 - 16:00 Function Speaker: Ivan Parra Izquierdo, US
PB1026 Acetyl-CoA Carboxylase Inhibition Alters Tubulin Acetylation 16:00 - 16:00 and Aggregation in Thrombin-stimulated Platelets Speaker: Marie Octave, BE
PB1027 Quantitative Assessment of Heterogeneity of Single Platelet 16:00 - 16:00 Calcium Responses to Activation Speaker: Fedor Balabin, RU
PB1028 Curcumin Inhibits Platelets by Activation of Adenosine A2 16:00 - 16:00 Receptor and cAMP/PKA Pathway Speaker: Valentina Shpakova, RU
PB1029 Annexin V Binding Detects Platelet Procoagulant Commitment 16:00 - 16:00 but Is Not Sensitive to Reductions in the Level of Platelet PS Exposure Speaker: Sarah Millington-Burgess, GB
PB1030 Resveratrol Prevents Platelet Activation by Inhibition of ROS 16:00 - 16:00 Formation Speaker: Nada Al Arawe, RU
PB1031 Combined Antiplatelet Therapy Reduces the Pro-inflammatory 16:00 - 16:00 Properties of Activated Platelets Speaker: Rory R Koenen, NL
107 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1032 Targeted Proteasomal Degradation of Platelet BTK and TEC as a 16:00 - 16:00 Novel Approach in Thrombosis Prevention Speaker: Attila Munkacsi, GB
PB1033 Antiplatelet Effect of Nobiletin Is Mediated by Activation of DP1 16:00 - 16:00 Receptor Speaker: Valentina Shpakova, RU
PB1034 Investigation of Core and Shell Platelet Mechanics through 16:00 - 16:00
P2Y12 Antagonism Speaker: Michael DeCortin, US
LPB0037 Neutrophil Extracellular Traps in Thrombosis of Ovine 16:00 - 16:00 Extracorporeal Membrane Oxygenation Models Speaker: Yang Zhang, CN
LPB0038 Neutrophil Binding on E-selectin: a Potential Biomarker of 16:00 - 16:00 Clinical Course and Response to Therapy in Sickle Cell Disease Speaker: Yuncheng Man, US
LPB0086 GDP/GTP Exchange Factor MADD Drives Activation and 16:00 - 16:00 Recruitment of Secretory Rab GTPases to Weibel-Palade Bodies Speaker: Marije Kat, NL
LPB0133 Endothelial Cell and Neutrophil Interactions Are Required for 16:00 - 16:00 the Activation of the Blood Coagulation Cascade Leading to Thrombus Formation Following a Laser-induced Injury Speaker: Estelle Carminita, FR
PB1035 Rapid Internalization and Nuclear Translocation of CCL5 and 16:00 - 16:00 CXCL4 in Endothelial Cells Speaker: Rory R Koenen, NL
PB1036 Dasatinib Impairs Vascular Integrity and Promotes Skin Wound 16:00 - 16:00 Healing in Mice Speaker: Surasak Wichaiyo, TH
PB1037 Targeting Pathways of Mitochondrial Neutrophil Extracellular 16:00 - 16:00 Trap Formation to Inhibit Progression of Abdominal Aortic Aneurysms in Preclinical Models Speaker: Sonja Bleichert, AT
PB1038 Ponatinib Induces Vasculitis with Immune Cells Expressing 16:00 - 16:00 Coagulation Factors FV & FVIII Speaker: Peng Zeng, US
PB1039 The Role of Nitric Oxide and Cationic Groups in Cardiovascular 16:00 - 16:00 and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Speaker: Joanna Miklosz, PL
PB1040 A 3D in vitro Model of Inflammation-associated Bleeding 16:00 - 16:00 Speaker: Rebecca Riddle, GB
PB1041 Elevated Circulating Endothelial Cells and Success in 16:00 - 16:00 Endothelial Colony-forming Cells Isolation
108 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Letícia Silva, BR
PB1042 Global Coagulation Assays in Chronic Kidney Disease 16:00 - 16:00 Speaker: Hui Yin Lim, AU
PB1043 The Role of Transforming Growth Factor ß1 (TGFß1) and 16:00 - 16:00 Fibrinogen in the Induction of Adhesive Properties of Vascular Endothelium (HUVECS) and the Spread of Acute Lymphoblastic Leukemia (ALL) Speaker: Vira Barilka, UA
PB1044 Hemophagocytic Lymphohistiocytosis Complicating Systemic 16:00 - 16:00 Diseases Speaker: Imen chabchoub, TN
PB1045 Global Coagulation Assays and Endothelial Biomarkers in 16:00 - 16:00 Patients with Diabetes Mellitus Speaker: Hui Yin Lim, AU
PB1046 Collagen Turnover Biomarkers in Atrial Fibrillation and their 16:00 - 16:00 Use in Clinical Management and the Study of Inflammatory Pathogenesis Speaker: Keaton Wieschhaus, US
LPB0039 The Extracellular Protease EpiP from S. aureus Triggers Blood 16:00 - 16:00 Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1 Speaker: Vincenzo De Filippis, IT
LPB0087 Activated Platelets Transfer miR-223 into Endothelial Cells via 16:00 - 16:00 Microparticles to Downregulate ICAM-1 Expression among Septic Conditions Speaker: Bernadett Szilágyi, HU
PB1047 The Effect of DNase I in Combination with Unfractionated 16:00 - 16:00 Heparin or Low Molecular Weight Heparin in a Mouse Model of Sepsis Speaker: Sarah Medeiros, CA
LPB0135 Platelet-rich Neutrophil-platelet Micro-emboli Contribute to 16:00 - 16:00 Cigarette Smoke-induced Influenza Severity Speaker: Tomasz W. Kaminski, US
LPB0040 rs2431697 of miR-146a Regulates NETosis Determining the 16:00 - 16:00 Thickness of the Carotid Intima-media in Patients with Rheumatoid Arthritis Speaker: Laura Reguilón Gallego, ES
LPB0088 Identification of Small Interfering RNAs for Allele-selective 16:00 - 16:00 Silencing of Murine von Willebrand Factor Speaker: Yvonne Kimberlee Jongejan, NL
PB1048 Platelet microRNA Release in the Context of Agonist- 16:00 - 16:00 stimulation and Thrombosis Speaker: Teresa Lara Krammer, AT
109 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0136 BMS-986141, a Selective PAR4 Antagonist, Reduces Platelet 16:00 - 16:00 Deposition in a Microfluidic Thrombosis Assay Speaker: Jason Chen, US
PB1049 Impact of ABO Incompatibility on the Outcome of Hematopoeitic 16:00 - 16:00 Stem Cell Transplantation Speaker: Munira Borhany, PK
PB1050 Could the Adjusted Version of the Global Antiphospholipid 16:00 - 16:00 Syndrome Score (aGAPSS) Be a Useful Tool to Select Patients with Primary Obstetric Antiphospholipid Syndrome (POAPS) for Primary Thromboprophylaxis with Aspirin? Speaker: Sebastian Udry, AR
PB1051 Clinical Course of Thrombotic Antiphospholipid Syndrome with 16:00 - 16:00 Positive IgA Anticardiolipin or IgA ?2-glycoprotein I Speaker: Luísa Figueiredo, BR
PB1052 Risk Factors for Recurrent Thrombosis and Cause of Death in 16:00 - 16:00 Patients with Antiphospholipid Syndrome; A Swedish Cohort Study Speaker: Natali Karandyszowska, SE
PB1053 Effect of Hydroxychloroquine on the Levels of Inflammatory 16:00 - 16:00 Cytokines and Tissue Factor in Patients with Primary Antiphospholipid Syndrome Speaker: Bruna Mazetto, BR
PB1054 Artificial Intelligence Classifies APS in Anticoagulated Patients 16:00 - 16:00 Based on Thrombin Generation Speaker: Romy de Laat-Kremers, NL
PB1055 A Novel ELISA Assay for the Detection of Anti-prothrombin 16:00 - 16:00 Antibodies in APS Patients at High Risk of Thrombosis Speaker: Nicola Pozzi, US
PB1056 The Utility of the Dilute Prothrombin Time Assay in the 16:00 - 16:00 Diagnosis of Antiphospholipid Syndrome Speaker: Tanner Storozuk, US
PB1057 A Diagnostic Solution for Lupus Anticoagulant Testing in 16:00 - 16:00 Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter Speaker: Georges Jourdi, CA
PB1058 The Diagnostic Utility of the Taipan Snake Venom Time in an 16:00 - 16:00 Era of DOACstop™ Speaker: Eleanor Foxton, GB
PB1059 Evaluation of a Gene Signature Related to Thrombotic 16:00 - 16:00 Manifestations in Antifospholipid Syndrome Speaker: Bruna Jacintho, BR
PB1060 Platelet Activity from Antiphospholipid Syndrome (APS) 16:00 - 16:00 Patients is Enhanced: Possible Role of the ADP Signaling Pathway
110 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Guilherme Leonardi, BR
PB1061 Plasmocytoid Dendritic Cells Activity in Asymptomatic 16:00 - 16:00 Antiphospholipid Carriers and in Primary and Secondary Antiphospholipid Syndrome with Thrombosis Speaker: Ana Paula Rosa dos Santos, BR
PB1062 Rivaroxaban versus Vitamin K Antagonist for the Secondary 16:00 - 16:00 Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: A Systematic Review and Meta-analysis Speaker: Ruth Divine Agustin, PH
PB1063 Clinico-pathologic Characterization of Patients Tested for 16:00 - 16:00 Antiphospholipid Syndrome at a Tertiary Care Hospital Speaker: Krishnendhu Sajeeve, IN
PB1064 Automated Methods for the Enhancement of Lupus 16:00 - 16:00 Anticoagulant Mixing Study Sensitivities Speaker: Zhenghua Cao, US
PB1065 Successfully Treated Pediatric Catastrophic Antiphospholipid 16:00 - 16:00 Syndrome with Combination of Thrombolytic Agent, Rituximab and Sirolimus Speaker: Pongpak Pongphitcha, TH
PB1066 Evaluation of the Determination of Dabigatran, Rivaroxaban, 16:00 - 16:00 and Apixaban at Lupus Anticoagulans Positive Patients Speaker: Ludek Slavik, CZ
PB1067 Laboratory Testing Platform Discrepancy between Current 16:00 - 16:00 Singleplex-assay and New Multiplex-assay for Detecting and Quantifying IgM-anti-Cardiolipin-antibodies and other Anti- Phospholipid (APL)-antibodies: The Potential for Mis-diagnosis of the APL-syndrome Speaker: Miguel Escobar, US
PB1068 A Prolonged Actived Partial Thromboplastin Time Revealing a 16:00 - 16:00 Childhood Systemic Lupus erythematosus Speaker: Imen krichen, TN
PB1069 Association of Retest Interval with INR Control in Warfarin 16:00 - 16:00 Patients with Markedly Out of Range INRs Speaker: Brian Haymart, US
PB1070 Switching of Oral Anticoagulants in People with Atrial 16:00 - 16:00 Fibrillation: Insight from Australian General Practices Speaker: Adane Kefale, AU
PB1071 Evaluation of the Effect of Educational Intervention Adapted for 16:00 - 16:00 Patients on Warfarin with Poor Anticoagulation Control: A Controlled Clinical Trial Speaker: Maria Auxiliadora Parreiras Martins, BR
PB1072 A Comparative Cohort Study of Serum Rivaroxaban Levels in 16:00 - 16:00 Singaporean (SG) and British (UK) Non-valvular Atrial Fibrillation (NVAF) Patients
111 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Eng Xin Yong, SG
PB1073 A Comparison of the Incidence of Traumatic Brain Injury in 16:00 - 16:00 Anticoagulated and Non-anticoagulated Head Injured Patients Speaker: Fayad Al-Haimus, CA
PB1074 Efficacy and Safety of Direct Oral Anticoagulants in Patients of 16:00 - 16:00 Southern Italy with Atrial Fibrillation: Real-world Data from the EGINA Registry Speaker: Alessandro Ciavarella, IT
PB1075 Appropriate dose of Dabigatran in Asian Population 16:00 - 16:00 Speaker: Nonthakorn Hantrakun, TH
PB1076 Burden and Costs of Stroke/Systemic Embolism and Major 16:00 - 16:00 Bleeding among Elderly Non-valvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants Speaker: Amol Dhamane, US
PB1077 Quality of INR Control during the COVID-19 Pandemic 16:00 - 16:00 Speaker: Scott Kaatz, US
PB1078 The Impact of Strong Inducers on Direct Oral Anticoagulant 16:00 - 16:00 Plasma Levels: A Retrospective Study Speaker: Anne-Laure Sennesael, BE
PB1079 Effectiveness and Safety of Direct Oral Anticoagulants in Thai 16:00 - 16:00 Patients with Atrial Fibrillation Speaker: Saowaluk Srikajornlarp, TH
PB1080 Use of Dabigatran Assessed By Thrombin Generation Assay 16:00 - 16:00 (TGA): Paradoxical Results Speaker: Rita Duarte, BR
PB1081 Accounting of Symptoms and Ejection Fraction May Improve 16:00 - 16:00 Prediction of Left Atrial Thrombus in Patients with Non-valvular Atrial Fibrillation before Catheter Ablation or Cardioversion Speaker: Ivan Zaigraev, RU
PB1082 Inappropriate Direct Oral Anticoagulant Dosing in a Spanish 16:00 - 16:00 Cohort with Atrial Fibrillation Speaker: Begoña Navarro Almenzar, ES
PB1083 Comparative Effectiveness of Alternative Bridging Therapies for 16:00 - 16:00 Subtherapeutic INR in Patients with Left Ventricular Assist Devices Speaker: Grace Chung, US
PB1084 Procedural Success of Left Atrial Appendage Occlusion Device 16:00 - 16:00 in Patients with Chronic Kidney Disease: Meta-analysis of Real- world Data Speaker: Ambrish Singh, AU
PB1085 Self-report Instruments for Assessing Adherence to Oral 16:00 - 16:00 Anticoagulation with Warfarin: A Systematic Review Speaker: Mayara Sousa Vianna, BR
112 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1086 Prescribing Patterns, Efficacy and Safety of Direct Oral 16:00 - 16:00 Anticoagulants (DOAC) Usage in a Tertiary Hospital Speaker: Kar Ying Yong, SG
PB1087 Should We Check the Anticoagulant Activity Of Edoxaban, at 16:00 - 16:00 Least at the Beginning of the Treatment? Speaker: NATALIA GARCÍA-LEÓN, ES
LPB0041 Improved Patient-reported Treatment Satisfaction with 16:00 - 16:00 Rivaroxaban as Compared to Low Molecular Weight Heparins for Cancer Patients with Acute Venous Thromboembolism - Results from the CONKO-011 Trial Speaker: Hanno Riess, DE
LPB0042 Characterization of Thrombotic Risk in Patients with Cancer 16:00 - 16:00 Speaker: Javier Trujillo Santos, ES
LPB0089 Outcome of Cancer-associated Venous Thromboembolism Is 16:00 - 16:00 More Favourable among Patients with Hematologic Malignancies than with Solid Tumors Speaker: Ramón Lecumberri, ES
LPB0090 Active Cancer and Venous Thromboembolism: Safety and 16:00 - 16:00 Effectiveness of Edoxaban in Patients from the Noninterventional Global ETNA-VTE Program Speaker: Alexander Cohen, GB
LPB0137 Validation of the HULL Clinical Prognostic Rule (CPR) for 16:00 - 16:00 Incidental Pulmonary Embolism in Ambulatory Cancer Patients Speaker: Farzana Haque, GB
LPB0138 Results of a Prospective, Observational, Multi-center Cohort 16:00 - 16:00 Study of Venous Thromboembolism Outcomes in Thrombocytopenic Cancer Patients (TROVE Study) Speaker: Brian Carney, US
PB1089 The Role of Primary Thromboprophylaxis in People with 16:00 - 16:00 Cancer: A Systematic Review and Meta-analysis Speaker: Fiona Anne Dewar, GB
PB1090 Plasma Biomarkers for Predicting Risk of Venous 16:00 - 16:00 Thromboembolism (VTE) in Ambulatory Cancer Patients Receiving Chemotherapy Speaker: Danielle Roy, CA
PB1091 Characteristics and Outcomes of Patients on Concurrent Direct 16:00 - 16:00 Oral Anticoagulants and Targeted Anticancer Therapies – TacDOAC Registry Speaker: Tzu-Fei Wang, CA
PB1092 Management of Cancer Associated Thrombosis in France: A 16:00 - 16:00 National Survey in Vascular Disease and Supportive Care Specialists Speaker: Isabelle Mahé, FR
113 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1093 Prevalence, Treatment and Prognosis of Tumor Thrombi in 16:00 - 16:00 Renal Cell Carcinoma Speaker: Fleur H. J. Kaptein, NL
PB1094 Thromboembolic and Bleeding Complications fFowing Surgery 16:00 - 16:00 among Patients with Ovarian Cancer - A Single Centre Retrospective Cohort Study Speaker: Hanke M.G. Wiegers, NL
PB1095 Risk of Venous Thromboembolism and Major Bleeding in the 16:00 - 16:00 Clinical Course of Osteosarcoma and Ewing Sarcoma Patients Speaker: Milou Anne Maria Stals, NL
PB1096 Factor VIIIc Predicts Venous Thromboembolism in 16:00 - 16:00 Gynecological Cancer Patients Speaker: Lucy Norris, IE
PB1097 Could Thromboprophylaxis Influence the Clinical Course of 16:00 - 16:00 Patients with Active Cancer? Preliminary Results from the ACT4CAT Study Speaker: Nikolaos Tsoukalas, GR
PB1098 Association of KRAS Mutation with Arterial Thromboembolism 16:00 - 16:00 in Advanced Lung and Gastrointestinal Cancer Speaker: Satish Maharaj, US
PB1099 Laboratory Monitoring of Coagulation State in Children with 16:00 - 16:00 Acute Lymphoblastic Leukemia Speaker: Elena Seregina, RU
PB1100 Incidence and Impact of Venous Thromboembolism and Major 16:00 - 16:00 Bleeding in Patients with Glioblastoma Speaker: Fleur H. J. Kaptein, NL
PB1101 Association between Cancer and Anatomical Site of Venous 16:00 - 16:00 Thromboembolic Disease Speaker: David Froehling, US
PB1102 Risk Factors for Symptomatic Venous Thromboembolism in 16:00 - 16:00 Children and Adolescents with Lymphomas Speaker: Dmitrii Evstratov, RU
PB1103 Identification of Tumor-expressed MicroRNAs Associated with 16:00 - 16:00 Venous Thrombosis in Colorectal Cancer Speaker: Rayna J. S. Anijs, NL
PB1104 The Role of Thrombophilia in Asparaginase Related Venous 16:00 - 16:00 Thromboembolism in Pediatric and Young Adult Patients Affected by Acute Lymphoblastic Leukemia Speaker: Alessandra Serrao, IT
PB1105 Cumulative Incidence of Recurrent Venous Thromboembolism 16:00 - 16:00 by Cancer and Provoking Status – A Population-based Study Speaker: Kai Ding, US
PB1106 Bleeding and Venous Thromboembolism Recurrence in Patients 16:00 - 16:00
114 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
with Gastrointestinal and Genitourinary Malignancies Treated with Anticoagulation Speaker: Doaa Attia, US
PB1107 Role of Tissue Factor in the Procoagulant Shift of Endothelial 16:00 - 16:00 Cells upon Exposure to Cancer Cell-derived Microparticles Speaker: Rania DJEDIDI-AMRANE, FR
PB1108 Impact of a Smartphrase Venous Thromboembolism Risk 16:00 - 16:00 Assessment Tool on Prophylaxis Prescribing Rates in a Gynecologic Oncology Clinic Speaker: Marissa Duco, US
PB1109 The RIETE Score: A Useful Screening Tool for Occult 16:00 - 16:00 Malignancy in VTE and STP? Speaker: David McBriar, GB
PB1110 Differential Associations of Aromatase Inhibitors and Tamoxifen 16:00 - 16:00 with Thrombin Generation and Sensitivity to Thrombomodulin: A Prospective Cohort Study Speaker: Marc Blondon, CH
PB1111 Direct Oral Anticoagulants vs. Low-molecular-Weight Heparin 16:00 - 16:00 for the Treatment of Acute Venous Thromboembolism Associated with Gastrointestinal Cancer: A Systematic Review and Meta-analysis Speaker: Tarinee Rungjirajittranon, TH
PB1113 Risk of Vascular Occlusive Events with PARPis in Cancer: A 16:00 - 16:00 Systematic Review and Meta-analysis Speaker: Helene Haguet, BE
PB1114 Clinical Risk Factors for Venous Thromboembolism in 16:00 - 16:00 Hematologic Malignancies Speaker: Agnerys López Sacerio, CU
PB1115 Treatment of Venous Thromboembolism (VTE) Events with 16:00 - 16:00 Cancer as a Risk Factor in a Teaching Hospital: 2015 – 2020 Speaker: Huw Rowswell, GB
PB1116 Treatment of Cancer-associated Thrombosis with Six Months of 16:00 - 16:00 Prophylactic-dose Enoxaparin after Initial Full-dose Anticoagulation: A Pilot Study Speaker: Jesse Popov, CA
PB1117 Venous Thromboembolism in Children with Acute 16:00 - 16:00 Lymphoblastic Leukemia in China: A Multi-center Clinical Study Speaker: Mengmeng Yin, CN
PB1118 Anticoagulant Therapy and Related Bleeding Complications in 16:00 - 16:00 Internal Medicine Wards Speaker: Maria Teresa Sartori, IT
PB1119 Circulating Extracellular Vesicles in Patients with Cancer and 16:00 - 16:00 Venous Thromboembolism: A Systematic Review and Meta-
115 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
analysis Speaker: Ozgun Varol, CA
PB1120 Venous Thromboembolisms are Significantly Associated with 16:00 - 16:00 Central Venous Catheter Loss in Pediatric Cancer Patients Speaker: Zara Forbrigger, CA
PB1121 A Population-Based Descriptive Study of Long-term 16:00 - 16:00 Anticoagulation in the Treatment and Secondary Prophylaxis of Venous Thromboembolism in Men with Prostate Cancer in Sweden Speaker: Gunnar Brobert, SE
PB1122 Janus Kinase 2 (JAK2V617F) Mutations in Patients with 16:00 - 16:00 Splanchnic Vein Thrombosis, a Single Centre Experience Speaker: SiewLian Chong, MY
PB1123 The Use of DOACS in Catheter Related Thrombosis in Cancer 16:00 - 16:00 Speaker: Uzma Faruqi, GB
PB1124 Factor VIII and Prothrombin Time during Induction Therapy 16:00 - 16:00 Correlate with Response to Treatment in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients Speaker: Joana Vieira, PT
PB1125 Prediction of Venous Thromboembolism among Ambulatory 16:00 - 16:00 Cancer Patients with Gastrointestinal Malignancies - A Retrospective Analysis Speaker: Keechilat Pavithran, IN
PB1126 The Association among von Willebrand Factor, ADAMTS-13, D- 16:00 - 16:00 dimer, and Soluble P-selectin with Venous Thromboembolism Incidence in Cancer Patients: Systematic Review and Meta- analysis Speaker: Boby Pratama Putra, ID
PB1127 Endothelial Dysfunction in Patients with Polycythemia Vera on 16:00 - 16:00 Cytoreductive and / or Antiplatelet Therapy Speaker: Natalya Korsakova, RU
PB1128 Breast Cancer, Doxorubicin and Cardiotoxicity: Can Thrombin 16:00 - 16:00 Generation Test Be Useful? Speaker: Rodrigo Mendonça Cardoso Pestana, BR
PB1129 Risk Factors of Catheter-related Thrombosis in Patients with 16:00 - 16:00 Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Speaker: Anna Hoppe, PL
PB1130 Risk Factors for Reccurence of Catheter Related upper 16:00 - 16:00 Extremity Deep Venous Thrombosis in Cancer Patients Speaker: Simon Soudet, FR
PB1131 Effect of Therapy on Thrombin Generation in Patients with 16:00 - 16:00 Polycythemia Vera
116 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Natalya Korsakova, RU
PB1132 Concurrent Atypical Thrombotic Complications of Acute 16:00 - 16:00 Promyelocytic Leukemia (APL) in an Anticoagulated Patient: A Rare Case Report Speaker: Ashwini Ashwath, US
PB1133 Safety and Effectiveness of an Institutional Recommendation on 16:00 - 16:00 the Management of Cancer Associated Venous Thrombosis: Results of a Real World Study with One-year Follow-up Speaker: Cynthia Rothschild, BR
PB1134 Development of a Multi-language Mobile App to Implement the 16:00 - 16:00 2019 ITAC Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Cancer Patients Speaker: Corinne Frere, FR
PB1135 Thrombotic and Hemorrhagic Complications in Patients 16:00 - 16:00 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Speaker: Eduardo Gonzalez Gomez, ES
PB1136 Pancreatic-miRaCan-VTE: A R Shiny App to Aid in the 16:00 - 16:00 Diagnosis of Pancreatic Cancer-associated VTE Speaker: Julia Oto Martínez, ES
PB1137 Biomarkers Of Thrombosis As Predictors Of Venous 16:00 - 16:00 Thromboembolism In Cancer Patients: Preliminary Results From Fiit Project Speaker: Sara Lopes, PT
PB1138 Secondary Prophylaxis of Venous Thromboembolism with 16:00 - 16:00 Direct Oral Anticoagulants in Patients with Major Congenital Thrombophilia vs Non-thrombofilic Patients Speaker: Giovanni Manfredi Assanto, IT
PB1139 Is Hematopoietic Clonality of Indetermined Potential a Risk 16:00 - 16:00 Factor for Pulmonary Embolism? Speaker: Simon Soudet, FR
PB1140 Tumor Somatic Mutations as Predictors of CDK4/6 Inhibitor 16:00 - 16:00 Associated Thromboembolism in Women with Metastatic Breast Cancer Speaker: Malinda West, US
PB1141 ABO Blood Groups as a Risk Factor for the Development of 16:00 - 16:00 Deep Vein Thrombosis of the Lower Extremities in Elderly and Senile Patients Speaker: Alina Tomchenko, RU
PB1142 Hemostatic Genetic Risk Factors of Aseptic Cerebral Venous 16:00 - 16:00 Thrombosis Speaker: Kostiantyn Stepanchenko, UA
PB1143 VKORC1 -1639AA Genotype Is a Possible Protective Factor for 16:00 - 16:00 Venous Thromboembolism Development in Patients with FII
117 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
G20210A Mutation from North-Western Russia Speaker: Vitaly Soldatenkov, RU
PB1144 FACTOR XII 46 C/T Gene Polymorphism as a Possible Risk 16:00 - 16:00 Factor for Late-onset Venous Thromboembolism in Patients from the North-Western Russia Speaker: Anna Chechulova, RU
PB1145 The Evaluation of the Children with Intracranial Thrombosis 16:00 - 16:00 Speaker: Adalet Meral Güne?, TR
PB1146 Pulmonary Embolism in the Onset of Hematogenous 16:00 - 16:00 Thrombophilia Speaker: Tatyana Luchnikova, RU
PB1147 Evaluation of Fibrinogen Level In non-Diabetic Hypertensive 16:00 - 16:00 Patients at the University of Nigeria Teaching Hospital Ituku- Ozalla Speaker: Eyiuche Ezigbo, NG
LPB0091 Predictors of the Development of the Post-thrombotic 16:00 - 16:00 Syndrome: A Sub-analysis of the ATTRACT Trial Speaker: Felix Rinfret, CA
PB1148 Statins for Venous Event Reduction in Patients with Venous 16:00 - 16:00 Thromboembolism: A Multicenter Randomized Controlled Pilot Trial with a Focus on Prevention of Post-thrombotic Syndrome Speaker: Aurelien Delluc, CA
PB1150 Role of Individual Venous Symptoms and Signs at Baseline in 16:00 - 16:00 Predicting Future Development of Post-thrombotic Syndrome: Sub-analysis of the ATTRACT Trial Speaker: Felix Rinfret, CA
PB1151 Development of a New Disease-specific Health-related Quality 16:00 - 16:00 of Life Questionnaire after Deep Vein Thrombosis: Qualitative Phase of a Mixed Method Development Speaker: Elia Asady, NO
PB1152 Pathologically Stiff Erythrocytes Can Promote Thrombosis by 16:00 - 16:00 Impeding Contraction of Blood Clots Speaker: Valerie Tutwiler, US
PB1153 Abnormal Thrombin Generation in Children with Thrombosis 16:00 - 16:00 Speaker: Susan Kuldanek, US
PB1154 Additional Risk Factors of Hereditary Thrombophilia in the 16:00 - 16:00 North-Western Region of Russia Speaker: Vitaly Soldatenkov, RU
PB1155 A Potential Risk of Venous Thrombosis Induced by 16:00 - 16:00 Nanomaterials and the Protection Role of Nrf2 Speaker: Yiying Bian, CN
PB1156 Impact of Thrombophilia Testing in Splanchnic Vein 16:00 - 16:00 Thrombosis Management
118 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Rihab Rouached, TN
PB1157 Thrombin Generation in Newly Diagnosed Multiple Myeloma 16:00 - 16:00 Speaker: Diego Velasco-Rodríguez, ES
PB1158 Clinical and Molecular Characterization of Chinese Patients with 16:00 - 16:00 Protein S deficiency Speaker: Donglei Zhang, CN
PB1159 Role of Inherited Thrombophilia in the Occurrence of Arterial 16:00 - 16:00 Thrombosis after Venous Thromboembolism Speaker: Alessandro Ciavarella, IT
PB1160 Reversible Factor Xa Inhibitors Specifically Inhibit, in Clot 16:00 - 16:00 Growth, via the Intrinsic Tenase Complex: A Tool to Determine Specifically the In- and Extrinsic Contribution to Clot Growth Speaker: Cornelis Kluft, NL
PB1161 Activated Charcoal to Remove DOAC from Patients’ Plasma. 16:00 - 16:00 Potential Usefulness for Routine Coagulation and Thrombophilia Testing in DOAC Treated Patients Speaker: Pierre Toulon, FR
PB1162 Appropriateness of Thrombophilia Evaluation and 16:00 - 16:00 Anticoagulation Management: A Multi-specialty Survey of Practitioners at Tower Health Reading Hospital Speaker: Timothy Johnson, US
PB1163 C20209T Prothrombin Gene Mutation in a Caucasian Woman 16:00 - 16:00 with a History of Venous Thrombosis Speaker: Didier jambou, FR
PB1164 Heterozygosity for factor V Leiden with a Catastrophic 16:00 - 16:00 Presentation Speaker: Rita Pombal, PT
PB1165 The Role of Thrombophilia in Deep Vein Thrombosis of Unusual 16:00 - 16:00 Sites Speaker: Imen chabchoub, TN
PB1166 Incidence of Thrombosis in Patients with MTHFR C677T 16:00 - 16:00 Homozygosity and Hyperhomocysteinemia Speaker: Giovanna Maria Nicolò, IT
PB1167 Deep Vein Thrombosis in Young Woman Reveals a Novel 16:00 - 16:00 Mutation on SERPINC1 Gene Speaker: Filipa Bargado, PT
PB1168 Duration of Thromboprophylaxis with Low Molecular Weight 16:00 - 16:00 Heparins after Cesarean Delivery in Carriers of Leiden Mutation, F5g1691a Genotype Speaker: Mariya Nikolaeva, RU
PB1169 Discrepancy between Genotype and Phenotype for Factor V 16:00 - 16:00 Leiden Mutation in Recipients of Liver and Stem Cell Transplantation
119 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Joseph Rigano, AU
PB1170 Inpatient Thrombophilia Testing – Adding Unnecessary Cost to 16:00 - 16:00 the Clot? Speaker: Sudeepthi Bandikatla, US
PB1171 Frequency of Hereditary Thrombophilia in Venous 16:00 - 16:00 Thromboembolic Disease Speaker: Khalida Mendi, DZ
LPB0043 Annexin A2-mediated Surface Fibrinolysis Is Impaired in Non- 16:00 - 16:00 alcoholic Steatohepatitis (NASH) Cirrhosis and May Contribute to Portal Vein Thrombosis Speaker: Hana I Lim, US
PB1172 Non-malignant Portal Vein Thrombi in Patients with Cirrhosis 16:00 - 16:00 Consist of Intimal Fibrosis with or without a Fibrin-rich Thrombus Speaker: Ellen G. Driever, NL
PB1173 Subacute Mesenteric Venous Thrombosis Secondary to 16:00 - 16:00 COVID-19: A Late Thrombotic Complication in a Non-severe Patient Speaker: Leonardo Cano Cevallos, EC
PB1174 Does Anticoagulation Affect Outcome of Splenic Vein 16:00 - 16:00 Thrombosis in Acute Pancreatitis? Speaker: Lúcia Vieira, PT
PB1175 Detection of Right Ventricular Dysfunction in Acute Pulmonary 16:00 - 16:00 Embolism by CT Scan: A Systematic Review and Meta-analysis Speaker: Nicholas Chornenki, CA
PB1176 ISTH Definition of Pulmonary Embolism-related Death and 16:00 - 16:00 Classification of the Cause of Death in Venous Thromboembolism Studies: An Autopsy Study Speaker: Tobias Tritschler, CA
PB1177 Comparing "Clinical Hunch" against Clinical Decision Scores 16:00 - 16:00 (PERC Rule, Wells Score, Revised Geneva Score, YEARS Criteria) in Acute Pulmonary Embolism Diagnostics Speaker: Koshiar Medson, SE
PB1178 Pulmonary Embolism Diagnosis: Let’s Practice what we 16:00 - 16:00 Preach. A Quality Improvement Study to Increase Adherence to Evidence-based PE Diagnosis in the Emergency Department Speaker: Federico Germini, CA
PB1179 Agreement between Physician and Nurse Derived Wells Score 16:00 - 16:00 as Part of the Assessment of Deep Vein Thrombosis in a Rapid Access Ambulatory Clinic Speaker: Constanza Martínez, CA
PB1181 Echocardiographic Parameters Predicted Short-term Outcomes 16:00 - 16:00 in Acute Pulmonary Embolism
120 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Diaconu Nadejda, MD
PB1182 A Simplified Decision Rule to Rule out Deep Vein Thrombosis 16:00 - 16:00 Using Clinical Assessment and D-dimer Speaker: Keying Xu, CA
PB1183 D-dimer to Rule out Venous Thromboembolism during 16:00 - 16:00 Pregnancy: A Systematic Review and Meta-analysis Speaker: Marta Bellesini, CH
PB1184 Diagnostic Accuracy of D-dimer for Splanchnic Vein 16:00 - 16:00 Thrombosis: A Systematic Review and Meta-analysis Speaker: Laura Maria Attard, MT
PB1185 Clinical Implications of V/Q SPECT Scans Being Inconclusive in 16:00 - 16:00 20% of Patients Referred on Suspicion of Pulmonary Embolism Speaker: Koshiar Medson, SE
PB1186 Predictors for Prognosis in Patients with Nonfatal Pulmonary 16:00 - 16:00 Embolism in COVID-19 Pandemic Speaker: Nadejda Diaconu, MD
PB1187 Elevated D-dimer Levels and DVT Following Neurosurgery 16:00 - 16:00 Speaker: Maria Teresa Sartori, IT
PB1188 Diagnosing Deep Venous Thrombosis using Artificial Neural 16:00 - 16:00 Networks and Metabolomics by 1H-NMR Data Speaker: Tiago D. Martins, BR
LPB0092 Alteration of the Circulating Plasma Proteome by FXa Inhibition 16:00 - 16:00 in Venous Thromboembolism and the Relationship with Clinical Outcome Speaker: Alejandro Pallares Robles, DE
LPB0139 Association of FXI Activity with Thrombo-inflammation, 16:00 - 16:00 Extracellular Matrix Interactions, Lipid Metabolism and Apoptosis in Venous Thromboembolism Speaker: Alejandro Pallares Robles, DE
LPB0140 Long-term Survival after Venous Thromboembolism: A 16:00 - 16:00 Prospective Cohort Study Speaker: Henning Nilius, CH
PB1190 Thromboembolism is Prevalent and Adversely Affects Overall 16:00 - 16:00 Survival in Adults with Hemophagocytic Lymphohistiocytosis Speaker: Jennifer Croden, CA
PB1191 Erythrocytosis and Thromboembolic Events in Transgender 16:00 - 16:00 Individuals Undergoing Masculinizing Therapy with Testosterone Speaker: Michael Oakes, US
PB1192 Venous Thromboembolism in Patients Hospitalized with 16:00 - 16:00 COVID-19: Results from the Brazilian COVID-19 Registry Speaker: Maira Viana Rego Souza Silva, BR
121 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1193 Association between Cardiovascular Risk Factors and Venous 16:00 - 16:00 Thrombosis in the Elderly Speaker: Huijie Wang, NL
PB1194 Premature Mortality Burden Related to Pulmonary Embolism in 16:00 - 16:00 Cuba Speaker: Karen Valdés-Díaz, CU
PB1195 Location and Burden of Extremity Vein Thrombosis in Patients 16:00 - 16:00 with Solitary versus Multiple Subsegmental Pulmonary Emboli Speaker: Ryan Meverden, US
PB1196 The Roles of Individual and Neighborhood Income on Regional 16:00 - 16:00 and Racial Differences in Risk of Venous Thromboembolism in the United States: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS) Speaker: Jordan Munger, US
PB1197 Coagulation Factors Levels during and after Anabolic 16:00 - 16:00 Androgenic Steroid Use: Data from the HAARLEM Study Speaker: Eleonora Camilleri, NL
PB1198 Acute VTE in HIV versus Non-HIV population - Nationwide 16:00 - 16:00 Analysis of Mortality, Morbidity, Demographics and Healthcare Utilization Speaker: Muhammad Junaid Tariq, US
PB1199 Recurrence and Mortality Following First Venous 16:00 - 16:00 Thromboembolism among Saudi Population: Single-centre Cohort Study Speaker: Reem Almanea, SA
PB1200 Development of a Computable Phenotype for Venous 16:00 - 16:00 Thrombosis Present on Admission: The Medical Inpatient Thrombosis and Hemostasis (MITH) Study Speaker: Ryan Thomas, US
PB1201 National Survey of Hospital–associated Venous 16:00 - 16:00 Thromboembolism Prevention in NHS England: Findings from the GIRFT Thrombosis Survey Speaker: Lara Roberts, GB
PB1202 How Common Are Uterine Venous Plexus Thrombi in Women 16:00 - 16:00 Attending the Gynaecology Clinic? Speaker: Hannah Cohen, GB
PB1203 Machine Learning and Algorithmic Diagnosis Identification of 16:00 - 16:00 PatientsTreated by Direct Oral Anticoagulants Using Medico- administrative Databases Speaker: Joseph Emmerich, FR
PB1204 Risk Factors of Venous Thromboembolism at Patients with 16:00 - 16:00 Endoscopic Urological Interventions Speaker: Dina Shorikova, UA
122 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1205 Hypoalbuminemia, Not Proteinuria, Is Associated with 16:00 - 16:00 Increased Venous Thromboembolism Risk among Primary Glomerulonephritis Patients with Nephrotic Syndrome: A Meta- analysis of Cohort Studies Speaker: Boby Pratama Putra, ID
PB1206 Incidence of Venous Thromboembolic Disease during Primary 16:00 - 16:00 Hyperparathyroidism: A 20-year Single Center Study Speaker: Maria Orlova, AR
PB1207 Incidence and Treatment Pattern of Venous Thromboembolism 16:00 - 16:00 from 2014 to 2018: The 3rd Korean Nationwide Study Speaker: Hun-Gyu Hwang, KR
PB1208 Solitary versus Multiple Subsegmental Pulmonary Emboli: 16:00 - 16:00 Clinical Characteristics and Outcomes Speaker: Yumiko Hirao-try, US
PB1209 ISTH Membership and Research Output: A Comparative Study 16:00 - 16:00 of Sub-Saharan Africa and Europe Speaker: Edeghonghon Olayemi, GH
PB1210 Prospective Cohort: A 10 Years Experience with Hospitalized 16:00 - 16:00 Patients with Venous Thromboembolic Disease from a Single- center Institutional Registry, Argentina Speaker: Fernando Javier Vázquez, AR
PB1211 Differences of Profile and Management of Cancer-associated 16:00 - 16:00 Thrombosis in a RIETE’s Hospital in Brazil Speaker: Júlia de Abreu Couto Vieira, BR
PB1212 Trombophilia and Other Risk Factors of Cerebral Venous Sinus 16:00 - 16:00 Thrombosis in 255 Patients Speaker: Adela Gwozdowska, PL
PB1213 Prevalence and Incidence of Deep Vein Thrombosis in Medical 16:00 - 16:00 Critically Ill Patients: A Prospective Analysis in a Single Tertiary Care Centre in Thailand Speaker: Saengrawee Arunothai, TH
PB1214 Low Awareness of Venous Thromboembolism among the 16:00 - 16:00 General Population: A Call for Increased Public Enlightenment Programs Speaker: Helen Okoye, NG
PB1215 Venous Thromboembolism Profile and Management Differences 16:00 - 16:00 between Ages in a RIETE’s Hospital of Brazil Speaker: Roberto Santos de Oliveira Júnior, BR
PB1216 Clinical Observations in Patients with Cerebral Venous Sinus 16:00 - 16:00 Thrombosis Speaker: Thura W Htut, GB
PB1217 Implementation of a Multidisciplinary Surveillance Team to 16:00 - 16:00 Improve Inferior Vena Cava Filter Retrieval and Outcomes
123 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Sharon Chao, AU
PB1218 Comparison of 0.9% Normal Saline (NS) Flush and 16:00 - 16:00 Unfractionated Heparin (UFH) Flush for Maintenance of Central Venous Catheter Line Patency Speaker: Alexandra N. Landmesser, US
PB1219 Can Combining a Risk Score Derived from Ubiquitous 16:00 - 16:00 Biomarkers with a Clinical Risk Assessment Model Better Predict 90-day Post-discharge Hospital-associated Venous Thromboembolism among Medical Patients? Speaker: Scott Woller, US
PB1220 VTE Prophylaxis in Foot and Ankle Surgery: A Worldwide 16:00 - 16:00 Survey Speaker: Roberto Zambelli, BR
PB1221 Safety and Efficacy of Low-Molecular Weight Heparin Regimes 16:00 - 16:00 for Venous Thromboembolism Prophylaxis in Bariatric Surgery Speaker: Allen Li, CA
PB1222 Comparing Adherence of Low Molecular Weight Heparin versus 16:00 - 16:00 Unfractionated Heparin for Thromboprophylaxis of Medical Inpatients Speaker: Marcus Trybula, US
PB1223 A Systematic Review and Meta-analysis on the Use of 16:00 - 16:00 Chemoprophylaxis in the Prevention of Venous Thromboembolism in Colorectal Cancer Surgery in Asian Population Speaker: Shih Jia Janice Tan, SG
PB1224 Pharmacologic Profiles of Direct Oral Anticoagulants in Patients 16:00 - 16:00 Receiving Rituximab-CHOP Chemotherapy Speaker: Teerachat Punnachet, TH
PB1225 Venous Thromboembolism Risk Profiles and Prophylaxis in 16:00 - 16:00 Medical Oncology Inpatients: a Subgroup Analysis of the Observational DissolVE-2 Study Speaker: Chen Wang, CN
PB1226 Using the Caprini Risk Score to Increase VTE Awareness in the 16:00 - 16:00 Community. The Know Your Score Project Speaker: Hassan Saadaldin, EG
PB1227 Assessing Use of Surrogate Outcome Measures in Randomized 16:00 - 16:00 Controlled Trials Investigating Venous Thromboembolism Prophylaxis Speaker: Ali Eshaghpour, CA
PB1228 Venous Thromboembolism Prophylaxis in Patients with Severe 16:00 - 16:00 Burns in a Large Trauma Hospital Speaker: Rose Brazilek, AU
PB1229 International Survey of Secondary Thromboprophylaxis 16:00 - 16:00 Practice Patterns in Pediatrics
124 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Neil A. Goldenberg, US
PB1230 A Multi-disciplinary Approach to Improving Temporary IVC 16:00 - 16:00 Filter Retrieval Rates Speaker: Jozef Kamp, GB
PB1231 Incidence of Thrombohaemorrhagic Complications in the 16:00 - 16:00 Periprocedural of Oral Anticoagulant Treatment with Vitamin K Antagonists Speaker: María Argüello Marina, ES
PB1232 Final Results (765 Answers) of the Brazilian National Survey in 16:00 - 16:00 Thromboprophylaxis for Varicose Vein Surgery Speaker: Alcides Jose Ribeiro, BR
PB1233 Success of Online CME at Improving Knowledge and 16:00 - 16:00 Confidence around Guideline-directed Management of Cancer- associated Thrombosis Speaker: Margaret Harris, US
PB1234 VTE Risk at Discharge 16:00 - 16:00 Speaker: Kishan Patel, US
PB1235 D-Dimer Test and Postoperative Thromboprophylaxis 16:00 - 16:00 Speaker: Tatjana Makarovska Bojadjieva, MK
PB1236 Outcomes of Non-bleeding Patients on Warfarin with an INR > 16:00 - 16:00 10, who Received Vitamin K or Conservative Therapy Speaker: Aubrey Jones, US
PB1237 Long-term Risk of Recurrent Venous Thromboembolism after a 16:00 - 16:00 First Contraceptive-related Event: Data from REVERSE Cohort Study Speaker: David Aziz, CA
PB1238 Results of DOAC Dipstick Test in Outpatients with Venous 16:00 - 16:00 Thromboembolic Disease Are Comparable to Plasma Levels of Direct Oral Inhibitors - An Efficient Assessment Tool Speaker: Loula Papageorgiou, FR
PB1239 Differences in the Clot Based and Amidolytic Anti-Xa Assays for 16:00 - 16:00 the Neutralization Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Speaker: Fakiha Siddiqui, US
PB1240 Association of Adding Antiplatelet Therapy to Warfarin for 16:00 - 16:00 Management of Venous Thromboembolism with Bleeding and Other Adverse Events Speaker: Melinda Song, US
PB1241 Development of a Modified Thrombin Generation Assay with 16:00 - 16:00 Improved Sensitivity to Factor XIa Inhibition by the Novel Small Molecule Milvexian (BMS-986177/JNJ-70033093) Speaker: Matthew Bunce, US
PB1242 Recurrent Thromboembolic Risk in Paroxysmal Nocturnal 16:00 - 16:00
125 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Hemoglobinuria Patients not on Anticoagulation Treated with Terminal Complement Inhibition Speaker: Gloria Gerber, US
PB1243 DASH Score for Prediction of Recurrent Venous 16:00 - 16:00 Thromboembolism: Updated Long-term Outcomes from a Single-centre Speaker: Will Thomas, GB
PB1244 Anticoagulation Strategies during Conditioning-induced 16:00 - 16:00 Thrombocytopenia in Hematopoietic Cell Transplant Patients with Venous Thromboembolism Speaker: Kylee Martens, US
PB1245 Effectiveness and Safety of DOACs for the Prevention of 16:00 - 16:00 Recurrent VTE: A Prospective Cohort Study Speaker: Alessandra Vinci, IT
PB1246 Antithrombotic Management of Patients with Deep Vein 16:00 - 16:00 Thrombosis and Venous Stents: An International Registry Speaker: Andrea Cervi, CA
PB1247 Safety Profile of Rivaroxaban in First-time Users Treated for 16:00 - 16:00 Deep Vein Thrombosis and Pulmonary Embolism without a Recent History of Cancer Speaker: Gunnar Brobert, SE
PB1248 Usefulness of Measuring Anti–Factor Xa Activity to Guide the 16:00 - 16:00 Treatment with Low-molecular-weight Heparins in Patients with Acute Pulmonary Embolism Speaker: Jose Bonorino, AR
PB1249 A Retrospective Evaluation of the Management of Isolated 16:00 - 16:00 Distal Deep Vein Thrombosis in Australia Speaker: Brandon Lui, AU
PB1250 Comparative Effectiveness of Oral Anticoagulants in Venous 16:00 - 16:00 Thromboembolism: On-treatment Analysis in GARFIELD-VTE Speaker: Sylvia Haas, DE
PB1251 Using an App to Educate Patients on the Pros and Cons of 16:00 - 16:00 Extended Anticoagulation after Venous Thromboembolism: A Randomized Controlled Trial Speaker: Maria A. de Winter, NL
PB1252 Real-world Data on the Use of Oral Anticoagulants for the 16:00 - 16:00 Treatment of Venous Thromboembolism in Sweden: Oral Anticoagulant Use and Baseline Characteristics from the Venous Thromboembolism Treatment Study Speaker: Anders Gottsäter, SE
PB1253 Neutralization of the Oral and Parenteral Anti-Xa Agents by 16:00 - 16:00 Andexanet Alfa Speaker: Fakiha Siddiqui, US
126 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1254 Oral Anticoagulant Use in Patients with Morbid Obesity: A 16:00 - 16:00 Systemic Review and Meta-analysis Speaker: Tzu-Fei Wang, CA
PB1255 Statins for Venous Event Reduction in Patients with Venous 16:00 - 16:00 Thromboembolism: A Randomized Controlled Pilot Trial Assessing Feasibility Speaker: Aurelien Delluc, CA
PB1256 A Real-world Experience of Venous Thromboembolism (VTE) 16:00 - 16:00 Management in Australia Speaker: Brandon Lui, AU
PB1257 VTE Treatment Planning: A Mixed-method Analysis of Clinical 16:00 - 16:00 Challenges, Knowledge, and Confidence Gaps in Selecting Evidence-based Treatment Speaker: Alex Spyropoulos, US
PB1258 Symptomatic versus Incidentally Noted Isolated Subsegmental 16:00 - 16:00 Pulmonary Embolus Outcomes Speaker: Danielle T Vlazny, US
PB1259 Neutralization of the Anticoagulant Effects of Sulodexide by 16:00 - 16:00 Protamine Sulfate Speaker: Bharathi Daravath, US
PB1260 AntiXa Heparin Dosing Protocol Evaluation at a Large Academic 16:00 - 16:00 Medical Center Speaker: Tania Ahuja, US
PB1261 Tailored Anticoagulant Treatment after a First Venous 16:00 - 16:00 Thromboembolism: Protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) Study, a Cohort Based Randomized Controlled Trial Speaker: J. Louise I. Burggraaf, NL
PB1262 Duration and Treatment Outcomes between Idiopathic and 16:00 - 16:00 Provoked Non-catheter-Related Axillary and Subclavian Vein Thromboses Speaker: Anamarija Sliskovic, HR
PB1263 Comparison of Real-world Effectiveness and Safety of 16:00 - 16:00 Enoxaparin versus Tinzaparin or Dalteparin in Cancer Patients with Venous Thromboembolism. The RIETECAT Cohort Study Speaker: Manuel Monreal, ES
PB1264 Direct Oral Factor-Xa-inhibitors for the Treatment of VTE in the 16:00 - 16:00 Obese: Do Body Weight and Body Composition Matter? A Prospective Pilot Study Speaker: Katharina Guetl, AT
PB1265 Patient Satisfaction with Quality of Care from a New 16:00 - 16:00 Multidisciplinary Thrombosis Service Speaker: Stephanie Young, CA
127 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1266 Using the Functional Resonance Analysis Method to Explore 16:00 - 16:00 how Elastic Compression Therapy Is Organized and Could Be Improved Speaker: Rachel H.P. Schreurs, NL
PB1267 International Multicentric Study: Laboratory in Patients Treated 16:00 - 16:00 with Apixaban or Rivaroxaban in Latin America (Larila): Final Results Speaker: Evelyn Cortina, MX
PB1268 Nationwide Children’s Hospital Pediatric and Adult 16:00 - 16:00 Comprehensive Anticoagulation Program: A Report on its Anticoagulation Management and Clinical Outcomes Speaker: Vilmarie Rodriguez, US
PB1269 Enhancement of Thrombin Generation in Lymphoma Cohort by 16:00 - 16:00 Andexanet Alfa Speaker: Fakiha Siddiqui, US
PB1270 A Survey of Current Anticoagulation Patient Education 16:00 - 16:00 Practices and Development Speaker: Aubrey Jones, US
PB1271 Statin Use and Recurrence of Venous Thromboembolic Event 16:00 - 16:00 Speaker: Maria Florencia Grande Ratti, AR
PB1272 A Realist Evaluation on Therapeutic Elastic Compression 16:00 - 16:00 Therapy Pathways for DVT- and CVD Patients to Develop Evidence-informed Improvement Strategies Speaker: Rachel H.P. Schreurs, NL
PB1273 Recurrent Thrombosis Rescued by Fondaparinux in High-risk 16:00 - 16:00 Patients: Case Series and Review of Literature Speaker: Mégane Tanguay, CA
PB1274 May-Thurner Syndrome-associated Deep Vein Thrombosis: Is 16:00 - 16:00 Oral Anticoagulation the Novel Approach? Speaker: Francis Albert Lo, SG
PB1275 Heparin Therapeutic Range for Five aPTT Reagents in Plasma 16:00 - 16:00 and One Point of Care Speaker: Karen Guadalupe Cortés-Cortés, MX
PB1276 Bleeding Complications in Patients on New Oral Anticoagulants 16:00 - 16:00 for Venous Thromboembolism in Kenya Speaker: Antonina Obayo, KE
PB1277 Predictors of Recurrence of Venous Thromboembolic Disease 16:00 - 16:00 after Suspension of Anticoagulation
PB1278 The Accelerated Regimen of Low Dose Recombinant Tissue- 16:00 - 16:00 type Plasminogen for the Treatment of Acute Pulmonary Embolism: A Case Series from Vietnam Speaker: Bui Hai Hoang, VN
PB1279 Efficacy and Safety Comparison of DOACs versus Enoxaparin 16:00 - 16:00
128 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
or Heparin with Concomitant Warfarin in Patients with Acute Venous Thromboembolism – A Systematic Review and Meta- analysis Speaker: Ikhwan Rinaldi, ID
PB1280 Experience with Direct Oral Anticoagulants (Doacs) for the 16:00 - 16:00 Treatment of Cancer Associated Thrombosis Speaker: Carlos Aguilar, ES
PB1281 Practical Considerations for Treatment of Left Ventricular 16:00 - 16:00 Thrombus with Direct-acting Oral Anticoagulants Speaker: Rose Brazilek, AU
PB1282 Standardized Direct Oral Anticoagulants Prescription for the 16:00 - 16:00 Treatment of Acute Deep Vein Thrombosis in the Emergency Department: A Quality Improvement Initiative Speaker: Laurence Poirier-Blanchette, CA
PB1283 Evaluation of the Efficacy and Safety of Enoxaparin Biosimilar 16:00 - 16:00 Treatment in Our Center Speaker: Maria Almudena Garcia Ruiz, ES
PB1284 Thromboembolic disease (VTE) and Inmune Trombocytopenia 16:00 - 16:00 (ITP): A Case Report Speaker: MANUEL R. LOPEZ, ES
LPB0044 Prothrombotic Biomarkers during Controlled Ovarian 16:00 - 16:00 Stimulation for Assisted Reproductive Techniques Speaker: Alessandro Casini, CH
LPB0141 Platelet Activation and Platelet Indices as Markers for Disease 16:00 - 16:00 Progression in Women with Breast Cancer Speaker: Yousra Tera, EG
LPB0142 Association between Non-O Blood Group and the Risk of 16:00 - 16:00 Venous Thromboembolism due to Oral Contraceptive Therapy Speaker: Anna Poretto, IT
PB1285 Hormonal Contraception (HC) and Thrombosis: Identifying the 16:00 - 16:00 Gaps in Knowledge among Young Woman Speaker: Yan Deng, CA
PB1286 A New Pharmacodynamic Test to Evaluate Effects of Oral 16:00 - 16:00 Contraceptives on Coagulation Speaker: Petra de Kruijf, NL
PB1287 A Major Knowledge Gap in Women’s Health: The Combined 16:00 - 16:00 Effect of Antifibrinolytics and Estrogen on Risk of Thromboembolism - A Scoping Review Speaker: Danielle Meschino, CA
PB1288 Heavy Menstrual Bleeding: Knowledge and Practice 16:00 - 16:00 Assessment among Tunisian Primary Care Physicians Speaker: Emna Hammami, TN
PB1289 Sex-specific Association of Endogenous PCSK9 with Memory 16:00 - 16:00
129 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Function in Elderly Subjects at High CV Risk Speaker: Paola Simeone, IT
PB1290 Transferability of the ETP-based APC Resistance Assay on the 16:00 - 16:00 ST Genesia System Speaker: Laure Morimont, BE
PB1291 Thrombin Generation Test and Use of Combined Oral 16:00 - 16:00 Contraceptive Speaker: Maria das Gracas Carvalho, BR
PB1292 The Influence of Thrombophilic Anamnesis and Thrombotic 16:00 - 16:00 Complications Heredity Speaker: Nadezda Vorobyeva, RU
LPB0045 Principles of Care for Women and Girls with Inherited Bleeding 16:00 - 16:00 Disorders Speaker: Karin van Galen, NL
LPB0046 The Impact of the ABO Blood Group on Postpartum 16:00 - 16:00 Haemorrhage Risk among Women with Thrombocytopenia Speaker: Sara Arcudi, IT
LPB0047 Management of Peripartum Anticoagulation in Women with 16:00 - 16:00 Venous Thromboembolism: An International Survey of Clinical Practice Speaker: Camille Simard, CA
LPB0093 An Overall Evaluation of the Adjusted Version of Global 16:00 - 16:00 Antiphospholipid Syndrome Score (aGAPSS) on Primary Obstetric Antiphospholipid Syndrome (POAPS) Patients Speaker: Gabriela de Larrañaga, AR
LPB0095 Bleeding Complications in Women with Venous 16:00 - 16:00 Thromboembolism during Pregnancy: A Systematic Review of the Literature Speaker: Camille Simard, CA
LPB0143 Is standard dose thromboprophylaxis (TP) as recommended by 16:00 - 16:00 the Royal College of Obstetricians and Gynaecologists (RCOG) adequate in pregnancy for women with prior venous thrombo- embolism (VTE)? Speaker: Emma Treharne, GB
LPB0144 Thrombocytopenia in Pregnancy: Identification and 16:00 - 16:00 Management at a Reference Centre in Pakistan Speaker: Munira Borhany, PK
PB1293 Thromboprophylaxis in High-risk Obese Pregnant Women: How 16:00 - 16:00 Much Is Enough? Speaker: Agustín Rodríguez Alén, ES
PB1294 Antepartum Anemia and Risk of Postpartum Hemorrhage: A 16:00 - 16:00 Comprehensive Review of the Literature Speaker: Hannah Glonnegger, DE
130 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PB1295 Diagnostic Significance of Definitions Soluble Fibrin Monomer 16:00 - 16:00 Complexes In Patients with Preeclampsia Speaker: Bakhodir Kurbanov, UZ
PB1296 Utility of Royal College of Obstetricians and Gynaecologists 16:00 - 16:00 (RCOG) Guidelines in Preventing Pregnancy Related Venous Thrombo-embolism (PA-VTE) Speaker: Emily Jackson, GB
PB1297 Interactions of Anemia with Race and Peripartum Transfusion in 16:00 - 16:00 Three Large US Registries Speaker: Elisabeth Davis, US
PB1298 Pregnancy and Heparin: Peripartum Management. Experience of 16:00 - 16:00 Two Centers in Argentina Speaker: Soledad Molnar, AR
PB1299 New Criteria for Assessing Hemostasis Disorders in Pregnant 16:00 - 16:00 Women with Chronic Kidney Disease Speaker: Irina Vasilenko, RU
PB1300 Preeclampsia and Inflammatory Lipid Mediators: A Longitudinal 16:00 - 16:00 Study Speaker: Luiza Perucci, BR
PB1302 Impact of Tissue Factor Pathway Inhibitor Gene Polymorphisms 16:00 - 16:00 (33T/C and 264V/M) on Plasma TFPI Levels and their Influence on Risk of Recurrent Pregnancy Loss in India Speaker: Kamal Kishor, IN
PB1303 Warfarin Anticoagulation and Fetal Central Nervous System 16:00 - 16:00 Abnormalities: A Case Report Speaker: Refilwe Monaheng, ZA
PB1304 Evaluation of the Effectiveness of Multidisciplinary Care Plans 16:00 - 16:00 for the Perinatal Management of Women with Bleeding Disorders Speaker: Natalya O'Neill, CA
PB1305 Deconstructing the Obstetric Antiphopholipid Syndrome (APS) 16:00 - 16:00 Speaker: Beatriz Grand, AR
PB1306 Novel Point of Care Rapid Coagulation Analyzer for Obstetrics – 16:00 - 16:00 Quantra (SEER Sonorheometry) Speaker: Arunthevaraja Karuppiah, US
PB1307 Outcomes of Treatment of Thromboembolic Disease during 16:00 - 16:00 Pregnancy and Postpartum – Single-center Experience Speaker: Matija Kozak, SI
PB1308 Bernard Soulier Syndrome in Pregnancy: Management of Two 16:00 - 16:00 Pregnancies in a Patient with Variant Bernard Soulier Syndrome Speaker: Bella Madan, GB
PB1309 Assessment of the Utility of the Pregnancy-adapted YEARS 16:00 - 16:00 Algorithm in Predicting Presence of Pulmonary Embolism (PE)
131 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
in Pregnant Women (PA-PE) Speaker: Aarabi Alexander, GB
PB1310 Perinatal Outcome of Normal Pregnant and Pregnant Women 16:00 - 16:00 Hospitalized for Hypertension (PIH: Pregnancy Induced Hypertension) and Studied for Antiphospholipid Antibodies (aPL) at Time of PIH Onset Speaker: Beatriz Grand, AR
PB1311 Review of Intrapartum Management of ITP in Pregnancy in John 16:00 - 16:00 Radcliffe Hospital Speaker: Jay Dhanapal, GB
PB1312 Prophylactic Radiological Interventions to Reduce Postpartum 16:00 - 16:00 Haemorrhage in Patients with Placenta Accreta Spectrum Disorders Speaker: L.R. Bonsen, NL
PB1313 Not Yet to Be Born: A Clinical Case of Pseudothrombocytopenia 16:00 - 16:00 in a Pregnant Woman Speaker: Ana Catarina B. Marques, PT
PB1314 The Effect of Prothrombin Complex Concentrate and 16:00 - 16:00 Cryoprecipitate on the Frequency and Severity of Multiple Organ Dysfunction Syndrome in Massive Obstetric Haemorrhage Speaker: Vladyslav Sedinkin, UA
PB1315 Hereditary Thrombophilia in Macedonian Women with in vitro 16:00 - 16:00 Fertilization Failure Speaker: Elena Petkovikj, MK
PB1316 Bombay Phenotype and Twin Pregnancy: Case Report and 16:00 - 16:00 Literature Review Speaker: Michael Krigstein, AU
PB1317 Gender-specific Risk Prediction of Venous Thromboembolism 16:00 - 16:00 for Patients Admitted to Intensive Care Units (ICU) Speaker: Iheb Labbene, TN
Publication Only Abstracts 16:00 - 17:00 R4 Publish Only Abstracts PO100 Early Stage Atherosclerosis Regression, Using High-dose 16:00 - 16:00 Atorvastatin Administration Accompanied by B-mode Ultrasound-guided 5-aminolevulinic Acid-mediated Catheter- based Low Level Blue Laser Photodynamic Therapy Speaker: Hossein Mehrad, IR
PO101 Lipid-based Encapsulated Methotrexate Nanoparticles-mediated 16:00 - 16:00 Low Level Focused Ultrasound Sonoporation Therapy Decrease Inflammation and Restenosis after ArF Excimer Laser Angioplasty of Fibrocalcific Atherosclerosis Speaker: Hossein Mehrad, IR
132 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PO102 Ultrasound-guided Catheter-based 192Ir -mediated 16:00 - 16:00 ?-brachytherapy of Neointimal Hyperplasia Accompanied by Protoporphyrin IX–loaded Microbubbles-mediated Pulsed Low Level Focused Ultrasound Sonodynamic Therapy Speaker: Hossein Mehrad, IR
PO103 B-mode Ultrasound-guided Combined Catheter-based Q- 16:00 - 16:00 switched-Nd: YAG Laser and Pulsed Low Level Dual Frequency Focused Ultrasound Thrombolytic Therapy Reduce Thrombus Content in the Arterial Atherothrombotic Stenosis Speaker: Hossein Mehrad, IR
PO104 Extracorporeally Thrombolytic Therapy of Embolic Common 16:00 - 16:00 Carotid Artery Using Q-switched Nd:YAG Laser and Confocal Dual Pulse Electrohydraulic Shock Waves Accompanied by PESDA Microbubbles Administration Speaker: Hossein Mehrad, IR
PO106 Stable Fibroatheromatic Plaque Regression Using High-dose 16:00 - 16:00 Atorvastatin-loaded PESDA Microbubbles-mediated Extracorporeal Shock Wave Sonoporation Therapy Speaker: Hossein Mehrad, IR
PO107 Ultrasound-guided Laser-mediated Thermal Angioplasty of 16:00 - 16:00 Occluded Artery Accompanied by Combined 5-Aminolevulinic Acid-loaded Microbubbles-mediated Photodynamic Therapy and Catheter-based 192Ir-mediated ?-brachytherapy Speaker: Hossein Mehrad, IR
PO108 Improving of the of Biomechanical Parameters in an 16:00 - 16:00 Experimental Animal Abdominal Aorta Model of Thick- cap Fibroatheromatic Plaque Using Ultrasound-guided High-dose Atorvastatin-loaded PESDA Microbubbles and Low Level Focused Shock Waves Speaker: Hossein Mehrad, IR
PO109 Development of an Experimental Animal Carotid Artery Model of 16:00 - 16:00 Thick-cap Fibroatheromatic Plaque with Severe Stenosis (>80%) Using High Power Blue Laser-mediated Thermal Injury and High- cholesterol Diet Injury Speaker: Hossein Mehrad, IR
PO110 Ultrasound-guided Balloon Angioplasty of Occluded Artery 16:00 - 16:00 Accompanied by Combined Electrohydraulic Low Level Shock Wave Therapy and 125I- Mediated Gamma-intravascular Brachytherapy Speaker: Hossein Mehrad, IR
PO111 Intermediate Stage Atherosclerosis Regression Using Lipid- 16:00 - 16:00 based Encapsulated Methotrexate Nanoparticles-mediated B- mode Ultrasound-guided Pulsed Low Level Focused Ultrasound Sonoporation Therapy Speaker: Hossein Mehrad, IR
PO112 Treatment of Advanced Atherosclerotic Plaque with 16:00 - 16:00
133 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Neovascularization Using B-mode Ultrasound-guided HDL- loaded Microbubbles-mediated Low Level Focused Electrohydraulic Shock Wave Sonoporation Therapy and Cholesterol Diet Withdrawal Speaker: Hossein Mehrad, IR
PO113 Is There an Association of Diffuse Large B-cell Lymphoma with 16:00 - 16:00 Coronary Artery Disease? Speaker: Hrvoje Holik, HR
PO114 Endothelin and General Oxidative Ability as Markers of 16:00 - 16:00 Deadaptation in Sailors in the conditions of the Arctic Flight Speaker: Nadezda Vorobyeva, RU
PO115 Seasonal Changes of Platelet Aggregation Indexes at the 16:00 - 16:00 Patients with Stable Angina Speaker: Dina Shorikova, UA
PO116 Clinical Outcomes and Natural History of Critical Limb 16:00 - 16:00 Ischemia: A Real World Experience Speaker: Davide Ceccato, IT
PO117 A Case of Recurrent Myocardial Infarction and Heterozygous 16:00 - 16:00 Factor V Leiden Speaker: Eduarda Grinsztejn, US
PO118 Homocysteine Exchange in Athletes in the Arctic Region 16:00 - 16:00 Speaker: Nadezda Vorobyeva, RU
PO119 The Role of Thromboelastography in Search for Drug- 16:00 - 16:00 candidates Speaker: Aleksandr Samorodov, RU
PO120 Risk Factors for Venous Thromboembolism at the University 16:00 - 16:00 College Hospital, Ibadan Speaker: Wuraola Shokunbi, NG
PO121 Hemostatic Defects Associated with IgA Monoclonal 16:00 - 16:00 Gammopathy Speaker: Ming Ching Shen, TW
PO122 Liver Resection and Perioperative Coagulation Management in 16:00 - 16:00 Patient with Cirrhosis and HCC – A Case Report Speaker: Marija Skoko, HR
PO123 Hemostatic Function in Patients with Factor XI Deficiency 16:00 - 16:00 Speaker: Laura Montero Martín, ES
PO124 Recurrent Thrombosis and Antithrombin Deficiency 16:00 - 16:00 Speaker: Lucia Stanciakova, SK
PO125 Associated Factors of Adherence to the Use of Coumarin 16:00 - 16:00 Derivatives or Direct Oral Anticoagulants: Protocol of a Systematic Review Speaker: Maria Auxiliadora Parreiras Martins, BR
134 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PO126 D Dimer and other Biomarkers in Dengue Patients within a 16:00 - 16:00 Doble Viral Circulation Scenery (Dengue/COVID-19) Speaker: Marta Martinuzzo, AR
PO127 Association between FGB - 455 G/A and PAI-1 - 675 5G / 4G 16:00 - 16:00 Gene Polymorphisms and Covid-19 Severity Speaker: Bohdana Vatseba, UA
PO128 Immune Thrombocytopenia Refractory to Corticoid Therapy 16:00 - 16:00 Secondary to Covid-19. A Single-centre Experience Speaker: Bolivar Luis Diaz Jordan, ES
PO129 Alterations of the Coagulation Profile in Peruvians Admitted for 16:00 - 16:00 Pneumonia due to SARS-COV2: Cross-sectional Study Speaker: Rafael Pichardo Rodriguez, PE
PO131 SARS-CoV 2 and Venous Thromboembolism: A Risk beyond 16:00 - 16:00 Thromboprophylaxis Speaker: CARINA GUMPEL, AR
PO132 Mechanical Prosthetic Valve Thrombosis in COVID-19 Infection: 16:00 - 16:00 Case Report Speaker: Nadejda Diaconu, MD
PO133 IMPROVE Score and Coagulopathy Screening in Coronavirus 16:00 - 16:00 Disease 2019 Patients Speaker: Christian Syukur, ID
PO134 Reinforcement of Platelets Activity in Patients with Acute 16:00 - 16:00 Myeloid Leukemia (AML) and Concomitant COVID-19 Infection Speaker: Zinaida Stupakova, UA
PO135 On the Issue of Thrombinemia in Moderate COVID-19 16:00 - 16:00 Speaker: Nadezda Vorobyeva, RU
PO136 Management of a Patient with Hemorragic and Thrombotic Risk 16:00 - 16:00 Factors, a Brazilian Case Report Speaker: Newton de Freitas Centuriao, BR
PO137 Sepsis-induced Disseminated Intravascular Coagulation 16:00 - 16:00 Secondary to COVID-19 and Baricitinib Treatment Speaker: Ubaldo R. Madera Sanchez, PR
PO138 COVID-19 and Coagulation Abnormalities Diagnostic Dilemma 16:00 - 16:00 Speaker: Nike Odeleye, GB
PO140 Analysis of Hospitalization Factors of Hemophilia: 12 Years of 16:00 - 16:00 Experience in a Single Center Speaker: Cuiyun Qu, CN
PO141 Successful Immune Tolerance Induction with High Dose 16:00 - 16:00 Simoctocog Alfa in Hemophilia A Adult Patient with High Responder Inhibitor: A Case Report Speaker: Shin-Nan Cheng, TW
PO142 The Case of Acquired Haemophilia A 16:00 - 16:00
135 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Oleksandra Stasyshyn, UA
PO145 When Therapy with Anticoagulant and Antiplatelet Agents Hides 16:00 - 16:00 an Acquired Coagulopathy - A Case Report Speaker: Eunice Parcelas, PT
PO146 TSUBASA Study: An Observational Study of Emicizumab to 16:00 - 16:00 Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors Speaker: Keiji Nogami, JP
PO147 Management of Acquired Hemophilia A: A Case-report 16:00 - 16:00 Speaker: Joana Cabral, PT
PO148 Cocktail of Inherited Hemostatic and Red Cell Disorders in 16:00 - 16:00 Unrelated Families of Interior Sindh Speaker: Arshi Naz, PK
PO149 The Detection of Hemophilia C in a 66-year-Old Patient with 16:00 - 16:00 Postoperative Urinary Bleeding Speaker: Irina Melnichenko, AM
PO150 Severe Hemophilia C in a 70-year-old Woman: A Clinical Case 16:00 - 16:00 Speaker: Jordana Alicia Silveira Lopes, BR
PO151 Essential Thrombocythemia with Deep Vein Thrombosis and 16:00 - 16:00 Recurrent Gangrene Pedis Speaker: Hary Gustian, ID
PO154 Heterozygous FV Leiden Mutation Associated with Multiple 16:00 - 16:00 Cerebral Venous Thrombosis in Childhood. A Case Report Speaker: Yacine Larfi, DZ
PO155 Dentoalveolar Procedures in Immune Thrombocytopenia; 16:00 - 16:00 Systematic Review and Practical Recommendations Speaker: Wobke E. M. van Dijk, NL
PO156 A Refractory Thrombotic Thrombocytopenic Purpura Case 16:00 - 16:00 Complicated by Hepatic Sinusoidal Obstruction Syndrome and Successful Management with Defibrotide Speaker: Simge ERDEM, TR
PO157 Self-Administration of Romiplostim in Patients with Chronic 16:00 - 16:00 Immune Thrombocytopenia Compared with Administration by a Healthcare Provider: A Single Center Experience Speaker: Francisco José López Jaime, ES
PO158 Von Willebrand Factor Multimer Distribution Analysis in a 16:00 - 16:00 Group of Patients Diagnosed with von Willebrand Disease Speaker: Ewelina Wojtasinska, PL
PO159 Tetralogy of Fallot with Thrombolytic Ongoing Processes: A 16:00 - 16:00 Case Report Speaker: Bahram Badlou, NL
136 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PO160 Platelet Hyperaggregability and Migraine Headache – A Single 16:00 - 16:00 Centre Experience Speaker: Monika Brunclikova, SK
PO161 Refractory Thrombotic Thrombocytopenic Purpura - A Case 16:00 - 16:00 Report Speaker: Anil Aribandi, IN
PO162 Anti-lymphoma Therapy Improves Thrombocytopenia in a 16:00 - 16:00 Young Patient with Hodgkin Lymphoma: A Case Report Speaker: Muran Yang, CN
PO163 Systemic Lupus Erythematosus-induced Coagulopathy: A Case 16:00 - 16:00 Report Speaker: Guilherme Almeida Maia, BR
PO164 Real World Experience Use of DOAC in APLS Patients 16:00 - 16:00 Speaker: Yee Yee Yap, MY
PO165 A Rare Case of Bi-atrial Thrombi in a Stage IV Pancreatic 16:00 - 16:00 Cancer Patient with Atrial Fibrillation on Warfarin Speaker: Keun Young Kim, US
PO166 Thrombophilia and Thromboembolic Venous Disease in 16:00 - 16:00 Southern Tunisia Speaker: Imen chabchoub, TN
PO168 Unusual Laboratory Presentation of Lupus Anticoagulant: 16:00 - 16:00 Prolonged Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) without Severe Factor Deficiency Speaker: Catarina Guedes, PT
PO169 Investigation of Hereditary Thrombophilia in Women with 16:00 - 16:00 Recurrent Fetal Loss in LUMHS Hyderabad Speaker: Kaynat Ilyas, PK
PO170 How to Use the Data about Risk Factors for Thrombosis in 16:00 - 16:00 Practice Speaker: Lucia Stanciakova, SK
PO171 Cerebral Thrombosis during Treatment of Childhood Acute 16:00 - 16:00 Lymphoblastic Leukemia Speaker: Aylin Canbolat Ayhan, TR
PO172 Delays of VTE Prophylaxis 16:00 - 16:00 Speaker: Kishan Patel, US
PO173 Venous Thromboembolism Prophylaxis during Hospitalization: 16:00 - 16:00 Evidence-based Recommendation (by an Internal Medicine Team) Speaker: Fernando Javier Vázquez, AR
PO174 Pharmacological Venous Thromboembolism Prophylaxis in an 16:00 - 16:00 Internal Medicine Ward: Cross-sectional Observational Study Speaker: Goncalo Durao-Carvalho, PT
137 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
PO176 Efficacy and Safety of Direct Oral Anticoagulants in Morbidly 16:00 - 16:00 Obese Patients with Acute Venous Thromboembolism: A Meta- analysis Speaker: Barbara Borea, CH
PO177 Coagulation Abnormalities At Presentation of Childhood Acute 16:00 - 16:00 Lymphoblastic Leukemia Speaker: Aylin Canbolat Ayhan, TR
PO178 An Insilco Approach to Venous Thromboembolism (VTE) Using 16:00 - 16:00 Network Based Medicine with Direct Oral Anticoagulants (DOACs) Speaker: Asif Khan, PK
PO179 Management of Venous Thrombosis in Non-Hodgkin Lymphoma 16:00 - 16:00 Speaker: Vasile Musteata, MD
PO180 Management of Anticoagulation Therapy in Patients with 16:00 - 16:00 Idiopathic Mondor’s Disease Speaker: Giovanna Maria Nicolo', IT
PO181 Long Term Recurrence of Venous Thromboembolism: A 16:00 - 16:00 Retrospective Case-control Study Speaker: Giacomo Turatti, IT
PO182 Venous Thromboembolism as the First Presentation of Multiple 16:00 - 16:00 Myeloma Speaker: Xu Ye, CN
PO183 Misdiagnosing Protein C and Protein S Deficiency 16:00 - 16:00 Speaker: Carolina Peixoto, PT
PO184 Thrombosis in Elderly: Watch out Antipsychotic Agents! 16:00 - 16:00 Speaker: Maroua Mrouki, FR
PO185 Analysis of Risk Factors for Hemorrhagic Complications of 16:00 - 16:00 Anticoagulant Therapy Speaker: Nadezda Vorobyeva, RU
PO186 Efficacy of Preoperative Prevention in Venous 16:00 - 16:00 Thromboembolism at Endoscopic Urological Interventions Speaker: Dina Shorikova, UA
PO187 Rare Complications of DOAC Treatment 16:00 - 16:00 Speaker: Maria Hulikova, SK
PO188 “Heparin Failure” in Seminoma-related Dramatic 16:00 - 16:00 Hypercoagulable Melieu and Extended Vein Thrombosis: Is it BEP Protocol Ongoing Responsible? Speaker: Agnese Maria Fioretti, IT
PO189 Association of Complete Blood Parameters, D-dimer and Lupus 16:00 - 16:00 Anticoagulant with VTE Risk Score in Hospitalized Patients Speaker: Eyiuche Ezigbo, NG
PO190 Successful Infertility Treatment and Pregnancy Outcome in a 16:00 - 16:00
138 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Woman with Severe Treatment-refractory ITP Speaker: Boris Krastev, BG
PO191 The Case of Obstetric APS - A Therapeutic Challenge 16:00 - 16:00 Speaker: Justyna Teliga-Czajkowska, PL
PO192 The Role of Hydroxychloroquine in a Secondary Prevention of 16:00 - 16:00 Recurrent Thrombosis in Patient with Thrombophilia and Antiphospholipid Syndrome. A Case Report Speaker: Alisa Movsisyan, AM
PO194 Venous Thromboembolism in a 30 Year Old Female: Synergic 16:00 - 16:00 Effect of Oral Contraceptive and Elevated Factor VIII? Speaker: Falmata Laouan Brem, MA
139 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Sunday, 18. July 2021
Presentation Theater 07:00 - 07:45 R1 PT 01 - Presentation Theater Title: The Standard of Care for the Reversal of anticoagulants in Hospitalized Patients with Life- Threatening or Uncontrolled Bleeding
This session is supported by Alexion Pharmaceuticals, Coagulation
Please view the program here.
Presentation Theater 07:00 - 07:45 R2 PT 02 - Presentation Theater Title: Connecting the Dots in Hereditary Factor X Deficiency
This session is supported by BPL, Bio Products Laboratory
Please view the program here
Presentation Theater 07:00 - 07:45 R3 PT 03 - Presentation Theater Title: ADAMTS13 Diagnostics: a Review and Outlook
This session is supported by Technoclone
Please view the program here
Special Session 07:00 - 08:00 R5 TRA 01 - Trainee Session Moderator: Alan G.S. Harper, GB TRA 01.1 Welcome 07:00 - 07:05 Speaker: Caterina Casari, FR
TRA 01.2 Strategies for Encountering Bias as an Early Career 07:05 - 07:45 Professional Speaker: Maha Othman, CA Speaker: Melissa V. Chan, US Speaker: Dre’Von A. Dobson, US
Question and Answer 07:45 - 08:00
Break 07:45 - 08:15 R1 Virtual Exhibits Visits and Networking Break
140 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
State-of-the-Art Session 08:30 - 09:30 R1 SOA 01 - Contact Pathway Moderator: David Gailani, US Moderator: Stephanie A. Smith, US SOA 01.1 Pathogenic Factor XII Mutations: Form Determines Dysfunction 08:30 - 08:45 Speaker: Coen Maas, NL
SOA 01.2 FXII Regulation and Inhibition 08:45 - 09:00 Speaker: Helen Philippou, GB
SOA 01.3 FXI and FXII Structural Biology 09:00 - 09:15 Speaker: Jonas Emsley, GB
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R2 SOA 02 - Clinical Care for Hemophilia in 2021 and Beyond Moderator: Carmen Escuriola-Ettingshausen, DE Moderator: Amy Dunn, US SOA 02.1 Current and Future Hemophilia Treatment Options: Clinician 08:30 - 08:45 Perspective Speaker: Michael Makris, GB
SOA 02.2 Impact of Novel Therapies Around the World 08:45 - 09:00 Speaker: Margareth C. Ozelo, BR
SOA 02.3 Gene Therapy for Bleeding and Thrombotic Disease 09:00 - 09:15 Speaker: Edward George Denley Tuddenham, GB
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R3 SOA 03 - Unusual Site Thrombosis: Beyond DVT and PE Moderator: Kenneth A. Bauer, US Moderator: Omri Cohen, IT SOA 03.1 Splanchnic Vein Thrombosis 08:30 - 08:45 Speaker: Walter Ageno, IT
SOA 03.2 Retinal Vein Thrombosis 08:45 - 09:00 Speaker: Alejandro Lazo-Langner, CA
SOA 03.3 Cerebral Venous and Sinus Thrombosis 09:00 - 09:15 Speaker: Ida Martinelli, IT
Question and Answer 09:15 - 09:30
141 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
State-of-the-Art Session 08:30 - 09:30 R4 SOA 04 - Crosstalk of Immunology, Platelets and the Vessel Wall Moderator: Michele P. Lambert, US Moderator: Paula G. Heller, AR SOA 04.1 Platelet and Megakaryocyte Glycobiology 08:30 - 08:45 Speaker: Karin Hoffmeister, US
SOA 04.2 Role of Complement in HIT 08:45 - 09:00 Speaker: Gowthami Arepally, US
SOA 04.3 Platelet Mechanotransduction 09:00 - 09:15 Speaker: Wilbur Lam, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R5 SOA 05 - Arterial Thromboembolism Moderator: Geoffrey Barnes, US Moderator: Julia Glaser, US SOA 05.1 Role of DOAC in PAD 08:30 - 08:45 Speaker: Connie Ng Hess, US
SOA 05.2 Advanced Imaging 08:45 - 09:00 Speaker: David E. Newby, GB
Question and Answer 09:00 - 09:15
State-of-the-Art Session 08:30 - 09:30 R6 SOA 06 - Hemostatic Complications of Pregnancy Moderator: Annemarie E. Fogerty, US Moderator: Rezan Abdul-Kadir, GB SOA 06.1 Disparities in Pregnancy Outcomes: Differences by Condition 08:30 - 08:45 and Community Speaker: Andra H. James, US
SOA 06.2 Hemostatic Management of Postpartum Hemorrhage 08:45 - 09:00 Speaker: Peter Collins, GB
SOA 06.3 Complement Dysregulation in Pregnancy 09:00 - 09:15 Speaker: Robert Brodsky, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R7 SOA 07 - Cancer Immunotherapy and Coagulation Moderator: Janusz Rak, CA Moderator: Marina Marchetti, IT
142 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
SOA 07.1 Endothelial Activation During CD19 CAR-T Cell Therapy 08:30 - 08:45 Speaker: Cameron Turtle, US
SOA 07.2 Hemostatic Factors and Tumor Immunity – a Double Edged 08:45 - 09:00 Sword Speaker: Joseph S. Palumbo, US
Question and Answer 09:00 - 09:15
Break 09:30 - 10:00 R1 Virtual Exhibits Visits and Networking Break
Plenary Session 10:00 - 10:30 R1 PL 02 - Marion I. Barnhard Memorial Plenary Lecture - From Bench to Bedside: P-Selectin Blockade in Sickle Cell Disease Moderator: Charles S. Abrams, US PL 02.1 From Bench to Bedside: P-Selectin Blockade in Sickle Cell 10:00 - 10:30 Disease Speaker: Rodger P. McEver, US Speaker: Kenneth I. Ataga, US
Break 10:30 - 11:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 11:00 - 12:00 R1 OC 01 - Interplay Between Hemostasis and Inflammation Moderator: Patricia Liaw, CA Moderator: Matthew Cormier, CA OC 01.1 Crosstalk between the Complement Pathway and the Contact 11:00 - 11:12 Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H Speaker: Cristina Puy, US
OC 01.2 Podocyte Tissue Factor Suppresses Spontaneous Sterile Renal 11:12 - 11:24 Inflammation Speaker: Jayakumar Manoharan, DE
OC 01.3 Myeloid Par2 Deficiency Protects Mice during IAV Infection 11:24 - 11:36 Speaker: Randall C. Gunther, US
OC 01.4 Acquired Platelet GPVI Signaling Deficiency Occurs Early in 11:36 - 11:48 Patients with Gram-Positive or Gram-negative Sepsis Speaker: Lukas Johannes Weiss, DE
Question and Answer 11:48 - 12:00
143 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 11:00 - 12:00 R2 OC 02 - Molecular and Genetic Mechanisms in Fibrinolysis Moderator: Ton Lisman, NL Moderator: Zelda de Lange-Loots, ZA OC 02.1 Granulocyte Microvesicles with a High Plasmin Generation 11:00 - 11:12 Capacity Promote Clot Lysis and Improve Outcome in Septic Shock Speaker: Sylvie Cointe, FR
OC 02.2 Controlled Long-term Knockdown of Plasminogen in Mice and 11:12 - 11:24 Dogs using siRNA: Assessment of Phenotype and Toxicity Speaker: Amy W Strilchuk, CA
OC 02.3 Defining Two Separate, but Functional, ?-granule Pools in in- 11:24 - 11:36 vitro-grown Megakaryocytes (MKs): Lessons from Urokinase Plasminogen Activator (uPA) Speaker: Sergei Zaitsev, US
OC 02.4 Role of Shear Stress and tPA Concentration in the Fibrinolytic 11:36 - 11:48 Potential of Thrombi Speaker: Claire S. Whyte, GB
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R3 OC 03 - Mechanisms of Thrombosis in COVID-19 Moderator: Anna Falanga, IT Moderator: Neil A. Zakai, US OC 03.1 Biphasic Thrombus Development during Coronavirus Infection 11:00 - 11:12 Speaker: Manuel Salzmann, AT
OC 03.2 SARS-CoV-2 Infection of K18-hACE2 Transgenic Mice Induces 11:12 - 11:24 an Early Hyperactive Phenotype in Circulating Platelets Speaker: Saravanan Subramaniam, US
OC 03.3 Suppression of Fibrinolysis and Hypercoagulability Link Lung 11:24 - 11:36 Injury and Mortality in Severe COVID-19 Speaker: Lyra Olson, US
OC 03.4 Lipid-binding Antiphospholipid Antibodies Trigger Autoimmune 11:36 - 11:48 Signaling in Severe COVID-19 Speaker: Anne Hollerbach, DE
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R4 OC 04 - OMICS Moderator: Sarah Westbury, GB Moderator: Leonard Edelstein, US
144 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 04.1 High Throughput Sequencing for the Molecular Diagnosis of 11:00 - 11:12 Inherited Platelet Disorders in Spain. Experience of the GEAPC Group Speaker: Jose Maria Bastida, ES
OC 04.2 High-sensitivity Platelet Proteomics Maps the Response to 11:12 - 11:24 Different Levels of Thrombin Speaker: Callum Houlahan, AU
OC 04.3 Unraveling Mild Antithrombin Deficiency with Mass 11:24 - 11:36 Spectrometry in a Patient Presenting with Recurrent Pregnancy Loss Speaker: Mirjam Kruijt, NL
OC 04.4 13C Metabolic Flux Analysis in Resting and Thrombin Activated 11:36 - 11:48 Platelets Speaker: Cara Sake, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R5 OC 05 - Molecular Mechanisms of Coagulation Moderator: Paul Y. Kim, CA Moderator: Elsa Bianchini, FR OC 05.1 Crystal Structure of Factor IXa with an Anticoagulant Aptamer 11:00 - 11:12 Bound to an Allosteric Site Speaker: Vladimir Kolyadko, US
OC 05.2 Fluorescence Correlation Spectroscopy Provides New Insights 11:12 - 11:24 into the Mechanism of Prothrombin Recognition by the Prothrombinase Complex Speaker: Nicola Pozzi, US
OC 05.3 A Novel Prediction Platform to Enhance the Design of 11:24 - 11:36 Therapeutic SERPINs Speaker: Wariya Sanrattana, NL
OC 05.4 Evolutionary Adaptation of the Gamma-carboxyglutamic Acid 11:36 - 11:48 Domain in Venom Factor X from the Australian Common Brown Snake Speaker: Shuzhen Cheng, NL
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R6 OC 06 - Anticoagulants for the Treatment and Prevention of Cancer-Associated Thrombosis Moderator: Annie Young, GB Moderator: Gary H. Lyman, US OC 06.1 Improved Overall Survival with Warfarin Compared with Direct 11:00 - 11:12 Oral Anticoagulants in Cancer-associated Venous
145 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Thromboembolism: A SEER-medicare Analysis Speaker: Thita Chiasakul, TH
OC 06.2 Extended Thromboprophylaxis Following Major 11:12 - 11:24 Abdominal/Pelvic Cancer-related Surgery: A Systematic Review and Meta-analysis of the Literature Speaker: William Knoll, CA
OC 06.3 Safety of Direct Acting Oral Anticoagulants (DOACs) in 11:24 - 11:36 Comparison to Low Molecular Weight Heparin (LWMH) in Gastrointestinal and Genito-urinary Cancers Speaker: Shafia Rahman, US
OC 06.4 Association of Anticoagulation Resumption and Repeat Imaging 11:36 - 11:48 on Venous Thromboembolism Recurrence after Allogeneic Hematopoietic Cell Transplantation (HCT) Speaker: Kylee Martens, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R7 OC 07 - Monitoring Joint Health in Hemophilia Moderator: Annette von Drygalski, US Moderator: Bruno U.K. Steiner, US OC 07.1 Implementation of Tele-guidance for Patient Self-imaging of 11:00 - 11:12 Arthropathic Joints Using Mobile Ultrasound Devices –– Results from a Pilot Study Speaker: Peter Aguero, US
OC 07.2 The Role of Point-of-Care Musculoskeletal Ultrasound for 11:12 - 11:24 Routine Joint Evaluation and Management Considerations in Hemophilia Clinic Speaker: Nicolas Gallastegui, US
OC 07.3 Long-term Joint Outcomes in Hemophilia through Ultrasound: 11:24 - 11:36 2-year Interim Results from the Prospective J-DaUPHIN Study Speaker: Azusa Nagao, JP
OC 07.4 Detection of Joint Effusions in Pediatric Patients with 11:36 - 11:48 Hemophilia Using Artificial Intelligence-assisted Ultrasound Scanning; Early Insights from the Development of a Self- management Tool Speaker: Pascal Tyrrell, CA
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R8 OC 08 - Hemophilia: Real World Data Moderator: Beverly Schaefer, US OC 08.1 First Interim Analysis of a 24-month French, Multicentre, 11:00 - 11:12
146 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Prospective, Non-interventional Study Evaluating the Real- world Usage and Effectiveness of the Extended Half-life Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B (B-SURE) Speaker: Antoine Rauch, FR
OC 08.2 Long-term Outcomes in Adolescents with Moderate or Severe 11:12 - 11:24 Hemophilia A: A PedNet Study Speaker: David Emanuel Schmidt, SE
OC 08.3 Peri-operative PK-guided Dosing of Desmopressin Combined 11:24 - 11:36 with FVIII Concentrates in Hemophilia A: Final Results of the DAVID Study Speaker: Lorenzo Gaetano Renata Romano, NL
OC 08.4 Real-world Use of Damoctocog Alfa Pegol in Patients with 11:36 - 11:48 Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database Speaker: Maria Elisa Mancuso, IT
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R9 OC 09 - VWF Structure and Function Moderator: Peter Lenting, FR Moderator: Andrew Yee, US OC 09.1 Piggyback Knockdown Screen of Glycosyltransferases in 11:00 - 11:12 Zebrafish: Identification of Novel Regulators of von Willebrand Factor Levels Speaker: Neha Iyer, US
OC 09.2 Crystal Structure of the von Willebrand Factor A1 Domain - 11:12 - 11:24 Caplacizumab Complex Speaker: Alexander Brown, GB
OC 09.3 Expression and Functional Studies of a Compound 11:24 - 11:36 Heterozygous Mutation in Cis Position in the D’D3 (p.R924Q ) and D4 (p.A2178S) Domains of von Willebrand Factor (VWF) Speaker: Monica Sacco, IT
OC 09.4 Structure of the von Willebrand Factor C6 Domain and Effect of 11:36 - 11:48 Variant p.Gly2705Arg Speaker: Angelika Mojzisch, DE
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R10 OC 10 - Platelet Receptors and Signaling I Moderator: John Kostyak, US Moderator: Mortimer Poncz, US
147 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 10.1 Regulation of P2Y12 Receptor Expression and Activity by cAMP 11:00 - 11:12 Mediated PKA Signalling in Human Platelets; A Novel Mode of Action of Anti-platelet Drugs? Speaker: Jawad Khalil, GB
OC 10.2 Impairment of Platelet Purinergic Signaling in Sickle Cell 11:12 - 11:24 Disease Speaker: Tomasz Brzoska, US
OC 10.3 Platelet Proteome and Variability in the Responsiveness to Low- 11:24 - 11:36 dose Aspirin in Patients with Cardiovascular Disease Speaker: Sonia Ciotti, IT
OC 10.4 Loss of P2Y1 Receptor Desensitization Does Not Impact in vivo 11:36 - 11:48 Hemostasis or Thrombosis Despite Increased Platelet Reactivity in vitro Speaker: David S. Paul, US
Question and Answer 11:48 - 12:00
Break 12:00 - 12:30 R1 Virtual Exhibits Visits and Networking Break
Supported Symposium 12:30 - 13:30 R1 LS 01 - Supported Symposium Title: From Basic Research to Clinical Data: the Future of Patient Management
This session is supported by Roche Diagnostics International Ltd
Please view the program here
Lunch, Industry Exhibits and Poster Viewing 12:30 - 13:30 R1 Lunch, Industry Exhibits and Poster Viewing
Supported Symposium 12:30 - 13:30 R2 LS 02 - Supported Symposium Title: Challenges and Emerging Therapies in the Management of ITP
This session is supported by Sanofi Genzyme
Please view the program here
148 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Supported Symposium 12:30 - 13:30 R3 LS 03 - Supported Symposium Title: Personalized Care in Hemophilia: What Does the Future Hold?
This session is supported by Takeda Pharmaceutical Company
Please view the program here
Supported Symposium 12:30 - 13:30 R4 LS 04 - Supported Symposium Title: Rising to the Challenge: Managing Acute and Extended VTE Treatment … What Can We Learn From Complex Case Studies?
This session is supported by Bayer AG
Please view the program here
Supported Symposium 12:30 - 13:30 R5 LS 05 - Supported Symposium Title: Role of Spleen Tyrosine Kinase (SYK) and SYK Inhibition in Disease Pathways
This session is supported by Rigel Pharmaceuticals, Inc. / Grifols
Please view the program here
Supported Symposium 12:30 - 13:30 R6 LS 06 - Supported Symposium Title: Advancements in the Management of Bleeding in Congenital Hemophilia A and B with Inhibitors
This session is supported by LFB - HEMA Biologics
Please view the program here
Supported Symposium 12:30 - 13:30 R7 LS 07 - Supported Symposium Title: Reversing DOACs: Providing Answers on Why, When, and How?
This session is supported by Alexion Pharmaceuticals, Coagulation
Master Class Session 12:30 - 13:15 R8 Role of Anticoagulants in Atherosclerotic Disease Role of Anticoagulants in Atherosclerotic Disease 12:30 - 13:15 Speaker: Michelle O’Donoghue, US
149 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Master Class Session 12:30 - 13:15 R9 Gene Therapy Gene Therapy 12:30 - 13:15 Speaker: Katherine A. High, US
Master Class Session 12:30 - 13:15 R10 Heavy Menstrual Bleeding in Adolescents Heavy Menstrual Bleeding in Adolescents 12:30 - 13:15 Speaker: Ayesha Zia, US
Master Class Session 12:30 - 13:15 R11 Heparin-Induced Thrombocytopenia Heparin-Induced Thrombocytopenia 12:30 - 13:15 Speaker: Douglas B. Cines, US
Master Class Session 12:30 - 13:15 R12 Preventing Pathological Complement Activation Preventing Pathological Complement Activation 12:30 - 13:15 Speaker: Wenchao Song, US
Master Class Session 12:30 - 13:15 R13 Platelet Phosphoproteomics Platelet Phosphoproteomics 12:30 - 13:15 Speaker: Albert Sickmann, DE
Master Class Session 12:30 - 13:15 R14 The Art and Science of Computational Models of Clotting The Art and Science of Computational Models of Clotting 12:30 - 13:15 Speaker: Karin Leiderman, US Speaker: Keith Neeves, US
Master Class Session 12:30 - 13:15 R15 Intrinsic and Extrinsic Regulation of Megakaryopoiesis Intrinsic and Extrinsic Regulation of Megakaryopoiesis 12:30 - 13:15 Speaker: Diane Krause, US
150 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Master Class Session 12:30 - 13:15 R16 Fibrinogen and Thrombosis Fibrinogen and Thrombosis 12:30 - 13:15 Speaker: John W. Weisel, US
Master Class Session 12:30 - 13:15 R17 Protease Activated Receptors Protease Activated Receptors 12:30 - 13:15 Speaker: Marvin T. Nieman, US
Career Development Session 12:30 - 13:15 R18 Maximizing Your Career as a Physician Scientist Maximizing Your Career as a Physician Scientist 12:30 - 13:15 Speaker: Lawrence F. Brass, US
Career Development Session 12:30 - 13:15 R19 Collaboration with Industry in Basic Science Coagulation Collaboration with Industry in Basic Science Coagulation 12:30 - 13:15 Speaker: John E. Murphy, US
Career Development Session 12:30 - 13:15 R20 Differentiating From Your Mentor Differentiating From Your Mentor 12:30 - 13:15 Speaker: Courtney Griffin, US
Career Development Session 12:30 - 13:15 R21 To Collaborate or Not, Management of Collaborations To Collaborate or Not, Management of Collaborations 12:30 - 13:15 Speaker: David Lillicrap, CA
Break 13:30 - 14:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 14:00 - 15:00 R1 OC 11 - Platelets, Thrombosis and Hemostasis Moderator: Alisa S. Wolberg, US Moderator: Li Zhu, CN OC 11.1 VWF-bound GPIb? under Flow Activates Human Platelet TF and 14:00 - 14:12
151 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Surface-bound FVII, Sparking Clotting Reactions, Thrombin Generation and Fibrin Deposition Speaker: Diego Mezzano, CL
OC 11.2 Platelet Binding to Polymerizing Fibrin is Avidity-driven and 14:12 - 14:24 Requires Activated ?IIb?3 Speaker: Claudia Lorena Buitrago, US
OC 11.3 Active Sorting of Platelets and Red Blood Cells in Contracting 14:24 - 14:36 Blood Clots is Driven by Platelet-generated Forces that Stiffen Fibrin Speaker: Valerie Tutwiler, US
OC 11.4 Force-Independent Cleavage of Talin by Calpain Promotes 14:36 - 14:48 Platelet-mediated Fibrin Clot Contraction Speaker: Karen Pei Yi Fong, US
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R2 OC 12 - Bleeding and Mortality in Patients with Cancer-Associated Thrombosis Moderator: Chatree Chai-Adisaksopha, TH Moderator: Alok A. Khorana, US OC 12.1 The Khorana Score Is a Marker of Poor Cancer Prognosis, 14:00 - 14:12 Independent of Development of VTE Speaker: Gerald Soff, US
OC 12.2 Three Available Risk Scores Modestly Predict Hemorrhage in 14:12 - 14:24 Patients with Cancer-associated Thrombosis (CAT) Speaker: Kristen M. Sanfilippo, US
OC 12.3 Estimating Bleeding Risk in Patients with Cancer-associated 14:24 - 14:36 Thrombosis: External Validation of Existing Risk Scores and Development of a New Risk Score Speaker: Maria A. de Winter, NL
OC 12.4 Risk Factors for Gastrointestinal Bleeding in Patients with 14:36 - 14:48 Gastrointestinal Cancer Using Edoxaban: Results from the Hokusai VTE Cancer Study Speaker: Floris Bosch, NL
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R3 OC 13 - Inherited and Acquired VWD Moderator: Michelle Lavin, IE Moderator: Mackenzie Bowman, CA OC 13.1 Shear-induced Platelet-GPIb? Shedding under Extracorporeal 14:00 - 14:12 Membrane Oxygenation Promotes Thrombocytopenia Independently from von Willebrand Factor
152 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Antoine Rauch, FR
OC 13.2 Response to Treatment for Gastro-intestinal Bleeding in 14:12 - 14:24 Patients Affected by von Willebrand Disease Speaker: Eugenia Biguzzi, IT
OC 13.3 Association of Genetic Alterations with Severity of Disease in 14:24 - 14:36 Type III vWD Patients Speaker: Muhammad Asif Naveed, PK
OC 13.4 Transcriptional Analysis of the Response to Stimulation in 14:36 - 14:48 ECFCs Derived from Type 1 VWD Patients Speaker: Robert Kloosterman, CA
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R4 OC 14 - Hemophilia-Novel Therapeutic Approaches and Mechanisms Moderator: Jamie O'Sullivan, IE Moderator: Denise Sabatino, US OC 14.1 Transplacental Delivery of Maternal FVIII for Induction of FVIII- 14:00 - 14:12 specific Immune Tolerance Speaker: Angelina Mimoun, FR
OC 14.2 A Single-domain Antibody Anti-protein Z Dependent Protease 14:12 - 14:24 Inhibitor Improves Thrombin Generation in Hemophilia Speaker: Claire Auditeau, FR
OC 14.3 Development of Monoclonal Antibodies that Protect FV/FVa 14:24 - 14:36 from APC-mediated Inactivation for the Treatment of Bleeding Speaker: Sean Quinn, US
OC 14.4 Thrombin Generation Rescued in Hemophilia A by Low-normal 14:36 - 14:48 Levels of FV Is Confirmed to Be Partially due to Substrate Competition Speaker: Karin Leiderman, US
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R5 OC 15 - Platelet, Neutrophil and Complement Responses to COVID-19 Moderator: Anne Angelillo-Scherrer, CH Moderator: Silvio Antoniak, US OC 15.1 Platelet Factor 4 (PF4) Enhances in vitro Neutrophil 14:00 - 14:12 Extracellular Traps (NET) Capture of Coronaviruses: Clinical and Therapeutic Implications Speaker: Maki Ishizuka, US
OC 15.2 Altered Platelet Proteome and Platelet-leukocyte Interactions in 14:12 - 14:24 Patients with COVID-19 Speaker: Ingeborg Hers, GB
153 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 15.3 Neutrophil Extracellular Traps in COVID-19 Patients Correlates 14:24 - 14:36 with Therapy, Disease Severity and Mortality Speaker: D.V. Kassina, RU
OC 15.4 Assessing Complement Activation in COVID-19 Predicts 14:36 - 14:48 Hypoxemia and Mortality Speaker: Alexander Leatherdale, CA
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R6 OC 16 - Vascular Cells and Coagulation I Moderator: Anna M. Randi, GB Moderator: Colin Evans, US OC 16.1 From Coagulation to Angiogenesis: Extra-coagulative Role of 14:00 - 14:12 FVIII Speaker: Cristina Olgasi, IT
OC 16.2 Regulation of Endothelial Cell Procoagulant Activity by TMEM16 14:12 - 14:24 Scramblases Speaker: Alec Schmaier, US
OC 16.3 Specialized SPARC-forming Regulatory T Cells Control Venous 14:24 - 14:36 Blood Clot Degradation Speaker: Christian Becker, DE
OC 16.4 A Mouse Model of Protease Activated Receptor 4 (PAR4) variant 14:36 - 14:48 rs2227376 Has Reduced Platelet Reactivity to Physiological Doses of Thrombin Speaker: Xu Han, US
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R7 OC 17 - Coronary Artery Disease from Genes to Stents Moderator: Roxana Mehran, US Moderator: Vijay Kunadian, GB OC 17.1 Mapping Gene and Gene Pathways Associated with Coronary 14:00 - 14:12 Artery Disease: A CARDIoGRAM Exome and Multi-ancestry UK Biobank Analysis Speaker: Praveen Hariharan, US
OC 17.2 Increased Levels of Coagulation Factor V in Atherosclerotic 14:12 - 14:24 Plaques - An Immune Regulated Response? Speaker: Benedicte Stavik, NO
OC 17.3 Case-fatality Rate of Major Bleeding Events among Patients 14:24 - 14:36 Treated with Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-eluting Stent: A Systematic Review and Meta-analysis
154 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Tobias Tritschler, CA
OC 17.4 Pharmacodynamics of Bolus with and without Infusion of 14:36 - 14:48 Cangrelor in Healthy Volunteers: A Dose-finding, Open-label, Pilot Trial Speaker: Georg Gelbenegger, AT
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R8 OC 18 - Diagnostic and Coagulation Moderator: Catherine P. M. Hayward, CA Moderator: Ze Zheng, US OC 18.1 Result of a Study on Inter-laboratory Variability in the 14:00 - 14:12 Measurement of Emicizumab and the Interference of Emicizumab in a Variety of Coagulation Tests Speaker: Moniek de Maat, NL
OC 18.2 Lupus Anticoagulant Interference Study on Various ACT Assays 14:12 - 14:24 Speaker: Shirrey Chen, US
OC 18.3 Haemostatic Components Are Associated with Risk of Venous 14:24 - 14:36 Thromboembolism after Lower Leg Trauma Speaker: Carolina Eveline Touw, NL
OC 18.4 Thrombin Generation Assay for Rivaroxaban, Apixaban, and 14:36 - 14:48 Edoxaban Measurements: A Prospective Multicenter Cross- sectional Study Speaker: Michael Nagler, CH
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R9 OC 19 - Genetics of VTE Moderator: Vivien Chen, AU Moderator: Julia Oto Martínez, ES OC 19.1 Multi-phenotype Analysis of Hemostatic Factors with Venous 14:00 - 14:12 Thromboembolism Reveals Novel Genetic Associations Speaker: Gerard Temprano-Sagrera, ES
OC 19.2 Patients with VEXAS Syndrome due to Somatic Mutations in 14:12 - 14:24 UBA1 Present Commonly with Thrombosis Speaker: Emma Groarke, US
OC 19.3 The R543L Protein Altering Variant in the FII Gene (F2) Is a 14:24 - 14:36 Major Determinant of Coagulation Potential in Mexican Americans Speaker: Tom Howard, US
OC 19.4 Interaction between the Von Willebrand Factor and ADAMTS13 14:36 - 14:48 on VTE Risk in Women. Results from the Retrove Project
155 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Dolors Llobet, ES
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R10 OC 20 - Bleeding and Thrombosis in Neonates Moderator: Martha Sola-Visner, US Moderator: Benjamin J. Samelson-Jones, US OC 20.1 NEOCLOT: Management of Catheter-related Venous 14:00 - 14:12 Thrombosis in Preterm and Term Neonates Speaker: C. Heleen Van Ommen, NL
OC 20.2 Investigation of Preterm Intraventricular Hemorrhage Induced 14:12 - 14:24 Inflammatory Response and microRNA Levels by Heme and Hypoxia in Human Choroid Plexus Epithelial Cells Speaker: Zsolt Fejes, HU
OC 20.3 The Effect of Platelets on Thrombin Generation in the Premature 14:24 - 14:36 Infant: The EVENT Study Speaker: Claire Murphy, IE
OC 20.4 Portal Vein Thrombosis(PVT) in Neonates and Children: A Ten- 14:36 - 14:48 year Prospective Registry of a Tertiary Care Single-centre in Argentina Speaker: Carolina Cervio, AR
Question and Answer 14:48 - 15:00
Poster Networking Session 15:00 - 16:00 R1 ePoster Networking LPB0002 Safety and Pharmacokinetics of Direct Oral Anticoagulants after 15:00 - 15:00 Bariatric Surgery: A Systematic Review Speaker: Russell Leong, CA
LPB0003 Persistence Pattern to Oral Anticoagulants among Non-valvular 15:00 - 15:00 Atrial Fibrillation Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants: A Cohort Study Speaker: Myrthe M.A. Toorop, NL
LPB0001 Impact of Heparin Induced Thrombocytopenia on the Outcomes 15:00 - 15:00 of Hospitalizations for Acute Myocardial Infarction: Analysis of National Inpatient Sample Speaker: Muhammad Usman Almani, US
LPB0004 Safety and Efficacy of Using Direct Oral Anticoagulants for 15:00 - 15:00 Stroke Prevention in Atrial Fibrillation Patients with Pre-obesity and Obesity Speaker: Qingui Chen, NL
LPB0005 Tissue-engineered Human Arteries Replicate Primary and 15:00 - 15:00 Secondary Haemostatic Functions Seen in vivo: A Replacement
156 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
for Mouse Arterial Thrombosis Models? Speaker: Jacob Ranjbar, GB
LPB0006 Recombinant Heparin: An Old Drug for the Modern World 15:00 - 15:00 Speaker: Bryan E. Thacker, US
LPB0008 ADP-induced Platelet-associated Tissue Factor Expression: 15:00 - 15:00 Unique Involvement of the P2Y12 Receptor and Modulation by Clopidogrel Treatment Speaker: Marta Brambilla, IT
LPB0007 Activated Protein C (APC) Resistance in FV-W1920R (FV-NARA) 15:00 - 15:00 Was Caused by the Defective Association between FV-W1920R and Protein S (PS) in the APC/PS/FVa Assembly Speaker: Naruto Shimonishi, JP
LPB0009 Systematic Screening for Pulmonary Embolism in Patients with 15:00 - 15:00 Suspected Covid-19 in the Emergency Department: A Prospective Cohort Study Speaker: Inge Luu, NL
LPB0010 Prevalence of Venous Thromboembolism and Pulmonary 15:00 - 15:00 Embolism among Patients Hospitalized with a COVID-19 Diagnosis in France Speaker: Amélie Gabet, FR
LPB0011 Immature Platelets as a Biomarker for Disease Severity and 15:00 - 15:00 Mortality in COVID-19 Patients Speaker: Daniel Welder, US
LPB0013 Evaluation of Heparin-induced Thrombocytopenia Before and 15:00 - 15:00 during the COVID-19 Pandemic at a US National Reference Laboratory Speaker: Edward Wong, US
LPB0014 Global Thrombosis Test: Occlusion by Coagulation or SIPA? 15:00 - 15:00 Speaker: Viviana Clavería, US
LPB0012 Effects of Liraglutide vs. Lifestyle Changes on sST2 and 15:00 - 15:00 Galectin-3 in Obese Subjects with Prediabetes or Type 2 Diabetes after Comparable Weight Loss Speaker: Romina Tripaldi, IT
LPB0015 Comparison of D-dimer values at peak and trough 15:00 - 15:00 concentrations of direct oral anticoagulants: result of D-dimer testing is not affected by plasma drug concentration Speaker: Sandra Margeti?, HR
LPB0018 Role of the "Mobile Loop" (Residues 142-150) in the Intrinsic 15:00 - 15:00 Instability of TAFIa Speaker: Haley Marier, CA
LPB0016 The Fibrin(ogen) ?-chain Integrin ?IIb?3 Binding Motif is 15:00 - 15:00 Dispensable for Platelet Accumulation but Modifies Cross- linking in the Injured Liver
157 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Lauren G. Poole, US
LPB0017 Activation Mechanism Dependent Surface Exposure of Cellular 15:00 - 15:00 FXIII on Platelets and Platelet Microparticles: Immunofluorescence and Immune Electron Microscopic Study Speaker: László Muszbek, HU
LPB0019 Expression of Adenovirus-mediated Human Coagulation Factor 15:00 - 15:00 IX Gene in SD Rat Adipose Mesenchymal Stem cells Speaker: ZHEN YU YAN, CN
LPB0020 Etranacogene Dezaparvovec (AAV5-Padua hFIX Variant, 15:00 - 15:00 AMT-061), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-severe Hemophilia B: 2.5 Year Data from a Phase 2b Trial Speaker: Annette von Drygalski, US
LPB0021 Practical Application of FIX-Padua Field Study Results Enables 15:00 - 15:00 a Comparison of FIX:C Results Across AAV Gene Therapy Trials Independent of FIX:C Assay Reported Speaker: Erald Shehu, GB
LPB0022 Global Seroprevalence of Pre-existing Immunity against AAV 15:00 - 15:00 Serotypes in People with Hemophilia A Speaker: Robert Klamroth, DE
LPB0023 Role of Tissue Factor in Delayed Bone Repair Induced by 15:00 - 15:00 Diabetic State in Mice Speaker: Kohei Tatsumi, JP
LPB0024 Coagulation-cancer Crosstalk; Von Willebrand Factor 15:00 - 15:00 Contributes to Pro-invasive and Pro-angiogenic Properties in Breast Cancer Cells Speaker: Sean Patmore, IE
LPB0026 How to Use Thrombolytic Agents in the Treatment of Neonatal 15:00 - 15:00 Thrombosis: A Systematic Review Speaker: Jay Patel, CA
LPB0027 Systematic Review on Neonatal Portal Vein Thrombosis 15:00 - 15:00 Speaker: Muneera Alhaddad, CA
LPB0028 Difference is Risk Factors and Clinical Outcomes in Pediatric 15:00 - 15:00 Patients with Deep Venous Thrombosis as Compared to Pulmonary Embolism Speaker: Shruthi Suryaprakash, US
LPB0029 Distinct Clonal Mutation Patterns between JAK2 V617F Positive 15:00 - 15:00 and CALR-mutated Essential Thrombocythemia Speaker: Rongfeng Fu, CN
LPB0030 Investigating Impact of von Willebrand Factor Deficiencies on 15:00 - 15:00 the Biogenesis of Weibel-Palade Bodies and Endothelial Cells Signaling Pathways Speaker: Hamideh Yadegari, DE
158 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0031 Activity and Cleavage of von Willebrand Disease Type 2B 15:00 - 15:00 Variants Speaker: Maria Brehm, DE
LPB0032 Genetic Characterization of von Willebrand Disease Type 2 in 15:00 - 15:00 Milan Cohort Patients Speaker: Omid Seidizadeh, IT
LPB0033 The Role of RAP1 Signaling in Platelet-coagulation Interplay 15:00 - 15:00 Speaker: Abigail Ballard, US
LPB0034 Effects of Depression and Antidepressant Use on Platelet 15:00 - 15:00 Reactivity Traits Speaker: Joseph Grech, US
LPB0035 Desialylation Primes Platelets for Apoptosis: A New Role for ß1 15:00 - 15:00 Integrin Speaker: Renata Grozovsky, US
LPB0036 Elevated Platelet-derived sGPVI Is a Biomarker of Venous In- 15:00 - 15:00 stent Stenosis in Patients with Post-thrombotic Syndrome Speaker: Adam Michael Gwozdz, GB
LPB0037 Neutrophil Extracellular Traps in Thrombosis of Ovine 15:00 - 15:00 Extracorporeal Membrane Oxygenation Models Speaker: Yang Zhang, CN
LPB0039 The Extracellular Protease EpiP from S. aureus Triggers Blood 15:00 - 15:00 Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1 Speaker: Vincenzo De Filippis, IT
LPB0040 rs2431697 of miR-146a Regulates NETosis Determining the 15:00 - 15:00 Thickness of the Carotid Intima-media in Patients with Rheumatoid Arthritis Speaker: Laura Reguilón Gallego, ES
LPB0038 Neutrophil Binding on E-selectin: a Potential Biomarker of 15:00 - 15:00 Clinical Course and Response to Therapy in Sickle Cell Disease Speaker: Yuncheng Man, US
LPB0043 Annexin A2-mediated Surface Fibrinolysis Is Impaired in Non- 15:00 - 15:00 alcoholic Steatohepatitis (NASH) Cirrhosis and May Contribute to Portal Vein Thrombosis Speaker: Hana I Lim, US
LPB0041 Improved Patient-reported Treatment Satisfaction with 15:00 - 15:00 Rivaroxaban as Compared to Low Molecular Weight Heparins for Cancer Patients with Acute Venous Thromboembolism - Results from the CONKO-011 Trial Speaker: Hanno Riess, DE
LPB0042 Characterization of Thrombotic Risk in Patients with Cancer 15:00 - 15:00 Speaker: Javier Trujillo Santos, ES
LPB0045 Principles of Care for Women and Girls with Inherited Bleeding 15:00 - 15:00
159 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Disorders Speaker: Karin van Galen, NL
LPB0044 Prothrombotic Biomarkers during Controlled Ovarian 15:00 - 15:00 Stimulation for Assisted Reproductive Techniques Speaker: Alessandro Casini, CH
LPB0046 The Impact of the ABO Blood Group on Postpartum 15:00 - 15:00 Haemorrhage Risk among Women with Thrombocytopenia Speaker: Sara Arcudi, IT
LPB0047 Management of Peripartum Anticoagulation in Women with 15:00 - 15:00 Venous Thromboembolism: An International Survey of Clinical Practice Speaker: Camille Simard, CA
Special Session 16:00 - 16:45 R1 Daily Headlines
160 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Monday, 19. July 2021
Supported Symposium 07:00 - 07:45 R1 MS 01 - Supported Symposium Title: Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTP
This session is supported by Physicians' Education Resource, LLC
Please view the program here
Supported Symposium 07:00 - 07:45 R2 MS 02 - Supported Symposium Title: Designing a New Future for Haemophilia Management: Therapy, Diagnostics & Devices
This session is supported by Novo Nordisk
Please view the program here
Supported Symposium 07:00 - 07:45 R3 MS 03 - Supported Symposium Title: Innovative Therapeutic Approaches for Immune Thrombocytopenia
This session is supported by UCB
Please view the program here
Presentation Theater 07:00 - 07:45 R4 PT 04 - Presentation Theater Title: From Insights to Outcomes in Hemophilia B
This session is supported by Sanofi Genzyme and Sobi
Please view the program here
Presentation Theater 07:00 - 07:45 R5 PT 05 - Presentation Theater Title: Behind the Bleed: VKA Reversal in Patients with Acute Major Bleeding
This session is supported by CSL Behring
Please view the program here
161 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Presentation Theater 07:00 - 07:45 R6 PT 06 - Presentation Theater Title: Current advances in the diagnosis of von Willebrand disease
This session is supported by Siemens Healthineers
Please view the program here
Break 07:45 - 08:15 R1 Virtual Exhibits Visits and Networking Break
State-of-the-Art Session 08:30 - 09:30 R1 SOA 08 - Structural Determinants of Function Moderator: Ingrid M. Verhamme, US Moderator: Muriel Maurer, US SOA 08.1 VWF Structure-Function in the Regulation of Cancer Metastasis 08:30 - 08:45 Speaker: Jamie O'Sullivan, IE
SOA 08.2 Factor VIII Structure: Determinants of Inhibitor Development 08:45 - 09:00 Speaker: Paul Clinton Spiegel, Jr., US
SOA 08.3 Specificity of ADAMTS13 and Regulation of ADAMTS13 09:00 - 09:15 Function Speaker: Colin Kretz, CA
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R2 SOA 09 - OMICS Moderator: Andrew Danner Johnson, US Moderator: Karin Hoffmeister, US SOA 09.1 Hemostatic Phenotypes and Genetic Disorders 08:30 - 08:45 Speaker: Kathleen Freson, BE
SOA 09.2 Role of Super Enhancers in Megakaryopoiesis and Thrombosis 08:45 - 09:00 Speaker: Mattia Frontini, GB
SOA 09.3 Proteomics in Thrombosis Research 09:00 - 09:15 Speaker: Jacob Odeberg, NO
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R3 SOA 10 - Hot Topics in Neonatal and Pediatric Thrombocytopenia Moderator: Alan E. Mast, US SOA 10.1 The Role of Platelet Transfusions to Manage Bleeding: Lessons 08:30 - 08:45
162 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
From Randomized Trials (Including Neonates and Children) Speaker: Simon Stanworth, GB
SOA 10.2 Platelets in the Neonate: Not Just a Small Adult 08:45 - 09:00 Speaker: Martha Sola-Visner, US
Question and Answer 09:00 - 09:15
State-of-the-Art Session 08:30 - 09:30 R4 SOA 11 - Novel Aspects of Fibrinogen in Disease Moderator: Marlien Pieters, ZA Moderator: Christian J. Kastrup, CA SOA 11.1 Fibrin(ogen) in Human Disease 08:30 - 08:45 Speaker: Marguerite Neerman-Arbez, CH
SOA 11.2 Clot Structure in Thrombotic Patients 08:45 - 09:00 Speaker: Anetta Undas, PL
Question and Answer 09:00 - 09:15
State-of-the-Art Session 08:30 - 09:30 R5 SOA 12 - What's New in VTE Prophylaxis Moderator: Suely Meireles Rezende, BR Moderator: Neil A. Zakai, US SOA 12.1 Venous Thromboprophylaxis in Critically Ill Patients 08:30 - 08:45 Speaker: Yaseen Arabi, SA
SOA 12.2 Extended VTE Prophylaxis in Medically Ill Patients 08:45 - 09:00 Speaker: Allison E. Burnett, US
Question and Answer 09:00 - 09:15
State-of-the-Art Session 08:30 - 09:30 R6 SOA 13 - Mechanisms of Thrombosis in Cancer and Clonal Disorders Moderator: Robson de Queiroz Monteiro, BR Moderator: Agnes Y.Y. Lee, CA SOA 13.1 Role of Exosomes and Exomeres in Cancer and Coagulation 08:30 - 08:45 Speaker: David Charles Lyden, US
SOA 13.2 Clonal Hematopoiesis and Thrombosis 08:45 - 09:00 Speaker: Benjamin Ebert, US
SOA 13.3 Mechanistic Insights From 3-D Visualization of Thrombus 09:00 - 09:15 Formation in Cancer Speaker: Laurence Panicot-Dubois, FR
Question and Answer 09:15 - 09:30
163 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
State-of-the-Art Session 08:30 - 09:30 R7 SOA 14 - Platelet-Microbe Interactions Moderator: Milka Koupenova, US Moderator: Robert A. Campbell, US SOA 14.1 Building a Better NET: Neutrophil Extracellular Trap 08:30 - 08:45 Stabilization to Enhance Microbe Entrapment Speaker: Kandace Gollomp, US
SOA 14.2 Sepsis and the Interplay Between Platelets and Coagulation 08:45 - 09:00 Speaker: Tom van der Poll, NL
Question and Answer 09:00 - 09:15
Break 09:30 - 10:00 R1 Virtual Exhibits Visits and Networking Break
Plenary Session 10:00 - 10:30 R1 PL 03 - Earl Davie Memorial Plenary Lecture - Novel Regulators of Coagulation Moderator: Rodney M. Camire, US PL 03.1 Novel Regulators of Coagulation 10:00 - 10:30 Speaker: James H. Morrissey, US
Break 10:30 - 11:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 11:00 - 12:00 R1 LB 01 - Late-breaking Abstract Session I Moderator: Saskia Middeldorp, NL Moderator: Michael Nagler, CH LB 01.1 Prevention of Arterial And Venous Vascular Events in 11:00 - 11:12 Symptomatic Peripheral Arterial Disease Patients after Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone Speaker: Scott D. Berkowitz, US
LB 01.2 Abelacimab for Prevention of Venous Thromboembolism 11:12 - 11:24 Speaker: Jeffrey I. Weitz, CA
LB 01.3 A Six-week versus Three-month Duration of Anticoagulation for 11:24 - 11:36 Acute Provoked Venous Thromboembolism in Patients < 21 Years Old: Results of the Multinational Kids-DOTT Randomized Controlled Trial Speaker: Neil A. Goldenberg, US
LB 01.4 The Management of SubSegmental Pulmonary Embolism 11:36 - 11:48
164 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
without Anticoagulation Speaker: Grégoire Le Gal, CA
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R2 OC 21 - Novel Diagnostic Aspects of Platelet Disorders Moderator: Rachael Grace, US Moderator: Ruchika Sharma, US OC 21.1 Diagnosing Inherited Platelet Disorders: Immunofluorescence 11:00 - 11:12 on the Blood Smear in Comparison with Genetic Testing Speaker: Carlo Zaninetti, DE
OC 21.3 Spectrum of Acquired Platelet Dysfunction with Eosinophilia 11:12 - 11:24 (APDE) in Tertiary Care Centre in South India Speaker: Rutvi Dave, IN
OC 21.4 Identification of Novel Variants by Panel-based High-throughput 11:24 - 11:36 Sequencing Associated with Platelet Function Disorders Speaker: Harald Schulze, DE
Question and Answer 11:36 - 11:48
Oral Communication Session 11:00 - 12:00 R3 OC 22 - Fibrinogen and Factor XIII in Disease Moderator: John W. Weisel, US Moderator: Claire S. Whyte, GB OC 22.1 Genetic Truncation of the Fibrinogen ?C-region in Mice Results 11:00 - 11:12 in Severe Hypofibrinogenemia with Preservation of Hemostasis and Protection from Venous Thrombosis Speaker: Woosuk Steve Hur, US
OC 22.2 The Difference in the Transglutaminase Activities of 11:12 - 11:24 Proteolytically and Non-proteolytically Activated FXIII A is Dependent on the Substrates Speaker: Rameesa Darul Amne Syed Mohammed, US
OC 22.3 Factor XIII Increases Cerebral Infarct Size by Promoting 11:24 - 11:36 Thrombus Stabilization and Resistance to Revascularization Treatments in Ischemic Stroke Speaker: Juan Marta-Enguita, ES
OC 22.4 Mechanisms Coupling Fibrinogen to Colitis Pathogenesis 11:36 - 11:48 Speaker: Bal Krishan Sharma, US
Question and Answer 11:48 - 12:00
165 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 11:00 - 12:00 R4 OC 23 - Risk Assessment in Cancer-Associated Thrombosis Moderator: Marc Carrier, CA Moderator: Kristen M. Sanfilippo, US OC 23.1 Personalized Cancer-associated Thrombosis Risk Assessment: 11:00 - 11:12 Integration of Plasma Proteomics, Clinical Characteristics, and Machine Learning Speaker: Jeffrey Zwicker, US
OC 23.2 Risk of Venous and Arterial Thromboembolic Events in Patients 11:12 - 11:24 Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study Speaker: Florian Moik, AT
OC 23.3 The Prognostic Value of Symptoms and Performance Status in 11:24 - 11:36 Ambulatory Cancer Patients and Unsuspected Pulmonary Embolism: Analysis of an International, Prospective, Observational Cohort Study Speaker: Anthony Maraveyas, GB
OC 23.4 Identification of Patients at High Thrombotic Risk in a Large 11:36 - 11:48 Prospective Cancer Patient Cohort Undergoing Anticancer Treatment Speaker: Cristina Verzeroli, IT
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R5 OC 24 - Hemophilia: Basic Science Moderator: Christoph Königs, DE Moderator: Carol H. Miao, US OC 24.1 Evaluation of the Tissue Factor-Independent Mechanism of 11:00 - 11:12 Action for Eptacog Beta Speaker: Jean-Luc Plantier, FR
OC 24.2 Neutralizing and Non-neutralizing Anti-FVIII Antibodies in Black 11:12 - 11:24 and White Hemophilia A Subjects: A Natural History Profile Speaker: Kathleen P. Pratt, US
OC 24.3 Pharmacokinetic Analysis of fVIII Exposure Identifies an 11:24 - 11:36 Immunogenicity Threshold after AAV-FVIII Gene Therapy in a Murine Hemophilia A Model Speaker: Taran S. Lundgren, US
OC 24.4 Altered vWF-FVIII Binding Modulates the Factor VIII Immune 11:36 - 11:48 Response Speaker: Amelia Wilhelm, US
Question and Answer 11:48 - 12:00
166 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 11:00 - 12:00 R6 OC 25 - Health Outcomes in VTE Moderator: Chee Wee Tan, AU Moderator: Allyson Pishko, US OC 25.1 Trends in Venous Thromboembolism and Death in COVID-19 11:00 - 11:12 Positive Patients in 2020 Speaker: Ahmed Pasha, US
OC 25.2 Venous Thromboembolism in Critically-ill Patients with 11:12 - 11:24 Pneumonia in the Pre-COVID-19 Era: Data from a Large Public Database Speaker: Miguel Pisani Leme Ferreira, BR
OC 25.3 36-month Clinical Outcomes of Patients with Venous 11:24 - 11:36 Thromboembolism: GARFIELD-VTE Speaker: Alexander G G Turpie, CA
OC 25.4 Outcomes Associated with Mandatory Venous 11:36 - 11:48 Thromboembolism (VTE) Risk Assessment in General Obstetric and Gynecologic Patients Speaker: Sriganesh Sharma, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R7 OC 26 - Hemostatic Agents and Hemostatic Efficacy Moderator: Eric Scott Mullins, US Moderator: Flora Peyvandi, IT OC 26.1 Efficacy and Safety of Valoctocogene Roxaparvovec Adeno- 11:00 - 11:12 associated Virus Gene Transfer for Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial Speaker: Margareth C. Ozelo, BR
OC 26.2 Cryoprecipitate, and Not Fibrinogen Concentrate, Enhances 11:12 - 11:24 Early Clot Formation in an in vitro Microfluidic Model of Dilutional Coagulopathy Speaker: Susan Shea, US
OC 26.3 Five Year Data Confirms Stable FIX Expression and Sustained 11:24 - 11:36 Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B Speaker: Wolfgang Miesbach, DE
OC 26.4 Plasmin-responsive Procoagulant Synthetic Platelets for Fibrin 11:36 - 11:48 Clot Stabilization in Hemorrhage Control Speaker: Anirban Sen Gupta, US
Question and Answer 11:48 - 12:00
167 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 11:00 - 12:00 R8 OC 27 - Regulation of Activated Protein C and Factor V Moderator: Elisabetta Castoldi, NL Moderator: Rinku Majumder, US OC 27.1 Thrombin Spatial Distribution Determines the Contribution of 11:00 - 11:12 Activated Protein C to Endogenous Anti-coagulant Activity during Hemostasis and Thrombosis in vivo Speaker: Timothy Stalker, US
OC 27.2 Kallikrein Augments the Anticoagulant Function of Protein C 11:12 - 11:24 System in Thrombin Generation Speaker: Jun Wan, NL
OC 27.3 Heparin Modulates FV Procofactor Regulatory Region and 11:24 - 11:36 Susceptibility to APC Speaker: Francis Ayombil, US
OC 27.4 A Unique Loop Structure in the A2-domain of Pseudonaja 11:36 - 11:48 textilis Factor Va Prevents Activated Protein C-catalyzed A2-domain Dissociation Speaker: Mark Schreuder, AU
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R9 OC 28 - Vascular Cells and Coagulation II Moderator: Guillermo García-Cardeña, US Moderator: Cristina Olgasi, IT OC 28.1 Inhibition of Neutrophil Extracellular Traps Reveals their 11:00 - 11:12 Differential Role in the Pathogenesis of Abdominal Aortic Aneurysms in Distinct Mouse Models Speaker: Nahla Ibrahim, AT
OC 28.2 Innocuous Levels of Pulmonary Thrombosis Protect against 11:12 - 11:24 Inflammatory Lung Injury via Endothelial Alox15 and HIF1? Speaker: Colin Evans, US
OC 28.3 Interleukin-4 Signaling Enhances Survival of Circulating 11:24 - 11:36 Monocytes in vivo Speaker: Patrick Haider, AT
OC 28.4 Candida albicans Expresses an Integrin-like Protein that 11:36 - 11:48 Promotes Endothelial Attachment and Vascular Leakage during Fungal Sepsis Speaker: Danielle Nader, IE
Question and Answer 11:48 - 12:00
168 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 11:00 - 12:00 R10 OC 29 - Megakaryopoiesis and Platelet Life Cycle, I Moderator: Kellie Machlus, US Moderator: Alessandra Balduini, IT OC 29.1 Early Endosomal GTPase Rab5 Regulates GPIb Trafficking and 11:00 - 11:12 Platelet Production in vitro Speaker: Ivana Bertovi?, HR
OC 29.2 Loss of G6b-B Confines Megakaryocyte Differentiation Potential 11:12 - 11:24 and Promotes Osteosclerosis in Mice Speaker: Isabelle Carlotta Becker, DE
OC 29.3 CRISPR Edited Megakaryocytes for Rapid Screening of Platelet 11:24 - 11:36 Gene Functions Speaker: Emilie Montenont, US
OC 29.4 Transcriptomics and Proteomics to Study the Effect of 11:36 - 11:48 Hyperactive SRC Kinase during Megakaryopoiesis Speaker: Lore De Kock, BE
Question and Answer 11:48 - 12:00
Break 12:00 - 12:30 R1 Virtual Exhibits Visits and Networking Break
Supported Symposium 12:30 - 13:30 R1 LS 08 - Supported Symposium Title: Countdown to Zero: Reducing Bleeds in Hemophilia A to Improve Quality of Life
This session is supported by F. Hoffmann-La Roche Ltd
Please view the program here
Lunch, Industry Exhibits and Poster Viewing 12:30 - 13:30 R1 Lunch, Industry Exhibits and Poster Viewing
Supported Symposium 12:30 - 13:30 R2 LS 09 - Supported Symposium Title: Elevating Expectations for Factor Replacement to go Beyond Current Paradigms in Hemophilia A
This session is supported by Sanofi Genzyme and Sobi
Please view the program here
169 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Supported Symposium 12:30 - 13:30 R3 LS 10 - Supported Symposium Title: Long-term Effects of ADAMTS13 Deficiency – What Do We Know?
This session is supported by Takeda Pharmaceutical Company
Please view the program here
Supported Symposium 12:30 - 13:30 R4 LS 11 - Supported Symposium Title: Behind the Bleed: Hemophilia B - Severe disease is only the tip of the iceberg
This session is supported by CSL Behring
Please view the program here
Supported Symposium 12:30 - 13:30 R5 LS 12 - Supported Symposium Title: Attaining and maintaining FVIII immune tolerance
This session is supported by Grifols
Please view the program here
Supported Symposium 12:30 - 13:30 R6 LS 13 - Supported Symposium Title: From Clinical Insights to Patient Experience: Suzanne’s Journey with von Willebrand Disease
This session is supported by Octapharma AG
Please view the program here
Supported Symposium 12:30 - 13:30 R7 LS 14 - Supported Symposium Title: Gene Therapy Research in Hemophilia: Liver Health and Patient Preparation; Experience from Clinical Trials
This session is supported by BioMarin Pharmaceutical Inc
Please view the program here
Master Class Session 12:30 - 13:15 R8 Coagulation Regulation Coagulation Regulation 12:30 - 13:15 Speaker: Tilman Mathias Hackeng, AN
170 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Björn Dahlbäck, SE
Master Class Session 12:30 - 13:15 R9 Real World Use of DOACs in Children Real World Use of DOACs in Children 12:30 - 13:15 Speaker: Leslie Raffini, US
Master Class Session 12:30 - 13:15 R10 Platelet Function Disorders Platelet Function Disorders 12:30 - 13:15 Speaker: Andrew Mumford, GB
Master Class Session 12:30 - 13:15 R11 ITP and Pregnancy ITP and Pregnancy 12:30 - 13:15 Speaker: Terry B. Gernsheimer, US
Master Class Session 12:30 - 13:15 R12 Platelet Pharming Platelet Pharming 12:30 - 13:15 Speaker: Cedric Ghevaert, GB
Master Class Session 12:30 - 13:15 R13 Dissecting Mechanisms in Clot Formation and Function in Health and Disease Dissecting Mechanisms in Clot Formation and Function in 12:30 - 13:15 Health and Disease Speaker: Alisa S. Wolberg, US
Master Class Session 12:30 - 13:15 R14 Genome-Wide Genomics Studies (GWAS, WGS, RNA-Seq) Of Platelet and Hemostasis Traits Genome-Wide Genomics Studies (GWAS, WGS, RNA-Seq) Of 12:30 - 13:15 Platelet and Hemostasis Traits Speaker: Andrew Danner Johnson, US
Master Class Session 12:30 - 13:15 R15 Duration of Anticoagulation After VTE Duration of Anticoagulation After VTE 12:30 - 13:15 Speaker: Suzanne Cannegieter, NL
171 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Master Class Session 12:30 - 13:15 R16 Immune Tolerance in the Era of Novel Therapeutics Immune Tolerance in the Era of Novel Therapeutics 12:30 - 13:15 Speaker: Shannon L. Meeks, US Speaker: Bhavya Doshi, US
Master Class Session 12:30 - 13:15 R17 Diagnosis and Management of VWD Diagnosis and Management of VWD 12:30 - 13:15 Speaker: Veronica Flood, US
Career Development Session 12:30 - 13:15 R18 Trainee/Recent Faculty Appointment & Young Family: (Semi) Pro Tips Trainee/Recent Faculty Appointment & Young Family: (Semi) 12:30 - 13:15 Pro Tips Speaker: Renee Eslick, AU
Career Development Session 12:30 - 13:15 R19 Collaboration with Industry in Clinical Coagulation Science Collaboration with Industry in Clinical Coagulation Science 12:30 - 13:15 Speaker: Diane Nugent, US
Career Development Session 12:30 - 13:15 R20 Opportunities in Academia: When to Say Yes/No and How to be Productive Opportunities in Academia: When to Say Yes/No and How to be 12:30 - 12:40 Productive Speaker: Adam Cuker, US
Career Development Session 12:30 - 13:15 R21 How to Establish a Clinical Research Team How to Establish a Clinical Research Team 12:30 - 13:15 Speaker: Neil A. Goldenberg, US
Break 13:30 - 14:00 R1 Virtual Exhibits Visits and Networking Break
172 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R1 OC 30 - Mechanisms and Genetics of Cancer-Associated Thrombosis Moderator: Keith R. McCrae, US Moderator: Oluwatoyosi Muse, US OC 30.1 Podoplanin and Tissue Factor Cooperate in Triggering 14:00 - 14:12 Microthrombosis in Experimental Glioblastoma and Are Released to Systemic Circulation as Cargo of Extracellular Vesicles Speaker: Nadim Tawil, CA
OC 30.2 Tumor Gene Expression Associates with Venous 14:12 - 14:24 Thromboembolism in Patients with Pancreatic Cancer Speaker: Floris Bosch, NL
OC 30.3 CDKN2A Mutational Status is Associated with Venous 14:24 - 14:36 Thromboembolism in Patients with Glioblastoma Speaker: Maaike Y. Kapteijn, NL
OC 30.4 Different Profiles of Plasma microRNAs in Chronic 14:36 - 14:48 Thromboembolic Pulmonary Hypertension and Pulmonary Embolism Related to Occult Cancer Speaker: Julia Oto Martínez, ES
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R2 OC 31 - Novel Findings of Inherited Platelet Disorders Moderator: Carlo Zaninetti, DE Moderator: Jose Rivera Pozo, ES OC 31.1 Transcription Factor RUNX1 Regulates Factor XIIIA Subunit 14:00 - 14:12 (F13A1) Expression in Platelets and Megakaryocytic Cells: Decreased Platelet F13A1 Expression and Clot Retraction in RUNX1 Haplodeficiency Speaker: Natthapol Songdej, US
OC 31.2 Clinical and Biological Assessment of the Largest Family with 14:12 - 14:24 SRC-RT due to p.E527K Gain-of-Function Variant Speaker: Nuria Revilla, ES
OC 31.3 Platelets from Patients with MYH9 Related Disorders Are 14:24 - 14:36 Mechanically Stiffer Speaker: Laura Sachs, DE
OC 31.4 Characterization of a New Family with Lifelong 14:36 - 14:48 Macrothrombocytopenia Caused by a Novel Nonsense Variant in TPM4 Speaker: Ana Marín-Quílez, ES
Question and Answer 14:48 - 15:00
173 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R3 OC 32 - Novel Biotherapeutics in Hemophilia: Clinical Moderator: Jayanthi Alamelu, GB Moderator: Peter H. Cygan, US OC 32.1 Ex vivo Assessment of the Importance of Activated Factor IX 14:00 - 14:12 (FIXa) Levels in the Procoagulant Effect of Recombinant FIX Concentrates in Emicizumab-treated Patients Speaker: Elena G Arias-Salgado, ES
OC 32.2 Emicizumab Prophylaxis and Monitoring: Real World Data 14:12 - 14:24 Speaker: Gili Kenet, IL
OC 32.3 Immunogenicity in the Concizumab Phase 2 Clinical Trials: 14:24 - 14:36 Clinical Impact of Anti-drug Antibodies Speaker: Giancarlo Castaman, IT
OC 32.4 Long-term Safety and Efficacy of the Anti-TFPI Monoclonal 14:36 - 14:48 Antibody Marstacimab in Patients with Severe Haemophilia A or B: Results from a Phase 2 Long-term Treatment Study Speaker: Johnny Mahlangu, ZA
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R4 OC 33 - Complications of Pregnancy Moderator: Michael Paidas, US Moderator: A. Kinga Malinowski, CA OC 33.1 ISTH Registry on Pregnancy and COVID-19 Associated 14:00 - 14:12 Coagulopathy (COV-PREG-COAG) - First Report Speaker: Sajida Kazi, GB
OC 33.2 AI_PREMie: A Novel Risk Stratification Tool for Preeclamptic- 14:12 - 14:24 toxaemia Speaker: Paulina B. Szklanna, IE
OC 33.3 Increased Plasma Concentration of Pentraxin 3 and Fibroblast 14:24 - 14:36 Growth Factor 2 in Preeclampsia Speaker: Flávia Santiago de Oliveira, BR
OC 33.4 Are Antiphospholipid Antibodies a Poor Prognostic Factor for 14:36 - 14:48 HELLP Syndrome? Speaker: Mathilde Pécourt, FR
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R5 OC 34 - Risk Factors for VTE Moderator: Lisa Baumann Kreuziger, US Moderator: Fionnuala Ní Áinle, IE
174 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 34.1 Pulmonary Embolism and Deep Vein Thrombosis – Incidence, 14:00 - 14:12 Comorbidities and Temporary Provoking Factors - A Nationwide Registry Study of 298,172 Patients Speaker: Katarina Glise Sandblad, SE
OC 34.2 The Role of Acute-phase Circulating miRNAs in Modulating 14:12 - 14:24 Clinical Outcome in Patients with Venous Thromboembolism Speaker: Vincent Ten Cate, DE
OC 34.3 Remote History of Venous Thrombosis and the Risk of Venous 14:24 - 14:36 Thrombosis beyond the Age of 70 Years Speaker: Huijie Wang, NL
OC 34.4 Pregnancy from in vitro Fertilization is Associated with Increase 14:36 - 14:48 in Risk of Venous Thromboembolism when Compared to Normal Pregnancy: A Systematic Review and Meta-analysis Speaker: Raditya Dewangga, ID
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R6 OC 35 - TFPI-Regulation and Function Moderator: Tilman Mathias Hackeng, AN Moderator: Josefin Ahnström, GB OC 35.1 Platelet TFPI? Dampens Prothrombotic and Fibrotic Responses 14:00 - 14:12 to Radiation Injury in Mouse Heart Speaker: Susan Maroney, US
OC 35.2 Protein S Coordinates the Synergistic Inhibition of 14:12 - 14:24 Prothrombinase by Tfpi? and Activated Protein C Speaker: Xian Li, US
OC 35.3 Protein Arginine Deiminase 4 Inactivates Tissue Factor Pathway 14:24 - 14:36 Inhibitor by Post-translational Modification of Functional Arginine Residues Speaker: Rory R Koenen, NL
OC 35.4 A Major Reservoir for Heparin-releasable TFPI? is Extracellular 14:36 - 14:48 Matrix Speaker: Julie Peterson, US
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R7 OC 36 - Emerging Biomarkers in Arterial Thrombosis Moderator: Diana Adrienne Gorog, GB OC 36.1 Growth Differentiation Factor-15 Predicts Major Bleeding, 14:00 - 14:12 Cardiovascular Events, and All-cause Mortality in Patients with End-stage Renal Disease on Hemodialysis Speaker: Stephan Nopp, AT
175 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 36.2 Estimating the Causal Association between Body Mass Index 14:12 - 14:24 and Platelet Properties: Evidence for a Positive Association with Immature Platelet Count Speaker: Lucy Goudswaard, GB
OC 36.3 Immature Platelet Count is Associated with Platelet Functional 14:24 - 14:36 Responses in Patients Receiving Aspirin Speaker: Kate Burley, GB
OC 36.4 Targeted Protein Biomarker Discovery to Predict 14:36 - 14:48 Cardiovascular Outcome in Peripheral Artery Disease Speaker: Bram Kremers, NL
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R8 OC 37 - Platelet Receptors and Signaling II Moderator: Debra K. Newman, US Moderator: Anh T. Ngo, US OC 37.1 Loss of the Rap-GAP, Rasa3 Leads to Severe 14:00 - 14:12 Thrombocytopenia Primarily due to ?IIb?3 Integrin-dependent Platelet Clearance in the Spleen Speaker: Robert Lee, US
OC 37.2 Identification of an Alternate Covalent Form of Platelet ?IIb?3 14:12 - 14:24 Integrin that Selectively Partitions into Focal Adhesions where it Has Extended Residency Time and Altered Function Speaker: Aster E. Pijning, AU
OC 37.3 Affimers Modulate GPVI Interactions with Collagen/Fibrinogen 14:24 - 14:36 and GPVI-mediated Platelet Aggregation Speaker: Rui-Gang Xu, GB
OC 37.4 The Intracellular Tail of GPIb? Augments GPVI-mediated 14:36 - 14:48 Signaling in Mice Speaker: Isabelle I Salles-Crawley, GB
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R9 OC 38 - The Immune Response to Factor VIII Moderator: Glaivy Batsuli, US Moderator: Jan Voorberg, NL OC 38.1 The Role of VWF/FVIII Association in Anti-FVIII Immune 14:00 - 14:12 Responses in Hemophilia A Mice Speaker: Yuanhua Cai, US
OC 38.2 Oral Delivery of Factor VIII Reduces the Magnitude of the Anti- 14:12 - 14:24 FVIII Immune Response and Increases Splenic Treg Numbers Speaker: Tanzila Afrin, CA
176 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 38.3 BAFF Inhibition Prevents FVIII Inhibitor Formation in a Marginal 14:24 - 14:36 Zone B Cell-independent Manner Speaker: Bhavya Doshi, US
OC 38.4 Elimination of Factor VIII Inhibitors by the IgG-degrading 14:36 - 14:48 Enzyme of Streptococcus pyogenes Speaker: Melissa Bou-Jaoudeh, FR
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R10 OC 39 - Neutrophils and EVs Moderator: Ángel García, ES Moderator: Kimberly Martinod, BE OC 39.1 Quantitative Proteomic Analysis of Circulating Extracellular 14:00 - 14:12 Vesicles from VTE Patients Reveals the Anti-inflammatory Potential of Rivaroxaban Speaker: Luisa Weiss, IE
OC 39.2 Nanomedicine Targeting to Activated Neutrophils and 14:12 - 14:24 Neutrophil-platelet Complexes Provides Effective Thromboprotection Speaker: Dillon Bohinc, US
OC 39.3 New strategy to improve the detection of large neutrophil- 14:24 - 14:36 derived extracellular vesicles in plasma by fluo-sensitive flow cytometry Speaker: Amandine Bonifay, FR
OC 39.4 Genome Wide Association Analysis of Neutrophils Extracellular 14:36 - 14:48 Traps Speaker: Gaëlle Munsch, FR
Question and Answer 14:48 - 15:00
Poster Networking Session 15:00 - 16:00 R1 ePoster Networking LPB0049 Cardiovascular Outcomes in Patients with Essential 15:00 - 15:00 Thrombocythemia: Analysis of the National Inpatient Sample (NIS) Speaker: Guillermo Tafur, US
LPB0051 ACTIMIS Trial: Safety Interim Analysis Data of Glenzocimab, a 15:00 - 15:00 Novel Antiplatelet Agent on Top of Acute Ischemic Stroke Standard of Care Speaker: Andrea Comenducci, FR
LPB0050 History of Cancer is Associated with Increased Platelet Activity 15:00 - 15:00 and Atherothrombosis in Patients with Peripheral Artery Disease
177 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Lucas Cofer, US
LPB0048 Association between Plaque Vulnerability and Neutrophil 15:00 - 15:00 Extracellular Traps (NETs) Levels: The Plaque at RISK Study Speaker: Judith de Vries, NL
LPB0052 Characterization of Andexanet Alfa-associated Heparin 15:00 - 15:00 Resistance: Implications for Management Speaker: Nabil Thalji, US
LPB0053 Activated FVIII Inactivation Occurs Outside of the Intrinsic Xase 15:00 - 15:00 Complex Speaker: Amelia Wilhelm, US
LPB0055 Exploration of TFPI-mediated Inhibitory Mechanisms in 15:00 - 15:00 Coagulation Flow Model Speaker: Kenji Miyazawa, US
LPB0054 Experimental Acetaminophen-induced Acute Liver Failure Is 15:00 - 15:00 Associated with a Profound Consumptive Coagulopathy Speaker: Dafna Jordana Groeneveld, US
LPB0056 Pre-admission Anticoagulant Therapy and Mortality in 15:00 - 15:00 Hospitalized COVID-19 Patients: A Covid Predict Retrospective Cohort Study Speaker: Thijs F. van Haaps, NL
LPB0057 Diagnostic Management of Suspected Pulmonary Embolism in 15:00 - 15:00 Patients with COVID-19: A Prospective Cohort Study Speaker: Milou Anne Maria Stals, NL
LPB0058 D-dimer Elevation at Time of Admission Is Associated with 15:00 - 15:00 Need for Ventilator Support among Pediatric Patients with COVID-19 Infection Speaker: Nathan Wilken, US
LPB0061 Impact of Characteristic Inhibition Kinetics of Different FVIII 15:00 - 15:00 Inhibitors on the Inhibitor Titer Quantification in the Modified Nijmegen-Bethesda Assay Speaker: Carolin Ketteler, DE
LPB0062 Smartphone-based Detection of Platelet Activation in 15:00 - 15:00 Microfluidic Strips Speaker: Daniel Hodge, GB
LPB0060 The Incidence of Severe Infusion Reactions Associated with 15:00 - 15:00 Common Iron Repletion Strategies Speaker: Asad Arastu, US
LPB0066 Decreased Clot Burden is Associated with Factor XIII Val34Leu 15:00 - 15:00 Polymorphism and Better Functional Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis Speaker: Zsuzsa Bagoly, HU
LPB0063 Epigenome-wide Association Study of DNA Methylation in 15:00 - 15:00
178 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Blood and Circulating Fibrinogen Levels Speaker: Julie Hahn, US
LPB0064 The Role of Activated Thrombin Activatable Fibrinolysis 15:00 - 15:00 Inhibitor on Thrombus Stability in Venous Thromboembolism Speaker: James Chessum, CA
LPB0065 Mutation of Sortase A Cleavage Site and Potential Impact on 15:00 - 15:00 Human Plasminogen Binding by PAM Speaker: Bradley Readnour, US
LPB0068 Efficacy of Parenteral Formulations of Desmopressin in the 15:00 - 15:00 Treatment of Bleeding Disorders: A Systematic Review Speaker: Stuart McKinlay, CA
LPB0067 Drastic Decrease in FVIII Response after Repeated Daily 15:00 - 15:00 Desmopressin Administrations in Peri-operative Non-severe Hemophilia A Patients: Final Results of Tachyphylaxis in the DAVID and Little DAVID Study Speaker: Lorenzo Gaetano Renata Romano, NL
LPB0070 Efficacy and Safety of Human Fibrinogen Concentrate for 15:00 - 15:00 Treatment of on-demand Bleeding in Adolescent and Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-02 and FORMA-04 Clinical Trials Speaker: Claudia Djambas-Khayat, LB
LPB0069 Self-Propelled Hemostatic Powder Safely Achieves and 15:00 - 15:00 Maintains Hemostasis in a Live Porcine Model of Upper Gastrointestinal Bleeding Speaker: Nabil Ali-Mohamad, CA
LPB0071 Coagulation Factor 5 (F5) Is an Estrogen-responsive Gene in 15:00 - 15:00 Breast Cancer Cells Speaker: Benedicte Stavik, NO
LPB0073 Platelet Function Is Inhibited by Dengue Virus 15:00 - 15:00 Speaker: M Alejandro Mosso-Pani, US
LPB0072 Aspirin vs P2RY12-Inhibitors to Reduce Cancer Associated 15:00 - 15:00 Thrombosis and Tumor Growth in Digestive Cancers Speaker: Ana Luisa Palacios Acedo, FR
LPB0074 Platelet Transfusion Does Not Prevent Experimental 15:00 - 15:00 Polymicrobial-induced Septic Shock in Mice Speaker: Yannick RABOUEL, FR
LPB0075 Treatment of Catheter-related Arterial Thrombosis in Children: 15:00 - 15:00 A 15-year Single Center Experience Speaker: Manuela Albisetti, CH
LPB0076 Cerebral Sinovenous Thrombosis and Asparaginase Re- 15:00 - 15:00 exposure in Patients Aged 1 to 45 Years with Acute Lymphoblastic Leukemia: A NOPHO ALL2008 Study Speaker: Mette Tiedemann Skipper, DK
179 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0077 Management of Localized Intravascular Coagulopathy with 15:00 - 15:00 Rivaroxaban in Children with Venous Malformations: Report of 6 Cases Speaker: Fatma Burcu Belen Apak, TR
LPB0078 Intracranial Involvement and Neurologic Manifestations in 15:00 - 15:00 Lemierre Syndrome: Analysis of 712 Patients Speaker: Luca Valerio, DE
LPB0079 Evaluation of the Different Platelet-dependent von Willebrand 15:00 - 15:00 Factor Activity Assays Capacity to Assess the in vivo Inhibitory Effect of Caplacizumab on the VWF-platelet Interaction Speaker: Paola Colpani, IT
LPB0080 Clinical and Biological Assessment of the Second Pedigree 15:00 - 15:00 Affected with X-linked GATA-1 Related Thrombocytopenia and Blood Group Lutheran Null Speaker: Verónica Palma-Barqueros, ES
LPB0081 Low Adhesion and Interaction Forces of Myh9 Mutant Platelets 15:00 - 15:00 Lead to Impaired Clot Retraction and Unstable Thrombus Formation Speaker: Juliane Baumann, DE
LPB0082 Enrichment of Variants in Platelet Genes in Patients with 15:00 - 15:00 Bleeding of Unknown Cause Speaker: Mackenzie Bowman, CA
LPB0084 GPVI, a New Binding Partner for pro-coagulant Factor VIII on 15:00 - 15:00 Platelets Speaker: Rohini Sekar, FR
LPB0085 The Predominant Role of Arrestin3 in General GPCR 15:00 - 15:00 Desensitization in Platelets Speaker: PREETI KUMARI CHAUDHARY, KR
LPB0083 Temporal Assessment of Platelet Proteome and fFnction during 15:00 - 15:00 ex vivo Anticoagulation Speaker: Samuel Tassi Yunga, US
LPB0086 GDP/GTP Exchange Factor MADD Drives Activation and 15:00 - 15:00 Recruitment of Secretory Rab GTPases to Weibel-Palade Bodies Speaker: Marije Kat, NL
LPB0087 Activated Platelets Transfer miR-223 into Endothelial Cells via 15:00 - 15:00 Microparticles to Downregulate ICAM-1 Expression among Septic Conditions Speaker: Bernadett Szilágyi, HU
LPB0088 Identification of Small Interfering RNAs for Allele-selective 15:00 - 15:00 Silencing of Murine von Willebrand Factor Speaker: Yvonne Kimberlee Jongejan, NL
LPB0089 Outcome of Cancer-associated Venous Thromboembolism Is 15:00 - 15:00 More Favourable among Patients with Hematologic
180 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Malignancies than with Solid Tumors Speaker: Ramón Lecumberri, ES
LPB0090 Active Cancer and Venous Thromboembolism: Safety and 15:00 - 15:00 Effectiveness of Edoxaban in Patients from the Noninterventional Global ETNA-VTE Program Speaker: Alexander Cohen, GB
LPB0091 Predictors of the Development of the Post-thrombotic 15:00 - 15:00 Syndrome: A Sub-analysis of the ATTRACT Trial Speaker: Felix Rinfret, CA
LPB0092 Alteration of the Circulating Plasma Proteome by FXa Inhibition 15:00 - 15:00 in Venous Thromboembolism and the Relationship with Clinical Outcome Speaker: Alejandro Pallares Robles, DE
LPB0093 An Overall Evaluation of the Adjusted Version of Global 15:00 - 15:00 Antiphospholipid Syndrome Score (aGAPSS) on Primary Obstetric Antiphospholipid Syndrome (POAPS) Patients Speaker: Gabriela de Larrañaga, AR
LPB0095 Bleeding Complications in Women with Venous 15:00 - 15:00 Thromboembolism during Pregnancy: A Systematic Review of the Literature Speaker: Camille Simard, CA
Special Session 16:00 - 16:45 R1 Daily Headlines
Supported Symposium 18:00 - 18:45 R1 MS 01R - Supported Symposium (Session Replay) Title: Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTP
This session is supported by Physicians' Education Resource, LLC
Please view the program here
Presentation Theater 18:00 - 18:45 R2 PT 04R - Presentation Theater (Session Replay) Title: From Insights to Outcomes in Hemophilia B
This session is supported by Sanofi Genzyme and Sobi
Please view the program here
181 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Tuesday, 20. July 2021
Supported Symposium 07:00 - 07:45 R1 MS 04 - Supported Symposium Title: Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes
This session is supported by Bristol Myers Squibb and Pfizer Alliance
Please view the program here
Supported Symposium 07:00 - 07:45 R2 MS 05 - Supported Symposium Title: ADVATE® [Antihemophilic Factor (Recombinant)] Clinical Presentation
This session is supported by Takeda Pharmaceutical Company
Please view the program here
Supported Symposium 07:00 - 07:45 R3 MS 06 - Supported Symposium Title: Factor XI Inhibition: the Holy Grail of Hemostasis?Sparing Anticoagulation
This session is supported by Anthos Therapeutics, Inc.
Please view the program here
Supported Symposium 07:00 - 07:45 R4 MS 07 - Supported Symposium Title: Embarking on the Gene Therapy Journey With Your Patient: Key Topics for Shared Decision Making
This session is supported by uniQure
Please view program here
Presentation Theater 07:00 - 07:45 R5 PT 07 - Presentation Theater Title: Evolving Care in aTTP – New Treatment Perspectives
This session is supported by Sanofi Genzyme
Please view program here
182 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Presentation Theater 07:00 - 07:45 R6 PT 08 - Presentation Theater Title: Behind the Bleed: Could New VWD Guidelines Help Us Change the Course of the Patient Journey?
This session is supported by CSL Behring
Please view the program here
Presentation Theater 07:00 - 07:45 R7 PT 09 - Presentation Theater Title: Two Topics, One Session: Mental Health in Hemophilia and an Extended Half-life Treatment Option for Hemophilia A
This session is supported by Novo Nordisk
Please view the program here
Presentation Theater 07:00 - 07:45 R8 PT 10 - Presentation Theater Title: Building a Future in Haemostasis Lab Workflow with the Sysmex CN-Series: Optimising Efficiency in Routine Workflow and the Clinical Utility of Chemiluminescence Testing for the COVID Era and Beyond
This session is supported by Sysmex Corporation
Please view the program here
Break 07:45 - 08:15 R1 Virtual Exhibits Visits and Networking Break
State-of-the-Art Session 08:30 - 09:30 R1 SOA 15 - COVID and Coagulation in 2021 Moderator: Lawrence F. Brass, US Moderator: Anne Angelillo-Scherrer, CH SOA 15.1 COVID-Associated Thrombosis: Where We Are 18 Months Into 08:30 - 08:45 the Pandemic Speaker: Neil A. Zakai, US
SOA 15.2 What We Know About Drivers of Thrombosis in COVID 08:45 - 09:00 Speaker: Jason S. Knight, US
SOA 15.3 Vaccine-Induced Thrombocytopenia and Thrombosis: Current 09:00 - 09:15 Thoughts on Mechanism and Management Speaker: Andreas Greinacher, DE
183 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
SOA 15.4 Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R2 SOA 16 - Vascular Permeability and Inflammation Moderator: Florea Lupu, US Moderator: Nigel Mackman, US SOA 16.1 Vascular Inflammatory Responses 08:30 - 08:45 Speaker: Paul Kubes, CA
SOA 16.2 VEGF and Vascular Permeability 08:45 - 09:00 Speaker: Lena Claesson-Welsh, SE
SOA 16.3 Molecular Analysis of Vascular Gene Expression 09:00 - 09:15 Speaker: Audrey C. Cleuren, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R3 SOA 17 - Novel Mechanisms Driving Arterial Thromboembolism Moderator: Michelle O’Donoghue, US Moderator: Donald Lynch, Jr., US SOA 17.1 Platelets as Inducers of Atherogenesis 08:30 - 08:45 Speaker: Jeffrey Berger, US
SOA 17.2 Lp(a) as a Novel Target for Thrombosis 08:45 - 09:00 Speaker: Sotirios Tsimikas, US
SOA 17.3 Genetics of Peripheral Artery Disease Highlight the Role of 09:00 - 09:15 Arterial Thrombosis Speaker: Scott M. Damrauer, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R4 SOA 18 - Effect of Health and Disease States on VWF/VWD Moderator: Jorge A. Di Paola, US Moderator: Veronica Flood, US SOA 18.1 The Impact of Aging and Inflammation on Plasma VWF Levels 08:30 - 08:45 Speaker: Frank W.G. Leebeek, NL
SOA 18.2 Understanding Acquired VWD in Cardiovascular Disorders: 08:45 - 09:00 From Pathophysiology to Patient Care Speaker: Sophie Susen, FR
SOA 18.3 Pregnancy, Postpartum and Periods: Current Challenges in the 09:00 - 09:15 Management of Women With VWD Speaker: Michelle Lavin, IE
184 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R5 SOA 19 - Cell-Dependent Fibrinolysis and Proteolysis Moderator: Moniek de Maat, NL SOA 19.1 Fibrin(ogen)-Endothelial Cell Interactions in Inflammation 08:30 - 08:45 Speaker: Leonid Medved, US
SOA 19.2 Cellular Aspects of Thrombus Resolution 08:45 - 09:00 Speaker: Toni M. Antalis, US
SOA 19.3 Role of Fibrinolytic Proteins in Neuorinflammation 09:00 - 09:15 Speaker: Eric Scott Mullins, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R6 SOA 20 - Thromboembolism in Women Moderator: Maha Othman, CA Moderator: Barbara A. Konkle, US SOA 20.1 DOACs in Pregnancy: The ISTH Registry and Beyond 08:30 - 08:45 Speaker: Saskia Middeldorp, NL
SOA 20.2 Prothrombotic Aspects of SCD, Sickle Trait and Other 08:45 - 09:00 Hemoglobinopathies in Contraception and Pregnancy Speaker: Rakhi Naik, US
SOA 20.3 VTE Risk in Premenopausal Women: Questions Still 09:00 - 09:15 Unanswered Speaker: Suzanne Cannegieter, NL
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R7 SOA 21 - Frontiers of OMICS Moderator: Wilbur Lam, US Moderator: Lawrence E. Goldfinger, US SOA 21.1 Blood Glycoprotein Homeostasis in the Pathogenesis of 08:30 - 08:45 Disease Speaker: Jamey D. Marth, US
SOA 21.2 Platelet Lipidomics and Signaling 08:45 - 09:00 Speaker: Valerie B. O'Donnell, GB
SOA 21.3 Microbiota and Thrombosis 09:00 - 09:15 Speaker: Christoph Reinhardt, DE
Question and Answer 09:15 - 09:30
185 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Break 09:30 - 10:00 R1 Virtual Exhibits Visits and Networking Break
Plenary Session 10:00 - 10:30 R1 PL 04 - Sol Sherry Memorial Plenary Lecture - Hormones and Thrombosis Moderator: Leslie Raffini, US PL 04.1 Hormones and Thrombosis 10:00 - 10:30 Speaker: Shannon M. Bates, CA
Break 10:30 - 11:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 11:00 - 12:00 R1 OC 40 - Hemostatic Problems in Pediatric ECMO and COVID-19 Patients Moderator: Meera Chitlur, US Moderator: Fareeda Walidah Haamid, US OC 40.1 Thrombotic Complications in Pediatric Patients Hospitalized 11:00 - 11:12 with COVID-19 Disease or Associated Multisystem Inflammatory Syndrome in Children (MIS-C) Speaker: Marcela Torres, US
OC 40.2 Acquired von Willebrand Disease in Pediatric Patients 11:12 - 11:24 Undergoing ECMO Support Speaker: Joppe Drop, NL
OC 40.3 Platelet Fibrinogen Receptor Expression and Platelet Function 11:24 - 11:36 Decreases as Duration of ECMO Increases in Paediatric Veno- arterial ECMO Patients Speaker: Suelyn Van Den Helm, AU
OC 40.4 Novel, Point-of-Care Coagulation Test Detects Anticoagulation 11:36 - 11:48 Resistance Predictive of Thrombotic Events in Pediatric ECMO Patients Speaker: Jun Teruya, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R2 OC 41 - Tumor Growth and Hemostasis I Moderator: Joseph S. Palumbo, US Moderator: Claudine Graf, DE OC 41.1 Platelet microRNAs Inhibit Primary Tumor Growth via Broad 11:00 - 11:12 Modulation of Tumor Cell mRNA Expression in Ectopic Pancreatic Cancer in Mice Speaker: Lawrence E. Goldfinger, US
186 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 41.2 The Factor XII-uPAR Axis Drives Ovarian Cancer Maintenance 11:12 - 11:24 and Progression Speaker: Kara L. Bane, US
OC 41.3 Plasminogen, but Not Fibrinogen, Promotes Pancreatic Ductal 11:24 - 11:36 Adenocarcinoma Tumor Growth and Metastasis Speaker: Yi Yang, US
OC 41.4 The Role of the Thrombin/PAR Axis in the Anti-tumor CD8+ T 11:36 - 11:48 Cell Response Following Immune Checkpoint Inhibition Therapy Speaker: Rachel Cantrell, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R3 OC 42 - Cellular and Molecular Functions of Fibrinogen and Factor XIII Moderator: Matthew J. Flick, US Moderator: Dafna Jordana Groeneveld, US OC 42.1 Role of the Coagulation Factor XIII Binding Site on Crosslinking 11:00 - 11:12 of Fibrinogen ?C (233 - 425) Speaker: Francis Dean Ablan, US
OC 42.2 Cellular Factor XIII in Macrophage Derived Foam Cells 11:12 - 11:24 Speaker: Laura Somodi, HU
OC 42.3 Controlled Knockdown of Fibrinogen with siRNA Modulates 11:24 - 11:36 Fibrinogen-mediated Inflammation Speaker: Lih Jiin Juang, CA
OC 42.4 Cryoprecipitate Transfusion Significantly Decreases the Rate of 11:36 - 11:48 Plasmin Generation in Trauma Patients Speaker: Gael B Morrow, GB
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R4 OC 43 - VWF and ADAMTS13 Moderator: Caterina Casari, FR OC 43.1 Deep Mutational Scan of the VWF C Domains to Define 11:00 - 11:12 Mutations Associated with VWD Speaker: Taylor Sparring, CA
OC 43.2 Quantifying the Concentration-effect Relation of Desmopressin 11:12 - 11:24 on the von Willebrand Factor Activity in Patients with von Willebrand Disease Speaker: Michael Cloesmeijer, NL
OC 43.3 Inhibition of ADAMTS13 Rescues Acquired von Willebrand 11:24 - 11:36 Syndrome in a Preclinical Left Ventricular Assist Device Animal Model
187 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Shannen J Deconinck, BE
OC 43.4 ADAMTS-13/VWF Ratio as Biomarker for Portal Vein 11:36 - 11:48 Thrombosis (PVT) Development in Cirrhotic Patients: A Prospective Study Speaker: Raimondo De Cristofaro, IT
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R5 OC 44 - Antiphospholipid Antibodies and Antiphospholipid Syndrome Moderator: Wendy Lim, CA Moderator: Deepa J. Arachchillage, GB OC 44.1 Clinical Characteristics and Prognosis of Antiphospholipid 11:00 - 11:12 Syndrome Patients Based on Cluster Analysis: A 10-year Cohort Study Speaker: Wanting Qi, CN
OC 44.2 Predictors of Lupus Anticoagulant Test Variability over Time 11:12 - 11:24 and its Associations with Future Thrombotic Events: Results from the Vienna Lupus Anticoagulant and Thrombosis Study (LATS) Speaker: Meaghan Colling, AT
OC 44.3 Progression of Ischaemic and Haemorrhagic Brain Lesions on 11:24 - 11:36 MRI in APS Patients on Antithrombotic Therapy Speaker: Maria Efthymiou, GB
OC 44.4 Origin of Antiphospholipid Antibodies in Autoimmunity and 11:36 - 11:48 Viral Infection Speaker: Nadine Müller-Calleja, DE
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R6 OC 45 - Assay Evaluation Moderator: Cheryl L. Maier, US OC 45.1 Multicenter Performance Evaluation and Reference Range 11:00 - 11:12 Determination for the Quantitative Assessment of Factor XI Activity by One-stage Factor Assay on the Cobas t 711 Analyzer Speaker: Martin Büchsel, DE
OC 45.2 Comparison of Alternative Viscoelastic Hemostatic Assays – 11:12 - 11:24 Rotational Thromboelastometry versus Sonorheometry for Rapid Diagnosis in Trauma Patients: An Interim Analysis Speaker: Jared Mark Wohlgemut, GB
OC 45.3 Overt DIC Score Predicts Mortality in Liver Insufficiency, a 11:24 - 11:36 Comparison with the MELD-Na Score Speaker: Juergen Grafeneder, AT
188 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 45.4 Recovery of BAY 94-9027 [Jivi®] with One-stage Clotting and 11:36 - 11:48 Chromogenic Assays: A Multicentre Study Speaker: Piet Meijer, NL
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R7 OC 46 - Modulation of Hemostasis-Clinical Assessment Moderator: Jean Marie Connors, US Moderator: Jan Beyer-Westendorf, DE OC 46.1 Peri-procedural Heparin Use in Patients Receiving Edoxaban: 11:00 - 11:12 Analyses of the Noninterventional Global EMIT (Edoxaban Management in Diagnostic and Therapeutic Procedures) Study Speaker: Amparo Santamaria, ES
OC 46.2 Fibrinolytic Shutdown Is Associated with Death, Mild Lung 11:12 - 11:24 Injury and a New VV ECMO Requirement after Cardiac Surgery; A Single Center Case-control Study of 742 Patients Speaker: Sean Wickers, US
OC 46.3 Growth Differentiation Factor-15 for Prediction of Bleeding in 11:24 - 11:36 Cancer Patients Speaker: Frits Mulder, NL
OC 46.4 VMX-C001 Is an Effective FXa-DOAC Reversal Agent and 11:36 - 11:48 Displays No Thrombogenic Potential in Comparison to Andexanet Alfa and 4PCC Speaker: Daniël Verhoef, NL
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R8 OC 47 - Platelet Biology in Prothrombotic Disorders Moderator: Amrita Sarkar, US Moderator: A. Valance Washington, US OC 47.1 Prevention of Thrombocytopenia and Thrombosis in Heparin- 11:00 - 11:12 induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT? Speaker: Amrita Sarkar, US
OC 47.2 A Thrombospondin-1 Release Assay (TRA) Coupled to 11:12 - 11:24 PF4-treated Frozen Platelets is Highly Accurate for the Detection of Pathogenic HIT Antibodies: Implications for Development of a Near-patient HIT in vitro Diagnostic Assay Speaker: Anand Padmanabhan, US
OC 47.3 Both Immunoreceptor Tyrosine-based Activation Motif (ITAM) 11:24 - 11:36 and G-protein Coupled Receptors (GPCR) Are Individually Required in Venous Thrombosis (VT) Pathogenesis Speaker: Jean Mwiza, US
189 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 47.4 Features of Aspirin-resistant Biomechanical Platelet Activation 11:36 - 11:48 in Fibromuscular Dysplasia Speaker: Rohan Bhandari, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R9 OC 48 - Novel Biotherapeutics in Hemophilia: Laboratory Moderator: Yesim Dargaud, FR Moderator: Lacramioara Ivanciu, US OC 48.1 A Blood Coagulation Factor IX Variant that Functions 11:00 - 11:12 Independently of Factor VIII Mitigates the Hemophilia A Phenotype in Patient Plasma Speaker: Viola J.F. Strijbis, NL
OC 48.2 Transplacental Delivery of Recombinant Fc-fused Factor VIII 11:12 - 11:24 (rFVIIIFc) in FVIII-deficient Mice Speaker: Alejandra Reyes-Ruiz, FR
OC 48.3 Therapeutic Knockdown of Plasminogen with siRNA in 11:24 - 11:36 Hemophilia A and von Willebrand disease Mouse Models Speaker: Paul Batty, CA
OC 48.4 Orally Delivered Factor VIII Restores Hemostasis in a 11:36 - 11:48 Hemophilia A Dog Speaker: Timothy C. Nichols, US
Question and Answer 11:48 - 12:00
Oral Communication Session 11:00 - 12:00 R10 OC 49 - Bone and Joint Health in Hemophilia Moderator: Fernando F. Corrales-Medina, US Moderator: Nihal Bakeer, US OC 49.1 Bone Disease in Hemophilia: The Role of Different Bone Cells 11:00 - 11:12 Speaker: Stefano Lancellotti, IT
OC 49.2 Emicizumab: Will it Suffice for Bone Metabolism? 11:12 - 11:24 Speaker: Marilyn Manco-Johnson, US
OC 49.3 Efficacy and Safety of Intraarticular Injection of Mononuclear 11:24 - 11:36 Stem Cells in Hemophilia Patients with Arthropathy Speaker: Mehran Karimi, IR
OC 49.4 Joint Status of Patients with Non-severe Hemophilia A 11:36 - 11:48 Speaker: Fabienne Kloosterman, NL
Question and Answer 11:48 - 12:00
190 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Break 12:00 - 12:30 R1 Virtual Exhibits Visits and Networking Break
Supported Symposium 12:30 - 13:30 R1 LS 15 - Supported Symposium Title: Long-term Monitoring of Clinical Efficacy and Safety Parameters for Hemophilia Gene Therapy
This session is supported by Pfizer
Please view the program here
Lunch, Industry Exhibits and Poster Viewing 12:30 - 13:30 R1 Lunch, Industry Exhibits and Poster Viewing
Supported Symposium 12:30 - 13:30 R2 LS 16 - Supported Symposium Title: What are we Monitoring in Hemophilia?
This session is supported by Sanofi Genzyme
Please view program here
Supported Symposium 12:30 - 13:30 R3 LS 17 - Supported Symposium Title: Evolution of Care in Von Willebrand Disease: How Can the Ash ISTH NHF WFH 2021 Guidelines Advance Clinical Practice?
This session is supported by Takeda Pharmaceutical Company
Please view the program here
Supported Symposium 12:30 - 13:30 R4 LS 18 - Supported Symposium Title: Independent, CME Accredited Symposium: Improving clinical outcomes in hemophilia through a better understanding of hemostasis
This session is supported by Springer Healthcare IME
Please view the program here
191 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Supported Symposium 12:30 - 13:30 R5 LS 19 - Supported Symposium Title: Factor in the Future: Informed Treatment Decisions for Haemostasis and Beyond
This session is supported by Octapharma AG
Please view the program here
Supported Symposium 12:30 - 13:30 R6 LS 20 - Supported Symposium Title: Practical Considerations on the use of TPO-RAs in ITP
This session is supported by COR2ED
Please view the program here
Supported Symposium 12:30 - 13:30 R7 LS 21 - Supported Symposium Title: Viscoelastic Hemostasis Testing in Trauma: An on-going Discussion
This session is supported by Haemonetics
Master Class Session 12:30 - 13:15 R8 Biochemistry of Coagulation and Fibrinolysis Biochemistry of Coagulation and Fibrinolysis 12:30 - 13:15 Speaker: Paul Y. Kim, CA
Master Class Session 12:30 - 13:15 R9 Imaging Platelets and Megakaryocytes by High Resolution Fluorescence Microscopy Imaging Platelets and Megakaryocytes by High Resolution 12:30 - 13:15 Fluorescence Microscopy Speaker: Walter H.A. Kahr, CA
Master Class Session 12:30 - 13:15 R10 Vascular Diversity Vascular Diversity 12:30 - 13:15 Speaker: Mark Kahn, US
Master Class Session 12:30 - 13:15 R11 Treating Bleeds in Patients on Emicizumab
192 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Treating Bleeds in Patients on Emicizumab 12:30 - 13:15 Speaker: Glaivy Batsuli, US Speaker: Angela C. Weyand, US
Master Class Session 12:30 - 13:15 R12 Big Data and Thrombosis Big Data and Thrombosis 12:30 - 13:15 Speaker: Scott M. Damrauer, US
Master Class Session 12:30 - 13:15 R13 Coagulation Lab Monitoring in Hemophilia and RBD Coagulation Lab Monitoring in Hemophilia and RBD 12:30 - 13:15 Speaker: Steven Kitchen, GB
Master Class Session 12:30 - 13:15 R14 Measuring Microparticles in Clinical Studies Measuring Microparticles in Clinical Studies 12:30 - 13:15 Speaker: Romaric Lacroix, FR
Master Class Session 12:30 - 13:15 R15 Platelet Biology & Genomics Platelet Biology & Genomics 12:30 - 13:15 Speaker: Kathleen Freson, BE
Master Class Session 12:30 - 13:15 R16 Biomarkers to Predict Thrombosis in Cancer Biomarkers to Predict Thrombosis in Cancer 12:30 - 13:15 Speaker: Anna Falanga, IT
Master Class Session 12:30 - 13:15 R17 Antiphospholipid Syndrome Antiphospholipid Syndrome 12:30 - 13:15 Speaker: Stéphane Zuily, FR
Career Development Session 12:30 - 13:15 R18 Picking a Doctoral or Post-Doctoral Laboratory/Mentor Picking a Doctoral or Post-Doctoral Laboratory/Mentor 12:30 - 13:15 Speaker: Karin Hoffmeister, US
193 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Career Development Session 12:30 - 13:15 R19 Deciding Between Academics and Industry Deciding Between Academics and Industry 12:30 - 13:15 Speaker: Tovo David, CH Speaker: Leonard Edelstein, US
Career Development Session 12:30 - 13:15 R20 How to be an Effective Reviewer of Manuscripts How to be an Effective Reviewer of Manuscripts 12:30 - 13:15 Speaker: José A. López, US
Career Development Session 12:30 - 13:15 R21 Strengths and Mistakes in the 1st 5 Years of a Faculty Appointment Strengths and Mistakes in the 1st 5 Years of a Faculty 12:30 - 13:15 Appointment Speaker: Shannon L. Meeks, US
Break 13:30 - 14:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 14:00 - 15:00 R1 OC 50 - Informative Biomarkers of COVID-19 Moderator: Bruce A. Sullenger, US Moderator: Jecko Thachil, GB OC 50.1 Development of an Artificial Intelligence Model to Predict 14:00 - 14:12 Venous Thromboembolic Disease in COVID-19 Patients at Hospital Admission Speaker: Bruno Barbosa Miranda Paiva, BR
OC 50.2 Hemostatic Profile of COVID-19 Convalescent Plasma (CCP) 14:12 - 14:24 Donors from Bergamo Area Speaker: Carmen Julia Tartari, IT
OC 50.3 Biomarkers of Coagulation, Endothelial Function and 14:24 - 14:36 Fibrinolysis in Critically-ill Patients with COVID-19: A Single Centre Prospective Longitudinal Study Speaker: Ganeem K Juneja, CA
OC 50.4 The Prognostic Value of ADAMTS13 and von Willebrand Factor 14:36 - 14:48 in COVID-19 Patients: A Prospective Study by Care Setting Speaker: Giovanni L. Tiscia, IT
Question and Answer 14:48 - 15:00
194 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R2 OC 51 - New Diagnostics Moderator: Keith Neeves, US Moderator: Andrew Mumford, GB OC 51.1 Prospective Cohort Study on the Use of Low Molecular Weight 14:00 - 14:12 Heparin Calibrated Anti-Xa Assay to Estimate Levels of Direct Oral Xa Inhibitors in Ex-vivo Patient Samples Speaker: Ming Sheng Lim, AU
OC 51.2 Paediatric D-dimer and Fibrin Degradation Products (FDP) 14:12 - 14:24 Reference Intervals Using STA® Liatest D-Di Plus and STA® Liatest FDP Speaker: Natasha Letunica, AU
OC 51.3 Breakthrough in Laboratory Functional Testing of HIT Using 14:24 - 14:36 Flow Cytometry and Artificial Intelligence. Towards Augmented Diagnostics? Speaker: MATTHIEU STOLL, FR
OC 51.4 Measurement of von Willebrand Factor Levels via Fiber Optic- 14:36 - 14:48 surface Plasmon Resonance Speaker: Bas Calcoen, BE
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R3 OC 52 - Platelet Interactions with Neutrophils and the Endothelium Moderator: Wolfgang Bergmeier, US Moderator: Valerie Tutwiler, US OC 52.1 The Importance of the GPIb? Intracellular Tail in VWF-mediated 14:00 - 14:12 Platelet Signaling Events and Platelet/Neutrophil Interactions Speaker: Isabelle I Salles-Crawley, GB
OC 52.2 Characterization of the Role of Integrin ?5?1 in Platelet 14:12 - 14:24 Function, Haemostasis and Arterial Thrombosis in Mice Speaker: Emily Janus-Bell, FR
OC 52.3 Platelet Chemokines and Integrins Antagonistically Steer 14:24 - 14:36 Neutrophil Activation in Arterial Thrombus Formation Speaker: Claudia Schönichen, NL
OC 52.4 Deconstructing the Role of Vessel Wall Architecture on 14:36 - 14:48 Hemostasis in a Microfluidic Model of Microvascular Bleeding Speaker: Matthew Sorrells, US
Question and Answer 14:48 - 15:00
195 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R4 OC 53 - TTP Across the Age Continuum Moderator: Marshall Mazepa, US Moderator: Karen Vanhoorelbeke, BE OC 53.1 Major Adverse Cardiovascular Events Are a Major Cause of 14:00 - 14:12 Morbidity after Recovery from Immune Thrombotic Thrombocytopenic Purpura Speaker: Max Brodsky, US
OC 53.2 Children with Hereditary Thrombotic Thrombocytopenic 14:12 - 14:24 Purpura (hTTP) Have a High Incidence of Acute Episodes: Data from the International Hereditary TTP Registry (IHTTP Registry) Speaker: Erika Tarasco, CH
OC 53.3 Outcomes of Subsequent Pregnancy in Women with a History 14:24 - 14:36 of Immune Thrombotic Thrombocytopenic Purpura Speaker: Jenna Brown, US
OC 53.4 Anti-ADAMTS13 Antibodies in Patients with Hereditary 14:36 - 14:48 Thrombotic Thrombocytopenic Purpura (hTTP) Speaker: Silvan Rolf Heeb, CH
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R5 OC 54 - Contact Pathway-Molecular Regulation and Clinical Assessment Moderator: Evi X. Stavrou, US Moderator: Nicola Mutch, GB OC 54.1 A Mechanism for Hereditary Angioedema Caused by a 14:00 - 14:12 plasminogen Lys311Glu Substitution Speaker: S Kent Dickeson, US
OC 54.2 Severe High Molecular Weight Kininogen (HK) Deficiency: 14:12 - 14:24 Clinical Characteristics, and KNG1 Mutations in Reported and New Cases Speaker: Anke Adenaeuer, DE
OC 54.3 Histidine-rich Glycoprotein Attenuates Catheter Thrombosis in 14:24 - 14:36 Rabbits Speaker: Rida A. Malik, CA
OC 54.4 Studying Factor XII Structure-function Relationships Using 14:36 - 14:48 Factor XII-HGFA Chimeric Proteins Speaker: Aleksandr Shamanaev, US
Question and Answer 14:48 - 15:00
196 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R6 OC 55 - Inhibitors in Hemophilia A Moderator: Samantha C. Gouw, NL Moderator: Radoslaw Kaczmarek, US OC 55.1 IgG2 as Hallmark of Inhibitor Persistence in a Longitudinal 14:00 - 14:12 Analysis of PUPs in the First 50 Exposure Days to FVIII Speaker: Syna Miri, IT
OC 55.2 Purifying the Needle in the Haystack: A Novel 14:12 - 14:24 Immunoproteomic Pipeline for the Characterization Anti-FVIII Antibodies in Hemophilia A Inhibitor Patients Speaker: Robert Chen, US
OC 55.3 Factor VIII Inhibitors: Effects of Mutation and FVIII Antigen 14:24 - 14:36 Revisited Speaker: Susan Kuldanek, US
OC 55.4 No Difference in Inhibitor Incidence in Previously Untreated 14:36 - 14:48 Patients (PUPs) with Severe and Moderately Severe Hemophilia A Treated with a Third-generation Recombinant Factor VIII when Compared with Plasma-derived Factor VIII Speaker: Alessandra Nunes Loureiro Prezotti, BR
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R7 OC 56 - Genetics and Gene Therapy in Hemophilia Moderator: Robert Klamroth, DE Moderator: Jill Johnsen, US OC 56.1 Deep Molecular Mechanisms of F8 exon 19 Variants and 14:00 - 14:12 Translational Approaches in Hemophilia A Speaker: Dario Balestra, IT
OC 56.2 Comparative Analysis of Residual Factor VIII Expression from 14:12 - 14:24 Recurrent F8 Nonsense Mutations Indicates that Localization in the B-domain Favours Readthrough-mediated Protein Output Speaker: Maria Francesca Testa, IT
OC 56.3 Identification and Characterization of F9 Deep Intronic 14:24 - 14:36 Variations in Haemophilia B Patients Speaker: Amy Dericquebourg, FR
OC 56.4 F8 Genetic Variants Associated with Inhibitor Development in a 14:36 - 14:48 Multiethnic Population of Non-severe Hemophilia A Speaker: Ming Yeong Lim, US
Question and Answer 14:48 - 15:00
197 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R8 OC 57 - Benefits and Harms of Antithrombotic Therapy in Patients with a History of VTE Moderator: Lana A. Castellucci, CA Moderator: Thita Chiasakul, TH OC 57.1 Management of Patients with Venous Thromboembolism and a 14:00 - 14:12 High Recurrence Risk Estimated by the Vienna Prediction Model Speaker: Lisbeth Eischer, AT
OC 57.2 Individual Benefits and Harms of Extended Anticoagulation in 14:12 - 14:24 Patients with Venous Thromboembolism: The VTE-PREDICT Model Speaker: Maria A. de Winter, NL
OC 57.3 Prediction of Mortality in Patients with Recently Diagnosed 14:24 - 14:36 Venous Thromboembolism: The GARFIELD-VTE Mortality Risk Model Speaker: Alfredo E. Farjat, GB
OC 57.4 Effectiveness and Safety of Concomitant Use of Direct Oral 14:36 - 14:48 Anticoagulants and Antiplatelet Agents among Patients with Venous Thromboembolism: A Population-based Multinational Cohort Study Speaker: Antonios Douros, CA
Question and Answer 14:48 - 15:00
Oral Communication Session 14:00 - 15:00 R9 OC 58 - Tumor Growth and Hemostasis II Moderator: Robert Flaumenhaft, US Moderator: Diane Mege, FR OC 58.1 The “Double-edged Sword”: The Role of LMWPTP in Platelet 14:00 - 14:12 Hyperactivity in Cancer Patients Speaker: Alessandra Valeria Sousa Faria, BR
OC 58.2 Delineating the Role of Low Molecular Weight Heparin in Breast 14:12 - 14:24 Cancer Metastasis Speaker: Sukhraj Pal Singh Dhami, IE
OC 58.3 The Tumor Promoting Activity of Osteopontin Is Solely 14:24 - 14:36 Dependent on its Cleavage by Thrombin Speaker: John Morser, US
OC 58.4 Platelets Stimulate Programmed Death-ligand 1 Expression by 14:36 - 14:48 Cancer Cells: Inhibition by Anti-platelet Drugs Speaker: Amir Asgari, CA
Question and Answer 14:48 - 15:00
198 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Oral Communication Session 14:00 - 15:00 R10 OC 59 - Rare Bleeding Disorders Moderator: Diane Nugent, US Moderator: Karen Leigha Zimowski, US OC 59.1 Oral Pazopanib Results in Durable Hemostasis in Patients with 14:00 - 14:12 Severe Bleeding and RBC Transfusion-dependent Hereditary Hemorrhagic Telangiectasia Speaker: Hanny Al-Samkari, US
OC 59.2 SIG-009: Novel Encapsulated Non-viral Cell-based Therapy for 14:12 - 14:24 FVII Deficiency Speaker: Marissa Donovan, US
OC 59.3 Hemostatic Treatment of Patients with Rare Bleeding Disorders 14:24 - 14:36 in the Netherlands: Real-life Data from the RBiN Study Speaker: D.P.M.S.M. Maas, NL
OC 59.4 Studies of LMAN1 and MCFD2 Deficient Cell Lines Provide New 14:36 - 14:48 Insight into Intracellular Trafficking of FV and FVIII Speaker: Yuan Zhang, US
Question and Answer 14:48 - 15:00
Poster Networking Session 15:00 - 16:00 R1 ePoster Networking LPB0059 Population Pharmacokinetics of Anti-Xa Levels in COVID-19 ICU 15:00 - 15:00 Patients Receiving Prophylaxis for Thrombo-embolic Events Using Nadroparin Speaker: Lorenzo Gaetano Renata Romano, NL
LPB0098 A Simple Score to Evaluate Bleeding Risk in Medical Patients 15:00 - 15:00 Taking Antiplatelets for Cardiovascular Prevention Speaker: Sofia Barbar, IT
LPB0096 Development of a 3D Tissue-engineered Neointimal Model as an 15:00 - 15:00 Alternative to Animal Models of Human Atherosclerosis Speaker: Jassim Echrish, GB
LPB0097 Role of Low-dose Aspirin on the Release of Circulating 15:00 - 15:00 Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes Speaker: Paola Simeone, IT
LPB0099 Absence of CCR5/CCL5 Axis Inhibits Thrombus Resolution 15:00 - 15:00 through Reduced uPA, tPA and VEGF Expressions in DVT Model Speaker: Mizuho Nosaka, JP
LPB0100 Mapping Prothrombin Binding on Pseutarin C by Site-directed 15:00 - 15:00 PEGylation Speaker: Fatma Isik Ustok, GB
199 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0101 Nucleotides Inhibit Serine Proteases Involved in Blood Clotting 15:00 - 15:00 and Other Cellular Processes Speaker: Fabienne Birkle, US
LPB0102 Blockade Of COVID-19 Antiphospholipid Antibody-Induced 15:00 - 15:00 Thrombosis by a Specific Inhibitor of the TF Initiation Complex Speaker: Denise Pedrosa, DE
LPB0103 Circulating Cellular Clusters Are Correlated with Thrombotic 15:00 - 15:00 Complications and Clinical Outcomes in COVID-19 Speaker: Ander Dorken Gallastegi, US
LPB0104 Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 15:00 - 15:00 Can Be Overcome by N-acetylcysteine in vitro Speaker: Dorothée Faille, FR
LPB0105 External Validation of IMPROVE-DD Risk Assessment Model for 15:00 - 15:00 Venous Thromboembolism among Inpatients with COVID-19 Speaker: Stephanie K. Lin, US
LPB0106 Enhancing Transfusable Platelets Using mRNA Therapy to 15:00 - 15:00 Produce Exogenous Proteins Speaker: Jerry Leung, CA
LPB0107 Preoperative Measurement of Platelet Contribution to Clot 15:00 - 15:00 Stiffness (PCS) with the Quantra® QPlus® System and Bleeding after Cardiac Surgery Speaker: Wim Houdijk, US
LPB0108 Usefulness of an Academic High-throughput Sequencing Panel 15:00 - 15:00 to Detect Copy Number Variations in Patients with Syndromic Thrombocytopenia Speaker: Sandra Santos-Mínguez, ES
LPB0109 Full Automation of the Bethesda Assay 15:00 - 15:00 Speaker: Thomas Siegemund, DE
LPB0110 FXIIIa-mediated Fibrin ?-chain Crosslinks Are Critical for Fibrin 15:00 - 15:00 Fiber Stiffness and Resistance to Rupture Speaker: Tímea Feller, GB
LPB0111 Molecular Interactions of Coagulation Factor XIII B Subunit 15:00 - 15:00 Speaker: Krisztina Pénzes, HU
LPB0112 Monocytes Expose Factor XIII-A and Stabilize Thrombi against 15:00 - 15:00 Fibrinolytic Degradation Speaker: Fahad Alshehri, GB
LPB0113 Streptococcal Surface Enolase (SEN) Is Overshadowed by P 15:00 - 15:00 lasminogen-binding Group A Streptococcal M-protein (PAM) for Human Plasminogen Acquisition and Activation Speaker: Sheiny Tjia-Fleck, US
LPB0114 Safety of FEIBA and Emicizumab (SAFE): Dose Escalation 15:00 - 15:00 Study Evaluating the Safety of in vivo Administration of Activated Prothrombin Complex Concentrate in Hemophilia A
200 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Patients with Inhibitors on Emicizumab Speaker: Hande Kizilocak, US
LPB0116 An Accurate and Simple Liquid Chromatography Tandem Mass- 15:00 - 15:00 spectrometric Method for the Quantification of Emicizumab in People with Hemophilia A Speaker: Anouk Donners, NL
LPB0115 High Impact and Severe Outcomes of Intracranial Hemorrhage 15:00 - 15:00 (ICH) in an Italian Population of Adult Mild Hemophiliac Patients: Data from the EMO.REC Registry Speaker: Ezio Zanon, IT
LPB0117 The Association of Emicizumab and rFVIIa for Major 15:00 - 15:00 Orthopaedic Surgery Speaker: Christian Carulli, IT
LPB0118 Clinically Meaningful and Long-term Improvements in Fatigue 15:00 - 15:00 with the C3 Inhibitor Pegcetacoplan In Paroxysmal Nocturnal Hemoglobinuria: Post-hoc Analyses from the PEGASUS Study Week 48 Speaker: David Cella, US
LPB0120 Correlation between Procoagulant Platelets and 15:00 - 15:00 Hypercoagulability in Lung Cancer Patients Speaker: Mark Schreuder, AU
LPB0119 Impact of Vancomycin-induced Shift of the Gut Microbiome in 15:00 - 15:00 Gram Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized, Controlled Trial Speaker: Soerajja Bhoelan, NO
LPB0121 Quantitative and Qualitative Changes in Platelet Traits of 15:00 - 15:00 Sunitinib-treated Patients with Renal Cell Carcinoma in Relation to Circulating Sunitinib Levels: A Proof-of-Concept Study Speaker: Marijke J.E. Kuijpers, NL
LPB0123 Thrombotic Complications in a Cohort of Children with 15:00 - 15:00 Myeloproliferative Neoplasms Speaker: Nicole Kucine, US
LPB0124 Low Hemoglobin as a Biomarker for Paediatric Sinus 15:00 - 15:00 Thrombosis Speaker: Bushra Moiz, PK
LPB0122 Severe FXI Deficiency a Pediatric Cohort 15:00 - 15:00 Speaker: Assaf Arie Barg, IL
LPB0125 Characteristics of Pediatric Oncology Patients with Tumour 15:00 - 15:00 Thrombus Speaker: Nasrin Samji, CA
LPB0126 Whole Blood Impedance Aggregometry: A Usefool Tool but Still 15:00 - 15:00 Not the Gold Standard Speaker: Syrine Ellouze, FR
201 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
LPB0127 Defective Platelet Endocytosis of Albumin in RUNX1 15:00 - 15:00 Haplodeficiency Associated with Altered Caveolin-dependent Albumin Trafficking in Megakaryocytic Cells Speaker: Fabiola Del Carpio-Cano, US
LPB0128 Phase 3 Trial Results: Prophylaxis with Recombinant von 15:00 - 15:00 Willebrand Factor in Patients with Severe von Willebrand Disease Speaker: Flora Peyvandi, IT
LPB0129 Platelet-specific Deletion of Acetyl-CoA Carboxylase 1 15:00 - 15:00 Decreases Phospholipid Content and Impairs Platelet Functions Speaker: Marie Octave, BE
LPB0132 Chronic Edible Dosing of ?9-tetrahydrocannabinol (THC) in Non- 15:00 - 15:00 human Primates Reduces Systemic Platelet Activity and Function Speaker: Stephanie E. Reitsma, US
LPB0130 A Multiscale Framework for Patient-specific Predictions of 15:00 - 15:00 Thrombus Growth Speaker: Kaushik Shankar, US
LPB0131 Inhibition of Surface-induced Platelet Activation on Hydrogel 15:00 - 15:00 Films Speaker: Gurunath Apte, DE
LPB0133 Endothelial Cell and Neutrophil Interactions Are Required for 15:00 - 15:00 the Activation of the Blood Coagulation Cascade Leading to Thrombus Formation Following a Laser-induced Injury Speaker: Estelle Carminita, FR
LPB0135 Platelet-rich Neutrophil-platelet Micro-emboli Contribute to 15:00 - 15:00 Cigarette Smoke-induced Influenza Severity Speaker: Tomasz W. Kaminski, US
LPB0136 BMS-986141, a Selective PAR4 Antagonist, Reduces Platelet 15:00 - 15:00 Deposition in a Microfluidic Thrombosis Assay Speaker: Jason Chen, US
LPB0137 Validation of the HULL Clinical Prognostic Rule (CPR) for 15:00 - 15:00 Incidental Pulmonary Embolism in Ambulatory Cancer Patients Speaker: Farzana Haque, GB
LPB0138 Results of a Prospective, Observational, Multi-center Cohort 15:00 - 15:00 Study of Venous Thromboembolism Outcomes in Thrombocytopenic Cancer Patients (TROVE Study) Speaker: Brian Carney, US
LPB0139 Association of FXI Activity with Thrombo-inflammation, 15:00 - 15:00 Extracellular Matrix Interactions, Lipid Metabolism and Apoptosis in Venous Thromboembolism Speaker: Alejandro Pallares Robles, DE
LPB0140 Long-term Survival after Venous Thromboembolism: A 15:00 - 15:00
202 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Prospective Cohort Study Speaker: Henning Nilius, CH
LPB0143 Is standard dose thromboprophylaxis (TP) as recommended by 15:00 - 15:00 the Royal College of Obstetricians and Gynaecologists (RCOG) adequate in pregnancy for women with prior venous thrombo- embolism (VTE)? Speaker: Emma Treharne, GB
LPB0141 Platelet Activation and Platelet Indices as Markers for Disease 15:00 - 15:00 Progression in Women with Breast Cancer Speaker: Yousra Tera, EG
LPB0142 Association between Non-O Blood Group and the Risk of 15:00 - 15:00 Venous Thromboembolism due to Oral Contraceptive Therapy Speaker: Anna Poretto, IT
LPB0144 Thrombocytopenia in Pregnancy: Identification and 15:00 - 15:00 Management at a Reference Centre in Pakistan Speaker: Munira Borhany, PK
Special Session 16:00 - 16:45 R1 Daily Headlines
Presentation Theater 18:00 - 18:45 R1 PT 07R - Presentation Theater (Session Replay) Title: Evolving Care in aTTP – New Treatment Perspectives
This session is supported by Sanofi Genzyme
Please view the program here
203 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Wednesday, 21. July 2021
Presentation Theater 07:00 - 07:45 R1 PT 11 - Presentation Theater Title: An Early Treatment Option For The Management Of Chronic Immune Thrombocytopenia (ITP) In Adult Patients
This session is supported by Sobi
Please view the program here
Presentation Theater 07:00 - 07:45 R2 PT 12 - Presentation Theater Title: Clinical and Health Economic impact of the automated HemosIL Acustar ADAMTS13 Activity assay
This session is supported by WERFEN
Please view program here
Break 07:45 - 08:15 R1 Virtual Exhibits Visits and Networking Break
State-of-the-Art Session 08:30 - 09:30 R1 SOA 22 - New Concepts in Pediatric Thrombosis Moderator: Leonardo Brandão, CA Moderator: C. Heleen Van Ommen, NL SOA 22.1 Peripheral Arterial Thrombosis in Children 08:30 - 08:45 Speaker: Manuela Albisetti, CH
SOA 22.2 Pulmonary Embolism in Children 08:45 - 09:00 Speaker: Madhvi Rajpurkar, US
SOA 22.3 Anticoagulation for Pediatric ECMO: Can We Improve 09:00 - 09:15 Outcomes? Speaker: Heidi J. Dalton, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R2 SOA 23 - Platelets in Infectious Disease Moderator: Elisabeth M. Battinelli, US Moderator: Matthew Rondina, US SOA 23.1 Platelets: Influenza and Other Viral Responses 08:30 - 08:45 Speaker: Jane Freedman, US
204 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
SOA 23.2 Hemostasis in Malaria Pathogenesis 08:45 - 09:00 Speaker: James O'Donnell, IE
SOA 23.3 Platelet-Leukocyte Interactions in COVID-19: Contributions to 09:00 - 09:15 Inflammation, Hypercoagulability and Disease Severity Speaker: Patricia T. Bozza, BR
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R3 SOA 24 - Translational Research in Rare Bleeding Disorders Moderator: Jordan Shavit, US Moderator: Savita Rangarajan, GB SOA 24.1 Factor XIII and Factor VII 08:30 - 08:45 Speaker: Diane Nugent, US
SOA 24.2 Regulation of Factor VIII by APC and Potential Therapeutic 08:45 - 09:00 Implications Speaker: Lindsey A. George, US
SOA 24.3 Rationale Design of Therapeutics in Hemophilia 09:00 - 09:15 Speaker: Christopher B. Doering, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R4 SOA 25 - Cancer-Associated VTE Moderator: Cihan Ay, AT Moderator: Marcello di Nisio, IT SOA 25.1 Primary Thromboprophylaxis: Who, What, and How? 08:30 - 08:45 Speaker: Marc Carrier, CA
SOA 25.2 Treatment of Cancer-Associated VTE: Drugs, Duration 08:45 - 09:00 Speaker: Casey O'Connell, US
SOA 25.3 Myeloproliferative Neoplasm-Associated Thrombosis 09:00 - 09:15 Speaker: Tiziano Barbui, IT
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R5 SOA 26 - Biology of the Endothelium Moderator: Anne Eichmann, US Moderator: Juan M. Melero-Martin, US SOA 26.1 Blood Cell Formation From Hemogenic Endothelium 08:30 - 08:45 Speaker: Nancy A. Speck, US
SOA 26.2 Flow-Dependent Endothelial Cell Functional Phenotypes 08:45 - 09:00
205 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: Guillermo García-Cardeña, US
SOA 26.3 Vascular Hemodynamics and Malformations 09:00 - 09:15 Speaker: Christopher C. W. Hughes, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R6 SOA 27 - New Insights Into Megakaryocyte and Platelet Biology Moderator: Yotis Senis, FR Moderator: Laura Gutiérrez, ES SOA 27.1 Single Cell Approaches to Study Normal and Malignant 08:30 - 08:45 Megakaryopoiesis Speaker: Bethan Psaila, GB
SOA 27.2 Bone Marrow Reprogramming by Platelet Vesicles 08:45 - 09:00 Speaker: Kellie Machlus, US
SOA 27.3 iPS Cells and New Insights Into Inherited Platelet Disorders 09:00 - 09:15 Associated With an Increased Risk of Malignancies Speaker: Paul Gadue, US
Question and Answer 09:15 - 09:30
State-of-the-Art Session 08:30 - 09:30 R7 SOA 28 - Dynamic Regulation of Blood Coagulation Moderator: Mettine Bos, NL Moderator: Roger Preston, IE SOA 28.1 Functional Disulfide Bonds in Hemostasis and Thrombosis 08:30 - 08:45 Speaker: Philip Hogg, AU
SOA 28.2 Intermolecular Interactions that Stabilize Multimeric FXIII 08:45 - 09:00 Speaker: Verena Schroeder, CH
SOA 28.3 Structural Basis of Antagonizing the Vitamin K Catalytic Cycle 09:00 - 09:15 for Anticoagulation Speaker: Weikai Li, US
Question and Answer 09:15 - 09:30
Break 09:30 - 10:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 10:00 - 11:00 R1 OC 60 - Anticoagulants: Novel Strategies and Mechanisms Moderator: Henri Spronk, NL Moderator: Helen Philippou, GB
206 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 60.1 A Randomized, Double-blind, Placebo-controlled, Phase 2 Study 10:00 - 10:12 Evaluating Safety and Efficacy of AB023 in Hemodialysis Patients Speaker: Christina Lorentz, US
OC 60.2 Antithrombotic Potential of a Single-domain Antibody 10:12 - 10:24 Enhancing the Anticoagulant Activity of Protein S Speaker: Josepha-Clara Sedzro, FR
OC 60.3 Targeting Coagulation Factor Xa and IIa Differentially Regulate 10:24 - 10:36 Inflammation Speaker: Khurrum Shahzad, DE
OC 60.4 Discovery and in vitro Characterization of an Antibody 10:36 - 10:48 Fragment (Fab) which Neutralizes Milvexian (BMS-986177/JNJ-70033093) Speaker: Yiming Wu, US
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R2 OC 61 - Platelet Biology Moderator: Elizabeth Gardiner, AU Moderator: Gowthami Arepally, US OC 61.1 Pleiotropic Role of miR-146a in Driving Metabolism 10:00 - 10:12 Reprogramming Causes Platelet Hyperreactivity and Thrombosis Speaker: Sonia Águila, ES
OC 61.2 Dense Granules Are Released Cooperatively in Activated 10:12 - 10:24 Platelets Speaker: Taisia O. Shepeliuk, US
OC 61.3 A Novel Particle-based Model Delivers Mechanistic Insights into 10:24 - 10:36 Arterial Thrombus Heterogeneity Speaker: Anastasia A. Masalceva, RU
OC 61.4 Understanding the Role of Mitochondria in Platelet Function 10:36 - 10:48 Speaker: Kanakanagavalli Shravani Prakhya, US
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R3 OC 62 - Critical Hemostatic Issues with Childbirth Moderator: Andra H. James, US Moderator: Homa Khorrami Ahmadzia, US OC 62.1 Women-specific Bleeding in Inherited Platelet Function Defects: 10:00 - 10:12 A Cross-sectional Study Speaker: Marieke C. Punt, NL
OC 62.2 Clinical Value of Early Assessment of Hyperfibrinolysis by 10:12 - 10:24
207 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Rotational Thromboelastometry during Postpartum Hemorrhage for the Prediction of Severity of Bleeding: A Multicenter Prospective Cohort Study in the Netherlands Speaker: Marije Tahitu, NL
OC 62.3 Obstetric Analgesia and Anaesthesia in Women with Inherited 10:24 - 10:36 Bleeding Disorders Speaker: Ozlem Turan, GB
OC 62.4 Postpartum Hemorrhage in Women with von Willebrand Disease 10:36 - 10:48 and Carriers of Hemophilia: A Retrospective Analysis Speaker: Marieke C. Punt, NL
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R4 OC 63 - Diagnosis of VTE Moderator: Ponlapat Rojnuckarin, TH Moderator: Kerstin de Wit, CA OC 63.1 Assessing the Clinical Probability of Pulmonary Embolism 10:00 - 10:12 during Pregnancy: The Pregnancy-Adapted Geneva (PAG) Score Speaker: Helia Robert-Ebadi, CH
OC 63.2 Development of Neuro-Fuzzy Networks for Venous 10:12 - 10:24 Thromboembolism Recurrence Prediction Speaker: Tiago D. Martins, BR
OC 63.3 Optimization of Calf Pump Function Measurements by Venous 10:24 - 10:36 Plethysmography for Prediction of Deep Vein Thrombosis Speaker: Damon Houghton, US
OC 63.4 Diagnosis of Acute Pulmonary Embolism across Different 10:36 - 10:48 Healthcare Settings: A Systematic Review and Individual Patient Data Meta-analysis Speaker: Geert-Jan Geersing, NL
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R5 OC 64 - Residual Venous Obstruction and Post-Thrombotic Syndrome Moderator: Susan R. Kahn, CA Moderator: Suresh Vedantham, US OC 64.1 Associations of Residual Venous Obstruction, d-Dimers, fFctor 10:00 - 10:12 VIII and CRP with Long-term Outcomes of Deep Vein Thrombosis Speaker: Aaron F.J. Iding, NL
OC 64.2 25mmHg vs. 35mmHg Elastic Compression Stockings to 10:12 - 10:24 Prevent Post Thrombotic Syndrome after Deep Vein
208 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Thrombosis: The CELEST Double-blind Trial Speaker: jean Philippe galanaud, CA
OC 64.3 Contact Activation and Coagulation in Residual Venous 10:24 - 10:36 Obstruction Speaker: Aaron F.J. Iding, NL
OC 64.4 Incidence and Predictors of Post-thrombotic Syndrome: Results 10:36 - 10:48 from GARFIELD-VTE Speaker: Paolo Prandoni, IT
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R6 OC 65 - Risk and Prevention of Stroke in Atrial Fibrillation Moderator: Deirdre A. Lane, GB Moderator: Matthew C. Hyman, US OC 65.1 Cancer is Associated with an Increased Stroke Risk in Patients 10:00 - 10:12
with Atrial Fibrillation and CHA2DS2-VASc Score ≤ 2 Speaker: Avi Leader, IL
OC 65.2 Changes in Prescription Patterns of Oral Anticoagulants and 10:12 - 10:24 Clinical Outcomes among Newly Diagnosed Non-valvular Atrial Fibrillation Patients in the Netherlands Speaker: Qingui Chen, NL
OC 65.3 Improving Outcomes with Integrated Care of Patients with Atrial 10:24 - 10:36 Fibrillation and Multimorbidity Using Mobile Health Technology: A Report from the mAFA II Trial Speaker: Yutao Guo, CN
OC 65.4 Prescription Patterns and Impact of Anticoagulant Therapy in 10:36 - 10:48 Patients with Atrial Fibrillation who Had Active Cancer Speaker: Chatree Chai-Adisaksopha, TH
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R7 OC 66 - ADAMTS13, Complement and Thrombotic Microangiopathies Moderator: Colin Kretz, CA Moderator: Sarah E. Sartain, US OC 66.1 Investigating the Resistance of ADAMTS13 towards Protease 10:00 - 10:12 Inhibitors Speaker: Kanwal Singh, CA
OC 66.2 Anti-cysteine/Spacer Autoantibodies that Open the 10:12 - 10:24 Conformation of ADAMTS13 Are a Common Feature of the Autoimmune Response in Immune-mediated Thrombotic Thrombocytopenic Purpura Speaker: Laure De Waele, BE
209 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 66.3 Von Willebrand Factor Contributes to Alternative Complement 10:24 - 10:36 Pathway Activation, Microangiopathy, and Renal Dysfunction in Murine Thromboinflammation Speaker: Paula Jacobi, US
OC 66.4 Development of an Easy-to-Use ADAMTS13 Conformation 10:36 - 10:48 Assay Using Fiber Optic Surface Plasmon Resonance Technology Speaker: Charlotte Dekimpe, BE
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R8 OC 67 - Safety and Efficacy in Gene Therapy for Hemophilia Moderator: Janice Staber, US Moderator: Sara Boyce, GB OC 67.1 Hemostatic Response is Maintained for up to 5 Years Following 10:00 - 10:12 Treatment with Valoctocogene Roxaparvovec, an AAV5-hFVIII- SQ Gene Therapy for Severe Hemophilia A Speaker: Michael Laffan, GB
OC 67.2 Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression 10:12 - 10:24 after AAV Gene Transfer for Hemophilia A Speaker: Lindsey A. George, US
OC 67.3 Clinical Outcomes in Adults with Hemophilia B with and without 10:24 - 10:36 Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial Speaker: Frank W.G. Leebeek, NL
OC 67.4 Liver Safety Case Report from the Phase 3 HOPE-B Gene 10:36 - 10:48 Therapy Trial in Adults with Hemophilia B Speaker: Steven W. Pipe, US
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R9 OC 68 - SARS-CoV2 and the Endothelium Moderator: Wolfram Ruf, DE Moderator: Ning Tang, CN OC 68.1 Morphological and Functional Alterations in Endothelial Colony- 10:00 - 10:12 forming Cells from Recovered COVID-19 Patients Speaker: JORGE DAVILA-MORENO, MX
OC 68.2 Circulating Levels of Platelet, Endothelial and Red Blood Cell 10:12 - 10:24 Microvesicles in COVID-19: Association with Biomarkers of Coagulation, Fibrinolysis and Angiogenesis Speaker: Mayck Silva Barbosa, BR
210 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 68.3 The Link between Inflammation, Coagulation and Endothelium 10:24 - 10:36 Damage in COVID-19: Evidence from an Exploratory Cross- sectional Study Speaker: Maria Rita Peralta, GB
OC 68.4 Vascular Endothelial Damage in the Pathogenesis of 10:36 - 10:48 Preeclampsia and SARS-CoV-2 Infection in Pregnancy Speaker: Marta Palomo, ES
Question and Answer 10:48 - 11:00
Oral Communication Session 10:00 - 11:00 R10 LB 02 - Late-breaking Abstract Session II Moderator: David Lillicrap, CA Moderator: Kandace Gollomp, US LB 02.1 The VWF-A1 Domain Binding Aptamer BT200 Prolongs the Half- 10:00 - 10:12 lives of Different Factor VIII (FVIII) Products in Patients with Severe Hemophilia A and Increases FVIII Levels in Non-severe Hemophilia A Speaker: Cihan Ay, AT
LB 02.2 Towards Understanding ChAdOx1 nCov-19 Vaccine-induced 10:12 - 10:24 Immune Thrombotic Thrombocytopenia (VITT) Speaker: Andreas Greinacher, DE
LB 02.3 Mechanism of the Development of Thrombotic 10:24 - 10:36 Thrombocytopenia in Covid-19 Infected Patients and after Vaccination Speaker: Thi Huong Nguyen, DE
Question and Answer 10:36 - 10:48
Break 11:00 - 11:30 R1 Virtual Exhibits Visits and Networking Break
Supported Symposium 11:30 - 12:30 R1 LS 22 - Supported Symposium Title: Management of high-risk VTE patients: what’s new in 2021?
This session is supported by Sanofi
Please view the program here
211 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Supported Symposium 11:30 - 12:30 R2 LS 23 - Supported Symposium Title: Investigational AAV Gene Therapy - Next Frontier of Immunomodulation
This session is supported by Spark Therapeutics
Please view the program here
Supported Symposium 11:30 - 12:30 R3 LS 24 - Supported Symposium Title: Evolving treatment considerations for patients with atypical-HUS
This session is supported by Alexion Pharmaceuticals, Coagulation
Break 12:30 - 13:00 R1 Virtual Exhibits Visits and Networking Break
Oral Communication Session 13:00 - 14:00 R1 OC 69 - Pathogenesis and Management of Pediatric Thrombosis Moderator: Anthony Kam Chuen Chan, CA Moderator: Irene Klaassen, NL OC 69.1 Management Practices of Catheter-related Arterial Thrombosis 13:00 - 13:12 in Children and Neonates: Results of a Multinational Survey Speaker: Mattia Rizzi, CH
OC 69.2 Efficacy and Safety of Dabigatran in the Treatment and 13:12 - 13:24 Secondary Prevention of Venous Thromboembolism in Children with Central Line or Implantable Device–related Thrombosis Speaker: Manuela Albisetti, CH
OC 69.3 Abdominal Thromboses in Pediatric Patients: What Do we 13:24 - 13:36 Know? Speaker: Susan Kuldanek, US
OC 69.4 Pediatric Leukemic Lymphoblasts Produce Hemostatic System 13:36 - 13:48 Factors: A Novel Contributor to the Hemostatic Imbalance in Pediatric Acute Lymphoblastic Leukemia Speaker: Ghada Aborkhees, CA
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R2 OC 70 - COVID, Platelets and Possible Targeted Therapies Moderator: Nadine Ajzenberg, FR Moderator: Jason S. Knight, US
212 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 70.1 cAMP Prevents Antibody Induced Thrombus Formation in 13:00 - 13:12 COVID-19 Speaker: Jan Zlamal, DE
OC 70.2 Anti-thrombotics and Anti-hypertensives with Direct Action 13:12 - 13:24 against SARS-CoV-2 Speaker: Marian Brennan, IE
OC 70.3 Endothelial Targeting in the Treatment of Early Clinical Stages 13:24 - 13:36 of COVID-19: Results of a Randomized Placebo-controlled Trial Speaker: Alejandro Gonzalez Ochoa, MX
OC 70.4 Platelet Activation via PI3K/AKT Signaling Pathway in COVID-19 13:36 - 13:48 Speaker: Lisann Pelzl, DE
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R3 OC 71 - Modulation of Coagulation and Disease Moderator: Alvin H. Schmaier, US Moderator: Cristina Puy, US OC 71.1 Pharmacological Targeting of Coagulation Factor XI Mitigates 13:00 - 13:12 the Development of Experimental Atherosclerosis in Low- density Lipoprotein Receptor-deficient Mice Speaker: Anh Ngo, US
OC 71.2 Apolipoprotein A-IV Polymorphisms Q360H and T347S Reduce 13:12 - 13:24 its Inhibitory Effect against Thrombosis Speaker: Daniel MacKeigan, CA
OC 71.3 The Procoagulant and Fibrinolytic Balance of Microvesicles 13:24 - 13:36 Predicts Mortality in Septic Shock Patients Speaker: Romaric Lacroix, FR
OC 71.4 Modulation of the Procoagulant and Cytotoxic Effects of 13:36 - 13:48 Histones by Glycosaminoglycans Speaker: Neha Sharma, CA
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R4 OC 72 - Novel Therapeutic Strategies Involving Platelets and VWF Moderator: Jenny M. Despotovic, US Moderator: Cihan Ay, AT OC 72.1 BT200 Increases von Willebrand Factor (VWF), FVIII and Platelet 13:00 - 13:12 Counts in Patients with von Willebrand Disease (VWD) Type IIb Speaker: Cihan Ay, AT
OC 72.2 Phase I/II Ongoing Study of Rilzabrutinib, an Oral Bruton 13:12 - 13:24 Tyrosine Kinase Inhibitor, in Immune Thrombocytopenia: Extended Follow-up and Long-term Analyses with Optimal Dose
213 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Speaker: David J. Kuter, US
OC 72.3 Assessing the Pharmacodynamics of RUC-4 (Zalunfiban), a 13:24 - 13:36 Novel ?IIb?3 Antagonist, Using VerifyNow Assays in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Treated with Aspirin and Ticagrelor Speaker: Ohad S. Bentur, US
OC 72.4 Durability of Platelet Count Response in Patients Treated with 13:36 - 13:48 Avatrombopag for Immune Thrombocytopenia (ITP): Post-hoc Results from the Phase 3 Core and Open-label Extension Study Speaker: Shivi Jain, US
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R5 OC 73 - Pulmonary Embolism: Diagnosis, Prognosis and Management Moderator: Damon Houghton, US Moderator: Erik Klok, NL OC 73.1 Inhibition of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) 13:00 - 13:12 to Accelerate Clot Lysis in Patients with Acute Pulmonary Embolism: A Phase 2 Randomized Study Speaker: Thomas Vanassche, BE
OC 73.2 Safety and Efficiency of Diagnostic Strategies for Ruling out 13:12 - 13:24 Pulmonary Embolism in Important Patient Subgroups: A Systematic Review and Individual-patient Data Meta-analysis Speaker: Milou Anne Maria Stals, NL
OC 73.3 Prognostic Impact of Acute Kidney Injury in Patients with Acute 13:24 - 13:36 Pulmonary Embolism. Data from the RIETE Registry Speaker: Laurent Bertoletti, FR
OC 73.4 Use of the National Early Warning Score for Predicting 13:36 - 13:48 Deterioration of Patients with Acute Pulmonary Embolism Speaker: Milou Anne Maria Stals, NL
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R6 OC 74 - Megakaryopoiesis and Platelet Life Cycle, II Moderator: Koji Eto, JP Moderator: Diane Krause, US OC 74.1 Evolution of the Tubulin Post-translational Modification 13:00 - 13:12 Repertoire during Megakaryopoiesis Speaker: Quentin Kimmerlin, FR
OC 74.2 A Heterozygous Mutation in SLFN14 Influences Species-specific 13:12 - 13:24 Haematopoietic Regulation in Platelet and Erythroid Lineages Speaker: Rachel Stapley, GB
214 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
OC 74.3 ß1 and ß3 Integrins Limit the Passage of Entire Megakaryocytes 13:24 - 13:36 across the Sinusoids of the Bone Marrow Speaker: Cyril Scandola, FR
OC 74.4 Platelets Preferentially Bind Senescent Red Blood Cells and 13:36 - 13:48 Regulate in their Clearance Speaker: Brendan McMorran, AU
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R7 OC 75 - Basic and Laboratory Aspects of Gene Therapy for Hemophilia Moderator: Dan Hart, GB Moderator: Paul Batty, CA OC 75.1 Prenatal Therapy with Placental Cells Transduced with an 13:00 - 13:12 Engineered fVIII Transgene Results in Curative fVIII Plasma Levels for 3 Years after Birth, Without Immune- or Toxicity- related Adverse Events Speaker: Martin Rodriguez, US
OC 75.2 Investigation of Early Outcomes Following Adeno-associated 13:12 - 13:24 Viral Gene Therapy in a Canine Hemophilia Model Speaker: Paul Batty, CA
OC 75.3 In vitro and In vivo Models to Understand One-stage and 13:24 - 13:36 Chromogenic Factor VIII Activity Assay Discrepancy of Hepatocyte-derived Factor VIII Speaker: Anna Rose Sternberg, US
OC 75.4 AAV Delivery of a Novel Human Factor VIII Variant with 13:36 - 13:48 Improved Secretion Results in Higher FVIII Expression in Hemophilia A Dogs Speaker: Giang Nguyen, US
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R8 OC 76 - Effectiveness and Safety of Anticoagulants for VTE Moderator: Julia A. M. Anderson, GB Moderator: Eric Tseng, CA OC 76.1 Rivaroxaban for the Treatment of Symptomatic Isolated Distal 13:00 - 13:12 Deep Vein Thrombosis – RIDTS Study Speaker: Walter Ageno, IT
OC 76.2 Association of Single Nucleotide Polymorphisms with Major 13:12 - 13:24 Bleeding Risk during Vitamin K Antagonists Treatment: A Case- cohort Study Speaker: Eleonora Camilleri, NL
OC 76.3 Effectiveness and Safety of Apixaban vs Warfarin among 13:24 - 13:36
215 / 216 Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S.
Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Thrombophilia Speaker: Alexander Cohen, GB
OC 76.4 Safety and Efficacy of the Direct Oral Anticoagulants in Cerebral 13:36 - 13:48 Vein Thrombosis: A Systematic Review and Meta-analysis Speaker: Francesca Galea, MT
Question and Answer 13:48 - 14:00
Oral Communication Session 13:00 - 14:00 R9 OC 77 - Thrombo-Inflammation and Disease Moderator: Joan D. Beckman, US Moderator: Steven Grover, US OC 77.1 Monocyte-macrophage Synthesis of FVII Contributes to the 13:00 - 13:12 Development of Atherosclerosis Speaker: Romina Wolz, DE
OC 77.2 Coagulation Factor XII Signaling via uPAR- ?1 Integrin Promotes 13:12 - 13:24 Renal Tubular Senescence in Diabetic Nephropathy Speaker: Ahmed Elwakiel, DE
OC 77.3 LMWH Prevents Platelet and Extracellular Vesicle Mediated 13:24 - 13:36 Thrombo-inflammation in Preeclampsia Speaker: Shrey Kohli, DE
OC 77.4 Thrombin Mediated Activation of Protease Activated Receptor 1 13:36 - 13:48 Contributes to Doxorubicin Induced Cardiac Injury Speaker: Steven Grover, US
Question and Answer 13:48 - 14:00
Special Session 14:00 - 14:45 R1 Congress Highlights
216 / 216